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All you really need to know for the moment is that the universe is a lot 
more complicated than you might think, even if you start from a 

































The drug discovery process 
The discovery and development of new small molecule medicines is a long and expensive 
process, which requires numerous fields of research to come together. The general timeline 
for the discovery and development of new drugs is depicted in Figure 1.1.1,2 Initially, in the 
drug discovery phase, a biological target has to be found and validated. Next, the stages of 
hit finding and optimization are aimed at the discovery of molecules to effectively modulate 
the target. The best molecule, a so-called lead, is then taken into the lead optimization 
phase, where typically animal models are used to optimize the pharmacokinetic, efficacy  
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Figure 1.1 | Overview of the general stages of drug discovery and development, the timeline, and cumulative 
cost and success rate. Figure constructed based on Ref 1 with data from Ref 2.1,2  
 
and safety profile of the leads, through iterative rounds of synthesis and testing. Once the 
drug candidate has been selected for drug development, extensive optimisation of the 
pharmaceutical formulation and pre-clinical toxicological profiling is performed, before the 
compound is tested in humans. The next 3 stages are referred to as the clinical trials. Phase 
1 typically utilizes healthy volunteers mainly to assess the pharmacokinetic and safety 
profile of the drug candidate. Phase 2 has an emphasis on finding an efficacious dose in a 
small cohort of patients. If successful, phase 3 enrols a large patient cohort to determine 
the efficacy and safety of the experimental drug. It can then be submitted for approval by 
the authorities. Even after the drug enters the market, data is gathered to assess safety in 
the larger population, a process often referred to as phase 4. This stringent process of 
clinical trials is associated with high attrition rates, meaning that less than 1 in 10 devised 
therapies actually make it to the patient. This is exemplified in Figure 1.1 where the 
cumulative cost and success rate of drug discovery and development is tracked over time.1 
Failure in the clinical stage is mostly due to toxicity or to lack of efficacy. The high cost and 
slow progress in drug development is a major concern, as this inevitably pushes up drug 
prices. 
 
Target-based drug discovery 
As discussed above, modern drug discovery projects typically start from either a well-
established biological target, or by validating a novel target. The biological target can be 
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anything from a co-factor to a protein-complex and generally performs a function which is, 
in the given condition, unwanted. Currently, four major classes of drug targets can be 
discerned: transporters, ion channels, receptors (nuclear or G-protein coupled) and 
enzymes, together accounting for just under 90% of the FDA approved drugs.3 This thesis 
will focus primarily on enzymes. Pharmaceutical intervention in the functioning of enzymes, 
barring a few exceptions, always aims at inhibiting the reaction they catalyze. This is 
typically achieved by compounds that block the binding site of the natural substrate of the 
enzyme, called competitive inhibition.4 To find the molecules that have the required 
interactions to efficiently block the binding site of a given protein, a plethora of techniques 
have been developed which found their way to the drug industry’s toolbox. 
The most important approach to find new inhibitors is, although conceptually simple, 
technically very challenging. So-called high-throughput screening campaigns typically use 
some biochemical or cellular assay capable of measuring the protein activity in a highly 
controlled sample and run this assay for thousands or even millions of compounds. This 
kind of screening is performed by specialized, highly expensive robots and are mostly 
restricted to the pharmaceutical industry. Smaller screens can be performed with less 
sophisticated robots or even by hand.  
With the dawn of computers, it did not take long before they were put to use in the drug 
discovery world.5 This field of research often utilizes virtual screenings, which are enabled 
by the availability of many 3D structures of proteins, either from crystal structures, NMR-
structures, or homology models.6 In virtual screenings, large numbers of molecules are 
tried, or docked, inside the (proposed) binding site of a protein, making it essentially the 
digital mimic of above-mentioned high-throughput screenings. The field of computational 
drug discovery comprises a broad set of other applications, which are not necessarily 
structure-based. Quantitative structure activity relations (QSAR) or machine learning 
approaches also strongly contribute, and the field, together with the number of developed 
techniques, is still growing. With the advent of machine learning and artificial intelligence 
this growth is likely to persist.  
 
Off-target activity 
The key of target-based drug discovery is that a specific enzyme is targeted to be 
inhibited. This inhibition is known or predicted to have a designated effect on physiology, 
which is supposed to be beneficial for the therapeutic indication at hand. With an estimated 
number of around 20,000 translated genes, it seems inevitable that the binding site of 
some proteins will be highly similar.7 This is especially true for enzymes one step preceding 
or following the targeted enzyme in an enzyme cascade, as the product and substrate of 
these are identical. It is also the case for protein families within (large) protein families, with 
high overall similarity, such as the kinases or serine hydrolases. The high similarity of 
binding sites between proteins can lead to small molecules unintendedly inhibiting other 
proteins. These are referred to as off-targets.  
Interfering with a number of proteins simultaneously can have additive beneficial effects 
and is referred to as polypharmacology.8 Some drugs are actively tuned to inhibit multiple 
targets, which can be a challenging undertaking.9 Usually however, small molecule 
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inhibitors are carefully optimized to minimize the cross-reactivity with off-targets, to 
minimize the chance of unwanted side effects or toxicity.10  
 
The endocannabinoid system 
The endocannabinoid system (ECS) influences many physiological processes in the 
human body, including food intake, energy balance, motor coordination, pain sensation, 
memory formation and anxiety.11,12 The ECS has, therefore, been under active investigation 
for therapeutic exploitation in which its receptors and several metabolic enzymes serve as 
possible drug targets.13,14 There are two main cannabinoid receptors, CB1R and CB2R, 
which belong to the family of GPCRs. They are activated by two endogenous ligands, i.e. 
anandamide (AEA) and 2-arachidonoyl glycerol (2-AG).15,16 The production and degradation 
of these endocannabinoids is mainly performed by serine hydrolases (Figure 1.2). 
Diacylglycerol lipase-α and -β (DAGL-α and -β) are the main enzymes responsible for the 
biosynthesis of 2-AG through the sn-1-specific hydrolysis of diacylglycerol (DAG).17–19 The 
DAGL-α isoform is expressed mainly in the brain, whereas the DAGL-β isoform is 
predominantly found in the periphery, and is highly abundant in macrophages.20,21 
Monoacylglycerol lipase (MAGL) and α/β-hydrolase-domain containing protein 6 and 12 
(ABHD6 and ABHD12) together account for 99% of the 2-AG hydrolysis to arachidonic acid 
(AA) and glycerol in the brain.22,23 The Ca2+-dependent biosynthesis of endogenous AEA is 
mediated by the subsequent actions of PLA2G4E24 and N-acylphosphatidylethanolamine-
phospholipase D (NAPE-PLD) or ABHD425, although other biosynthetic pathways have also 
been uncovered.13,14,26 Fatty acid amide hydrolase (FAAH) is the key enzyme for the 
hydrolysis of AEA to AA.27,28 Several drugs targeting the ECS have already entered the 
market: ∆9-tetrahydrocannabinol (THC, marketed as Marinol®), cannabidiol (CBD, 
marketed as Epidiolex®), a combination of THC and CBD (marketed as Sativex®) and 
Rimonabant®. The latter was withdrawn from the market after the discovery of 
psychological side effects. Several FAAH and MAGL inhibitors have entered clinical trials, 
but they have not (yet) reached the market.29–34  
The exact function and tissue specific roles of the ECS are still poorly understood.14 
Inhibitors of the metabolic enzymes are thus crucial to investigate the biological role of the 
hydrolases and may serve as drug candidates to modulate the endocannabinoid levels in 
human disease. With its central role in the production of the main ECS signaling lipid 2-AG, 
modulation of DAGL activity holds large therapeutic promise. Specifically, DAGL modulation 
might aid in the alleviation of symptoms in neuroinflammatory conditions, such as observed 
in Parkinson’s and Alzheimer’s disease.35,36  
 
Activity-based protein profiling 
The DAGLs, like most of the synthetic and degradative enzymes in the ECS, belong to 
the superfamily of the serine hydrolases (SH).37 This enzyme family has a conserved 
mechanism of action where a nucleophilic serine is used to hydrolyze ester or amide bonds. 
In the process, the serine forms a covalent bond with the substrate. This covalent 
intermediate is exploited in mechanism-based, covalent inhibitors, as well as in activity-
based protein profiling (ABPP).38 The enzymes of the endocannabinoid system have been  
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Figure 1.2 | Schematic overview of the main biosynthetic pathways within the endocannabinoid system. All 
enzymes except NAPE-PLD belong to the serine hydrolase protein family. PC: phosphatidylcholine; PE: 
phosphatidylethanolamine; DAG: diacylglycerol; NAPE: N-acylphosphatidylethanolamine; AA: arachidonic acid; 
PLA2G4E: phospholipase A2 group IV E; DAGL: diacylglycerol lipase; NAPE-PLD: N-acylphosphatidylethanol-
amine phospholipase D; MAGL: monoacylglycerol lipase; ABHD: α/β-hydrolase-domain containing protein; 
FAAH: fatty acid amide hydrolase. 
 
extensively investigated using ABPP.24,39–45 Specifically the development of the tailored 
activity-based probe (ABP) MB064 to study the DAGLs was instrumental in the further 
development of several inhibitor classes.39,42,43 
Activity-based protein profiling (ABPP) for serine hydrolases was introduced in the late 
´90s (Figure 1.3).46 In ABPP a chemical probe, typically consisting of a reactive ‘warhead’ 
and a reporter tag, reacts with the catalytically active nucleophilic serine of a serine 
hydrolase. The reporter tag can be either a fluorophore to visualize the probe-protein adduct 
by SDS-PAGE and fluorescence scanning,47 or a biotin-group to enrich proteins from 
proteomes for identification by high resolution LC-MS/MS48 or visualization by western 
blotting.46 As the labeling of enzymes is typically activity dependent, inhibitor function can 
be studied using so-called competitive ABPP. This technique is used in drug discovery to 
efficiently profile activity of inhibitors in a wide variety of proteomes. Importantly, the 
selectivity of inhibitors over a protein family can also be investigated in native biological 
samples. Other advances in chemical biology, such as photoaffinity labeling, efficient bio-
orthogonal chemistry, and improvements in analysis techniques such as proteomics, have 
broadened the scope of applications of this protein profiling technique significantly. The 
flexibility in potential protein sources and robust application to more complex samples 
make ABPP a powerful technique in all stages of drug discovery. 
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Figure 1.3 | General scheme of activity-based protein profiling. Probe binds specifically to active enzymes, 
which enables competitive ABPP (bottom). Probe labeling can be visualized using SDS-PAGE or LC-MS/MS 
analysis. 
 
Aim and outline of this thesis 
The aim of the research presented in this thesis is to develop methods to assess or 
predict the selectivity of (endocannabinoid related) inhibitors, and to use those methods in 
the discovery of better inhibitors of diacylglycerol lipase. The outline of this thesis is as 
follows: 
Chapter 2 discusses the activity- and selectivity-driven optimization of a new scaffold of 
DAGL inhibitors found in a previously reported high-throughput screening campaign.49 The 
structure activity relations are studied in detail and the optimized inhibitor is fully profiled 
biochemically. This is then further tested in cultures of murine neuroblastoma cells, before 
finally being administered to mice in a proof of target engagement study.  
Chapter 3 combines the structural insights of Chapter 2 with those from literature42 to 
enhance the physicochemical properties of the inhibitors from Chapter 2. The dual aim is 
to generate more drug-like compounds by enhancing pharmacokinetic properties, 
combined with increasing the topological polar surface area to restrict brain access. In this 
way, the more peripherally expressed DAGL-β isoform could be targeted selectively, 
reducing the risk of side effects mediated centrally. A small library of piperazine derivatives 
is synthesized and profiled biochemically, before testing the most promising compounds in 
situ.  
Chapter 4 focusses more on the fundamental aspects of binding of covalent inhibitors. 
DH376 derivatives, wherein the number and positioning of the nitrogen atoms in the 
heterocyclic ring vary, are synthesized.50 These are tested in an adapted surrogate 
substrate assay to determine the kinetics of enzyme inhibition and to study the role of 
affinity (Ki) and reactivity (kinact). Surprisingly, the heterocycle is found to be more important 
in the former than in the latter. Insight in the specific binding kinetics is expected to aid in 
the design of inhibitors that are more potent and more selective, by increasing Ki and 
reducing kinact, respectively. 
Chapter 5 presents the work on the selectivity profiling of the experimental drug 
BIA 10-2474, which was designed as a FAAH inhibitor. This drug made headlines worldwide 
when, during a phase 1 first-in-human clinical trial in January 2016, a healthy volunteer 
passed away and four others were hospitalized with severe neurological symptoms.51,52 Off-
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target activity was quickly hypothesized as a possible cause of the observed toxicity. This 
hypothesis was investigated using activity-based protein profiling techniques, the results of 
which are disclosed in this chapter. BIA 10-2474, an important metabolite and three 
alkynylated derivatives are synthesized and extensively tested. It is shown that BIA 10-2474 
is an a-specific and covalent inhibitor that severely disrupts neural lipid metabolism in situ 
through the inhibition of several serine hydrolase lipases.  
Chapter 6 extends the chemical toolbox to study the endocannabinoid serine 
hydrolases. A new fluorophosphonate (FP) activity-based probe is synthesized and 
characterized. The profound influence on enzyme labeling efficiency due to the change in 
fluorophore is investigated in detail. The FP probe is found to label FAAH and MAGL at low-
nanomolar concentrations, allowing it to be combined with MB064 to create an efficient 
probe cocktail capable of labeling most of the ECS-related serine hydrolases in one 
experiment. This cocktail is validated and used to profile the inhibition of two covalent MAGL 
inhibitors.  
Chapter 7 attempts to take a prospective approach to target selectivity. By employing a 
relatively new machine learning algorithm, t-distributed Stochastic Neighbour Embedding 
(t-SNE), molecular similarity is shown for a large set of clinically relevant substances.53 The 
same approach is able to visualize similarity in the protein sequences of the serine 
hydrolase superfamily, recapitulating phylogenetic information. A workflow is envisioned 
wherein bio-activity data spanning large amounts of compounds and targets are used to 
predict interaction profiles for serine hydrolase inhibitors.  
Chapter 8 builds on the concepts explored in Chapter 7 for serine hydrolases and applies 
it to the more extensively studied kinase family. Using the Published Kinase Inhibitor Set, a 
model is trained and validated capable of predicting interaction profiles across the 
kinome.54,55 The validated model is used to find new leads for the oncogene FLT356, which 
are validated in parallel using high-throughput methods. Two hits are resynthesized and 
profiled in vitro and in situ against acute myeloid leukaemia derived cells. The presented 
model is completely open source, and released as a readily usable executable.  
Chapter 9 summarizes the work presented in this thesis, and shows future directions for 
the disclosed research.   
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If the elements are the alphabet of chemistry, then the 


















2. Hit-to-lead optimization 













Diacylglycerol lipase (DAGL)-α and DAGL-β inhibitors have been under active 
investigation as potential drugs for the treatment of metabolic and neurodegenerative 
disorders for nearly a decade.1,2 The recent generations of optimized inhibitors can be 
divided in three chemotypes: the α-ketoheterocycles (LEI104 and LEI1053,4), the glycine 
sulfonamides (e.g. LEI106)5,6 and the triazole ureas (KT109, DO34 and DH3767,8). These 
inhibitors have been used successfully in a variety of cellular and animal models to study 
the effect of DAGL inhibition in detail.1,4,7–9 However, as potential drugs, each of these 
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inhibitor classes has its own set of shortcomings. The α-ketoheterocycles are the most 
selective inhibitors published to date, with no known off-targets reported for LEI105.4 
However, LEI105 has a very low oral bioavailability due to its low solubility and high 
metabolic clearance (unpublished data). The glycine sulfonamides are dual DAGL and 
α/β-hydrolase domain containing protein 6 (ABHD6) inhibitors, and have a few further 
unidentified off-targets in vitro.5 The free acid of the glycine moiety was found to be crucial 
for activity, but likely caused the observed significantly reduced cellular potency and low 
brain penetration.9 Although the triazole urea derivatives DO34 and DH376 are less 
lipophilic and more selective than the original hit KT1091, they still have several other 
serine hydrolases as off-targets. In all, the current state-of-the-art for DAGL inhibitors leaves 
room for improvement and warrants the search for new chemical scaffolds. 
To find new hits for DAGL-α, a high throughput screening campaign was performed in 
collaboration with the Pivot Park Screening Centre and the European Lead Factory.10 Initial 
screening at 10 µM in a previously reported surrogate substrate assay yielded 1932 hits 
(Figure 2.1).3 These were confirmed at a lower concentration (1.25 µM) and verified in an 
orthogonal activity-based protein profiling (ABPP) assay. After final selections based on 
purity and legal restrictions, 46 qualified hits were disclosed. This set of compounds yielded 
a series of 1,2,4-triazole-3-sulfon(amide) urea inhibitors (1-3, Figure 2.1) that was selected 
for further optimization, because of its promising physicochemical properties (1: CLogP = 
2.07, tPSA = 85.6, MW = 337). Here, the results of the structure activity relationship (SAR) 
investigations are described, leading to the most polar in vivo active triazole urea DAGL 
inhibitor reported to date.  
 
 
Figure 2.1 | Summary of the high throughput screening campaign for DAGL-α. The triazole sulfonamide series 
was selected from the initial hits to be further optimized.  
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Results and discussion 
To investigate the SAR of the triazole-sulfonamide-ureas a library of 65 compounds was 
synthesized at the European Lead Factory and screened using a previously reported 
colorimetric DAGL-α surrogate substrate assay.3 The SAR is described in a topological 
fashion below. The initial variations focussed on finding the minimal requirements of the 
scaffold to inhibit DAGL-α (Table 2.1). The desired polar core of the scaffold was 
maintained, while varying the substituents on the sulfonamide (1-8) and on the urea moiety 
(9-25). Removal of one (4) or both (5) sulfonamide substituents significantly reduced DAGL-
α inhibitory activity. Piperidine- (6) and morpholine- (7) substituted sulfonamides lost 
potency, while an inhibitor substituted with two isobutyl groups (8) was tolerated. This 
suggested that conformational flexibility and/or a lipophilic substituent on the sulfonamide 
is beneficial for the inhibitory activity. 
Changing the diethyl substitution at the urea to a monomethyl (9), monoethyl (10) or di-
methoxyethyl (11) group abolished activity against DAGL-α, but the dimethylamine (12) was 
active. Cyclization of the diethylamine substituents to pyrrolidine (13) or piperidine (14), but 
not morpholine (15) or 4-methylpiperazine (16), was tolerated. Even when decorated with 
a benzyl, mono-substituted amines failed to inhibit DAGL-α (17 and 18). Decorating the 
cyclic amines with a 3-phenyl or 2-benzyl substituent (19-21), but not a 2-phenyl (22 and 
23), greatly improved binding to DAGL-α yielding a single digit nanomolar potent inhibitor 
(21). This is in line with the observations made by Hsu et al. in the optimization towards 
KT10911 and suggests that 2-benzyl piperidine is a preferred motif for DAGL and the binding 
mode of this 3-substituted 1,2,4-triazole urea scaffold is comparable to that of the 
4-substituted 1,2,3-triazole ureas. The loss of activity for compounds 24 and 25 further 
illustrates the lipophilic nature of the binding pocket. 
Next the sulfonamide substitution pattern was further explored using the 3-phenyl-
pyrrolidine, the 2-benzylpyrrolidine and the 2-benzylpiperidine as substituents on the amine 
urea for matched-molecular pair analysis (Table 2.2, 26-51). In general, it was found that 
the 2-benzylpyrrolidine series (19, 26-33) was the least active, while the 2-benzylpiperidine 
series (21, 45-51) delivered the most active inhibitors. The SAR trend within each series 
was generally consistent across the three chemotypes. It was found that the increase in the 
size of the cycloalkyl substituent on the sulfonamide provided more active compounds. 
Virtually all methyl substituted variants (19-21, 26-28, 34-37 and 45-46) were more potent 
than their hydrogen counterparts (29-33, 38-44 and 47-51, respectively). None of the 
sulfonamide variants, however, provided an improvement over the originally found methyl 
aniline in 19-21. 
Finally, to investigate the necessity of the sulfonamide moiety a small selection of 
sulfide, sulfoxide and sulfone variants (52-65, Table 2.3) was tested. The sulfonamide was 
not required for potent inhibitory activity (e.g. 58, 60, 64 and 65) and oxidation of the sulfur 
significantly increased the potency of the inhibitors (e.g. 52, 53 and 54 or 55 vs. 56, 57 vs. 
58, 59 vs. 60 and 61 vs. 62).   
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Table 2.1 | Initial variations of the sulfonamide substitution and urea bound amine groups. pIC50s were 
determined by a surrogate substrate assay using membrane fractions of hDAGL-α overexpressing HEK293T 
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Table 2.2 | Sulfonamide variations for the three most promising retaining groups. pIC50s were 
determined by a surrogate substrate assay using membrane fractions of hDAGL-α overexpress-
sing HEK293T cells, and are reported as mean of N=2, n=2 experiments. 
 
R1 
   
R2 # pIC50 DAGL-α # pIC50 DAGL-α # pIC50 DAGL-α 
 
26 6.0 34 6.9 - 
 
27 5.9 35 7.9 45 7.6 
 
28 7.0 36 8.0 46 8.1 
 
19 7.5 20 7.5 21 8.6 
 
- 37 7.2 - 
 
- 38 6.5 - 
 
29 6.0 39 7.1 47 7.2 
 
30 6.7 40 7.4 48 7.8 
 
31 6.9 41 7.6 49 7.6 
 
32 6.8 42 7.6 50 7.5 
 
33 6.9 43 6.9 51 7.5 
 
- 44 7.2 - 
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Table 2.3 | Sulfide, sulfone and sulfoxide variations for the two most promising 
urea substitutions. pIC50s were determined by a surrogate substrate assay using 
membrane fractions of hDAGL-α overexpressing HEK293T cells, and are 















R2 # pIC50 DAGL-α # pIC50 DAGL-α 
 
52 6.1 61 6.6 
 





54 7.7 62 7.8 
 
55 5.8 - 
 
56 7.3 63 7.3 
 





58 8.0 64 8.0 
 
59 5.8 - 
 
60 8.0 65 8.0 
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Figure 2.2 | Correlation analysis of calculated lipophilicity (CLogP) and 
measured pIC50 for DAGL-α. Grey markers denote sulfide compounds 52, 55, 
57, 59 and 61. Regression line with 99% confidence interval is shown.  
 
For all compounds the CLogP was calculated (Chemdraw 16.0) and plotted against the 
potency (pIC50) for a correlation analysis (Figure 2.2). Although in general lipophilic groups 
tended to increase potency, only a poor correlation with an R2 of 0.25 was found. This 
indicates that the potency of the inhibitors might not only be dependent on an increase in 
entropy due to the de-solvation effect, but may also reflect enthalpic interactions and steric 
clashes with the enzyme. The most notable example is the sulfide series (52, 55, 57, 59, 
61; grey markers in Figure 2.2), which indicated that the sulfone-oxygen atoms present in 
the sulfonamide and sulfone variants and not present in the sulfides have a positive 
contribution to the overall potency, potentially due to an increased electron withdrawing 
character. Compound 21 truly stands out in this plot, showcasing its large lipophilic 
efficiency (LipE = 4.4), which is only surpassed by a few more promiscuous molecules like 
12 (Figure 2.3). 
 
Off-target profiling 
Next all compounds were screened for off-targets using activity-based protein profiling 
(ABPP). Two broad spectrum activity-based probes (ABPs) were used: the commercially 
available FP-TAMRA (ActiveX®) and the tailored ABP MB064, which together label most of 
the endocannabinoid serine hydrolases. This approach uniquely enables the medicinal 
chemistry program to focus not only on potency in the primary assay, but also to be steered 
towards the more selective compounds. Initial screening was performed at 10 µM inhibitor 
concentration, but for the more active compounds (pIC50 > 7.5) the screening was repeated 
at 100 nM. A typical screening result is displayed in Figure S2.1. A direct comparison of the 
most promising compounds is shown in Figure 2.3. The ABPP-data indicate that the 
3-phenylpyrrolidine series is more promiscuous than the 2-benzylpyrrolidines and 
especially the 2-benzylpiperidines. The latter series shows a dramatic reduction in inhibitory 
activity against several enzymes, among which ABHD16A, ABHD12 and FAAH. In all, 
compound 21 was selected for further biological profiling, as it displayed the highest overall 
activity (pIC50 = 8.6), large lipophilic efficiency (LipE = 4.4) and relatively good in vitro 
selectivity. 
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Figure 2.3 | Inhibition profiling of a selection of potent inhibitors in Table 2.1, 2.2 and 2.3 in in vitro treated 
mouse brain membrane proteome. Profiling was performed at compound concentrations of 10 µM (A, C) and 
100 nM (B, D), using MB064 (A, B) and FP-TAMRA (C, D) for protein labeling.  
 
Resynthesis of 21 and its activity-based probe (77) 
Resynthesis of 21 was performed to enable further biological studies and was performed 
analogous to the synthetic methods used for the library synthesis (Scheme 2.1). In brief, 
2-benzylpyridine (66) was hydrogenated using platinum oxide to yield the 2-benzyl-
piperidine (67). In parallel, 1,2,4-triazole-3-thiol (68) was benzylated using benzylbromide. 
These were coupled in a triphosgene mediated coupling reaction to yield the triazole urea 
70. In a one-pot reaction the thioether was oxidized by in situ generated Cl2 (from HCl and 
NaOCl) to the sulfonyl chloride, which was trapped by the addition of a large excess of N-
methylaniline. This furnished 21 in moderate overall yield.  
To use the covalent mode of action of these inhibitors to visualize target engagement, a 
two-step activity-based probe was designed (77, Scheme 2.1). This was done by fusing the 
previously described 5-propargylether substituted (S)-2-benzylpiperidine (76) of DH376 to 
the 1,2,4-triazole sulfonamide leaving group (74).8 To this end, a new synthetic procedure 
was developed wherein the triphosgene coupling featured as the last step, to avoid putting 
the valuable chiral 2-benzyl piperidine through the harsh and low yielding chlorination step. 
The benzylated 1,2,4-triazole-3-thiol (69) was coupled to commercially available 
diphenylcarbamic chloride (71), before being reacted with chlorine and N-methylaniline. 
The urea moiety was then hydrolyzed using strong base and the resulting 1,2,4-triazole 
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Scheme 2.1 | Synthesis of 21 and 77. Synthesis of 75 was described in Deng et al.8 Reagents and conditions: 
i) H2, HCl, PtO2, EtOH, 2 bar, 18 h, 64%; ii) benzylbromide, DMF, 18 h, 98%; iii) 67, triphosgene, TEA, DCM,  
-5 °C → RT, 2 h, then 69, K2CO3, DMF, 18 h, 32%; iv) HCl, NaOCl, DCM, -10 °C, 30 min, then N-methylaniline, 
-10 °C → RT, 2h, 52%; v) 69, 71, DIPEA, DMAP, THF, 65 °C, 5 h, 88%; vi) HCl, NaOCl, DCM, -10 °C, 20 min, 
then N-methylaniline, -10 °C → RT, 2h, 69%; vii) KOH, H2O/THF (1:1), 18 h, 53%; viii) TFA, DCM, 5 h; ix) 76, 
triphosgene, DIPEA, DCM, 0 °C → RT, 1 h, then 74, DMAP, DIPEA, THF, 65 °C, 5 h, 67%. 
 
Full in vitro and in situ profiling of 21 and 77 
Next, two orthogonal assays were performed to verify the activity of 21 and 77. First, 21 
and 77 were profiled in a competitive ABPP setting in a dose response fashion. Second, the 
compounds were tested in a previously developed natural substrate assay.12 The resulting 
inhibition data are displayed in Table 2.4. Both compounds showed a slight reduction of 
potency in the competitive ABPP assay, compared to the surrogate substrate (PNP) assay, 
which could be due to a species difference as the surrogate substrate assay utilized human 
DAGL-α, whereas the ABPP assay was performed on mouse brain proteome. Both 
compounds showed a moderate selectivity in vitro over the major off-target ABHD6 of 
approximately 100-fold. In the natural substrate assay the activity of (human) DAGL-α was 
less potently inhibited, in line with previously reported observations.  
The cellular activity of both compounds was tested in mouse Neuro-2a cells. Cells were 
treated with the compounds for one hour before the cells were harvested and analyzed by 
gel-based ABPP. The resulting gels (Figure 2.4) and quantification (Table 2.4) showed a 
similar potency for mouse DAGL-β in situ as for DAGL-α in the natural substrate assay, with 
a pIC50 of 6.5 and 7.2 for 21 and 77, respectively. The potency for ABHD6 is remarkably 
increased to the single-digit nanomolar range, which is evidence of efficient cellular 
penetration of the compounds.  
 
Table 2.4 | Activity data for 21 and 77 in the used biochemical and ABPP assays. Values are reported as 
mean ± standard deviation of N=3 (for ABPP) or N=2, n=2 (for PNP- and SAG-assay) replicates.  
Compound 
pIC50 DAGL-α  
PNP-assay 
pIC50 DAGL-α  
ABPP-assay 
pIC50 ABHD6  
ABPP-assay 
pIC50 DAGL-α  
SAG-assay 
pIC50 DAGL-β  
in situ-assay 
21 8.6 ± 0.3 8.1 ± 0.1 6.1 ± 0.1 6.4 ± 0.2 6.5 ± 0.1 
77 8.6 ± 0.2 8.5 ± 0.1 6.8 ± 0.1 7.4 ± 0.1 7.2 ± 0.1 
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Figure 2.4 | Neuro-2a cells treated in situ with 21 (A) and 77 (B), labeled post-lysis with MB064 (2 µM, 20 min, 
RT). Coomassie was used for protein loading control. 
 
21 and 77 are in vivo active 
Considering the favourable physicochemical properties, in vitro and in situ potency and 
relatively high selectivity, both compounds were tested in mice to assess their in vivo target 
engagement. To this end, the compounds were administered intraperitoneal, using a high 
dose of 50 mg/kg of compound or vehicle (18:1:1 (v/v/v) saline:ethanol:PEG-40). The mice 
were sacrificed after two hours and the organs were harvested. Both the brain and the 
spleen were selected to assess target engagement of DAGL-α/β and ABHD6 in the central 
nervous system and peripheral organs. To visualize residual protein activity, the membrane 
proteomes were treated with both MB064 and FP-TAMRA (Figure 2.5). Compounds 21 and 
77 abolished or reduced the fluorescent labeling of DAGL-α and ABHD6. This indicated that 
the compounds are in vivo active and are able to cross the blood-brain barrier. 77 was less 
active than 21, as judged by the only partial inhibition of DAGL-α (Figure 2.5A). Both 
compounds seem to be quite selective, but 21 at this high dose also inhibited FAAH (band 
at 60 kDa labeled by FP-TAMRA). In the spleen the number of off-targets observed was 
somewhat higher. The strong band disappearing at 60 kDa is likely a group of carboxylic 
esterases, which are well-known to bind these types of inhibitors.7,13 The labeling of DAGL-β 
in the spleen was faint, but inhibited by 21.  
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Figure 2.5 | Membrane fractions of mouse brain (A) and spleen (B) treated in vivo i.p. with 50 mg/kg of 21 




All together, the discovery and optimization of a new series of DAGL inhibitors, based on 
a 1,2,4-triazole urea sulfonamide scaffold was reported in this Chapter. The optimized 
inhibitors had favourable physicochemical properties leading to a high lipophilic efficiency. 
Activity-based protein profiling was used to guide the optimization of potency and selectivity 
in parallel on endogenously expressed enzymes in brain lysates. Compound 21 proved 
cellular active and demonstrated in vivo activity in mice. Further dose-response studies 
have to be performed to establish the minimum dose required for complete DAGL-α 
inhibition in the brain.  
 
Acknowledgements 
The research received support from the Innovative Medicines Initiative Joint Undertaking 
grant n' 115489, resources are composed of financial contribution from the European 
Union's Seventh Framework Programme (FP7 / 2007-2013) and EFPIA companies' in-kind 
contribution. Freek Janssen, Marc Baggelaar, Hui Deng and Bobby Florea are kindly 
acknowledged for their help in the experimental parts of this research.  
  
 
28  |  Chapter 2 
Methods 
Chemical Biology Methods 
Cell Culture 
HEK293T (human embryonic kidney) and Neuro-2a (mouse neuroblastoma) cells were cultured at 37 °C under 
7% CO2 in DMEM containing phenol red, stable glutamine, 10% (v/v) New Born Calf Serum (Thermo Fisher), 
and penicillin and streptomycin (200 µg/mL each; Duchefa). Medium was refreshed every 2-3 days and cells 
were passaged twice a week at 80-90% confluence by resuspension in fresh medium.  
Cells lines were purchased from ATCC and were regularly tested for mycoplasma contamination. Cultures were 
discarded after 2-3 months of use. 
 
Transient transfection 
One day prior to transfection HEK293T cells were seeded to 15-cm dishes (~62.500 cells/cm2). Prior to 
transfection, culture medium was aspirated and a minimal amount of medium was added. A 3:1 (m/m) mixture 
of polyethyleneimine (PEI) (60 µg/dish) and human DAGL-α plasmid DNA (20 µg/dish) was prepared in serum-
free culture medium and incubated for 15 min at RT. Transfection was performed by dropwise addition of the 
PEI/DNA mixture to the cells. Transfection with the empty pcDNA3.1 vector was used to generate control 
samples. After 24 h, medium was refreshed. Medium was aspirated 48 or 72 h post-transfection and cells 
were harvested by resuspension in PBS. Cells were pelleted by centrifugation (5 min, 1,000 g) and the pellet 
was washed with PBS. Supernatant was discarded and cell pellets were frozen in liquid nitrogen and stored at 
-80 °C until sample preparation. 
 
In situ treatment of Neuro-2a cells  
Cells were seeded in 6-well plates. In situ treatment was initiated 24 h later. Medium was aspirated and serum-
free medium containing inhibitor or DMSO as vehicle was added (1.0 % v/v DMSO). After 1 h exposure to 
treatment medium, the medium was aspirated and cells were harvested and stored as described above until 
sample preparation. 
 
Whole cell lysate 
Cell pellets were thawed on ice, resuspended in cold lysis buffer (20 mM HEPES pH 7.2, 2 mM DTT, 250 mM 
sucrose, 1 mM MgCl2, 2.5 U/mL benzonase) and incubated on ice (15-30 min). The cell lysate was used for 
membrane preparation (below) or was diluted to 2.0 mg/mL concentration in cold storage buffer (20 mM 
Hepes, pH 7.2, 2 mM DTT) for use as whole lysate. Protein concentrations were determined by a Quick Start™ 
Bradford Protein Assay and diluted samples were flash frozen in liquid nitrogen and stored at -80 °C until 
further use. 
 
Membrane preparation from overexpression lysate 
The membrane and cytosolic fractions of cell or tissue lysates were separated by ultracentrifugation (93,000 g, 
45 min, 4 °C). The supernatant was collected (cytosolic fraction) and the membrane pellet was resuspended 
in cold storage buffer by thorough pipetting and passage through an insulin needle. Protein concentrations 
were determined by a Quick Start™ Bradford Protein Assay and samples were diluted to 2.0 mg/mL with cold 
storage buffer, flash frozen in liquid nitrogen and stored at -80 °C until further use.  
 
Tissue preparation 
Organs were isolated from C57BL/6 mice following standard guidelines as approved by the ethical committee 
of Leiden University (DEC#13191). Isolated organs were frozen in liquid nitrogen and stored at -80 °C. Organs 
were thawed on ice and homogenized by a glass stick douncing homogenizer in cold lysis buffer (20 mM 
HEPES, pH 7.2, 2 mM DTT, 1 mM MgCl2, 2.5 U/mL benzonase). The resulting suspension was centrifuged at 
1000 g for 5 minutes at 4 °C to get rid of residual solid tissue. The supernatant was centrifuged 45 minutes 
at 93,000 g at 4 °C to separate soluble (cytosol) and insoluble (membrane) fractions. The pellet (membrane) 
was resuspended in storage buffer (20 mM HEPES, pH 7.2, 2 mM DTT) using an insulin syringe. The protein 
concentration was measured using a QubitTM protein assay and was adjusted to 2 mg/mL using storage buffer. 
The resulting lysates were frozen in liquid nitrogen and stored at -80 °C for later use.  
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Natural substrate-based fluorescence assay DAGL-α 
The diacylglycerol substrate assay was performed as reported previously.12 Standard assay conditions: 
0.2 U/mL glycerol kinase (GK), glycerol-3-phosphate oxidase (GPO) and horseradish peroxidase (HRP), 
0.125 mM ATP, 10 µM Amplifu™Red, 5% DMSO in a total volume of 200 µL. The assay additionally contained 
5 µg/mL MAGL-overexpressing membranes, 100 µM SAG and 0.0075% (w/v) Triton X-100, with a final protein 
concentration of 50 µg/mL.  
 
Surrogate substrate assay 
The biochemical DAGL-α activity assay is based on the method previously described.3 200 µL reactions were 
performed in flat bottom Greiner 96-wells plates in a 50 mM pH 7.2 Hepes buffer. Membrane protein fractions 
from HEK293T cells transiently transfected with hDAGL-α (0.05 µg/µL final concentration) were used as 
hDAGL-α source. Inhibitors were introduced in 5.0 µL DMSO. The mixtures were incubated for 20 minutes 
before 10.0 µL 6 mM PNP-butyrate (final concentration 0.3 mM) in 50% DMSO was added (final DMSO 
concentration 5.0%). Reactions were allowed to progress for 30 minutes at 20 °C before OD (420 nm) was 
measured using a TECAN GENios plate reader. All experiments were performed at N=2, n=2 for experimental 
measurements and N=2, n=4 for controls.  
Z’-factor of each plate was determined for the validation of each experiment, using the following formula: 
Z’ = 1-3(σpc+ σnc)/(µpc - µnc). The OD from the positive control (pc: DAGL DMSO), and the negative control 
(nc: 10 µM THL) was used. Plates were accepted for further analysis when Z’ > 0.6. Measurements were 
corrected for the average absorption of the negative control. The average, standard deviation (SD) and 
standard error of mean (SEM) were calculated and normalized to the corrected positive control. Data was 
exported to Graphpad Prism 7.0 for the calculation of the pIC50 using a non-linear dose-response analysis with 
variable slope. 
 
Activity-based protein profiling 
For in vitro inhibition, lysates (19 µL per sample, 2 µg/µL) were thawed on ice. 0.5 µL of the inhibitor (40x 
stock in DMSO) or pure DMSO (as vehicle) was added to the sample, vortexed briefly and incubated for 20 
minutes at RT. Subsequently, 0.5 µL probe (40x stock in DMSO, final concentration 250 nM for MB064, 
500 nM for FP-TAMRA) was added to the proteome sample, vortexed briefly and incubated for 15 minutes at 
RT. For in situ inhibition, the in situ-treated cells (19.5 µL whole lysate) were directly incubated with the activity-
based probe (40x stock in DMSO, final concentration 2 µM for MB064, 500 nM for FP-TAMRA, 20 min, RT). 
For in vivo inhibition the procedure is identical to in vitro inhibition, but the inhibitor incubation is skipped. Final 
volume in all cases was 20 µL (max. 5% DMSO). The reaction was quenched by the addition of 7.5 µL of 
4*Laemmli-buffer (final concentrations: 60 mM Tris (pH 6.8), 2% (w/v) SDS, 10% (v/v) glycerol, 1.25% (v/v) 
β-mercaptoethanol, 0.01% (v/v) bromophenol blue). 10 µL (14 µg protein) of quenched reaction mixture was 
resolved on 10% acrylamide SDS-PAGE gels (180 V, 75 min). Fluorescence was measured using a Biorad 
ChemiDoc MP system (fluorescence channels Cy2 (460-490 nm), Cy3 (520-545 nm), Cy5 (625-650 nm) 
filters). Gels were then stained using coomassie staining and imaged for protein loading control. 
 
Labeling quantification 
Fluorescence quantification was performed using Imagelab 6.0 (Biorad). Intensities were normalized to the 
DMSO control and corrected for protein loading by coomassie staining. pIC50 values were calculated using 
GraphPad Prism 7.0. For all gel-based pIC50 determinations three replicates of each condition were used. 
 
In vivo treatment 
The animal experiments were conducted in accordance with the guidelines of the ethical committee of Leiden 
University (DEC#14137). In vivo studies were conducted in C57BL/6 mice. Mice were injected i.p. with the 
inhibitor dissolved in 18:1:1 (v/v/v) mixture of saline/ethanol/PEG-40 (ethoxylated castor oil, 100 µL 
injections). For the target engagement study, mice were treated with the compounds for 2 h and euthanized 
by cervical dislocation. Organs were harvested, flash frozen in liquid nitrogen and stored at -80 °C until sample 
preparation. 
 
Triazole urea library 
The triazole urea library was synthesized and characterized by the European Screening Centre in Dundee, 
Schotland. The general synthetic procedure is identical to that described for 21 (vide infra). Compounds were 
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purified by preparative HPLC/MS and analysed by H-NMR and LC/MS and only submitted to the library if the 




All reactions were performed using oven- or flame-dried glassware and dry (molecular sieves) solvents. 
Reagents were purchased from Alfa Aesar, Sigma-Aldrich, Acros, and Merck and used without further 
purification unless noted otherwise. All moisture sensitive reactions were performed under an argon or 
nitrogen atmosphere.  
1H and 13C NMR spectra were recorded on a Bruker DPX-300 (300 MHz), AV-400 (400 MHz) or DRX-500 (500 
MHz). Used software for interpretation of NMR-data was Bruker TopSpin 1.3 and MestreNova 11.0. Chemical 
shift values are reported in ppm with tetramethylsilane or solvent resonance as the internal standard (CDCl3: 
δ 7.26 for 1H, δ 77.16 for 13C; ACN-d3: δ 1.94 for 1H, δ 1.32 for 13C; MeOD: δ 3.31 for 1H, δ 49.00 for 13C).14 
Data are reported as follows: chemical shifts (δ), multiplicity (s = singlet, d = doublet, dd = double doublet, td 
= triple doublet, t = triplet, bs = broad singlet, m = multiplet), coupling constants J (Hz), and integration.  
Liquid chromatography analysis was performed on a Finnigan Surveyor LC/MS system, equipped with a C18 
column. Flash chromatography was performed using SiliCycle silica gel type SiliaFlash P60 (230−400 mesh). 
TLC analysis was performed on Merck silica gel 60/Kieselguhr F254, 0.25 mm. Compounds were visualized 
using KMnO4 stain (K2CO3 (40 g), KMnO4 (6 g), and water (600 mL)) or CAM stain (Ce(NH4)4(SO4)4·2H2O (ceric 
ammonium sulfate: 10.0 g); ammonium molybdate (25 g); conc. H2SO4 (100 mL); H2O (900 mL)). Preparative 
HPLC (Waters, 515 HPLC pump M; Waters, 515 HPLC pump L; Waters, 2767 sample manager; Waters SFO 
System Fluidics Organizer; Waters Acquity Ultra Performance LC, SQ Detector; Waters Binary Gradient Module) 
was performed on a Waters XBridgeTM column (5 µM C18, 150 x 19 mm). Diode detection was done between 
210 and 600 nm. Gradient: ACN in (H2O + 0.2% TFA). High resolution mass spectra (HRMS) were recorded by 
direct injection on a q-TOF mass spectrometer (Synapt G2-Si) equipped with an electrospray ion source in 
positive mode with Leu-enkephalin (m/z = 556.2771) as an internal lock mass. The instrument was calibrated 
prior to measurement using the MS/MS spectrum of Glu-1-fibrinopeptide B. 
 
 (R,S)-2-Benzylpiperidine (67) 
2-Benzylpyridine (5 mL, 31.1 mmol) was dissolved in absolute ethanol (100 mL) and 
concentrated HCl (10 mL) was added. Then PtO2 (112 mg, 0.49 mmol) was added and the 
mixture was shaken under a hydrogen atmosphere of 2 bar at RT. After overnight shaking, solids 
were filtered off over celite. The solvent was removed under reduced pressure and the residue 
was purified using silica gel chromatography (10% methanol in DCM) to yield the title compound 
(4.2 g, 20 mmol, 64%). 1H NMR (300 MHz, CDCl3) δ 8.41 (s, 1H), 7.42 – 7.13 (m, 5H), 3.58 – 
3.38 (m, 2H), 3.25 – 3.02 (m, 1H), 3.02 – 2.73 (m, 2H), 2.14 – 1.47 (m, 5H), 1.47 – 1.10 (m, 1H). 13C NMR 
(75 MHz, CDCl3) δ 136.16, 129.51, 128.76, 127.04, 58.59, 45.11, 40.07, 27.97, 22.61. 
 
3-(Benzylthio)-1H-1,2,4-triazole (69) 
1H-1,2,4-Triazole-3-thiol (1.01 g, 10.0 mmol) and benzylbromide (1.09 mL, 10.0 mmol) 
were dissolved in DMF (10 mL) and stirred for 18 h. The reaction mixture was then diluted 
with EtOAc (50 mL) and washed with saturated aqueous NaHCO3 (50 mL). The organic 
phase was separated and the aqueous phase was extracted with EtOAc (50 mL). The combined organic phases 
were washed with water (50 mL) and brine (50 mL). The volatiles were removed in vacuo and the product was 
obtained as white solid (1.86 g, 9.75 mmol, 98%). 1H NMR (400 MHz, MeOD) δ 8.30 (s, 1H), 7.35 – 7.14 (m, 
5H), 4.33 (s, 2H). 13C NMR (101 MHz, MeOD) δ 147.99, 138.64, 129.91, 129.52, 128.48, 37.80. 
 
(2-Benzylpiperidin-1-yl)(3-(benzylthio)-1H-1,2,4-triazol-1-yl)methanone (70) 
A solution of triphosgene (229 mg, 0.77 mmol) in DCM (5 mL) was cooled 
to -5 °C, and a solution of 67 (90 mg, 0.51 mmol) in DCM (3 mL) was added 
dropwise over a period of 5 minutes. To this mixture was added dropwise 
over a period of 15-30 minutes a solution of TEA (0.21 mL, 1.54 mmol) in 
DCM (3 mL). The cold bath was removed and stirring at RT was continued for 
2 h. The mixture was diluted with DCM (10 mL) and washed with aqueous 1 M HCl (10 mL). The organic phase 
was separated, dried (MgSO4), filtered and evaporated to dryness. The residue was taken up in DMF (2 mL) to 
which 69 (32 mg, 0.17 mmol) and K2CO3 (116 mg, 0.84 mmol) were added while stirring at RT. After stirring 
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overnight, the reaction was quenched with water and the product was extracted into EtOAc. The organic phase 
was evaporated to dryness and the residual material was purified on preparative HPLC to yield the title 
compound as a yellow gum (22 mg, 54 µmol, 32%). 1H NMR (400 MHz, CDCl3) δ 8.31 (bs, 1H), 7.71 – 6.37 
(m, 10H), 4.63 (bs, 1H), 4.38 (d, J = 2.5 Hz, 2H), 3.98 (d, J = 13.1 Hz, 1H), 3.62 – 3.20 (m, 2H), 3.09 (d, J = 
3.5 Hz, 1H), 2.95 – 2.38 (m, 2H), 2.02 – 1.33 (m, 4H). 
 
1-(2-Benzylpiperidine-1-carbonyl)-N-methyl-N-phenyl-1H-1,2,4-triazole-3-sulfonamide (21) 
4 M HCl in dioxane (2 mL) was added to DCM (10 mL) and cooled to -10 °C. 
15%wt NaOCl solution (aq., 2 mL) was slowly added, a yellow-green colour was 
observed. After 30 minutes of stirring, 70 (100 mg, 0.255 mmol) in DCM (1 
mL) was added slowly. After 30 minutes N-methylaniline (2.0 mL, 18 mmol) 
was added in one batch and stirring was continued for 1 h on ice and 1 h at 
RT. The DCM was evaporated under reduced pressure and residual solvent was diluted with EtOAc (25 mL) 
and washed with 0.1 M aqueous HCl (25 mL). The aqueous layer was extracted with EtOAc (2x 25 mL). The 
combined organic layers were dried (MgSO4), filtered and concentrated. The residue was purified by 
preparative HPLC to yield the title compound as a green gum (58 mg, 0.13 mmol, 52%). 1H NMR (400 MHz, 
CDCl3) δ 7.91 (d, J = 18.9 Hz, 1H), 7.40 – 6.78 (m, 10H), 4.70 (s, 1H), 4.29 – 4.13 (m, 1H), 3.48 (s, 3H), 3.32 
– 3.20 (m, 1H), 3.13 (s, 1H), 2.61 (d, J = 18.2 Hz, 1H), 1.74 (m, 6H). HRMS: Calculated for [C22H25N5O3S + 
Na]+ = 462.1570, found = 462.1573. 
 
3-(Benzylthio)-N,N-diphenyl-1H-1,2,4-triazole-1-carboxamide (72) 
69 (2.137 g, 11.17 mmol) was dissolved in dry THF (40 mL) and 
diphenylcarbamic chloride (2.85 g, 12.3 mmol), DIPEA (2.34 mL, 13.4 mmol) 
and a catalytic amount of DMAP were added. The mixture was refluxed for 5 h 
and stirred for 18 h at RT. The reaction was quenched by the addition of sat. 
aq. Na2CO3 (40 mL). The organic layer was separated and the aqueous phase 
extracted with EtOAc (2x 40 mL). The combined organic layers were washed with brine (40 mL), dried (MgSO4), 
filtered and concentrated. Column chromatography afforded the title compound as a white solid (3.81 g, 9.86 
mmol, 88%). 1H NMR (400 MHz, CDCl3) δ 8.70 (s, 1H), 7.46 – 7.10 (m, 15H), 3.86 (s, 2H). 13C NMR (101 MHz, 




4 N HCl in dioxane (2 mL) was added to DCM (5 mL) and cooled to -10 °C. 15%wt 
NaOCl (aq., 2 mL) was added slowly, forming a yellow-green Cl2 solution. After 
30 min 72 (100 mg, 0.259 mmol) was added dropwise as a solution in DCM 
(1 mL). After 20 min N-methylaniline (1 mL, 9 mmol) was added. The mixture 
was stirred for 2 h at RT. The reaction was quenched by the addition of 0.1 M 
HCl (10 mL). The organic layer was separated and the water layer was extracted 
with EtOAc (2x, 10 mL). The combined organic layers were dried (MgSO4), filtered and concentrated. The 
residue was purified by column chromatography to yield the title compound as a brown solid (78 mg, 0.18 
mmol, 69%). 1H NMR (400 MHz, CDCl3) δ 8.80 (s, 1H), 7.47 – 6.99 (m, 15H), 3.07 (s, 3H). 13C NMR (101 MHz, 




73 (1.05 g, 2.42 mmol) was dissolved in 2 N KOH in a 1:1 (v/v) H2O/THF mixture (50 mL). 
The mixture was stirred for 18 h at RT. The mixture was concentrated and the residue was 
purified by column chromatography to yield the title compound (308 mg, 1.29 mmol, 53%). 
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(2R,5R)-2-Benzyl-5-(prop-2-yn-1-yloxy)piperidine 2,2,2-trifluoroacetate (76) 
Previously prepared tert-butyl (2R,5R)-2-benzyl-5-(prop-2-yn-1-yloxy)piperidine-1-carboxyl-
ate (30 mg, 91 µmol) was dissolved in DCM (6 mL) to which trifluoroacetic acid (2 mL, 26 
mmol) was added. The mixture was stirred for 5 h at RT. The volatiles were evaporated and 
the crude residue was coevaporated with toluene (3x 5 mL) and used without further 





76 (31.3 mg, 0.091 mmol) was dissolved in DCM (5 mL) and cooled to 0 °C. 
Triphosgene (13.5 mg, 0.046 mmol) and DIPEA (40 µL, 0.30 mmol) were 
added and the mixture was stirred for 1 h warming to RT. The reaction was 
quenched with ice water (5 mL) and the organic layer was separated. The 
aqueous layer was extracted with EtOAc (2x 5 mL). The combined organic 
layers were dried (MgSO4), filtered and concentrated under reduced pressure. 
The crude was taken up in dry THF (5 mL) and 74 (24 mg, 0.10 mmol), DMAP 
(11 mg, 0.091 mmol) and DIPEA (40 µL, 0.30 mmol) were added. The mixture 
was refluxed for 5 h. The reaction was quenched with saturated aqueous NH4Cl 
(5 mL). The organic layer was diluted with EtOAc (5 mL) and separated. The aqueous layer was extracted with 
EtOAc (2x 10 mL). The combined organic layers were washed with brine, dried (MgSO4), filtered and 
concentrated in vacuo. The residue was purified by flash column chromatography to yield the title compound 
as a white solid (30.2 mg, 61 µmol, 67%). 1H NMR (400 MHz, CDCl3) δ 7.99 (s, 1H), 7.42 – 6.78 (m, 10H), 
4.71 (s, 1H), 4.48 (s, 1H), 4.30 (s, 2H), 3.79 – 3.62 (m, 1H), 3.52 (s, 3H), 3.21 – 2.99 (m, 2H), 2.67 (s, 1H), 
2.49 (s, 1H), 2.10 (d, J = 19.3 Hz, 1H), 1.80 (d, J = 11.8 Hz, 3H). HRMS: Calculated for [C25H27N5O4S + Na]+ = 
516.1676, found = 516.1680. 
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Supplementary Figures 
 
Figure S2.1 | Typical off-target profiling screen using MB064 (A) and FP-TAMRA (B). Compound 
numbers correspond to compound ESC-library codes. Compounds were screened at a concen-
tration of 10 µM.  
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The signalling of 2-arachidonoylglycerol (2-AG) via the endocannabinoid system is 
implicated in a wide range of physiological effects, such as neurotransmission, 
inflammation and energy metabolism.1,2,3 The diacylglycerol lipase (DAGL) inhibitors, 
introduced in Chapter 2, have reasonable physicochemical properties and showed 
promising activity to study the role of DAGL in 2-AG signalling in vivo. They lacked, however, 
subtype selectivity over DAGL-α and DAGL-β, and also inhibited α/β-hydrolase domain 
containing protein 6 (ABHD6).4 Despite studies using genetic knock-out mice, the role and 
importance of the two distinct DAGL isoforms is still poorly understood, and should ideally 
 
36  |  Chapter 3  
be studied with isoform-selective inhibitors.1,5,6 Since there is no structural data of these 
enzymes available, the search for such selective inhibitors is challenging. The spatial 
distribution of the isoforms in the body does point towards an alternative way to obtain 
largely selective modulation of DAGL activity: DAGL-α is predominantly expressed in the 
central nervous system (CNS), whereas DAGL-β is more highly expressed in the periphery.7 
By employing the drug design principles that do not allow drugs to pass the blood-brain 
barrier, compounds could in principle be restricted to the periphery, making them spatially 
selective towards DAGL-β. By limiting the brain penetration, unwanted CNS-side effects 
such as those observed for the retracted drug Rimonabant could be reduced or even 
prevented completely.8  
It is generally accepted that the topological polar surface area (TPSA), together with the 
lipophilicity, expressed as (C)LogP, are the best predictors of brain penetration.9 Hitchcock 
and Pennington described an optimal range for the lipophilicity where the LogP is between 
2 and 4 and the limit for the polar surface area is below 90 Å2. Further requirements include 
a maximum of three hydrogen bond donors. Compounds that do not meet these criteria are 
less likely to penetrate the brain.  
The work presented here builds on the findings of Chapter 2 to work towards more 
drug-like and peripherally restricted compounds. Ultimately, these inhibitors could aid in 
the elucidation of the different physiological roles the DAG lipases play in human health 
and disease. 
 
Structure activity relationship study on 4-substituted piperazine derivatives 
During the hit optimization, which led to the discovery of in vivo active compound 1 
(Figure 3.1, Chapter 2),  a similarity in the structure activity relationships (SAR) with other 
triazole urea inhibitors was observed. The activity of DAGL inhibitor DO34 (Figure 3.1) 
demonstrated that there is ample room for variation in the 2-benzylpiperidine moiety10, 
therefore it was envisioned that optimization of this part of 1 could be exploited to increase 
the TPSA. First, the substituted piperazine featured in DO34 was resynthesized in a 7-step 
procedure from commercially available N-Boc-phenylalanine and N-benzylglycine (Scheme 
S3.1), and was subsequently coupled to the two most promising scaffolds of Chapter 2, i.e. 
the 1,2,4-triazoles substituted with either an N-methylaniline-sulfonamide (2) or a benzyl-
sulfone (3) (Table 3.1).  
The sulfone analogue 3 showed comparable activity to 2 for DAGL-α and -β in the 
previously published surrogate substrate assay employing para-nitrophenol butyrate 
(PNPB) (Table 3.1).11 In view of its synthetic accessibility, the sulfone scaffold was selected 
 
 
Figure 3.1 | Triazole urea compound 1, presented in Chapter 2, 
and DO34, a published DAGL inhibitor featuring a 4-substituted 
piperazine.  
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8.97 ± 0.08 8.62 ± 0.13 8.25 ± 0.07 4.63 115.2 4.34 
3 
 
8.71 ± 0.06 7.88 ± 0.14 8.40 ± 0.07 4.97 112.0 3.74 
 
to quickly generate SAR by varying the 4-piperazine substitutions in a matched molecular 
pair analysis. A small library was synthesized (Scheme S3.1) starting from the two 
1-protected piperazine intermediates, which were synthesized according to Scheme S3.2. 
The 4-position was modified by 1-step reactions to generate the desired substitution. The 
resulting piperazines were deprotected and coupled to 3-(benzylsulfonyl)-1H-1,2,4-triazole, 
which is available in two high-yielding steps from commercial building blocks. The resulting 
library was tested in both the PNPB-assay for DAGL-α and DAGL-β activity and in a 
competitive activity-based protein profiling (ABPP) assay using MB064 as the activity-based 
probe (Table 3.2). 
First, several amide variations were made with substituents increasing in size and 
lipophilicity from an acetyl (4), via cyclic and bulky alkyl substituents (5 and 6) to a benzoyl 
substituent (7). The potencies of the amides were all lower than tert-butyl carbamate 
containing compound 3. The largest potency reduction (200-fold) was observed for the 
acetyl substitution in 4. The more lipophilic substituents (5-7) retained most of their activity, 
with about a 10-fold reduced potency. The keto-piperazine analogue 8 showed a 10-fold 
drop as compared to the highly similar benzoyl substituted compound 7. Three related urea 
moieties were introduced: unsubstituted (9), ethyl substituted (10) and a Boc-like tert-butyl 
urea (11). These followed the same trend in activity with the more substituted and lipophilic 
substituents showing higher inhibitory activity. 
The introduction of a small alkyl substituent, generating a basic tertiary amine, did not 
dramatically reduce potency for the DAGLs (12-13). The calculated LipE for 13 (3.97) was 
the highest observed thus far, and was slightly better when using the (calculated) LogD for 
lipophilicity. As with the amide and urea substitutions, increasing the bulk and lipophilicity 
of the substituent increased the potency, reaching single digit nanomolar IC50s for all 
variations (14-18).  However, the TPSA of the most potent compounds (13-18) was actually 
reduced compared to the Boc-substituted 3, and was below the 90 Å2. Therefore, 
sulfonamide substitutions 19-22 were designed to incorporate another highly polar 
functionality in the scaffold. Again, a small substituent showed a large decrease in activity 
(19), but potency could be recovered by the introduction of an isopropyl (20) or phenyl 
substituent (21, 22). The sulfonamide substitution increased the TPSA to 120 Å2, making 
it unlikely these compounds will be centrally active. The low CLogP combined with rather 
high potency for DAGL-α resulted in a LipE for 20 of 4.13, slightly higher than amine 13. 
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8.71 ± 0.06 7.88 ± 0.14 8.40 ± 0.07 4.97 112.0 3.74 
4 
 
6.25 ± 0.08 5.61 ± 0.22 5.74 ± 0.22 2.58 102.7 3.67 
5 
 
7.41 ± 0.07 7.57 ± 0.45 7.25 ± 0.09 3.49 102.7 3.92 
6 
 
7.74 ± 0.07 7.91 ± 0.15 7.24 ± 0.07 4.44 102.7 3.30 
7 
 
7.71 ± 0.06 6.87 ± 0.25 7.24 ± 0.06 4.16 102.7 3.55 
8 
 
6.66 ± 0.20 6.14 ± 0.30 5.69 ± 0.14 4.58 102.7 2.08 
9 
 
< 5 < 5 < 5 1.77 128.7 - 
10 
 
6.52 ± 0.19 5.95 ± 0.19 6.27 ± 0.18 3.59 114.8 2.93 
11 
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7.46 ± 0.05 N.D. 7.54 ± 0.23 4.09 85.7 3.37 
13 
 
8.37 ± 0.08 7.95 ± 0.25 7.99 ± 0.08 4.40 85.7 3.97 
14 
 
8.92 ± 0.03 8.67 ± 0.09 8.35 ± 0.11 5.02 85.7 3.90 
15 
 
8.56 ± 0.10 N.D. 8.81 ± 0.18 4.82 85.7 3.74 
16 
 
9.05 ± 0.06 8.53 ± 0.15 8.98 ± 0.10 5.28 85.7 3.77 
17 
 




8.58 ± 0.11 7.83 ± 0.15 9.28 ± 0.12 5.55 85.7 3.03 
19 
 
6.75 ± 0.07 N.D. 6.73 ± 0.20 3.00 119.8 3.75 
20 
 
7.97 ± 0.12 7.72 ± 0.20 6.50 ± 0.31 3.84 119.8 4.13 
21 
 
8.50 ± 0.06 8.45 ± 0.10 7.88 ± 0.08 4.68 119.8 3.82 
22 
 
7.83 ± 0.11 N.D. 6.39 ± 0.30 4.82 119.8 3.01 
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Four piperazine substituents of the compounds with highest potency, LipE and drug-like 
character (Table 3.2) were combined with the N-methylaniline substituted 1,2,4-triazole 
sulfonamide scaffold of 1 to form compounds 23-26 (Table 2.2). The potency of the 
sulfonamide derivatives increased 5-10 fold compared to their sulfone analogues. Both 
amine compounds 23 and 24 showed sub-nanomolar potencies in the surrogate substrate 
assay and maintained high potency in the gel-based ABPP assays. Compounds 25 and 26 
were slightly less active, but still showed IC50s in the single nanomolar range. All four 
compounds were slightly less active against DAGL-β, consistent with the observations for 
compounds 3-22. The lipophilic efficiency was further increased. The TPSA of the amines 
is just below 90 Å2, which could allow these compounds to be centrally active. 25 and 26 
have a TPSA > 120 Å2, making it highly unlikely that they are able to cross the blood-brain 
barrier. Together, they could be employed to elucidate peripheral effects using 25 or 26, or 
central effects, by comparing the effects of 23 or 24 with 25 or 26. 
 
 
Table 3.3 | In vitro profiling of the four most promising piperazine groups combined with the sulfonamide 
leaving group. Activity-based protein profiling of DAGL-α is performed using mouse brain membrane 

















9.06 ± 0.07 8.93 ± 0.08 7.84 ± 0.25 8.54 ± 0.06 4.06 88.9 5.00 
24 
 
9.91 ± 0.11 9.45 ± 0.04 8.47 ± 0.19 8.44 ± 0.14 5.08 88.9 4.83 
25 
 
8.55 ± 0.10 7.97 ± 0.10 8.52 ± 0.11 7.70 ± 0.09 3.50 123.0 5.05 
26 
 
8.72 ± 0.12 9.44 ± 0.12 8.12 ± 0.08 8.26 ± 0.25 4.48 123.0 4.24 
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Cellular activity and selectivity of 23-26 
Cellular DAGL-β activity of compounds 23-26 was assessed by the treatment of murine 
neuroblastoma (Neuro-2a) cells for 1 hour with medium containing inhibitor or vehicle 
(DMSO) followed by gel-based ABPP. Post-lysis treatment with activity-based probes 
MB064, to visualize DAGL-β and other lipases such as Phospholipase DDHD2 (DDHD2) and 
ABHD6, showed clear inhibition of DAGL-β (Figure 3.2, Table 3.4). FP-BODIPY (Chapter 6) 
was used to label the endocannabinoid related hydrolase Fatty Acid Amide Hydrolase 
(FAAH) and to further assess general selectivity. Overall potency for DAGL-β of the inhibitors 
was reduced 10-50 fold in this setting. Quite surprisingly, the selectivity observed in the gel-
based assays in vitro was attenuated in situ. The potency of the inhibitors against ABHD6 
was equal or greater than that for DAGL-β, and further off-target activity was observed for 
DDHD2 and FAAH.  
 
 
Table 3.4 | In situ potency of the optimized piperazine derivatives 23-26 tested in Neuro-2a cells 
determined by post-lysis ABPP and SDS-PAGE analysis. 
# Structure pIC50 DAGL-β pIC50 DDHD2 pIC50 ABHD6 pIC50 FAAH 
23 
 
6.68 ± 0.13 5.57 ± 0.07 8.00 ± 0.05 6.16 ± 0.08 
24 
 
7.58 ± 0.10 6.76 ± 0.11 7.84 ± 0.05 6.01 ± 0.22 
25 
 
6.09 ± 0.12 5.53 ± 0.21 7.06 ± 0.12 5.48 ± 0.13 
26 
 
6.70 ± 0.08 6.31 ± 0.11 7.38 ± 0.07 5.35 ± 0.41 
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Figure 3.2 | Dose response in situ treatment of Neuro-2a cells with piperazine inhibitors 23-26. A) 
Representative gels of lysates labeled with MB064 (250 nM). B) Representative gels of lysates labeled with 
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Discussion and conclusion  
The optimization of the physicochemical properties of the DAG lipase inhibitors 
introduced in Chapter 2 was initiated by incorporating a previously published piperazine as 
the amine for the triazole urea scaffold.10 Successful implementation of a matched 
molecular pair strategy significantly sped up the generation of a library of 2-benzyl-4-
substituted piperazine triazole ureas. Similar trends were observed for acyl, alkyl, urea and 
sulfonyl substituents, with a strong preference for lipophilic and bulky sidechains. 
Intriguingly, the Boc-group (3), 3,3-dimethylbutyric acid (6) and tert-butylamine urea (11) 
variants show a nearly perfect trend, each decreasing a factor 10 in potency. The CLogP 
(ChemDraw 16.0) also follows a nearly perfect linear decrease, albeit with a slightly smaller 
slope: from 4.97 for 3, 4.44 for 6 to 4.14 for 11. This likely explains the observed drop in 
affinity.  
The optimized inhibitors 23-26 showed (sub)nanomolar potency and good selectivity in 
vitro, but both were attenuated in situ. For compounds 25 and 26 the TPSA is probably too 
high for efficient cell penetration. The decrease in selectivity has not been investigated in 
detail, but might be attributed to different physical conditions, such as local pH, and 
differences in enzyme activity in situ as compared to in vitro. Especially the small selectivity 
window with respect to FAAH should be noted, as this is the main metabolizing enzyme for 
anandamide, the other major endocannabinoid.12 Further profiling of the generated library 
in situ is warranted to possibly find more selective members. 
Overall potency on both DAGL isoforms was slightly improved, but more importantly the 
lipophilic efficiency was increased from 4.34 for 2 to 5.05 for 25, the highest LipE reported 
to date for a DAGL inhibitor. The topological polar surface area of 25 and 26 is > 120 Å2, 
which should be sufficient to restrict these compounds to the periphery. However, their high 
TPSA likely hampers their cell penetration and may affect their oral bioavailability. Future 
studies should test whether these compounds can be used in animal models to inhibit 
DAGL-β in the periphery without inhibiting DAGL-α in the brain.  
 
Acknowledgements 
For the optimization of the synthetic route towards 1,3-dibenzylpiperazine Jacob van 
Hengst is kindly acknowledged. Esmeralda Hemme and Esmee Schoof are acknowledged 
for the synthetic work towards 40 and 49, respectively. Annelot van Esbroeck and Floor 
Stevens are kindly acknowledged for their advice and cooperation in the in situ testing of 
the inhibitors.  
  
 
44  |  Chapter 3  
Methods 
Chemical Biology Methods 
Cell Culture 
HEK293T (human embryonic kidney) and Neuro-2a (mouse neuroblastoma) cells were cultured at 37 °C under 
7% CO2 in DMEM containing phenol red, stable glutamine, 10% (v/v) New Born Calf Serum (Thermo Fisher), 
and penicillin and streptomycin (200 µg/mL each; Duchefa). Medium was refreshed every 2-3 days and cells 
were passaged twice a week at 80-90% confluence by resuspension in fresh medium.  
Cells lines were purchased from ATCC and were regularly tested for mycoplasma contamination. Cultures were 
discarded after 2-3 months of use. 
 
Transient transfection 
One day prior to transfection HEK293T cells were seeded to 15-cm dishes (~62.500 cells/cm2). Prior to 
transfection, culture medium was aspirated and a minimal amount of medium was added. A 3:1 (m/m) mixture 
of polyethyleneimine (PEI) (60 µg/dish) and plasmid DNA (20 µg/dish, either mDAGL-α-FLAG or mDAGL-β-FLAG) 
was prepared in serum-free culture medium and incubated for 15 min at RT. Transfection was performed by 
dropwise addition of the PEI/DNA mixture to the cells. Transfection with the empty pcDNA3.1 vector was used 
to generate control samples. After 24 h, medium was refreshed. Medium was aspirated 48 h post-transfection 
and cells were harvested by resuspension in PBS. Cells were pelleted by centrifugation (5 min, 1,000 g) and 
the pellet was washed with PBS. Supernatant was discarded and cell pellets were frozen in liquid nitrogen and 
stored at -80 °C until sample preparation. 
 
In situ treatment of Neuro-2a cells  
Cells were seeded in 12-well plates. In situ treatment was initiated 24 h later. Medium was aspirated and 
medium (with serum) containing inhibitor or DMSO as vehicle was added (0.1% v/v DMSO). After 1 h exposure 
to the treatment medium, the medium was aspirated and cells were harvested and stored as described above 
until sample preparation. 
 
Whole cell lysate 
Cell pellets were thawed on ice, resuspended in cold lysis buffer (20 mM HEPES pH 7.2, 2 mM DTT, 250 mM 
sucrose, 1 mM MgCl2, 2.5 U/mL benzonase) and incubated on ice (15-30 min). The cell lysate was used for 
membrane preparation (below) or was diluted to 2.0 mg/mL concentration in cold storage buffer (20 mM 
Hepes, pH 7.2, 2 mM DTT) for use as whole lysate. Protein concentrations were determined by a Quick Start™ 
Bradford Protein Assay and diluted samples were flash frozen in liquid nitrogen and stored at -80 °C until 
further use. 
 
Membrane preparation from overexpression lysate 
The membrane and cytosolic fractions of cell lysates were separated by ultracentrifugation (93,000 g, 45 min, 
4 °C). The supernatant was collected (cytosolic fraction) and the membrane pellet was resuspended in cold 
storage buffer (20 mM HEPES, pH 7.2, 2 mM DTT) by thorough pipetting and passage through an insulin 
needle. Protein concentrations were determined by a Quick Start™ Bradford Protein Assay and samples were 




Organs were isolated from C57BL/6 mice following standard guidelines as approved by the ethical committee 
of Leiden University (DEC#13191). Isolated organs were frozen in liquid nitrogen and stored at -80 °C. Organs 
were thawed on ice and homogenized by a glass stick douncing homogenizer in cold lysis buffer (20 mM 
HEPES, pH 7.2, 2 mM DTT, 1 mM MgCl2, 2.5 U/mL benzonase). The resulting suspension was centrifuged at 
1000 g for 5 minutes at 4 °C to get rid of residual solid tissue. The supernatant was centrifuged 45 minutes 
at 93,000 g at 4 °C to separate soluble (cytosol) and insoluble (membrane) fractions. The pellet (membrane) 
was resuspended in storage buffer (20 mM HEPES, pH 7.2, 2 mM DTT) using an insulin syringe. The protein 
concentration was measured using a QubitTM protein assay and was adjusted to 2 mg/mL using storage buffer. 
The resulting lysates were frozen in liquid nitrogen and stored at -80 °C for later use.  
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Surrogate substrate assay 
The biochemical DAGL-α or -β activity assay is based on the method previously described.11 200 µL reactions 
were performed in flat bottom Greiner 96-wells plates in a 50 mM pH 7.2 HEPES buffer, for DAGL-β this buffer 
was supplemented with 5 mM CaCl2. Membrane protein fractions from HEK293T cells transiently transfected 
with mDAGL-α or -β (0.05 µg/µL final concentration) were used as mDAGL source. Inhibitors were introduced 
in 5.0 µL DMSO. The mixtures were incubated for 20 minutes before 10.0 µL 6 mM (DAGL-α) or 12 mM 
(DAGL-β) PNP-butyrate (final concentration 0.3 mM) in 50% DMSO was added (final DMSO concentration 
5.0%). Reactions were allowed to progress for 30 minutes at 20 °C before OD (420 nm) was measured using 
a TECAN GENios plate reader. All experiments were performed at N=2, n=2 for experimental measurements 
and N=2, n=4 for controls.  
Z’-factor of each plate was determined for the validation of each experiment, using the following formula: 
Z’ = 1-3(σpc+ σnc)/(µpc - µnc). The OD from the positive control (pc: DAGL DMSO), and the negative control 
(nc: 10 µM THL) were used. Plates were accepted for further analysis when Z’ > 0.6. Measurements were 
corrected for the average absorption of the negative control. The average, standard deviation (SD) and 
standard error of mean (SEM) were calculated and normalized to the corrected positive control. Data was 
exported to Graphpad Prism 7.0 for the calculation of the pIC50 using a non-linear dose-response analysis with 
variable slope. 
 
Activity-based protein profiling 
For in vitro inhibition, lysates (19 µL per sample, 2 µg/µL) were thawed on ice. 0.5 µL of the inhibitor (40x 
stock in DMSO) or pure DMSO (as vehicle) was added to the sample, vortexed briefly and incubated for 20 
minutes at RT. Subsequently, 0.5 µL probe (40x stock in DMSO, final concentration 250 nM for MB06411, 
500 nM for FP-TAMRA13, 1 µM for DH37910) was added to the proteome sample, vortexed briefly and incubated 
for 15 minutes at RT. For in situ inhibition, the in situ-treated cells (19.5 µL whole lysate) were directly 
incubated with the activity based probe (40x stock in DMSO, final concentration 2 µM MB064 or 500 nM 
FP-BODIPY, 20 min, RT). Final volume in all cases was 20 µL (max. 5% DMSO). The reaction was quenched by 
the addition of 7.5 µL of 4*Laemmli-buffer (final concentrations: 60 mM Tris (pH 6.8), 2% (w/v) SDS, 10% (v/v) 
glycerol, 1.25% (v/v) β-mercaptoethanol, 0.01% (v/v) bromophenol blue). 10 µL (14 µg protein) of quenched 
reaction mixture was resolved on 10% acrylamide SDS-PAGE (180 V, 75 min). Fluorescence was measured 
using a Biorad ChemiDoc MP system (fluorescence channels Cy2 (460-490 nm), Cy3 (520-545 nm), Cy5 (625-
650 nm) filters). Gels were then stained using coomassie staining and imaged for protein loading control. 
 
Labeling quantification 
Fluorescence quantification was performed using Imagelab 6.0 (Biorad). Intensities were normalized to the 
DMSO control and corrected for protein loading by coomassie staining. pIC50 values were calculated with 
GraphPad Prism 7.0 using a non-linear dose-response analysis with variable slope. For all pIC50 determinations 




All reactions were performed using oven- or flame-dried glassware and dry (molecular sieves) solvents. 
Reagents were purchased from Alfa Aesar, Sigma-Aldrich, Acros, and Merck and used without further 
purification unless noted otherwise. All moisture sensitive reactions were performed under an argon or 
nitrogen atmosphere. 1H and 13C NMR spectra were recorded on a Bruker DPX-300 (300 MHz), AV-400 (400 
MHz) or DRX-500 (500 MHz). Used software for interpretation of NMR-data was Bruker TopSpin 1.3 and 
MestreNova 11.0. Chemical shift values are reported in ppm with tetramethylsilane or solvent resonance as 
the internal standard (CDCl3: δ 7.26 for 1H, δ 77.16 for 13C; ACN-d3: δ 1.94 for 1H, δ 1.32 for 13C; MeOD: δ 
3.31 for 1H, δ 49.00 for 13C).14 Data are reported as follows: chemical shifts (δ), multiplicity (s = singlet, d = 
doublet, dd = double doublet, td = triple doublet, t = triplet, q = quartet, bs = broad singlet, m = multiplet), 
coupling constants J (Hz), and integration.  
Liquid chromatography analysis was performed on a Finnigan Surveyor LC/MS system, equipped with a C18 
column. Flash chromatography was performed using SiliCycle silica gel type SiliaFlash P60 (230−400 mesh). 
TLC analysis was performed on Merck silica gel 60/Kieselguhr F254, 0.25 mm. Compounds were visualized 
using KMnO4 stain (K2CO3 (40 g), KMnO4 (6 g), and water (600 mL)) or CAM stain (Ce(NH4)4(SO4)4·2H2O (ceric 
ammonium sulfate: 10 g); ammonium molybdate (25 g); conc. H2SO4 (100 mL); H2O (900 mL)). Preparative 
HPLC (Waters, 515 HPLC pump M; Waters, 515 HPLC pump L; Waters, 2767 sample manager; Waters SFO 
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System Fluidics Organizer; Waters Acquity Ultra Performance LC, SQ Detector; Waters Binary Gradient Module) 
was performed on a Waters XBridgeTM column (5 µM C18, 150 x 19 mm). Diode detection was done between 
210 and 600 nm. Gradient: ACN in (H2O + 0.2% TFA). High resolution mass spectra (HRMS) were recorded by 
direct injection on a q-TOF mass spectrometer (Synapt G2-Si) equipped with an electrospray ion source in 
positive mode with Leu-enkephalin (m/z = 556.2771) as an internal lock mass. The instrument was calibrated 




Scheme S3.1 | General scheme for the synthesis of the triazole urea inhibitors. i) introduction or substituent R;  
ii) deprotection of amine, General procedure 1 or 2; iii) triphosgene coupling to triazoles, General procedure 3.  
 
General Procedure 1: Debocylation of piperazine intermediate 
To a 1 M HCl solution in MeOH tert-butyl 4-substituted-2-benzylpiperazine-1-carboxylate was added (± 0.1 M). 
The mixture was stirred for 4-18 h until LC/MS analysis showed full conversion of starting material. Volatiles 
were removed under reduced pressure to yield the HCl salt of the deprotected piperazine. 
 
General Procedure 2: Removal of trifluoroacetyl protecting group from piperazine intermediate 
1-(2-Benzyl-4-substituted-piperazin-1-yl)-2,2,2-trifluoroethan-1-one was dissolved in 20% H2O in MeOH 
(± 0.1 M). 3 Equivalents of K2CO3 were added. The mixture was stirred for 20-40 h until LC/MS analysis 
showed full conversion of starting material. The solids were filtered off and the filtrate concentrated in vacuo 
to obtain the deprotected piperazine. 
 
General Procedure 3: Triphosgene coupling of piperazine derivative to 3-substituted-1H-1,2,4-triazoles 
1-Substituted-3-benzylpiperazine was dissolved in dry DCM (± 0.1 M) and 3 equivalents of Na2CO3 were added. 
The mixture was cooled to 0 °C and 0.75 equivalent of triphosgene was added. The mixture was stirred at 
0 °C for 1.5 h. The solids were filtered off and the solvent was evaporated under reduced pressure. The residue 
was redissolved in dry THF (± 0.1 M), brought under N2-atmosphere and 0.95 equivalent of 3-substituted-1H-
1,2,4-triazole, 0.1 equivalent of DMAP and 2 equivalents of DIPEA were added. The mixture was refluxed for 
6-18 h. The reaction mixture was concentrated in vacuo. 
 
3-(Benzylthio)-1H-1,2,4-triazole (27) 
1H-1,2,4-triazole-3-thiol (1.01 g, 10.0 mmol) and benzylbromide (1.09 mL, 10.0 mmol) 
were dissolved in DMF (10 mL) and stirred for 18 h. The reaction mixture was then diluted 
with EtOAc (50 mL) and washed with aqueous saturated NaHCO3 (50 mL). The organic 
phase was separated and the aqueous phase was extracted with EtOAc (50 mL). The combined organic phases 
were washed with water (50 mL) and brine (50 mL). The volatiles are removed in vacuo and the product was 
obtained as white solid (1.86 g, 9.75 mmol, 98%). 1H NMR (400 MHz, MeOD) δ 8.30 (s, 1H), 7.35 – 7.14 (m, 
5H), 4.33 (s, 2H). 13C NMR (101 MHz, MeOD) δ 147.99, 138.64, 129.91, 129.52, 128.48, 37.80. 
 
3-(Benzylsulfonyl)-1H-1,2,4-triazole (28) 
27 (2.91 g, 15.2 mmol) was dissolved in DCM (40 mL) and peracetic acid (8.9 mL, 47 
mmol) was slowly added. The reaction was stirred for 48 h at RT during which a white 
precipitate formed. The precipitate was filtered off and taken up in EtOAc (50 mL). This 
was washed with 1:1 saturated aqueous Na2S2O3 and Na2CO3 (50 mL). The aqueous 
phase was extracted with EtOAc (2x 50 mL). Combined organic layers were dried (MgSO4), filtered and 
concentrated to afford the title compound (2.60 g, 11.6 mmol, 76%).1H NMR (400 MHz, MeOD) δ 8.67 (s, 1H), 
7.48 – 7.11 (m, 5H), 4.70 (s, 2H). 13C NMR (101 MHz, MeOD) δ 161.51, 146.94, 132.20, 129.90, 129.58, 
128.47, 61.59.  
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Scheme S3.2 | Reagents and conditions: i) HBTU, DIPEA, ethyl benzylglycinate, DCM, RT, 99%; ii) a: TFA, DCM, b: 
DIPEA, MeOH, RT, 82%; iii) LiAlH4, THF, 65 °C, 90%; iv) Boc2O, DCM, RT, 95%; v) ammonium formate, Pd/C, EtOH, 
75 °C, 100%; vi) (CF3CO)2O, NEt3, Et2O, 100%; vii) ammonium formate, Pd/C, EtOH, 75 °C, 95%. 
 
Ethyl N-benzyl-N-((tert-butoxycarbonyl)-L-phenylalanyl)glycinate (30) 
(tert-Butoxycarbonyl)-L-phenylalanine 29 (4.38 g, 16.5 mmol) and DIPEA (3.41 mL, 19.5 
mmol) were dissolved in DCM (200 mL) on ice. HBTU (6.26 g, 16.5 mmol) was added 
and the mixture was stirred for 10 minutes. Ethyl benzylglycinate (2.76 mL, 15.0 mmol) 
was added and the mixture was stirred for 18 h at RT. The reaction was quenched with 
sat. aq. NH4Cl (100 mL) and the organic phase was separated. The aqueous layer was 
extracted with EtOAc (100 mL). The combined organic layers were dried (MgSO4), filtered 
and concentrated. The residue was purified by column chromatography to yield the title 
compound as a yellow oil (6.61 g, 15.0 mmol, 99%). 1H NMR (400 MHz, CDCl3) δ 7.47 – 
6.97 (m, 10H), 5.37 (dd, J = 22.3, 8.9 Hz, 1H), 5.03 – 4.90 (m, 1H), 4.78 – 4.43 (m, 2H), 4.23 – 4.07 (m, 2H), 
4.02 (dd, J = 20.2, 17.8 Hz, 1H), 3.78 (dd, J = 40.3, 17.8 Hz, 1H), 3.19 – 3.02 (m, 1H), 3.02 – 2.87 (m, 1H), 
1.39 (s, 9H), 1.30 – 1.20 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 172.89, 168.83, 155.03, 136.65, 136.46, 
135.98, 135.41, 129.73, 129.58, 129.54, 128.95, 128.66, 128.52, 128.42, 128.01, 127.72, 127.35, 
126.89, 126.86, 79.83, 61.73, 61.24, 51.98, 51.63, 50.11, 48.32, 47.12, 39.61, 28.34, 14.20 (carbon 
spectrum shows a mixture of rotamers). 
 
(S)-1,3-Dibenzylpiperazine-2,5-dione (31) 
30 (6.61 g, 15.0 mmol) was dissolved in DCM (100 mL) and TFA (20 mL) was added. The 
mixture was stirred for 3 h at RT. Volatiles were removed under reduced pressure and the 
residue was taken up in methanol (50 mL). DIPEA (26.2 mL, 150 mmol) was added and 
the mixture stirred for 18 h. The mixture was concentrated in vacuo and purified by column 
chromatography. Product was isolated as a white gum (3.62 g, 12.3 mmol, 82%). 1H NMR 
(400 MHz, CDCl3) δ 7.38 – 7.26 (m, 3H), 7.26 – 7.18 (m, 1H), 7.18 – 7.06 (m, 7H), 4.41 
(t, J = 3.7 Hz, 1H), 4.36 (t, J = 4.3 Hz, 1H), 4.22 (s, 1H), 3.38 (dd, J = 17.6, 2.8 Hz, 1H), 3.28 (dt, J = 13.7, 3.6 
Hz, 1H), 3.02 (dt, J = 13.7, 3.7 Hz, 1H), 2.61 (dd, J = 17.6, 2.9 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 169.56, 
169.05, 137.52, 137.50, 133.19, 131.83, 131.70, 131.58, 131.17, 130.47, 59.39, 52.73, 51.19, 43.44. 
 
1,3-Dibenzylpiperazine (32) 
To a 0 °C suspension of 31 (3.61 g, 12.26 mmol) in dry THF (250 mL) was added in batches 
2 M LiAlH4 in THF (30.7 mL, 61.3 mmol). The mixture was stirred on ice for 15 min after 
which the reaction was heated and refluxed for 4 h. The solution was cooled and the excess 
LiAlH4 was quenched by the careful addition of 2 M NaOH (8 mL). The cloudy mixture was 
stirred ON. Solids that formed were filtered off and the filtrate concentrated to provide 
1,3-dibenzylpiperazine (2.95 g, 11.1 mmol, 90%) as a pale coloured oil. 1H NMR (400 MHz, MeOD) δ 7.41 – 
7.09 (m, 10H), 3.56 – 3.38 (m, 2H), 3.02 – 2.90 (m, 1H), 2.86 (dt, J = 12.7, 3.0 Hz, 1H), 2.81 – 2.68 (m, 3H), 
2.65 – 2.59 (m, 2H), 2.07 (td, J = 11.5, 3.2 Hz, 1H), 1.84 (t, J = 10.6 Hz, 1H). 13C NMR (101 MHz, MeOD) δ 
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tert-Butyl 2,4-dibenzylpiperazine-1-carboxylate (33) 
32 (0.70 g, 2.6 mmol) was dissolved in DCM (30 mL) and Boc-anhydride (0.64 mL, 
2.8 mmol) was added. The mixture was stirred for 4 h. Volatiles were evaporated under 
reduced pressure and the resulting residue was purified by column chromatography 
yielding the title compound as a colourless oil (0.915 g, 2.50 mmol, 95%). 1H NMR (300 
MHz, CDCl3) δ 7.44 – 6.95 (m, 10H), 4.16 (s, 1H), 3.94 (s, 1H), 3.55 (d, J = 12.9 Hz, 1H), 
3.38 (d, J = 12.9 Hz, 1H), 3.22 (td, J = 12.7, 3.4 Hz, 1H), 3.08 (t, J = 11.0 Hz, 1H), 2.86 
(d, J = 11.1 Hz, 2H), 2.65 (dt, J = 11.4, 1.9 Hz, 1H), 2.09 (td, J = 11.7, 3.5 Hz, 1H), 1.99 (dd, J = 11.5, 3.9 Hz, 
1H), 1.40 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 138.46, 129.36, 128.40, 127.29, 126.13, 79.63, 63.10, 53.44, 
28.49. 
 
tert-Butyl 2-benzylpiperazine-1-carboxylate (34) 
33 (964 mg, 2.63 mmol) was dissolved in absolute EtOH and ammonium formate (829 mg, 
13.2 mmol) was added. The mixture was brought under N2-atmosphere and 10% Pd on 
carbon (50 mg) was added. The mixture was refluxed for 48 h. The catalyst was filtered off 
and the volatiles were evaporated. Coevaporation with toluene afforded the pure product in 
quantitative yield (727 mg, 2.63 mmol, 100%). 1H NMR (300 MHz, MeOD) δ 7.47 – 7.12 (m, 
5H), 4.46 – 4.12 (m, 1H), 4.12 – 3.72 (m, 1H), 3.27 – 2.53 (m, 7H), 1.34 (s, 9H). 13C NMR 
(75 MHz, CDCl3) δ 156.01, 140.16, 130.37, 129.37, 127.22, 80.68, 46.25, 35.86, 28.82, 28.54. 
 
1-(2,4-Dibenzylpiperazin-1-yl)-2,2,2-trifluoroethan-1-one (35) 
32 (2.01 g, 7.51 mmol) was dissolved in diethyl ether (30 mL) and triethylamine 
(1.15 mL, 8.26 mmol) was added. The mixture was cooled to 0 °C and 
2,2,2-trifluoroacetic anhydride (1.15 mL, 8.26 mmol) was added slowly. The mixture 
was stirred for 3 h at RT. The reaction was quenched by the addition of saturated 
aqueous Na2CO3 (20 mL). The organic phase was separated and the water layer 
extracted with Et2O (2x 25 mL). The combined organic layers were dried (MgSO4), filtered and concentrated to 
yield 35 (2.72 g, 7.51 mmol, 100%) as a yellow oil, which was used without further purification for the next 
reaction. 1H NMR (400 MHz, CDCl3) δ 7.47 – 6.81 (m, 10H), 4.68 – 4.29 (m, 1H), 4.13 – 3.90 (m, 1H), 3.81 
– 3.11 (m, 4H), 3.11 – 2.61 (m, 3H), 2.19 – 1.84 (m, 2H) (proton spectrum shows a mixture of rotamers). 13C 
NMR (101 MHz, CDCl3) δ 155.55 (q, J = 35.5 Hz), 155.35 (q, J = 35.5 Hz), 137.59, 137.43, 129.42, 129.32, 
129.22, 128.55, 128.35, 127.45, 127.42, 126.65, 126.47, 116.69 (q, J = 288.1 Hz), 116.45 (q, J = 288.0 
Hz), 62.51 (q, J = 7.0 Hz), 56.08 (q, J = 3.1 Hz), 52.74, 45.60, 41.90 (q, J = 3.7 Hz), 39.14, 36.67, 35.51, 
29.69 (carbon spectrum shows a mixture of rotamers). 
 
1-(2-Benzylpiperazin-1-yl)-2,2,2-trifluoroethan-1-one (36) 
35 (1.09 g, 3.00 mmol) was dissolved in absolute ethanol (30 mL) and ammonium formate 
(0.95 g, 15 mmol) was added. The mixture was brought under N2-atmosphere and 10% 
Pd/C catalyst (50 mg) was added. The mixture was refluxed for 70 h. Catalyst was filtered 
off and the solvent removed in vacuo. The residue was taken up in EtOAc (25 mL) and 
washed with saturated aqueous Na2CO3. The layers were separated and the aqueous 
phase extracted twice with EtOAc (25 mL). The combined organic layers were dried (MgSO4), filtered and 
concentrated to yield the title compound (0.773 g, 2.84 mmol, 95%). 1H NMR (400 MHz, CDCl3) δ 7.45 – 7.05 
(m, 5H), 4.74 – 3.96 (m, 1H), 3.79 – 3.58 (m, 1H), 3.58 – 3.39 (m, 1H), 3.28 – 2.47 (m, 7H) (proton spectrum 
shows a mixture of rotamers). 13C NMR (101 MHz, CDCl3) δ 155.80 (d, J = 35.4 Hz), 155.61 (d, J = 35.4 Hz), 
137.50, 137.44, 129.31, 129.28, 128.75, 128.52, 126.89, 126.68, 116.70 (q, J = 288.1 Hz), 116.45 (q, J 
= 288.2 Hz), 55.92, 52.16, 46.31 (d, J = 45.7 Hz), 46.14 (d, J = 55.0 Hz), 42.47 (q, J = 3.6 Hz), 39.50, 35.66, 
34.64 (carbon spectrum shows a mixture of rotamers). 
 
tert-Butyl 3-benzyl-4-(2,2,2-trifluoroacetyl)piperazine-1-carboxylate (37) 
36 (192 mg, 0.705 mmol) was dissolved in DCM (10 mL) and Boc-anhydride (0.180 mL, 
0.776 mmol) was added. The mixture was stirred for 18 h at RT. The solvents were 
removed under reduced pressure. The crude residue (263 mg, 0.706 mmol, quant.) was 
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tert-Butyl 3-benzylpiperazine-1-carboxylate (38) 
tert-Butyl 3-benzylpiperazine-1-carboxylate was synthesized from 37 (263 mg, 0.706 mmol) 
according to General Procedure 2. The crude residue (195 mg, 0.706 mmol, quant.) was of 
sufficient purity to be used without further purification in the next reaction. 1H NMR (400 MHz, 
CDCl3) δ 7.41 – 7.13 (m, 5H), 4.27 – 3.77 (m, 2H), 3.42 (bs, 1H), 3.04 – 2.73 (m, 4H), 2.71 – 
2.47 (m, 3H), 1.45 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 154.65, 137.49, 129.22, 128.70, 
126.73, 79.84, 56.16, 45.36, 39.78, 28.41. 
 
tert-Butyl 4-acetyl-2-benzylpiperazine-1-carboxylate (39) 
Acetylchloride (0.20 mL, 2.9 mmol), Net3 (0.5 mL, 3.4 mmol) and 34 (720 mg, 2.6 mmol) 
were dissolved in DCM (20 mL) and stirred at 0 °C for 2 hours. The solution was washed 
with water (20 mL) and the water layer was extracted with EtOAc (2x 20 mL). The combined 
organic layers were dried (MgSO4), filtered and concentrated in vacuo. The product was 
obtained as a yellow oil in quantitative yield (0.83 g, 2.6 mmol, 100%). 1H NMR (300 MHz, 
CDCl3) δ 7.21 – 6.86 (m, 5H), 4.41 – 3.99 (m, 2H), 3.92 – 3.47 (m, 2H), 3.09 – 2.82 (m, 
2H), 2.81 – 2.40 (m, 3H), 1.83 (s, 3H), 1.18 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 169.19, 
168.85, 153.78, 137.65, 137.26, 129.04, 128.63, 128.13, 127.86, 126.18, 125.85, 79.41, 59.66, 47.12, 
45.49, 42.22, 40.67, 35.48, 34.93, 27.69, 20.85, 20.60 (carbon spectrum shows a mixture of rotamers). 
 
1-(3-Benzylpiperazin-1-yl)ethan-1-one hydrochloride (40) 
1-(3-Benzylpiperazin-1-yl)ethan-1-one was synthesized from 39 (490 mg, 1.54 mmol) according to General 
Procedure 1. The crude residue (370 mg, 1.45 mmol, 94%) was of sufficient purity to be used without further 
purification in the next reaction, as judged by LC/MS analysis.  
 
tert-Butyl (S)-2-benzyl-4-(cyclobutanecarbonyl)piperazine-1-carboxylate (41) 
Cyclobutanecarboxylic acid (38.8 mg, 0.388 mmol), DIPEA (77 µL, 0.44 mmol) and HBTU 
(154 mg, 0.406 mmol) were dissolved in DCM (5 mL) and stirred for 20 minutes at RT. 
34 (102 mg, 0.369 mmol) was then added as a solution in DCM (1 mL). The mixture was 
stirred for 20 h. Volatiles were removed in vacuo and the residue was purified by column 
chromatograpy. The title compound was obtained as a white solid (106 mg, 0.296 mmol, 
80%). 1H NMR (400 MHz, CDCl3) δ 7.38 – 7.10 (m, 5H), 4.55 – 4.20 (m, 2H), 3.99 (s, 1H), 
3.71 – 3.24 (m, 1H), 3.23 – 2.82 (m, 3H), 2.82 – 2.60 (m, 2H), 2.57 – 2.32 (m, 2H), 2.32 – 2.12 (m, 2H), 
2.12 – 1.97 (m, 1H), 1.97 – 1.75 (m, 2H), 1.33 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 174.26, 173.81, 154.49, 
154.33, 138.20, 137.74, 129.60, 129.19, 128.65, 128.50, 126.76, 126.46, 80.23, 44.82, 43.27, 41.65, 
37.33, 36.88, 36.04, 29.76, 28.24, 25.61, 24.95, 18.11 (carbon spectrum shows a mixture of rotamers). 
 
(3-Benzylpiperazin-1-yl)(cyclobutyl)methanone hydrochloride (42) 
(3-Benzylpiperazin-1-yl)(cyclobutyl)methanone was synthesized from 41 (106 mg, 0.30 mmol) according to 
General Procedure 1. The crude residue (87 mg, 0.30 mmol, quant.) was of sufficient purity to be used without 
further purification in the next reaction, as judged by LC/MS analysis. 
 
tert-Butyl 2-benzyl-4-(3,3-dimethylbutanoyl)piperazine-1-carboxylate (43) 
3,3-Dimethylbutanoic acid (45.0 mg, 0.388 mmol), DIPEA (77 µL, 0.44 mmol) and HBTU 
(154 mg, 0.406 mmol) were dissolved in DCM (5 mL) and stirred for 20 minutes at RT. 
34 (102 mg, 0.369 mmol) was then added as a solution in DCM (1 mL). The mixture is 
stirred for 20 h. Volatiles were removed in vacuo and the residue was purified by column 
chromatograpy. The title compound was obtained as a white solid (67 mg, 0.18 mmol, 
49%). 1H NMR (400 MHz, DMSO, 353 K) δ 7.37 – 7.03 (m, 5H), 4.24 (s, 2H), 4.08 – 
3.59 (m, 2H), 3.37 – 3.11 (m, 2H), 2.93 – 2.54 (m, 3H), 2.30 (s, 2H), 1.31 (s, 9H), 1.03 
(s, 9H). 13C NMR (101 MHz, DMSO, 293 K) δ 169.88, 153.28, 137.94, 128.79, 127.77, 125.74, 78.59, 43.43, 
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1-(3-Benzylpiperazin-1-yl)-3,3-dimethylbutan-1-one hydrochloride (44) 
1-(3-Benzylpiperazin-1-yl)-3,3-dimethylbutan-1-one was synthesized from 43 (67 mg, 0.18 mmol) according to 
General Procedure 1. The crude residue (56 mg, 0.18 mmol, quant.) was of sufficient purity to be used without 
further purification in the next reaction, as judged by LC/MS analysis. 
 
tert-Butyl 4-benzoyl-2-benzylpiperazine-1-carboxylate (45) 
34 (120 mg, 0.434 mmol) was dissolved in DCM (5 mL) to which triethylamine (73 µL, 
0.52 mmol) was added. Benzoyl chloride (55 µL, 0.48 mmol) was added and the mixture 
was stirred for 18 h. The reaction was quenched by the addition of 0.1 M aqueous HCl 
(5 mL). The organic layer was separated and the aqueous phase was extracted with DCM 
(2x 10 mL). The combined organic layers were dried (MgSO4), filtered and concentrated. 
The residue was purified by column chromatography to yield the title compound (106 mg, 
0.279 mmol, 64%) as white solid. 1H NMR (400 MHz, CDCl3, 323 K) δ 7.42 (m, 5H), 7.17 
(m, 5H), 4.33 (s, 2H), 4.05 – 3.85 (m, 1H), 3.10 (m, 3H), 2.91 – 2.54 (m, 2H), 1.35 (s, 9H). 13C NMR (101 
MHz, CDCl3, 323 K) δ 171.10, 154.42, 137.91, 135.67, 129.99, 129.40, 128.62, 128.50, 127.33, 126.53, 
80.25, 53.48, 39.07, 36.10, 28.33 (carbon spectrum shows a mixture of rotamers). 
 
(3-Benzylpiperazin-1-yl)(phenyl)methanone hydrochloride (46) 
(3-Benzylpiperazin-1-yl)(phenyl)methanone was synthesized from 45 (106 mg, 0.279 mmol) according to 
General Procedure 1. The crude residue (88 mg, 0.28 mmol, quant.) was of sufficient purity to be used without 
further purification in the next reaction, as judged by LC/MS analysis. 
 
tert-Butyl (S)-(1-(benzyl(2-hydroxyethyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate (47) 
DIPEA (1.55 mL, 8.9 mmol) was added to a solution of Boc-L-phenylalanine (1.99 g, 7.5 
mmol) in DCM (100 mL) on ice. HBTU (2.85 g, 7.5 mmol) was added and the mixture 
was stirred for 10 minutes. 2-Benzylaminoethanol (0.97 mL, 6.8 mmol) was added to 
the reaction mixture. The reaction mixture was stirred at RT for 24 h. The mixture was 
washed with 0.1 M HCl (aq., 100 mL) The water layer was extracted with EtOAc (3x 
50 mL). The organic layers were combined and washed with 1 M NaOH (aq., 50 mL) and 
brine (50 mL). The organic layer was dried (MgSO4), filtered and concentrated under 
reduced pressure. The residue was purified by column chromatography affording the title compound as a 
yellow oil (1.61 g, 4.0 mmol, 59%).1H NMR (300 MHz, CDCl3) δ 7.41 – 6.89 (m, 11H), 5.36 (dd, J = 40.4, 8.1 
Hz, 1H), 5.07 – 4.74 (m, 1H), 4.34 (dd, J = 48.6, 16.0 Hz, 1H), 3.73 – 3.23 (m, 2H), 3.19 – 2.70 (m, 4H), 1.64 
(s, 1H), 1.41 (s, 9H) (proton spectrum shows a mixture of rotamers).  
 
tert-Butyl (S)-(1-(benzyl(2-chloroethyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate (48) 
Triethylamine (0.63 mL, 5.1 mmol) was added to a solution of 47 (0.88 g, 2.2 mmol) in 
DCM (20 mL) on ice. Methanesulfonylchloride (0.18 mL, 2.4 mmol) was added and the 
mixture was refluxed for 5 h. The mixture was washed with saturated aqueous NaHCO3 
(20 mL). The water layer was extracted with EtOAc (20 mL). The combined organic layers 
were washed with brine (20 mL), dried (MgSO4), filtered and concentrated in vacuo. The 
product was purified by column chromatography yielding the title compound (0.64 g, 1.5 
mmol, 70%). 1H NMR (300 MHz, CDCl3) δ 7.36 – 6.93 (m, 10H), 5.62 (t, J = 9.9 Hz, 1H), 
4.99 – 4.74 (m, 1H), 4.74 – 4.29 (m, 2H), 3.79 – 3.23 (m, 4H), 3.21 – 2.86 (m, 2H), 1.46 (s, 9H). 13C NMR 
(75 MHz, CDCl3) δ 172.75, 172.64, 155.36, 155.07, 136.72, 136.58, 136.11, 129.65, 129.60, 128.99, 
128.70, 128.64, 128.02, 127.93, 127.63, 127.07, 127.00, 79.91, 79.75, 52.44, 51.82, 49.44, 48.39, 
48.26, 40.89, 39.97, 28.40 (carbon spectrum shows a mixture of rotamers).  
 
1,3-Dibenzylpiperazin-2-one (49) 
48 (640 mg, 1.53 mmol) was dissolved in 1 M HCl in MeOH (20 mL) and stirred for 19 h. 
The volatiles were removed in vacuo and the residue was taken up in dry DMF (20 mL) and 
brought under argon atmosphere. K2CO3 (300 mg, 2.17 mmol) and a catalytic amount of 
tetrabutylammonium iodide were added and the temperature was raised to 80 °C. The 
mixture was stirred for 24 h. The mixture was diluted with water (20 mL). The aqueous 
phase was extracted with EtOAc (3x 40 mL), the combined organic layers were washed with brine (40 mL), 
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affording the title compound as a white solid (150 mg, 0.54 mmol, 35%). 1H NMR (300 MHz, MeOD) δ 7.67 – 
7.02 (m, 10H), 4.62 (dt, J = 31.0, 7.0 Hz, 1H), 4.37 – 4.16 (m, 1H), 3.99 – 3.75 (m, 1H), 3.75 – 3.49 (m, 1H), 
3.49 – 3.27 (m, 3H), 3.24 – 3.03 (m, 2H). 
 
3-Benzyl-4-(2,2,2-trifluoroacetyl)piperazine-1-carboxamide (50) 
36 (156 mg, 0.573 mmol) and potassium cyanate (93 mg, 1.15 mmol) were dissolved in 
H2O/AcOH (1:1, 6 mL) and stirred for 18 h at RT. The reaction was quenched by the 
addition of sat. aq. Na2CO3. The mixture was extracted with EtOAc (3x 20 mL). The 
combined organic layers were dried (MgSO4), filtered and concentrated. The residue was 
purified by column chromatography to yield the title compound as a white solid (91 mg, 
0.29 mmol, 50%). 1H NMR (400 MHz, CDCl3) δ 7.42 – 7.13 (m, 5H), 5.24 (s, 2H), 4.81 – 
4.66 (m, 1H), 4.51 – 4.01 (m, 2H), 3.80 (t, J = 13.4 Hz, 1H), 3.66 (dt, J = 13.6, 2.1 Hz, 
1H), 3.50 (ddd, J = 14.3, 11.8, 3.5 Hz, 1H), 3.27 – 3.13 (m, 1H), 3.10 (dd, J = 13.7, 4.0 Hz, 1H), 3.04 – 2.80 
(m, 4H) (proton spectrum shows a mixture of rotamers). 13C NMR (101 MHz, CDCl3) δ 158.67, 156.00 (q, J = 
35.8 Hz), 155.71 (q, J = 36.0 Hz), 136.46 (d, J = 3.2 Hz), 129.39, 129.07, 128.86, 127.42, 127.20, 116.52 
(q, J = 287.9 Hz), 116.25 (q, J = 288.0 Hz), 55.68 (d, J = 3.5 Hz), 53.53, 52.52, 44.66, 44.43, 43.16 (d, J = 
4.1 Hz), 41.23 (q, J = 3.3 Hz), 38.37, 36.23, 35.20 (carbon spectrum shows a mixture of rotamers). 
 
3-Benzylpiperazine-1-carboxamide (51) 
3-Benzylpiperazine-1-carboxamide was synthesized from 50 (91 mg, 0.29 mmol) according to General 
Procedure 2. The crude residue (63 mg, 0.29 mmol, quant.) was of sufficient purity to be used without further 
purification in the next reaction, as judged by LC/MS analysis. 
 
3-Benzyl-N-ethyl-4-(2,2,2-trifluoroacetyl)piperazine-1-carboxamide (52) 
36 (112 mg, 0.411 mmol) was dissolved in DCM (5 mL) and isocyanatoethane (39 µL, 
0.49 mmol) was added. The mixture was stirred for 18 h at RT. The reaction was 
quenched by the addition of 0.1 M HCl (aq., 10 mL). The organic layer was separated 
and the aqueous phase was extracted with DCM (2x 10 mL). The combined organic 
layers were dried (MgSO4), filtered and concentrated to yield the title compound (141 
mg, 0.411 mmol, 100%). 1H NMR (400 MHz, CDCl3) δ 7.44 – 7.15 (m, 5H), 4.81 – 4.40 
(m, 2H), 4.24 – 4.07 (m, 1H), 3.98 – 3.66 (m, 1H), 3.64 – 3.42 (m, 1H), 3.42 – 3.12 (m, 
3H), 3.08 – 2.78 (m, 4H), 1.16 (td, J = 7.2, 3.1 Hz, 3H) (proton spectrum shows a mixture of rotamers). 13C 
NMR (101 MHz, CDCl3) δ 157.47, 156.00 (q, J = 35.8 Hz), 136.70, 129.40, 129.06, 128.86, 127.41, 127.20, 
116.57 (q, J = 288.1 Hz), 116.30 (q, J = 288.0 Hz), 55.70 (q, J = 3.0 Hz), 53.53, 52.54, 44.56, 44.19, 43.11, 
43.00, 41.42 (q, J = 3.3 Hz), 38.54, 36.21, 35.91, 35.88, 35.09, 30.34, 29.74, 15.48 (carbon spectrum 
shows a mixture of rotamers). 
 
3-Benzyl-N-ethylpiperazine-1-carboxamide (53) 
3-Benzyl-N-ethylpiperazine-1-carboxamide was synthesized from 52 (141 mg, 0.41 mmol) according to 
General Procedure 2. The crude residue (102 mg, 0.41 mmol, quant.) was of sufficient purity to be used 
without further purification in the next reaction, as judged by LC/MS analysis. 
 
3-Benzyl-N-(tert-butyl)-4-(2,2,2-trifluoroacetyl)piperazine-1-carboxamide (54) 
36 (114 mg, 0.419 mmol) was dissolved in DCM (6 mL) and isocyanatoethane (70 µL, 
0.61 mmol) was added. The mixture was stirred for 18 h at RT. The reaction was 
quenched by the addition of 0.1 M HCl (aq., 10 mL). The organic layer was separated 
and the aqueous phase was extracted with DCM (2x 10 mL). The combined organic 
layers were dried (MgSO4), filtered and concentrated to yield the title compound (156 
mg, 0.419 mmol, 100%). 1H NMR (400 MHz, CDCl3) δ 7.47 – 7.12 (m, 5H), 4.75 – 4.64 
(m, 1H), 4.47 – 4.09 (m, 2H), 3.82 (d, J = 14.0 Hz, 1H), 3.61 – 3.37 (m, 2H), 3.26 – 
3.15 (m, 1H), 3.08 – 2.94 (m, 1H), 2.92 – 2.70 (m, 2H), 1.35 (s, 9H) (proton spectrum 
shows a mixture of rotamers). 13C NMR (101 MHz, CDCl3) δ 156.52, 156.48, 155.91 (q, J = 35.9 Hz), 136.75, 
136.68, 129.32, 129.26, 129.07, 128.85, 127.38, 127.14, 116.53 (q, J = 287.8 Hz), 116.25 (q, J = 288.0 
Hz), 55.50 (q, J = 2.6 Hz), 52.52, 51.02, 44.88, 44.36, 42.74, 42.60, 41.41 (q, J = 3.0 Hz), 38.56, 36.06, 
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3-Benzyl-N-(tert-butyl)piperazine-1-carboxamide (55) 
3-Benzyl-N-(tert-butyl)piperazine-1-carboxamide was synthesized from 54 (156 mg, 0.419 mmol) according to 
General Procedure 2. The crude residue (119 mg, 0.419 mmol, quant.) was of sufficient purity to be used 
without further purification in the next reaction, as judged by LC/MS analysis. 
 
1-(2-Benzyl-4-isopropylpiperazin-1-yl)-2,2,2-trifluoroethan-1-one (56) 
36 (194 mg, 0.71 mmol) and acetone (78 µL, 1.1 mmol) were dissolved in DCM (5 mL). 
The mixture was cooled to 0 °C and sodium triacetoxyborohydride (166 mg, 0.78 mmol) 
and acetic acid (49 µL, 0.86 mmol) were added. The mixture was stirred for 48 h at RT. 
The reaction was quenched by the addition of sat. aq. Na2CO3 (10 mL). The organic layer 
was separated and the aqueous phase was extracted with DCM (2x 10 mL). The combined 
organic layers were dried (MgSO4), filtered and concentrated. The residue was purified by 
column chromatography to yield the title compound (120 mg, 0.382 mmol, 54%).1H NMR (400 MHz, CDCl3) δ 
7.36 – 7.12 (m, 5H), 4.74 – 4.28 (m, 1H), 4.14 – 3.60 (m, 1H), 3.59 – 3.40 (m, 1H), 3.31 – 3.13 (m, 1H), 
2.94 – 2.57 (m, 4H), 2.38 – 2.22 (m, 1H), 2.22 – 2.05 (m, 1H), 1.06 – 0.91 (m, 6H). 13C NMR (101 MHz, 
CDCl3) δ 155.66 (q, J = 35.4 Hz), 155.45 (q, J = 35.4 Hz), 138.06, 137.92, 129.55, 129.44, 128.74, 128.54, 
126.89, 126.65, 116.84 (q, J = 288.1 Hz), 116.58 (q, J = 288.2 Hz), 56.20 (d, J = 3.0 Hz), 54.54, 54.49, 
52.83, 49.20, 48.77, 48.56, 48.32, 42.46 (d, J = 3.8 Hz), 39.62, 36.54, 35.40, 18.76, 18.70, 17.67, 17.58 
(carbon spectrum shows a mixture of rotamers). 
 
3-Benzyl-1-isopropylpiperazine (57) 
3-Benzyl-1-isopropylpiperazine was synthesized from 56 (120 mg, 0.38 mmol) according to General Procedure 
2. The crude residue (83 mg, 0.38 mmol, quant.) was of sufficient purity to be used without further purification 
in the next reaction, as judged by LC/MS analysis. 
 
tert-Butyl 2-benzyl-4-isobutylpiperazine-1-carboxylate (58) 
34 (53 mg, 0.19 mmol) and isobutyraldehyde (53 µL, 0.58 mmol) were dissolved in DCM 
(5 mL). The mixture was cooled to 0 °C and sodium triacetoxyborohydride (81 mg, 0.38 
mmol) and acetic acid (24 µL, 0.42 mmol) were added. The mixture was stirred for 18 h at 
RT. The reaction was quenched by the addition of sat. aq. NaHCO3 (10 mL). The organic 
layer was separated and the aqueous phase was extracted with DCM (2x 10 mL). The 
combined organic layers were dried (MgSO4), filtered and concentrated. The residue was purified by column 
chromatography to yield the title compound (58 mg, 0.17 mmol, 91%). 1H NMR (400 MHz, CDCl3) δ 7.40 – 
7.10 (m, 5H), 4.17 (s, 1H), 3.91 (s, 1H), 3.18 (td, J = 12.7, 3.5 Hz, 1H), 3.07 (d, J = 11.4 Hz, 1H), 2.97 – 2.69 
(m, 2H), 2.60 (dt, J = 11.6, 1.9 Hz, 1H), 2.04 (dd, J = 12.0, 7.6 Hz, 1H), 2.00 – 1.87 (m, 3H), 1.72 (m, 1H), 
1.39 (s, 9H), 0.94 (m, 6H) (proton spectrum shows a mixture of rotamers). 13C NMR (101 MHz, CDCl3) δ 154.83, 
139.66, 129.52, 128.44, 126.18, 79.50, 66.99, 55.11, 53.74, 36.42, 28.46, 25.58, 21.01. 
 
3-Benzyl-1-isobutylpiperazine hydrochloride (59) 
3-Benzyl-1-isobutylpiperazine was synthesized from 58 (58 mg, 0.17 mmol) according to General Procedure 
1. The crude residue (47 mg, 0.17 mmol, quant.) was of sufficient purity to be used without further purification 
in the next reaction, as judged by LC/MS analysis. 
 
tert-Butyl 2-benzyl-4-cyclopentylpiperazine-1-carboxylate (60) 
34 (50 mg, 0.18 mmol) and cyclopentanone (80 µL, 0.91 mmol) were dissolved in DCM 
(5 mL). The mixture was cooled to 0 °C and sodium triacetoxyborohydride (77 mg, 0.36 
mmol) and acetic acid (23 µL, 0.40 mmol) were added. The mixture was stirred for 18 h at 
RT. The reaction was quenched by the addition of sat. aq. NaHCO3 (10 mL). The organic 
layer was separated and the aqueous phase was extracted with DCM (2x 10 mL). The 
combined organic layers were dried (MgSO4), filtered and concentrated. The residue was 
purified by column chromatography to yield the title compound (54 mg, 0.16 mmol, 87%). 1H NMR (400 MHz, 
CDCl3) δ 7.37 – 7.12 (m, 5H), 4.16 (s, 1H), 3.91 (s, 1H), 3.24 – 3.01 (m, 2H), 3.00 – 2.80 (m, 2H), 2.74 (d, J 
= 11.5 Hz, 1H), 2.52 – 2.33 (m, 1H), 1.95 (qd, J = 12.8, 12.2, 3.6 Hz, 2H), 1.83 (dtd, J = 11.5, 7.2, 2.8 Hz, 
1H), 1.77 – 1.60 (m, 2H), 1.61 – 1.46 (m, 2H), 1.39 (s, 12H). 13C NMR (101 MHz, CDCl3) δ 154.78, 139.65, 
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3-Benzyl-1-cyclopentylpiperazine hydrochloride (61) 
3-Benzyl-1-cyclopentylpiperazine was synthesized from 60 (54 mg, 0.16 mmol) according to General 
Procedure 1. The crude residue (44 mg, 0.16 mmol, quant.) was of sufficient purity to be used without further 
purification in the next reaction, as judged by LC/MS analysis. 
 
tert-Butyl (S)-2-benzyl-4-(4-fluorobenzyl)piperazine-1-carboxylate (62) 
Commercial tert-butyl (S)-3-benzylpiperazine-1-carboxylate (50 mg, 0.18 mmol) and 
4-fluorobenzaldehyde (21.4 µL, 0.199 mmol) were dissolved in DCM (5 mL). The 
mixture was cooled to 0 °C and sodium triacetoxyborohydride (46 mg, 0.22 mmol) 
and acetic acid (16 µL, 0.22 mmol) were added. The mixture was stirred for 18 h at 
RT. The reaction was quenched by the addition of sat. aq. Na2CO3 (10 mL). The 
organic layer was separated and the aqueous phase was extracted with DCM (2x 10 mL). The combined 
organic layers were dried (MgSO4), filtered and concentrated. The residue was purified by column 
chromatography to yield the title compound (30 mg, 0.08 mmol, 43%). 1H NMR (400 MHz, CDCl3) δ 7.49 – 
6.91 (m, 9H), 4.13 (bs, 1H), 3.82 (bs, 1H), 3.51 (d, J = 13.0 Hz, 1H), 3.31 (d, J = 12.9 Hz, 1H), 3.20 (td, J = 
12.8, 3.4 Hz, 1H), 3.12 – 2.94 (m, 1H), 2.93 – 2.74 (m, 2H), 2.60 (dt, J = 11.4, 1.9 Hz, 1H), 2.12 – 2.01 (m, 
1H), 1.95 (dd, J = 11.5, 3.9 Hz, 1H), 1.38 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 162.13 (d, J = 245.0 Hz), 
154.72, 139.20, 133.91, 130.76 (d, J = 7.9 Hz), 129.37, 128.31, 126.11, 115.06 (d, J = 21.3 Hz), 79.62, 
62.13, 53.27, 28.35. 
 
(S)-3-Benzyl-1-(4-fluorobenzyl)piperazine 2,2,2-trifluoroacetate (63) 
62 (30 mg, 0.08 mmol) was dissolved in DCM (5 mL) and cooled to 0 °C. 2,2,2-trifluoroacetic acid (1 mL, 
13 mmol) was added and the mixture was stirred for 18 h at RT. The mixture was concentrated in vacuo. The 
residue was coevaporated with toluene (2x 5 mL). The residue was used without further purification in the next 
reactions. 
 
tert-Butyl (S)-2-benzyl-4-(4-ethynylbenzyl)piperazine-1-carboxylate (64) 
Commercial tert-butyl (S)-3-benzylpiperazine-1-carboxylate (50 mg, 0.18 mmol) and 
4-ethynylbenzaldehyde (25.9 mg, 0.199 mmol) were dissolved in DCM (5 mL). The 
mixture was cooled to 0 °C and sodium triacetoxyborohydride (46 mg, 0.22 mmol) 
and acetic acid (16 µL, 0.22 mmol) were added. The mixture was stirred for 18 h 
at RT. The reaction was quenched by the addition of sat. aq. Na2CO3 (10 mL). The 
organic layer was separated and the aqueous phase was extracted with DCM (2x 
10 mL). The combined organic layers were dried (MgSO4), filtered and concentrated. The residue was purified 
by column chromatography to yield the title compound (43 mg, 0.11 mmol, 61%). 1H NMR (400 MHz, CDCl3) δ 
7.54 – 7.42 (m, 2H), 7.31 (d, J = 7.8 Hz, 2H), 7.24 – 6.92 (m, 5H), 4.37 – 3.67 (m, 2H), 3.52 (d, J = 13.1 Hz, 
1H), 3.34 (d, J = 13.1 Hz, 1H), 3.20 (td, J = 12.5, 3.4 Hz, 1H), 3.08 (s, 1H), 3.01 (d, J = 12.4 Hz, 1H), 2.94 – 
2.69 (m, 2H), 2.63 – 2.54 (m, 1H), 2.15 – 2.02 (m, 1H), 1.97 (dd, J = 11.6, 3.8 Hz, 1H), 1.38 (s, 9H). 13C NMR 
(101 MHz, CDCl3) δ 139.42, 132.18, 129.47, 129.27, 128.43, 126.21, 121.03, 83.72, 79.67, 62.73, 53.47, 
29.83, 28.45. 
 
(S)-3-Benzyl-1-(4-ethynylbenzyl)piperazine 2,2,2-trifluoroacetate (65) 
64 (43 mg, 0.11 mmol) was dissolved in DCM (5 mL) and cooled to 0 °C. 2,2,2-trifluoroacetic acid (1 mL, 
13 mmol) was added and the mixture was stirred for 18 h at RT. The mixture was concentrated in vacuo. The 
residue was coevaporated with toluene (2x 5 mL). The residue was used without further purification in the next 
reactions. 
 
tert-Butyl (S)-3-benzyl-4-(3-(benzylsulfonyl)-1H-1,2,4-triazole-1-carbonyl)piperazine-1-carboxylate (66) 
28 (178 mg, 0.796 mmol) was reacted with commercial tert-butyl (S)-3-
benzylpiperazine-1-carboxylate (200 mg, 0.724 mmol) according to 
General Procedure 3. Column chromatography afforded the title compound 
as a white solid (363 mg, 0.691 mmol, 95%). Spectral data in accordance 
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(S)-(2-Benzylpiperazin-1-yl)(3-(benzylsulfonyl)-1H-1,2,4-triazol-1-yl)methanone hydrochloride (67) 
66 (363 mg, 0.691 mmol) was dissolved in diethylether (10 mL) and cooled 
to 0 °C. Hydrochloric acid (2 M in Et2O, 1.7 mL, 3.4 mmol) was added and the 
mixture was stirred for 24 h at RT. The mixture was concentrated in vacuo. 




27 (2.137 g, 11.17 mmol) was dissolved in dry THF (40 mL) and 
diphenylcarbamic chloride (2.85 g, 12.3 mmol), DIPEA (2.34 mL, 13.4 mmol) 
and a catalytic amount of DMAP were added. The mixture was refluxed for 5 h 
and stirred 18 h at RT. The reaction was quenched by the addition of sat. aq. 
Na2CO3 (40 mL). The organic layer was separated and the aqueous phase 
extracted with EtOAc (2x 40 mL). The combined organic layers were washed with 
brine (40 mL), dried (MgSO4), filtered and concentrated. Column chromatography afforded the title compound 
as a white solid (3.81 g, 9.86 mmol, 88%). 1H NMR (400 MHz, CDCl3) δ 8.70 (s, 1H), 7.46 – 7.10 (m, 15H), 
3.86 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 162.81, 148.53, 147.18, 142.64, 136.61, 129.58, 129.04, 
128.65, 127.60, 127.42, 126.80, 35.89. 
 
3-(N-Methyl-N-phenylsulfamoyl)-N,N-diphenyl-1H-1,2,4-triazole-1-carboxamide (69) 
4 N HCl in dioxane (2 mL) was added to DCM (5 mL) and cooled to -10 °C. 15%wt 
NaOCl (aq., 2 mL) was added slowly, forming a yellow-green Cl2 solution. After 30 
min 68 (100 mg, 0.259 mmol) was added dropwise as a solution in DCM (1 mL). 
After 20 min N-methylaniline (1 mL, 9 mmol) was added. The mixture was stirred 
for 2 h at RT. The reaction was quenched by the addition of 0.1 M HCl (10 mL). 
The organic layer was separated and the water layer was extracted with EtOAc 
(2x 10 mL). The combined organic layers were dried (MgSO4), filtered and concentrated. The residue was 
purified by column chromatography to yield the title compound as a brown solid (78 mg, 0.18 mmol, 69%). 1H 
NMR (400 MHz, CDCl3) δ 8.80 (s, 1H), 7.47 – 6.99 (m, 15H), 3.07 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 160.95, 
147.73, 147.28, 141.75, 140.35, 129.45, 128.87, 127.58, 127.47, 126.76, 126.40, 39.02. 
 
N-Methyl-N-phenyl-1H-1,2,4-triazole-3-sulfonamide (70) 
69 (1.05 g, 2.42 mmol) was dissolved in 2 N KOH in a 1:1 (v/v) H2O/THF mixture (50 mL). 
The mixture was stirred for 18 h at RT. The mixture was concentrated and the residue was 
purified by column chromatography to yield the title compound (308 mg, 1.29 mmol, 53%). 




70 (30 mg, 0.13 mmol) was reacted with commercial tert-butyl (S)-3-
benzylpiperazine-1-carboxylate (38.3 mg, 0.139 mmol) according to General 
Procedure 3. Column chromatography afforded the title compound as a white 
solid (54 mg, 0.10 mmol, 79%). 1H NMR (400 MHz, CDCl3) δ 8.09 (bs, 1H), 
7.38 – 7.08 (m, 9H), 6.98 (d, J = 8.0 Hz, 1H), 4.97 – 4.47 (m, 1H), 4.44 – 
3.83 (m, 3H), 3.49 (s, 3H), 3.42 (td, J = 13.1, 3.6 Hz, 1H), 3.28 – 2.59 (m, 
4H), 1.50 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 154.79, 147.38, 140.53, 136.59, 129.31, 129.21, 128.91, 
127.96, 127.22, 126.95, 80.87, 56.58, 40.60, 39.69, 35.88, 28.45. 
 
 





71 (54 mg, 0.10 mmol) was dissolved in DCM (5 mL) and cooled to 0 °C. 
2,2,2-trifluoroacetic acid (1 mL, 13 mmol) was added and the mixture was 
stirred for 5 h at RT. The mixture was concentrated in vacuo. The residue was 
coevaporated with toluene (2x 5 mL). The residue was used without further 
purification in the next reactions. 
 
 
tert-Butyl (S)-2-benzyl-4-isopropylpiperazine-1-carboxylate (73) 
Commercial tert-butyl (S)-3-benzylpiperazine-1-carboxylate (100 mg, 0.362 mmol) and 
acetone (268 µL, 3.62 mmol) were dissolved in DCM (10 mL). The mixture was cooled to 0 
°C and sodium triacetoxyborohydride (153 mg, 0.724 mmol) and acetic acid (46 µL, 0.80 
mmol) were added. The mixture was stirred for 18 h at RT. The reaction was quenched by the 
addition of sat. aq. Na2CO3 (10 mL). The organic layer was separated and the aqueous phase 
was extracted with DCM (2x 10 mL). The combined organic layers were dried (MgSO4), filtered 
and concentrated. The residue was purified by column chromatography to yield the title compound as a white 
solid (88 mg, 0.28 mmol, 76%). HPLC/MS: Calculated for [C19H30N2O2 + H]+ = 319.24, found = 319.07. 
 
(S)-3-Benzyl-1-isopropylpiperazine 2,2,2-trifluoroacetate (74) 
73 was dissolved in DCM (5 mL) and TFA (1 mL) was added. The mixture was stirred for 6 h at RT, when TLC 
showed full conversion of the starting material. The reaction mixture was concentrated in vacuo and used 




70 (50 mg, 0.21 mmol) was reacted with 38 (124 mg, 0.449 mmol) 
according to General Procedure 3. Column chromatography afforded the 
title compound as a white solid (41 mg, 0.076 mmol, 36%). 1H NMR (400 
MHz, CDCl3, 328K) δ 8.19 (bs, 1H), 7.49 – 6.81 (m, 10H), 4.74 (s, 1H), 
4.09 (m, 3H), 3.48 (m, 3H), 3.46 – 3.34 (m, 1H), 3.19 – 2.68 (m, 4H), 1.50 
(s, 9H). 13C NMR (101 MHz, CDCl3, 333K) δ 161.53, 154.89, 147.62, 
140.92, 136.80, 129.40, 129.34, 128.93, 127.89, 127.24, 127.01, 
80.88, 56.52, 53.46, 43.13, 39.69, 36.06, 28.54. HRMS: Calculated for 
[C26H32N6O5S + Na]+ = 563.2047, found = 563.2053. 
 
tert-Butyl 3-benzyl-4-(3-(benzylsulfonyl)-1H-1,2,4-triazole-1-carbonyl)piperazine-1-carboxylate (3) 
28 (150 mg, 0.67 mmol) was reacted with 38 (195 mg, 0.706 mmol) 
according to General Procedure 3. Column chromatography afforded the 
title compound as a white solid (254 mg, 0.483 mmol, 69%). 1H NMR (400 
MHz, CDCl3) δ 8.09 (s, 1H), 7.45 – 7.13 (m, 9H), 7.00 (s, 1H), 4.77 – 4.46 
(m, 3H), 4.39 – 3.73 (m, 3H), 3.48 – 3.28 (m, 1H), 3.18 – 2.60 (m, 4H), 
1.51 (s, 9H). HRMS: Calculated for [C26H31N5O5S + Na]+ = 548.1938, 
found = 548.1945. 
 
1-(3-Benzyl-4-(3-(benzylsulfonyl)-1H-1,2,4-triazole-1-carbonyl)piperazin-1-yl)ethan-1-one (4) 
28 (49 mg, 0.22 mmol) was reacted with 40 (51 mg, 0.20 mmol) according 
to General Procedure 3. Column chromatography afforded the title 
compound as a white solid (67 mg, 0.143 mmol, 72%). 1H NMR (400 MHz, 
DMSO-d6) δ 9.49 – 8.47 (m, 1H), 7.51 – 6.90 (m, 10H), 4.91 (s, 2H), 4.69 – 
4.21 (m, 2H), 4.03 (q, J = 7.1 Hz, 1H), 3.74 (d, J = 13.9 Hz, 1H), 3.60 – 3.36 
(m, 1H), 3.24 (t, J = 12.6 Hz, 1H), 2.98 – 2.66 (m, 3H), 2.14 (s, 1H), 1.99 (s, 
2H) (spectrum shows a mixture of rotamers). HRMS: Calculated for [C23H25N5O4S + H]+ = 468.1699, 
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(3-Benzyl-4-(3-(benzylsulfonyl)-1H-1,2,4-triazole-1-carbonyl)piperazin-1-yl)(cyclobutyl)methanone (5) 
28 (62 mg, 0.28 mmol) was reacted with 42 (76 mg, 0.29 mmol) 
according to General Procedure 3. Column chromatography afforded the 
title compound as a white solid (46 mg, 0.091 mmol, 31%). 1H NMR (400 
MHz, CDCl3) δ 8.13 – 7.79 (m, 1H), 7.53 – 6.72 (m, 10H), 4.97 – 4.68 (m, 
1H), 4.70 – 4.51 (m, 3H), 4.22 – 4.04 (m, 1H), 3.94 – 3.53 (m, 1H), 3.54 
– 3.09 (m, 3H), 3.07 – 2.51 (m, 3H), 2.51 – 1.79 (m, 6H) (spectrum shows 
a mixture of rotamers). HRMS: Calculated for [C27H33N5O4S + H]+ = 




28 (60 mg, 0.27 mmol) was reacted with 44 (78 mg, 0.28 mmol) 
according to General Procedure 3. Column chromatography afforded the 
title compound as a white solid (88 mg, 0.17 mmol, 59%). 1H NMR (400 
MHz, CDCl3) δ 8.01 (s, 1H), 7.45 – 6.84 (m, 10H), 5.04 – 4.74 (m, 1H), 
4.73 – 4.53 (m, 3H), 4.24 – 3.99 (m, 1H), 3.99 – 3.72 (m, 1H), 3.59 – 
3.18 (m, 2H), 3.17 – 2.98 (m, 1H), 2.98 – 2.60 (m, 2H), 2.44 – 2.07 (m, 
2H), 1.18 – 0.96 (m, 9H) (spectrum shows a mixture of rotamers). HRMS: 
Calculated for [C27H33N5O4S + H]+ = 524.2325, found = 524.2328. 
 
(4-Benzoyl-2-benzylpiperazin-1-yl)(3-(benzylsulfonyl)-1H-1,2,4-triazol-1-yl)methanone (7) 
28 (53 mg, 0.24 mmol) was reacted with 46 (70 mg, 0.25 mmol) 
according to General Procedure 3. Column chromatography afforded the 
title compound as a white solid (26.2 mg, 0.049 mmol, 20%). 1H NMR 
(400 MHz, CDCl3) δ 7.91 (s, 1H), 7.61 – 6.57 (m, 15H), 4.71 (bs, 1H), 
4.65 – 4.51 (m, 2H), 4.31 – 4.03 (m, 1H), 4.01 – 3.66 (m, 1H), 3.62 – 
3.29 (m, 2H), 3.29 – 2.84 (m, 3H) (spectrum shows a mixture of 
rotamers). HRMS: Calculated for [C28H27N5O4S + H]+ = 530.1856, 
found = 530.1857. 
 
1,3-Dibenzyl-4-(3-(benzylsulfonyl)-1H-1,2,4-triazole-1-carbonyl)piperazin-2-one (8) 
28 (53 mg, 0.24 mmol) was reacted with 49 (70 mg, 0.25 mmol) 
according to General Procedure 3. Column chromatography afforded the 
title compound as a white solid (118 mg, 0.223 mmol, 89%). 1H NMR 
(400 MHz, CDCl3) δ 7.97 (s, 1H), 7.52 – 7.02 (m, 14H), 6.92 (s, 1H), 
5.61 (s, 1H), 5.10 (s, 1H), 4.81 – 4.51 (m, 2H), 4.45 – 4.04 (m, 2H), 
3.41 (m, 2H), 3.31 – 3.04 (m, 2H), 2.92 – 2.66 (m, 1H). HRMS: 
Calculated for [C28H27N5O4S + H]+ = 530.1856, found = 530.1859. 
 
3-Benzyl-4-(3-(benzylsulfonyl)-1H-1,2,4-triazole-1-carbonyl)piperazine-1-carboxamide (9) 
28 (61 mg, 0.27 mmol) was reacted with 51 (63 mg, 0.29 mmol) according 
to General Procedure 3. Column chromatography afforded the title compound 
as a white solid (81.3 mg, 0.174 mmol, 60%). 1H NMR (400 MHz, CDCl3) δ 
8.13 (s, 1H), 7.43 – 7.11 (m, 9H), 6.99 (s, 1H), 5.01 (s, 2H), 4.78 – 4.48 (m, 
3H), 4.26 – 4.05 (m, 1H), 3.91 (m, 1H), 3.75 (d, J = 13.7 Hz, 1H), 3.43 (t, J = 
12.5 Hz, 1H), 3.15 (dd, J = 13.7, 3.8 Hz, 1H), 3.09 – 2.89 (m, 2H), 2.86 – 








28 (87 mg, 0.39 mmol) was reacted with 53 (102 mg, 0.41 mmol) 
according to General Procedure 3. Column chromatography afforded the 
title compound as a white solid (140 mg, 0.283 mmol, 69%). 1H NMR (400 
MHz, CDCl3) δ 8.18 (s, 1H), 7.42 – 7.11 (m, 9H), 7.00 (s, 1H), 4.84 – 4.52 
(m, 4H), 4.32 – 4.04 (m, 1H), 3.93 (d, J = 18.4 Hz, 1H), 3.72 (d, J = 13.6 
Hz, 1H), 3.51 – 3.36 (m, 1H), 3.34 – 3.16 (m, 2H), 3.17 – 2.87 (m, 3H), 
2.87 – 2.75 (m, 1H), 1.15 (t, J = 7.2 Hz, 3H). HRMS: Calculated for 




28 (92 mg, 0.41 mmol) was reacted with 55 (119 mg, 0.43 mmol) according 
to General Procedure 3. Column chromatography afforded the title 
compound as a white solid (184 mg, 0.351 mmol, 81%). 1H NMR (400 MHz, 
CDCl3) δ 8.28 (s, 1H), 7.44 – 7.15 (m, 9H), 7.05 (s, 1H), 4.73 – 4.49 (m, 3H), 
4.40 – 4.01 (m, 2H), 3.97 – 3.80 (m, 1H), 3.56 (d, J = 13.2 Hz, 1H), 3.41 (d, 
J = 12.3 Hz, 1H), 3.14 – 2.95 (m, 2H), 2.95 – 2.77 (m, 2H), 1.35 (s, 9H). 
HRMS: Calculated for [C26H32N6O4S + H]+ = 525.2278, found = 525.2286. 
 
(2-Benzyl-4-ethylpiperazin-1-yl)(3-(benzylsulfonyl)-1H-1,2,4-triazol-1-yl)methanone (12) 
67 (60 mg, 0.13 mmol) was dissolved in DCM (5 mL) and cooled to 0 °C. 
Acetaldehyde (8.0 µL, 0.14 mmol), acetic acid (9.1 µL, 0.16 mmol) and 
sodium triacetoxyhydroborate (33.0 mg, 0.156 mmol) were added and the 
mixture was stirred for 18 h warming up to RT. The reaction was quenched 
with saturated aqueous Na2CO3 and the organic layer was separated. The 
water layer was extracted twice with DCM. The combined organic layers were 
dried (MgSO4), filtered and concentrated. Column chromatography yielded the 
title compound as a white solid (20 mg, 44 µmol, 34%). 1H NMR (400 MHz, CDCl3) δ 8.04 (s, 1H), 7.54 – 6.82 
(m, 10H), 4.73 – 4.49 (m, 3H), 4.21 – 3.82 (m, 1H), 3.52 (t, J = 12.9 Hz, 1H), 3.38 – 3.16 (m, 1H), 3.03 (s, 
1H), 2.93 – 2.68 (m, 2H), 2.60 – 2.00 (m, 4H), 1.10 (t, J = 7.3 Hz, 3H). HRMS: Calculated for 
[C23H27N5O3S + H]+ = 454.1907, found = 454.1909. 
 
(2-Benzyl-4-isopropylpiperazin-1-yl)(3-(benzylsulfonyl)-1H-1,2,4-triazol-1-yl)methanone (13) 
28 (81 mg, 0.36 mmol) was reacted with 57 (83 mg, 0.38 mmol) according 
to General Procedure 3. Column chromatography afforded the title compound 
as a white solid (66.9 mg, 0.143 mmol, 38%). 1H NMR (400 MHz, CDCl3) δ 
8.02 (s, 1H), 7.25 (m, 9H), 7.07 – 6.91 (m, 1H), 4.66 – 4.49 (m, 3H), 4.19 – 
3.82 (m, 1H), 3.47 (t, J = 12.5 Hz, 1H), 3.28 (t, J = 11.4 Hz, 1H), 3.02 – 2.61 
(m, 4H), 2.53 – 2.18 (m, 2H), 1.08 – 0.92 (m, 6H). HRMS: Calculated for 
[C24H29N5O3S + H]+ = 468.2063, found = 468.2066. 
 
(2-Benzyl-4-isobutylpiperazin-1-yl)(3-(benzylsulfonyl)-1H-1,2,4-triazol-1-yl)methanone (14) 
28 (43 mg, 0.19 mmol) was reacted with 59 (40 mg, 0.17 mmol) according 
to General Procedure 3. Column chromatography afforded the title 
compound as a white solid (63.6 mg, 0.132 mmol, 76%). 1H NMR (400 
MHz, CDCl3) δ 8.04 (s, 1H), 7.44 – 6.83 (m, 10H), 4.71 – 4.41 (m, 3H), 
4.21 – 3.69 (m, 1H), 3.51 (td, J = 12.9, 3.5 Hz, 1H), 3.36 – 3.20 (m, 1H), 
3.08 – 2.66 (m, 3H), 2.33 – 1.85 (m, 4H), 1.85 – 1.54 (m, 1H), 0.95 (d, J 
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(2-Benzyl-4-cyclopentylpiperazin-1-yl)(3-(benzylsulfonyl)-1H-1,2,4-triazol-1-yl)methanone (15) 
28 (39 mg, 0.17 mmol) was reacted with 61 (38 mg, 0.16 mmol) according 
to General Procedure 3. Column chromatography afforded the title 
compound as a white solid (20.5 mg, 0.042 mmol, 27%). 1H NMR (400 
MHz, CDCl3) δ 8.01 (s, 1H), 7.43 – 6.90 (m, 10H), 4.69 – 4.47 (m, 3H), 
4.34 – 3.84 (m, 1H), 3.71 – 2.65 (m, 6H), 2.62 – 1.28 (m, 10H) (spectrum 
shows a mixture of rotamers). HRMS: Calculated for [C26H31N5O3S + H]+ = 
494.2220, found = 494.2223. 
 
(3-(Benzylsulfonyl)-1H-1,2,4-triazol-1-yl)(2,4-dibenzylpiperazin-1-yl)methanone (16) 
28 (46.1 mg, 0.206 mmol) was reacted with 32 (50 mg, 0.19 mmol) 
according to General Procedure 3. Column chromatography afforded the 
title compound as a white solid (85 mg, 0.17 mmol, 88%). 1H NMR (400 
MHz, CDCl3) δ 8.03 (s, 1H), 7.45 – 7.19 (m, 11H), 7.19 – 6.73 (m, 5H), 
4.60 (m, 3H), 4.12 (q, J = 7.0 Hz, 1H), 3.64 – 3.37 (m, 3H), 3.29 (t, J = 
11.3 Hz, 1H), 3.01 (d, J = 11.9 Hz, 1H), 2.79 (dd, J = 28.0, 9.1 Hz, 2H), 
2.34 – 2.07 (m, 2H). HRMS: Calculated for [C28H29N5O3S + H]+ = 516.2063, found = 516.2070.  
 
 (S)-(2-Benzyl-4-(4-fluorobenzyl)piperazin-1-yl)(3-(benzylsulfonyl)-1H-1,2,4-triazol-1-yl)methanone (17) 
28 (19 mg, 85 µmol) was reacted with 63 (22 mg, 77 µmol) according 
to General Procedure 3. Column chromatography afforded the title 
compound as a white solid (33 mg, 62 µmol, 80%). 1H NMR (400 MHz, 
CDCl3) δ 8.04 (s, 1H), 7.42 – 6.81 (m, 14H), 4.60 (m, 3H), 4.23 – 3.83 
(m, 1H), 3.62 – 3.12 (m, 4H), 2.99 (d, J = 11.8 Hz, 1H), 2.76 (dd, J = 
26.6, 9.8 Hz, 2H), 2.37 – 2.04 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 
162.33 (d, J = 245.7 Hz), 160.66, 147.88, 147.61, 137.47, 133.35 
(d, J = 3.2 Hz), 131.14, 130.74, 128.97, 128.87, 127.00, 126.37, 115.37 (d, J = 21.3 Hz), 77.36, 61.88, 
60.65, 56.96, 55.45, 55.06, 53.02, 52.52, 43.66, 41.47, 36.74, 35.95. HRMS: Calculated for 
[C28H28FN5O3S + H]+ = 534.1969, found = 534.1975. 
 
(S)-(2-Benzyl-4-(4-ethynylbenzyl)piperazin-1-yl)(3-(benzylsulfonyl)-1H-1,2,4-triazol-1-yl)methanone (18) 
28 (27 mg, 0.12 mmol) was reacted with 65 (32 mg, 0.11 mmol) 
according to General Procedure 3. Column chromatography 
afforded the title compound as a white solid (37 mg, 69 µmol, 62%). 
1H NMR (400 MHz, CDCl3) δ 8.04 (s, 1H), 7.56 – 6.83 (m, 14H), 
4.60 (m, 3H), 4.05 (m, 1H), 3.71 – 3.14 (m, 4H), 3.10 (s, 1H), 2.99 
(s, 1H), 2.76 (dd, J = 26.1, 11.7 Hz, 2H), 2.27 (s, 2H). 13C NMR (101 
MHz, CDCl3) δ 160.62, 148.16, 147.86, 147.58, 138.57, 137.39, 
132.30, 131.10, 129.22, 129.09, 128.94, 128.85, 126.98, 126.31, 121.38, 83.47, 77.32, 62.27, 60.61, 
56.91, 55.14, 53.06, 52.54, 43.63, 41.42, 36.69, 35.78, 30.39. HRMS: Calculated for [C30H29N5O3S + H]+ = 
540.2063, found = 540.2062. 
 
(S)-(2-Benzyl-4-(methylsulfonyl)piperazin-1-yl)(3-(benzylsulfonyl)-1H-1,2,4-triazol-1-yl)methanone (19) 
67 (60 mg, 0.13 mmol) was dissolved in DCM (5 mL). Mesyl chloride (12 µL, 
0.16 mmol) and Hünig’s base (68 µL, 0.39 mmol) were added. The mixture 
was stirred for 20 h at RT. The reaction mixture was concentrated under 
reduced pressure and purified by column chromatography to afford the title 
compound as a white solid (30 mg, 59 µmol, 45%). 1H NMR (400 MHz, CDCl3) 
δ 8.08 (s, 1H), 7.44 – 6.85 (m, 10H), 4.63 (s, 3H), 4.35 – 3.83 (m, 2H), 3.80 
– 3.63 (m, 1H), 3.61 – 3.32 (m, 1H), 3.21 (s, 1H), 2.83 (m, 6H). 13C NMR (101 
MHz, CDCl3) δ 160.92, 148.01, 147.84, 136.24, 131.14, 129.34, 129.03, 127.46, 126.34, 77.36, 60.58, 
60.51, 56.18, 53.58, 48.15, 45.31, 40.53, 35.80, 34.85, 29.80. HRMS: Calculated for [C22H25N5O5S2 + 
Na]+ = 526.1189, found = 526.1191. 
 
 





67 (68 mg, 0.15 mmol) was dissolved in DCM (5 mL) to which propane-2-
sulfonyl chloride (36 µL, 0.18 mmol) and DIPEA (77 µL, 0.44 mmol) were 
added. The mixture was stirred for 20 h at RT. The reaction mixture was 
concentrated under reduced pressure and purified by column 
chromatography to afford the title compound as a white solid (31.8 mg, 
60 µmol, 41%). 1H NMR (400 MHz, CDCl3) δ 7.95 (s, 1H), 7.43 – 6.86 (m, 
10H), 4.72 – 4.52 (m, 3H), 4.15 (d, J = 13.7 Hz, 1H), 4.01 (d, J = 13.0 Hz, 
1H), 3.79 (d, J = 12.9 Hz, 1H), 3.58 – 3.40 (m, 1H), 3.37 – 2.89 (m, 4H), 2.79 (d, J = 14.2 Hz, 1H), 1.40 – 
1.33 (m, 6H). 13C NMR (101 MHz, CDCl3) δ 160.88, 148.29, 147.65, 136.45, 131.15, 129.37, 129.28, 
129.05, 127.43, 126.44, 77.36, 60.57, 56.54, 53.82, 48.88, 45.68, 41.10, 35.80, 16.95, 16.88. HRMS: 
Calculated for [C24H29N5O5S2 + Na]+ = 554.1502, found = 554.1511. 
 
(S)-(2-Benzyl-4-(phenylsulfonyl)piperazin-1-yl)(3-(benzylsulfonyl)-1H-1,2,4-triazol-1-yl)methanone (21) 
67 (60 mg, 0.13 mmol) was dissolved in DCM (5 mL). Benzenesulfonyl 
chloride (20 µL, 0.16 mmol) and DIPEA (68 µL, 0.39 mmol) were added. 
The mixture was stirred for 20 h at RT. The reaction mixture was 
concentrated under reduced pressure and purified by column 
chromatography to afford the title compound as a white solid (21.2 mg, 
37 µmol, 29%). 1H NMR (400 MHz, CDCl3) δ 8.01 (s, 1H), 7.86 – 6.87 
(m, 15H), 4.80 – 4.51 (m, 3H), 4.26 – 4.08 (m, 1H), 4.08 – 3.86 (m, 1H), 
3.86 – 3.40 (m, 2H), 3.38 – 3.15 (m, 1H), 3.05 – 2.79 (m, 1H), 2.60 – 2.24 (m, 2H). 13C NMR (101 MHz, 
CDCl3) δ 160.89, 147.91, 147.74, 136.33, 135.02, 133.61, 131.13, 129.81, 129.56, 129.40, 129.33, 
129.13, 129.01, 127.83, 127.46, 77.36, 60.54, 56.10, 54.81, 48.59, 46.59, 45.57, 42.58, 40.39, 36.06. 




67 (68 mg, 0.15 mmol) was dissolved in DCM (5 mL). 
4-fluorobenzenesulfonyl chloride (43 µL, 0.18 mmol) and DIPEA 
(77 µL, 0.44 mmol) were added. The mixture was stirred for 20 h at 
RT. The reaction mixture was concentrated under reduced pressure 
and purified by column chromatography to afford the title compound 
as a white solid (52 mg, 89 µmol, 61%). 1H NMR (400 MHz, CDCl3) δ 
8.04 (s, 1H), 7.82 – 6.80 (m, 14H), 4.79 – 4.51 (m, 3H), 4.20 (d, J = 
13.7 Hz, 1H), 3.94 (d, J = 11.7 Hz, 1H), 3.78 – 3.41 (m, 2H), 3.39 – 
3.16 (m, 1H), 3.03 – 2.84 (m, 1H), 2.55 – 2.31 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 165.58 (d, J = 256.4 
Hz), 160.86, 148.32, 147.70, 136.15, 131.05, 130.49 (d, J = 9.4 Hz), 129.72, 129.29, 129.23, 129.02, 
128.92, 127.38, 126.21, 116.80 (d, J = 22.6 Hz), 77.27, 60.44, 55.97, 48.42, 46.41, 45.48, 40.22, 35.93. 




70 (60 mg, 0.25 mmol) was reacted with 72 (92 mg, 0.28 mmol) according 
to General Procedure 3. Column chromatography afforded the title compound 
as a white solid (56 mg, 0.12 mmol, 46%). 1H NMR (500 MHz, CDCl3) δ 8.03 
(s, 1H), 7.37 – 6.88 (m, 10H), 4.81 – 4.47 (m, 1H), 4.14 (d, J = 13.1 Hz, 1H), 
3.56 – 3.44 (m, 4H), 3.34 – 3.18 (m, 1H), 3.07 – 2.87 (m, 1H), 2.87 – 2.64 
(m, 3H), 2.55 – 2.14 (m, 2H), 1.13 – 0.87 (m, 6H). 13C NMR (126 MHz, CDCl3) 
δ 160.77, 148.18, 147.86, 147.27, 140.64, 137.85, 129.59, 129.32, 128.82, 127.93, 127.02, 126.89, 
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 (S)-1-(2-Benzyl-4-(4-fluorobenzyl)piperazine-1-carbonyl)-N-methyl-N-phenyl-1H-1,2,4-triazole-3-
sulfonamide (24) 
70 (98 mg, 0.18 mmol) was dissolved in DCM (5 mL) and cooled to 
0 °C. 4-Fluorobenzaldehyde (27 µL, 0.25 mmol), acetic acid (12 µL, 
0.21 mmol) and sodium triacetoxyhydroborate (45 mg, 0.21 mmol) 
were added and the mixture was stirred for 18 h warming up to RT. 
The reaction was quenched with saturated aqueous Na2CO3 and the 
organic layer was separated. The water layer was extracted twice with 
DCM. The combined organic layers were dried (MgSO4) and 
concentrated. Column chromatography yielded the title compound as a white solid (9.4 mg, 17 µmol, 10%).1H 
NMR (400 MHz, CDCl3) δ 8.03 (s, 1H), 7.47 – 6.77 (m, 14H), 4.83 – 4.48 (m, 1H), 4.32 – 4.06 (m, 1H), 3.64 
– 3.12 (m, 6H), 3.12 – 1.86 (m, 6H). HRMS: Calculated for [C28H29FN6O3S + H]+ = 549.2078, 




70 (205 mg, 0.37 mmol) was dissolved in DCM (10 mL). Propane-2-sulfonyl 
chloride (50 µL, 0.44 mmol) and Hünig’s base (194 µL, 1.11 mmol) were 
added and the reaction mixture was stirred for 18 h at RT. The mixture was 
concentrated under reduced pressure and purified by column 
chromatography to yield the title compound as a white solid (127 mg, 
232 µmol, 63%). 1H NMR (500 MHz, CDCl3) δ 7.97 (s, 1H), 7.44 – 6.80 (m, 
10H), 4.91 – 4.54 (m, 1H), 4.37 – 4.10 (m, 1H), 4.05 – 3.71 (m, 2H), 3.49 
(s, 4H), 3.37 – 2.90 (m, 4H), 2.87 – 2.75 (m, 1H), 1.42 – 1.29 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 160.93, 
148.39, 147.27, 140.41, 136.43, 129.62, 129.27, 129.14, 128.90, 127.95, 127.23, 126.87, 77.33, 61.85, 




70 (55 mg, 0.10 mmol) was dissolved in DCM (5 mL). 
4-Fluorobenzene-sulfonyl chloride (23 mg, 0.12 mmol) and Hünig’s 
base (52 µL, 0.30 mmol) were added and the reaction mixture was 
stirred for 18 h at RT. The mixture was concentrated under reduced 
pressure and purified by column chromatography to yield the title 
compound as a white solid (44.5 mg, 74 µmol, 74%). 1H NMR (500 
MHz, CDCl3) δ 8.04 (s, 1H), 7.81 – 6.87 (m, 14H), 5.03 – 4.52 (m, 
1H), 4.50 – 4.16 (m, 1H), 3.94 (d, J = 11.6 Hz, 1H), 3.82 – 3.53 (m, 2H), 3.48 (s, 3H), 3.40 – 3.16 (m, 1H), 
3.08 – 2.80 (m, 1H), 2.63 – 2.27 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 165.65 (d, J = 256.2 Hz), 161.21, 
148.18, 147.48, 140.44, 136.29, 131.13, 130.57 (d, J = 9.4 Hz), 129.37, 129.07, 128.08, 127.42, 127.07, 
116.88 (d, J = 22.7 Hz), 56.03, 54.60, 48.54, 46.52, 45.57, 42.53, 40.25, 39.85, 36.07, 35.05. HRMS: 
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4. Structure Kinetics Relationships 













The last decade has seen a renewed interest in the development of covalent inhibitors 
for several classes of drug targets, including the serine hydrolase and kinase superfamily.1,2 
Serine hydrolases perform a broad array of physiological functions and have diverse 
substrate preferences, but they all share a conserved catalytic nucleophilic serine residue. 
Serine hydrolases form a covalent acyl-enzyme intermediate, which can be exploited by 
irreversible, mechanism-based inhibitors. For example, PF-04457845 and ABX-1431 have 
entered clinical trials as fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase 
I had nothing to offer anybody but my own confusion.  
Jack Kerouac 
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(MAGL) inhibitors for the treatment of neurological diseases, respectively.3–8 Covalent, 
irreversible inhibitors initially bind in a reversible fashion to the protein (i.e. the Michealis-
Menten complex) followed by a time-dependent chemical reaction that inactivates the 
enzyme (Figure 4.1A and 4.1B).9 The half maximum inhibitory concentration (IC50) for 
covalent inhibitors is dependent on a combination of binding affinity (Ki) and reactivity 
(kinact). This fundamental dual aspect of covalent inhibition is often not taken into account 
during the optimization of covalent irreversible inhibitors, which is usually based on IC50 
values.2,10 This may lead to the prioritization of highly reactive molecules (large kinact) based 
on their high potency.11 Intrinsic high reactivity may, however, lead to a-specific binding to 
other members of the same enzyme family and unwanted adverse side effects as recently 
witnessed for BIA 10-2474 (Chapter 5).12,13 Of note, the specificity constant 	 
 is 
sometimes employed to guide inhibitor optimization to avoid IC50-values that are assay- and 
time-dependent.14–16 The specificity constant is determined by measuring the observed 
rate constants (kobs) using various inhibitor pre-incubation times, but does not allow the 
independent optimization of the affinity Ki, while minimizing the reactivity kinact. Thus, 
alternative methods are required to determine Ki and kinact in an independent manner. 
Diacylglycerol lipases (DAGL) are serine hydrolases responsible for the synthesis of the 
endocannabinoid 2-arachidonoylglycerol (2-AG).17 Modulation of DAGL activity holds 
therapeutic promise for the treatment of metabolic and neuroinflammatory diseases.18–20 
Several DAGL inhibitors, including KT109, DH376 and LEI105, have been developed 
(Figure 4.1C).20–22 KT109 and DH376 belong to the class of triazole urea inhibitors, which 
are capable of irreversibly binding the catalytic serine through the formation of a stable 
carbamate adduct, thereby expelling a triazole-moiety as a leaving group (Figure 4.1A). This 
class of compounds has also shown merit as inhibitors for other serine hydrolases, such as 
α/β-hydrolase domain containing protein (ABHD) 621, ABHD1123, DDHD domain-containing 
protein 2 (DDHD2)24 and MAGL11,25. Structure activity studies of the DAGL (KT109 and 
DH376) and MAGL (JJKK-048) inhibitors have shown that the heterocyclic leaving group is 
crucially important for inhibitor activity.11,26,27 The pKa of the leaving group as determinant 
for the reactivity of the urea28 was postulated to determine the activity of inhibitors.11 The 
exact kinetic parameters of binding for these inhibitors have, however, thus far not been 
experimentally measured, thus the precise role of the triazole heterocycle in the inhibitor 
activity is unknown.  
Here, we studied in detail the influence of the heterocycle in DAGL-α inhibitor DH376 on 
the binding and reactivity. To this end, we synthesized a coherent set of azole derivatives 
of DH376 to systematically investigate the role of the heterocycle in the activity of the 
inhibitor. Furthermore, we adapted a surrogate substrate assay of DAGL-α, which allowed 
us to independently measure Ki and kinact of the new inhibitors. Surprisingly, we found that 
the azole has a crucial role in the formation of the Michaelis-Menten complex, rather than 
in modulating the reactivity. 
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Figure 4.1 | A) Mechanism of action of mechanism based triazole urea inhibitors for serine hydrolases. B) The 
inhibition reactions for reversible and irreversible inhibition. E: enzyme, I: inhibitor, EI: Michaelis-Menten 
complex of E and I, E-I: covalently bound inhibitor-enzyme complex. C) Recently published potent DAGL 
inhibitors. D) Set of 5 inhibitors based on DH376 synthesized and characterized in this study. 
 
Results  
To study the role of the azole heterocycle in the activity of the DAGL inhibitor DH376, a 
focused set of DH376 analogues was synthesized (1-5) (Figure 4.1D). Four different 
heterocycles (1,2,3-triazole, 1,2,4-triazole, pyrazole and imidazole) and a regio-isomer were 
selected, because they differ five orders of magnitude in pKa.29–31 The compounds were 
synthesized according to Scheme 4.1. The enantioselective synthetic route towards 
(R)-2-benzylpiperidine was adapted from Deng et al.27 We replaced the low yielding 
transamination step, used to introduce an alkene at the free amine of 10, by a simple 
alkylation with 4-bromobut-1-ene after nosyl protection of the amine (Scheme 4.1). This 
protected diene was subjected to ring-closing metathesis and, after deprotection, yielded 
15 in a three-fold higher overall yield than previously reported.27 To synthesize the leaving 
group azole derivatives, a general synthetic route was devised featuring a Grignard reaction 
as core transformation to yield the di-(p-fluorophenyl)methanol moiety in a single step from 
accessible azole esters (Scheme 4.1). For all but the imidazole derivative this worked 
without the introduction of any protecting group. Tritylation of the imidazole ethyl ester was 
necessary to avoid degradation during the Grignard reaction. Finally, the secondary amine 
15 was first transformed in a carbamoyl chloride using triphosgene and subsequently 
reacted with the diphenyl azoles (18, 21, 25 and 29), which furnished the inhibitors 1-5.  
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Scheme 4.1 | Synthesis of 1-5 implementing the optimized 9-step procedure for the synthesis of 
(R)-2-benzylpiperidine 15 from commercially available N-Boc-L-phenylalanine (6), followed by the coupling to 
the biphenyl-azole leaving groups synthesized using a general Grignard reaction. a) N,O-di-Me-hydroxyl-
amine·HCl, EDCI·HCl, DCM, 0 °C → RT, 92%; b) LiAlH4, THF, -20 °C, 96%; c) MeP(Ph)3·Br, KHMDS, THF,  
-78°C → RT, 56%; d) HCl, MeOH/H2O, quant.; e) NsCl, NEt3, DMAP, DCM, 85%; f) 4-bromobut-1-ene, K2CO3, 
DMF, 70 °C, 80%; g) Grubbs’ 1st gen., DCM, 40 °C, 62%; h) PhSH, NaOH, ACN/H2O, 50 °C, 99%; i) RuCl3(H2O)3, 
NaBH4, DCE/MeOH, 87%; j) TMS-N3, 90 °C, 68%; k) 4-F-PhMgBr, THF, 0 °C, 94%; l) i) 15, triphosgene, Na2CO3, 
DCM; ii) 18, DIPEA, DMAP, THF, 66 °C, 1.5% (1) 1.2% (2); m) MeOH, SOCl2, 65 °C, 97%; n) 4-F-PhMgBr, THF, 
0 °C, 89%; o) i) 15, triphosgene, Na2CO3, DCM; ii) 21, DIPEA, DMAP, THF, 66 °C, 35%; p) KMnO4, H2O, 100 °C; 
q) H2SO4, EtOH, 78 °C, 47% (two steps); r) 4-F-PhMgBr, THF, 0 °C, 83%; s) i) 15, triphosgene, Na2CO3, DCM; 
ii) 25, DIPEA, DMAP, THF, 66 °C, 21%; t) TrtCl, TEA, DCM, 0 °C → RT, 97%; u) 4-F-PhMgBr, THF, 0 °C, 86%;  
v) TFA, H2O, DCM, 56%; w) i) 15, triphosgene, Na2CO3, DCM; ii) 29, DIPEA, DMAP, THF, 66 °C, 27%. 
 
To determine the binding kinetics of the inhibitors we adapted the previously reported 
para-nitrophenolbutyrate (PNPB) assay.32 The typical pre-incubation step with the inhibitors 
was omitted and enzyme activity was continuously measured from the start (t = 0). To 
obtain a higher specific signal at early time points, the substrate concentration was 
increased to 600 µM. Furthermore, the enzyme was pre-mixed with the assay buffer before 
addition to a 96-well plate, which contained concentrated inhibitor and substrate, to 
minimize initial mixing effects. This yielded reproducible substrate conversion curves 
(Figure 4.2).  
Most available literature models, including the standard observed rate approximation 
(kobs), assume that the enzyme concentration will not change during the incubation 
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(Ki >> [E]).14,33–35 These models can, however, not be applied to potent inhibitors, such as 
KT109 and DH376, that will decrease the enzyme concentration. Therefore, the kinetic 
model of Schwartz et al. was selected to fit to the substrate conversion curves.10 In this 
model, DynaFit software is used for the numerical fitting of the full set of differential 
equations governing the substrate conversion curves without making the Ki >> [E] 
assumption.10,36,37 The kinetic model from Schwartz et al. was slightly adapted to 
incorporate the spontaneous enzyme inactivation observed for blank measurements, 
where substrate depletion cannot explain the decrease in substrate conversion rate. As the 
substrate concentration was well below the predicted KM, the one-step substrate 
conversion proposed by Schwartz et al. was maintained. Initial values for the required rate 
constants were derived from several preliminary experiments, and were mostly left to be 
optimized by the algorithm (Figure S4.1).  
The assay was validated using irreversible DAGL inhibitors (KT109 and DH376) and a 
reversible inhibitor (LEI105) (Figure 4.1C). All three inhibitors were previously found to be 
highly active with (sub)nanomolar potency (pIC50 8.6 to 9).20,22,38 Using seven inhibitor 
concentrations around their reported IC50-values, a set of substrate conversion curves was 
generated. These curves were fitted with DynaFit (Figure S4.1). The resulting fits and values 
for Ki and kinact are shown in Figure 4.2. As was expected, the model does not find a fit for 
the kinact value for the covalent but reversible inhibitor LEI105. The found Ki-values (all 
between 0.2 and 0.4 nM) were generally in line with the high potency described in literature, 
although LEI105 was somewhat more active than previously reported.22 The inactivation 
rates for KT-109 and DH376 were similar (kinact = ± 0.07 min-1).  
 
 
Figure 4.2 | Kinetics of binding of KT109 (A), DH376 (B) and LEI105 (C), data fits are summarized in (D). For 
clarity not all substrate conversion curves used for the curve fitting are shown. Markers denote measured 
absorbance, lines denote fitted model. 
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Next, we tested inhibitors 1-5 to determine the influence of the leaving group on their 
potency in the standard surrogate substrate assay. A large range in IC50-values was 
observed (Figure 4.3A, Table 4.1). Both regioisomers 1 and 2 were low nanomolar 
inhibitors, whereas the 1,2,4-triazole (3) had a reduced potency (IC50 = 3.4 µM) and the 
imidazole (5) was inactive (IC50 > 10 µM). Pyrazole (4) had an intermediate potency with 
IC50 of 0.21 µM. The IC50-values were used to guide the selection of inhibitor concentrations 
for the kinetic assay (Figure 4.3B, Table 4.1). For all but the imidazole compound 5 we were 
able to determine the kinetic parameters. Intriguingly, the inactivation rates for 1 and 2 
(kinact = 0.22 and 0.32 min-1, respectively), were 2-3 times higher than for KT109 and 
DH376, but they had a lower binding affinity (Ki = 10 and 339 nM, respectively). 
Unexpectedly, the inactivation rates for 3 and 4 were comparable to DH376 and KT109, 
whereas there is 10,000-fold difference in pKa between these heterocycles (Table 4.1). Yet, 
the binding affinity of 3 and 4 was substantially reduced (Ki > 10 µM), thereby explaining 
their higher IC50-values. 
 
 
Figure 4.3 | pIC50 determination of compounds 1-5 (A) and kinetic fits (B). All data points are measured as 
N = 4, positive controls (DMSO) as N = 8. Markers denote mean values, error bars denote the SEM, lines are 
fitted data models. 
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Table 4.1 | Potency and kinetic parameters of the focused set of DH376 derivatives 1-5. 
Compound pIC50 Ki (nM) kinact (min-1)  pKa 
1 8.52 ± 0.27     10.4 ± 2.0    0.22 ± 0.03  9.331 
2 8.42 ± 0.28      339 ± 55    0.32 ± 0.04  9.331 
3 5.47 ± 0.07 13770 ± 910 0.075 ± 0.005  10.029 
4 6.68 ± 0.41 10800 ± 910 0.080 ± 0.005  14.230 




Figure 4.4 | pIC50 correlates with both pKi (A) and kinact (B) but pKa (C) does not correlate with reactivity for the 
inhibitors 1-4. Dashed lines denote 90% confidence interval. 
 
Discussion 
We developed a surrogate substrate based assay to determine the kinetic parameters 
of binding and reactivity of triazole urea inhibitors of the serine hydrolase DAGL-α. Having 
the ability to discern the kinetics of binding should enable the optimization of the affinity of 
the inhibitors for the enzyme, the Ki, while controlling the reactivity kinact, to minimize the 
off-target reactivity. The assay was validated using three well-characterized published DAGL 
inhibitors. Five DH376 derivatives were synthesized to study the role of the leaving group 
in the affinity and reactivity with DAGL-α. The IC50-values correlated with the Ki and kinact 
with an R2 of 0.73 and 0.77, respectively (Figure 4.4A, B). The main reason for the large 
differences observed in IC50-values for the five inhibitors was the strong reduction in binding 
affinity for the pyrazole and 1,2,4-triazole compounds compared to the 1,2,3-triazole 
inhibitors. Unexpectedly, it was shown that the 1,2,4-triazole 3 and pyrazole 4 inhibitors 
were as reactive as DH376 and KT109, which is in stark contrast to the five orders of 
magnitude difference in pKa. This showed that the leaving group acidity does not correlate 
with the rate of inactivation kinact (Figure 4.4C).  
The triazole heterocycles of DH376 and KT109 could be involved in hydrogen bonds with 
active site amino acids, as has been previously shown for α-positioned heterocycles for 
related serine hydrolases like FAAH and others.39,40 From our kinetic investigation we 
indeed conclude that the position of the nitrogen atoms in the ring is of great importance 
for the formation and strength of these bonds. Despite the lack of knowledge of the 
structure of DAGL-α, we could speculate that a major hydrogen bonding interaction has to 
occur from the direction in which His650 is drawn in Figure 4.5 (directionality relative to the 
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heterocycle). His650 is part of the catalytic triad and has been postulated to bind in this 
manner before, based on the covalent docking of α-ketoheterocycles in a homology model 
of DAGL-α.41 The 1,2,3-triazoles would both be capable of forming this bond. Compounds 
3-5 could not form this interaction, which would explain the strong drop in binding affinity. 
A second weaker hydrogen bonding interaction on the other side of the urea functionality 
could explain the further differences observed. A candidate hydrogen bond donor would be 
His471 (drawn in Figure 4.5).41 Compound 1 would be optimally positioned to bind both, 
leading to the low Ki observed. The N1-isomer could only bind His650, leading to a slight 
drop in potency. Compounds 3 and 4 could both bind only through the weaker second 
interaction, leading to a poor overall binding. Imidazole 5 would be unable to pick up either 
bond. The proposed hydrogen bonding interactions are unable to directly explain the slight 
difference in binding between 3 and 4, though the specific electronic properties of the 
azoles (i.e. the efficiency of the hydrogen bond formation) could be a cause.  
 
 
Figure 4.5 | Illustration of the hypotheses using potential hydrogen bonding to explain the difference in Ki. 
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The assay presented here, in combination with the data analysis through numerical 
fitting, could be translated to work on a multitude of serine hydrolases. As long as a 
sensitive and robust (surrogate) substrate assay is available that can be interrogated in a 
time-dependent manner it should in principle be possible to derive structure kinetics 
relationships. These relationships provide important insights into the mode of action and 
can aid in the optimization of covalent serine hydrolase inhibitors in an affinity directed 
manner. For the DAG lipase inhibitors, this may lead to more selective inhibitors more 
suitable for further in vivo target validation studies. 
 
Conclusion 
To conclude, we have developed a kinetic assay to study the influence of the heterocyclic 
core of triazole ureas as covalent, mechanism-based inhibitors of diacylglycerol lipase-α. 
We found that the pKa of the leaving group did not correlate with the reactivity of the 
inhibitors, but that the position of the nitrogen atom in the heterocycle is of importance in 
its binding affinity. Detailed knowledge of structure kinetic relationships is expected to 




Jacob van Hengst is kindly acknowledged for his essential contribution to the synthetic 
work described in this Chapter.  
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Methods 
Chemical biology methods 
Cell culture and membrane preparation 
HEK293T cells were grown in DMEM with stable glutamine and phenolred (PAA) with 10% New Born Calf 
serum, penicillin and streptomycin. Cells were passaged every 2-3 days by resuspending in medium and 
seeding them to appropriate confluence. Membranes were prepared from transiently transfected HEK293T 
cells. One day prior to transfection 107 cells were seeded in a 15 cm petri dish. Cells were transfected by the 
addition of a 3:1 mixture of polyethyleneimine (60 µg) and plasmid DNA (20 µg) in 2 mL serum free medium. 
The medium was refreshed after 24 hours, and after 72 h the cells were harvested by suspending them in 
20 mL medium. The suspension was centrifuged for 10 min at 1000 g, and the supernatant was removed. 
The cell pellet was stored at -80 °C until use.  
Cell pellets were thawed on ice and suspended in lysis buffer (20 mM Hepes, 2 mM DTT, 0.25 M sucrose, 
1 mM MgCl2, 25 U/mL benzonase). The suspension was homogenized by polytrone (3x 7 sec) and incubated 
for 30 min on ice. The suspension was subjected to ultracentrifugation (93,000 g, 30 min, 4 °C, Beckman 
Coulter, Type Ti70 rotor) to yield the cytosolic fraction in the supernatant and the membrane fraction as a 
pellet. The pellet was resuspended in storage buffer (20 mM Hepes, 2 mM DTT). The protein concentration 
was determined with Quick Start Bradford assay (Biorad). The protein fractions were diluted to a total protein 
concentration of 1 mg/mL and stored in small aliquots at -80 °C until use. 
 
Surrogate substrate assay 
The biochemical mDAGL-α activity assay is based on the method previously described.32 100 µL reactions were 
performed in flat bottom Greiner 96-wells plates in a 50 mM pH 7.2 Hepes buffer. Membrane protein fractions 
from HEK293T cells transiently transfected with mDAGL-α (0.05 µg/µL final concentration) were used as 
mDAGL-α source. Inhibitors were introduced in 2.5 µL DMSO. The mixtures were incubated for 20 minutes 
before 5.0 µL 6 mM PNP-butyrate (final concentration 0.3 mM) in 50% DMSO was added (final DMSO 
concentration 5.0%). Reactions were allowed to progress for 30 minutes at 20 °C before OD (420 nm) was 
measured using a TECAN GENios plate reader. All experiments were performed at N=2, n=2 for experimental 
measurements and N=2, n=4 for controls.  
Data analysis: Z’-factor of each plate was determined for the validation of each experiment, using the following 
formula Z’=1-3(σpc+ σnc)/(µpc - µnc). The OD from the positive control (pc: DAGL DMSO), and the negative control 
(nc: 10 µM THL) was used. Plates were accepted for further analysis when Z’>0.6. Measurements were 
corrected for the average absorption of the negative control (10 µM THL). The average, standard deviation 
(SD) and standard error of mean (SEM) were calculated and normalized to the corrected positive control. Data 
was exported to Graphpad Prism 7.0 for the calculation of the pIC50 using a non-linear dose-response analysis. 
 
DynaFit setup 
DynaFit version 4 was used with an academic license. For batch processing the command line interface was 
used. The raw data were pre-processed using Microsoft Excel 2016 and exported to tab delimited text files for 
use with DynaFit. Scripts were generated manually or using a purpose-made python script. An example DynaFit 
script is shown in Figure S4.1. 
The contents of the header [task] follow directly from the DynaFit manual and simply state that the program 
should fit progress curves using the data supplied.  
The section [mechanism] was built based on standard enzyme kinetics. The simplified hit and run  
(E + S ---> E + P) was used for the substrate conversion as the KM of the surrogate substrate is too high 
to be determined reliably experimentally.10,32 The additional enzyme degradation step (E ---> E*) was 
included as the progress rate curves for the DMSO blanks decreased more than could be explained by the 
reduction in substrate concentration (which is accounted for in the set of differential equations fitted). 
The rate constants defined in [constants] were set empirically but are all left to be optimized. The exception is 
kon, which is fixed to 100,000 µM-1·min-1, but the variable itself is dependent on koff (and vice versa), so only 
the ratio of the two (Ki) is physically meaningful in this experimental setup.  
As the enzyme is obtained by overexpression in HEK293T cells the exact concentration is unknown. Data from 
the previously published PNPB-based assay used for pIC50 determination indicate that the assay limit lies 
around 9, which puts the enzyme concentration at ± 1 nM. It is left to be optimised by DynaFit.  
The value for P given in the [responses] section is essentially the absorption coefficient of the converted 
surrogate substrate in AU·µM-1, which was determined experimentally (Figure S4.2). 
 




All reactions were performed using oven- or flame-dried glassware and dry (molecular sieves) solvents. 
Reagents were purchased from Alfa Aesar, Sigma-Aldrich, Acros, and Merck and used without further 
purification unless noted otherwise. All moisture sensitive reactions were performed under an argon or 
nitrogen atmosphere.  
1H and 13C NMR spectra were recorded on a Bruker DPX-300 (300 MHz), AV-400 (400 MHz) or DRX-500 (500 
MHz). Used software for interpretation of NMR-data was Bruker TopSpin 1.3 and MestreNova 11.0. Chemical 
shift values are reported in ppm with tetramethylsilane or solvent resonance as the internal standard (CDCl3: 
δ 7.26 for 1H, δ 77.16 for 13C; ACN-d3: δ 1.94 for 1H, δ 1.32 for 13C; MeOD: δ 3.31 for 1H, δ 49.00 for 13C).42 
Data are reported as follows: chemical shifts (δ), multiplicity (s = singlet, d = doublet, dd = double doublet, td 
= triple doublet, t = triplet, q = quartet, bs = broad singlet, m = multiplet), coupling constants J (Hz), and 
integration.  
Liquid chromatography was performed on a Finnigan Surveyor LC/MS system, equipped with a C18 column. 
Flash chromatography was performed using SiliCycle silica gel type SiliaFlash P60 (230−400 mesh). TLC 
analysis was performed on Merck silica gel 60/Kieselguhr F254, 0.25 mm. Compounds were visualized using 
KMnO4 stain (K2CO3 (40 g), KMnO4 (6 g), and water (600 mL)) or CAM stain (Ce(NH4)4(SO4)4·2H2O (ceric 
ammonium sulfate: 10 g); ammonium molybdate (25 g); conc. H2SO4 (100 mL); H2O (900 mL)). Preparative 
HPLC (Waters, 515 HPLC pump M; Waters, 515 HPLC pump L; Waters, 2767 sample manager; Waters SFO 
System Fluidics Organizer; Waters Acquity Ultra Performance LC, SQ Detector; Waters Binary Gradient Module) 
was performed on a Waters XBridgeTM column (5 µM C18, 150 x 19 mm). Diode detection was done between 
210 and 600 nm. Gradient: ACN in (H2O + 0.2% TFA). Chiral HPLC analysis was performed after benzoylation 
of the free amine on a Daicel Chiralpak AD column (250 x 4.5 mm, 10 µm particle size) using 10 % isopropyl 
alcohol in hexane as eluent (1.0 mL/min, UV-detection at 254 nm) Rt= 15.1 min (R-enantiomer 12.8 min). 
High resolution mass spectra (HRMS) were recorded by direct injection on a q-TOF mass spectrometer (Synapt 
G2-Si) equipped with an electrospray ion source in positive mode with Leu-enkephalin (m/z = 556.2771) as 




Scheme S4.1 | Synthesis of (R)-2-benzylpiperidine. Reagents and conditions: a) N,O-di-Me-hydroxylamine·HCl, 
EDCI·HCl, DCM, 0°C → RT, 92%; b) LiAlH4, THF, -20°C, 96%; c) MeP(Ph)3.Br, KHMDS, THF, -78 °C → RT, 56%; d) 
HCl, MeOH/H2O, quant.; e) NsCl, NEt3, DMAP, DCM 85%; f) 4-bromobut-1-ene, K2CO3, DMF; 70°C, 80%; g) Grubbs’ 
1st gen., DCM, 40°C, 62%; h) PhSH, NaOH, ACN/H2O, 50°C, 99%; i) RuCl3(H2O)3, NaBH4, DCE/MeOH, 87%. 
 
tert-Butyl (S)-(1-(methoxy(methyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamic acid (7) 
N-Boc-L-phenylalanine 6 (24.16 g, 91 mmol), N,O-dimethylhydroxylamine hydrochloride 
(9.95 g, 102 mmol) and 4-methylmorpholine (11.25 mL, 102 mmol) were dissolved in 
dichloromethane and cooled to 0 °C. EDCI-HCl (18.75 g, 98 mmol) was added in three 
portions with a 15 min interval. After consumption of the starting material, the reaction 
mixture was washed with sat. aq. NH4Cl, sat. aq. NaHCO3 and brine. The organic phase was 
dried (MgSO4), filtered and concentrated under reduced pressure to obtain the pure title 
compound as a honey like oil (25.9 g, 84 mmol, 92%).1H NMR (400 MHz, CDCl3) δ 7.36 – 7.06 (m, 7H), 5.04 
– 4.85 (m, 1H), 3.65 (s, 3H), 3.17 (s, 3H), 3.09 – 2.96 (m, 1H), 2.94 – 2.80 (m, 1H), 1.37 (s, 11H). 13C NMR 
(101 MHz, CDCl3) δ 155.27, 136.70, 129.56, 128.45, 126.86, 79.67, 61.65, 51.62, 43.93, 38.97, 28.42. 
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tert-Butyl (S)-(1-oxo-3-phenylpropan-2-yl)carbamate (8) 
7 (25.9 g, 84 mmol) was dissolved in THF and cooled to -15 °C. Subsequently a 1 M solution 
of LiAlH4 in THF (42 mL, 42 mmol) was added slowly. Upon completion, the reaction was 
quenched with 25% aq. KHSO4, allowed to warm up to RT and stirred vigorously. Ethyl 
acetate was added, and the organic phase was separated, washed with sat. aq. NaHCO3 
and brine, dried (MgSO4), filtered and concentrated under reduced pressure to give the title 
compound as a white solid. (20.2 g, 81 mmol, 96%). 1H NMR (400 MHz, CDCl3) δ 9.63 (s, 1H), 7.43 – 7.04 
(m, 5H), 5.18 – 4.99 (m, 1H), 4.43 (q, J = 6.8 Hz, 1H), 3.12 (d, J = 6.7 Hz, 2H), 1.41 (s, 9H). 13C NMR (101 
MHz, CDCl3) δ 199.56, 135.90, 129.46, 128.88, 127.19, 80.33, 60.91, 35.58, 28.39. 
 
tert-Butyl (S)-(1-phenylbut-3-en-2-yl)carbamate (9) 
To a solution of potassium bis(trimethylsilyl)amide (27 g, 135 mmol) in dry THF was added 
methyltriphenylphosphonium bromide (54.8 g, 153 mmol). The resulting mixture was stirred 
for 3 hr and subsequently cooled to -78 °C, after which a solution of 8 (22.5 g, 90 mmol) in 
THF was added. The reaction was allowed to warm up to RT overnight and quenched with 
sat. aq. NH4Cl. EtOAc was added and the organic phase was separated, washed with sat. 
aq. NaHCO3 and brine, dried (MgSO4), filtered and concentrated under reduced pressure. The residue was 
purified with silica chromatography (8% ethyl acetate in petroleum ether) to give the desired product as a 
white, waxy solid (12.6 g, 50.9 mmol, 56%).  1H NMR (400 MHz, CDCl3) δ 7.34 – 7.13 (m, 5H), 5.88 – 5.71 
(m, 1H), 5.16 – 5.03 (m, 2H), 4.45 (d, J = 27.0 Hz, 2H), 2.83 (d, J = 6.5 Hz, 2H), 1.40 (s, 9H). 13C NMR (101 
MHz, CDCl3) δ 155.33, 138.18, 137.53, 129.68, 128.44, 126.59, 114.84, 79.53, 53.58, 41.60, 28.47. 
 
(S)-1-Phenylbut-3-en-2-amine (10) 
9 (9.7 g, 39.2 mmol) was dissolved in absolute methanol and 4 M aq. HCl was added. After 
TLC showed full consumption of the starting material, the mixture was concentrated under 
reduced pressure and diluted with water. The solution was washed with diethyl ether and aq. 
NaOH was used to make the aqueous layer basic (pH > 12). The aqueous phase was extracted 
3x with chloroform. The organic layers were combined, dried (MgSO4), filtered and 
concentrated under reduced pressure to give the title compound in quantitative yield. Epimerised product that 
was formed during Wittig olefination was removed by recrystallization form toluene/n-propyl alcohol with N-
acetyl-L-leucine according to literature procedure,43 yielding the amine as a yellow oil with an enantiomeric 
ratio of 97:3 as determined by chiral HPLC (vide infra). 1H NMR (400 MHz, CDCl3) δ 7.36 – 7.12 (m, 5H), 5.89 
(ddd, J = 16.8, 10.3, 6.2 Hz, 1H), 5.14 (dt, J = 17.2, 1.5 Hz, 1H), 5.04 (dt, J = 10.3, 1.4 Hz, 1H), 3.64 – 3.52 
(m, 1H), 2.83 (dd, J = 13.3, 5.4 Hz, 1H), 2.62 (dd, J = 13.3, 8.3 Hz, 1H), 1.31 (s, 3H). 13C NMR (101 MHz, 
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(S)-2-Nitro-N-(1-phenylbut-3-en-2-yl)benzenesulfonamide (11) 
10 (3.5 g, 23.8 mmol), triethylamine (4.88 mL, 35.7 mmol), N,N-dimethylaminopyridine 
(1.45 g, 11.9 mmol) and 2-nitrobenzenesulphonyl chloride (6.85 g, 30.9 mmol) were 
dissolved in dry DCM and stirred overnight, after which the reaction mixture was concentrated 
under reduced pressure. Flash column chromatography (20% ethyl acetate in petroleum 
ether) yielded the desired product with trace impurities as an orange oil (6.7 g, 20 mmol, 
85%). 1H NMR (400 MHz, CDCl3) δ 8.01 – 7.90 (m, 1H), 7.83 – 7.71 (m, 1H), 7.69 – 7.58 (m, 2H), 7.18 – 
7.01 (m, 5H), 5.81 – 5.64 (m, 1H), 5.40 (d, J = 7.9 Hz, 1H), 5.13 (dt, J = 17.1, 1.2 Hz, 1H), 5.03 (dt, J = 10.3, 
1.1 Hz, 1H), 4.32 – 4.17 (m, 1H), 2.92 (dd, J = 13.8, 6.1 Hz, 1H), 2.79 (dd, J = 13.8, 7.8 Hz, 1H). 13C NMR 
(101 MHz, CDCl3) δ 137.21, 136.22, 134.84, 133.22, 132.92, 130.79, 129.46, 128.54, 127.03, 125.53, 
116.57, 58.68, 42.16. 
 
(S)-N-(But-3-en-1-yl)-2-nitro-N-(1-phenylbut-3-en-2-yl)benzenesulfonamide (12) 
11 (6.7g, 20.2 mmol) was dissolved in DMF and K2CO3 (11.1 g, 81 mmol) and 4-bromo-1-
butene (2.46 mL, 24.2 mmol) were added. The mixture was heated to 70 °C and stirred 
vigorously. After 24 hr, an extra portion of 4-bromo-1-butene (2.46 mL, 24.2 mmol) was 
added and the resulting mixture was stirred for 72 h. The reaction was allowed to cool down 
to RT, diluted with brine and extracted 3x with EtOAc. Combination, drying (MgSO4), filtration 
and concentration of the organic phases yielded the desired product as a brown oil (6.24 g, 
16.2 mmol, 80%). 1H NMR (400 MHz, CDCl3) δ 7.92 – 7.84 (m, 1H), 7.69 – 7.52 (m, 3H), 7.25 – 7.12 (m, 5H), 
5.89 – 5.64 (m, 2H), 5.17 – 5.02 (m, 4H), 4.72 – 4.62 (m, 1H), 3.50 – 3.31 (m, 2H), 3.08 (dd, J = 13.5, 5.9 
Hz, 1H), 2.95 (dd, J = 13.5, 9.2 Hz, 1H), 2.50 – 2.31 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 137.45, 135.28, 




A solution of 12 (6.24 g, 16.2 mmol) in DCM was purged with argon and 1st generation Grubbs 
catalyst (400 mg, 3 mol%) was added. The mixture was heated to 40 °C and stirred overnight. 
Volatiles were removed under reduced pressure and flash column chromatography (40% 
diethyl ether in petroleum ether) yielded the desired product as brown powder (3.57 g, 
9.96 mmol, 62%). 1H NMR (400 MHz, CDCl3) δ 7.85 (d, J = 7.7 Hz, 1H), 7.69 – 7.48 (m, 3H), 
7.25 – 7.09 (m, 5H), 5.87 – 5.74 (m, 1H), 5.62 (d, J = 10.6 Hz, 1H), 4.56 (s, 1H), 3.93 (dd, J 
= 14.4, 6.2 Hz, 1H), 3.15 (ddd, J = 15.2, 11.7, 4.1 Hz, 1H), 3.00 (dd, J = 13.1, 6.0 Hz, 1H), 2.89 (dd, J = 13.1, 
8.3 Hz, 1H), 2.21 – 2.04 (m, 1H), 1.93 (dt, J = 18.1, 5.0 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 137.28, 134.48, 
133.30, 131.84, 130.44, 129.69, 128.50, 127.27, 126.79, 125.61, 124.27, 55.78, 41.71, 39.11, 24.33. 
 
(S)-6-Benzyl-1,2,3,6-tetrahydropyridine (14) 
To a solution of thiophenol (2.56 mL, 24.9 mmol) in acetonitrile cooled with ice was added a 
2 M aq. solution of NaOH (12.45 mL, 24.9 mmol). After stirring for 10 minutes, the ice bath 
was removed and a solution of 13 (3.57 g, 9.96 mmol) in acetonitrile was added slowly. The 
resulting mixture was heated to 50 °C. When TLC showed full conversion of the starting 
material, the reaction was cooled to RT and diluted with aq. HCl so that the pH was below 2. 
The aqueous layer was washed with Et2O and diluted with aq. NaOH until the pH was above 12. 
It was then extracted 3x with ethyl acetate. The organic layers were combined, dried (MgSO4), filtered and 
concentrated to afford the desired product as yellow oil (1.71 g, 9.86 mmol, 99%). 1H NMR (400 MHz, CDCl3) 
δ 7.37 – 7.15 (m, 5H), 5.84 – 5.75 (m, 1H), 5.64 (dq, J = 10.1, 2.0 Hz, 1H), 3.61 – 3.51 (m, 1H), 3.17 – 2.99 
(m, 1H), 2.85 – 2.75 (m, 2H), 2.70 (dd, J = 13.2, 8.8 Hz, 1H), 2.26 – 2.12 (m, 1H), 2.02 – 1.91 (m, 1H). 13C 
NMR (101 MHz, CDCl3) δ 138.97, 130.25, 129.39, 128.57, 126.43, 126.22, 55.47, 42.56, 42.12, 25.86. 
 
(R)-2-Benzylpiperidine (15) 
In a three-neck flask containing two stoppers and one septum with empty balloons, 14 (1.70 g, 
9.81 mmol) was dissolved in dichloroethane/methanol 10:3. This solution was purged with 
argon and cooled to 0 °C, after which RuCl3(H2O)3 (257 mg, 0.98 mmol) was added. NaBH4 
(1.86 g, 49 mmol) was added quickly while capturing the formed H2 gas in the empty balloons, 
thus keeping the reaction under hydrogen atmosphere. The reaction was allowed to warm up 
to RT and stirred overnight. Aqueous HCl was then added, so that the water layer had a pH of 
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below 2. The aqueous layer was washed with Et2O and diluted with aq. NaOH until the pH was above 12. The 
water layer was extracted thrice with ethyl acetate. The organic layers were combined, dried (MgSO4), filtered 
and concentrated to yield the title compound as a yellow waxy solid (1.5 g, 8.6 mmol, 87%). 1H NMR (400 MHz, 
CDCl3) δ 7.38 – 7.03 (m, 5H), 3.08 – 2.89 (m, 1H), 2.77 – 2.64 (m, 2H), 2.64 – 2.46 (m, 2H), 1.84 – 1.73 (m, 
1H), 1.73 – 1.63 (m, 1H), 1.63 – 1.52 (m, 1H), 1.52 – 1.38 (m, 1H), 1.37 – 1.15 (m, 3H). 13C NMR (101 MHz, 
CDCl3) δ 139.12, 129.23, 128.39, 126.20, 58.26, 47.08, 43.81, 32.77, 26.08, 24.80. 
 
Methyl 1H-1,2,3-triazole-4-carboxylate (17) 
This protocol was based on literature procedure.44 A mixture of azidotrimethylsilane (2.6 mL, 
20 mmol) and methyl propiolate 16 (1.8 mL, 20 mmol) was heated for 4 h at 90 °C, 
concentrated and coevaporated with MeOH to yield the title compound as a white solid (1.74 g, 
14 mmol, 68%). 1H NMR (400 MHz, MeOD) δ 8.35 (s, 1H), 3.92 (s, 3H). 13C NMR (101 MHz, 
MeOD) δ 162.61, 139.63, 131.92, 52.53. 
 
Bis(4-fluorophenyl)(1H-1,2,3-triazol-4-yl)methanol (18) 
17 (100 mg, 0.787 mmol) was dissolved in THF and cooled to 0 °C. Under vigorous 
stirring, a 2M solution of 4-fluorophenylmagnesium bromide in Et2O (1.38 mL, 
2.75 mmol) was added dropwise. The reaction mixture was allowed to warm up to RT 
and stirred overnight. The reaction was quenched with sat. aq. NH4Cl. The aqueous phase 
was extracted with DCM (3x). The combined organic layers were dried (MgSO4), filtered 
and concentrated under reduced pressure. The residue was purified using flash column 
chromatography (40% to 60% ethyl acetate in pentane) in order to obtain the title 
compound as a white solid (210 mg, 0.731 mmol, 94%). 1H NMR (400 MHz, MeOD) δ 
7.60 (s, 1H), 7.45 – 7.33 (m, 4H), 7.15 – 6.98 (m, 4H). 
 
Methyl 1H-1,2,4-triazole-3-carboxylate (20) 
1H-1,2,4-triazole-3-carboxylic acid 19 (250 mg, 2.21 mmol) was dissolved in MeOH (50 mL) 
and cooled to 0 °C. Thionyl chloride (0.48 ml, 6.6 mmol) was slowly added to the solution. The 
mixture was then heated to reflux for 3 h after which it was cooled to RT and concentrated in 
vacuo to yield the title compound (271 mg, 2.14 mmol, 97%) as a white solid. 1H NMR (400 MHz, MeOD) δ 
9.24 (s, 1H), 4.05 (s, 3H). 
 
Bis(4-fluorophenyl)(1H-1,2,4-triazol-3-yl)methanol (21) 
20 (100 mg, 0.787 mmol) was dissolved in THF and cooled to 0 °C. Under vigorous 
stirring, a 2 M solution of 4-fluorophenylmagnesium bromide in Et2O (1.37 mL, 
2.75 mmol) was added dropwise. The reaction mixture was allowed to warm up to RT 
and stirred overnight. The reaction was quenched with sat. aq. NH4Cl. The aqueous phase 
was extracted with ethyl acetate (3x). The combined organic layers were dried (MgSO4), 
filtered and concentrated under reduced pressure, yielding the title compound as an off-
white solid (201 mg, 0.700 mmol, 89%). 1H NMR (400 MHz, CD3CN) δ 8.21 (s, 1H), 7.40 
(dd, J = 8.7, 5.4 Hz, 4H), 7.08 (t, J = 8.7 Hz, 4H). 13C NMR (101 MHz, MeOD) δ 163.23, 160.78, 140.15, 
133.42, 128.89 (d, J = 8.2 Hz), 115.17, 114.42 (d, J = 21.7 Hz), 76.63. 
 
1H-Pyrazole-3-carboxylic acid (23)  
Synthesis based on published procedure.45 3-Methyl-1H-pyrazole 22 (750 mg, 9.13 mmol) was 
dissolved in water, KMnO4 (3.18 g, 20.1 mmol) was added and the mixture was refluxed 
overnight. The reaction was cooled to room temperature, solids were filtered off, and the solvent 
was removed under reduced pressure. The resulting white powder was used directly without 
further purification. 
 
Ethyl 1H-pyrazole-3-carboxylate (24) 
Crude 23 was dissolved in anhydrous ethanol with a catalytic amount of concentrated H2SO4 
and refluxed overnight. The reaction was allowed to cool to RT, the solvent was partially 
removed and the residue was neutralized using sat. aq. NaHCO3. The aqueous phase was 









  Structure Kinetics Relationships for irreversible DAGL inhibitors  |  77 
 
filtered and concentrated under reduced pressure, yielding the title compound as a white power (607 mg, 4.33 
mmol, 47% over 2 steps). 1H NMR (400 MHz, MeOD) δ 7.73 (d, J = 2.3 Hz, 1H), 6.85 (d, J = 2.3 Hz, 1H), 4.39 
(q, J = 7.1 Hz, 2H), 1.40 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, MeOD) δ 108.84, 105.15, 61.94, 14.58. 
 
Bis(4-fluorophenyl)(1H-pyrazol-3-yl)methanol (25) 
24 (103 mg, 0.735 mmol) was dissolved in THF and cooled to 0 °C. Under vigorous 
stirring, a 2 M solution of 4-fluorophenylmagnesium bromide in Et2O (1.29 mL, 
2.57 mmol) was added dropwise. The reaction mixture was allowed to warm to RT and 
stirred overnight. The reaction was quenched with sat. aq. NH4Cl. The aqueous phase 
was extracted with DCM (3x). Combined organic layers were dried (MgSO4), filtered and 
concentrated under reduced pressure. The residue was purified using silica flash 
chromatography (30% to 60% EtOAc in pentane) yielding the title compound as yellowish 
solid (175 mg, 0.611 mmol, 83%). 1H NMR (400 MHz, CDCl3) δ 8.08 (s, 1H), 7.24 – 7.10 
(m, 5H), 7.03 – 6.85 (m, 4H), 5.83 (d, J = 2.2 Hz, 1H). 13C NMR (101 MHz, MeOH) δ 162.18 (d, J = 246.8 Hz), 
141.90 (d, J = 3.1 Hz), 131.77, 129.21 (d, J = 8.1 Hz), 114.90 (d, J = 21.4 Hz), 110.10, 105.43, 77.61. 
 
Ethyl 1-trityl-1H-imidazole-4-carboxylate (27) 
Ethyl 1H-imidazole-4-carboxylate 26 (100 mg, 0.714 mmol) was dissolved in DCM at 0 °C, 
after which trityl chloride (199 mg, 0.713 mmol) and triethylamine (0.117 mL, 0.856 mmol) 
were added. The reaction mixture was allowed to warm up to RT overnight, after which it 
was quenched with water. The organic phase was separated, dried (MgSO4), filtered and 
concentrated under reduced pressure, giving the title compound as a white powder 
(265 mg, 0.693 mmol, 97%). 1H NMR (400 MHz, CDCl3) δ 7.59 (d, J = 1.4 Hz, 1H), 7.45 (d, J = 1.4 Hz, 1H), 
7.40 – 7.32 (m, 9H), 7.16 – 7.06 (m, 6H), 4.35 (q, J = 7.1 Hz, 2H), 1.37 (t, J = 7.1 Hz, 3H). 
 
Bis(4-fluorophenyl)(1-trityl-1H-imidazol-4-yl)methanol (28) 
27 (265 mg, 0.693 mmol) was dissolved in THF and cooled to 0 °C. Under vigorous 
stirring, a 2 M solution of 4-fluorophenylmagnesium bromide in Et2O (1.38 mL, 2.75 
mmol) was added dropwise. The reaction mixture was allowed to warm up to RT and 
further stirred overnight. The reaction was quenched with sat. aq. NH4Cl. The aqueous 
phase was extracted 3x with ethyl acetate. The combined organic layers were dried 
(MgSO4), filtered and concentrated under reduced pressure. The residue was purified 
over silica column (50 % EtOAc in pentane) in order to obtain the product as a yellowish 
powder (315 mg, 0.596 mmol, 86%). 1H NMR (400 MHz, CDCl3) δ 7.85 (s, 1H), 7.47 – 
7.27 (m, 10H), 7.23 – 6.83 (m, 13H), 6.20 (s, 1H). 13C NMR (101 MHz, CDCl3) δ 162.18 (d, J = 246.9 Hz), 




28 (275 mg, 0.520 mmol) was dissolved in 50% TFA/DCM with a few mL of water and 
stirred overnight. Solvents were removed under reduced pressure and the crude product 
was dissolved in diethyl ether and extracted with a 1 M aq. HCl solution. The aqueous 
phase was made basic (pH > 12) with NaOH and extracted with ethyl acetate (3x). 
Combination, drying (MgSO4), filtered and concentration of the organic phases afforded 
crude product that was of sufficient purity to use in subsequent reactions as judged by 
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4-([1,1'-Biphenyl]-4-yl)-1H-1,2,3-triazole (30) 
A mixture of formaldehyde (12.5 mL, 168 mmol), acetic acid (1.44 ml, 25.2 mmol) and 1,4-dioxane 
(125 mL) was stirred for 15 min. Sodium azide (1.64 g, 25.2 mmol) was added, followed by 4-ethynyl-
1,1'-biphenyl (3.00 g, 16.8 mmol). After 10 min, sodium ascorbate (0.667 g, 3.37 mmol), and 
CuSO4·5H2O (0.210 g, 0.842 mmol) in 1 mL of water were added. The resulting mixture was stirred 
for 18 h at RT. It was diluted with H2O (60 mL) and extracted with chloroform (3x 30 mL). The 
combined organic layers were dried (MgSO4), filtered and concentrated. The residue was suspended 
in 2 M NaOH (6 mL) and stirred for 20 h at RT. The reaction was acidified with 4 M HCl (aq.) and the 
white precipitate was filtered off, yielding the desired product as a white solid (2.31 g, 10.4 mmol, 
62%). 1H NMR (400 MHz, DMSO) δ 15.18 (s, 1H), 8.40 (s, 1H), 7.99 – 7.93 (m, 2H), 7.81 – 7.75 (m, 
2H), 7.75 – 7.69 (m, 2H), 7.53 – 7.45 (m, 2H), 7.42 – 7.34 (m, 1H). 13C NMR (101 MHz, DMSO) δ 156.90, 
145.31, 139.56, 128.99, 127.60, 127.17, 126.56, 126.09. 
 
(R,S)-2-Benzylpiperidine (31) 
2-Benzylpyridine (5.0 mL, 31 mmol) was dissolved in ethanol (100 mL) and concentrated 
aqueous HCl (10 mL) was added. Then PtO2 (112 mg, 0.49 mmol) was added and the mixture 
was shaken under a hydrogen atmosphere of 2 bar at RT. After overnight shaking, solids were 
filtered off over celite. The solvent was removed under reduced pressure and the residue was 
purified using flash column chromatography (10% methanol in DCM) to yield the title compound 
(4.2 g, 20 mmol, 64%). 1H NMR (300 MHz, CDCl3) δ 8.41 (s, 1H), 7.42 – 7.13 (m, 5H), 3.58 – 3.38 (m, 2H), 
3.25 – 3.02 (m, 1H), 3.02 – 2.73 (m, 2H), 2.14 – 1.47 (m, 5H), 1.47 – 1.10 (m, 1H). 13C NMR (75 MHz, CDCl3) 
δ 136.16, 129.51, 128.76, 127.04, 58.59, 45.11, 40.07, 27.97, 22.61. 
 
General procedure 1: triphosgene coupling of 2-benzylpiperidine and bis(4-fluorophenyl) heterocycle 
Triphosgene (0.7 eq.) was dissolved in dry DCM (0.1 M) and to this solution 2-benzylpiperidine (1 eq.)  and 
Na2CO3 (1 eq.) were added at 0 °C. The mixture was stirred for 1 hour, warming to RT. The mixture was then 
filtered and concentrated in vacuo. The residue was taken up in dry THF, followed by addition of a bis(4-fluoro-
phenyl)heterocycle (1 eq.), DMAP (0.1 eq.) and DIPEA (1.1 eq.). The reaction mixture was refluxed to 
completion. The reaction was quenched with saturated NH4Cl (aq.), after which the water layer was extracted 
three times with EtOAc. The combined organic layers were washed with brine, dried with MgSO4, filtered and 




yl)methanone (2)  
Synthesized according to General Procedure 1 from 18 (123 mg, 0.428 
mmol). The N1-isomer was isolated as first eluting isomer (1.63 mg, 3.3 µmol, 
1.2%). 1H NMR (400 MHz, CDCl3) δ 7.41 – 6.57 (m, 14H), 4.76 (s, 1H), 4.40 
– 4.18 (m, 1H), 3.56 (d, J = 66.9 Hz, 1H), 3.41 – 2.81 (m, 2H), 2.65 (s, 1H), 
2.08 – 1.39 (m, 6H). HRMS: Calculated for [C28H26F2N4O2+H]+ = 488.2079, 
found = 488.2090. N2-isomer (2.14 mg, 4.4 µmol, 1.5%): 1H NMR (400 MHz, 
CDCl3) δ 7.48 (s, 1H), 7.40 – 6.70 (m, 13H), 5.04 – 3.66 (m, 2H), 3.47 (s, 
1H), 3.26 (t, J = 13.3 Hz, 1H), 3.16 – 2.81 (m, 2H), 1.94 – 1.43 (m, 6H). 
HRMS: Calculated for [C28H26F2N4O2+H]+ = 488.2079, found = 488.2091. 
 
(R)-(2-Benzylpiperidin-1-yl)(3-(bis(4-fluorophenyl)(hydroxy)methyl)-1H-1,2,4-triazol-1-yl)methanone (3) 
Synthesized according to General Procedure 1 from 21 (65 mg, 0.23 mmol). 
The title compound was obtained as a white solid (34.7 mg, 0.071 mmol, 
35%). 1H NMR (400 MHz, CD3CN) δ 8.04 (bs, 1H), 7.35 (d, J = 6.6 Hz, 4H), 
7.12 (s, 3H), 7.07 – 6.70 (m, 7H), 4.88 (s, 1H), 4.72 (s, 1H), 4.03 (d, J = 15.5 
Hz, 1H), 3.23 (t, J = 13.1 Hz, 1H), 2.70 (s, 1H), 1.83 – 1.32 (m, 6H). HRMS: 
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(R)-(2-Benzylpiperidin-1-yl)(3-(bis(4-fluorophenyl)(hydroxy)methyl)-1H-pyrazol-1-yl)methanone (4) 
Synthesized according to General Procedure 1 from 25 (65 mg, 0.23 mmol). 
The title compound was obtained as a white solid (21 mg, 0.043 mmol, 21%). 
1H NMR (400 MHz, CD3CN) δ 7.66 – 7.49 (m, 1H), 7.42 – 7.29 (m, 4H), 7.17 
(dd, J = 5.1, 1.9 Hz, 3H), 7.13 – 6.92 (m, 6H), 6.22 (d, J = 2.6 Hz, 1H), 4.77 
(s, 1H), 4.59 (s, 1H), 4.17 – 3.99 (m, 1H), 3.25 (td, J = 13.4, 3.0 Hz, 1H), 
3.10 (dd, J = 13.5, 9.0 Hz, 1H), 2.83 – 2.68 (m, 1H), 1.88 – 1.21 (m, 6H). 
HRMS: Calculated for [C29H27F2N3O2+H]+ = 488.2144, found = 488.2140. 
 
(R)-(2-Benzylpiperidin-1-yl)(4-(bis(4-fluorophenyl)(hydroxy)methyl)-1H-imidazol-1-yl)methanone (5) 
Synthesized according to General Procedure 1 from 29 (83 mg, 0.29 mmol). 
The title compound was obtained as a white solid (38 mg, 0.078 mmol, 27%). 
1H NMR (400 MHz, CD3CN) δ 7.42 (s, 1H), 7.38 – 6.99 (m, 13H), 6.27 (s, 1H), 
4.47 (s, 1H), 4.30 (qt, J = 7.1, 3.8 Hz, 1H), 3.81 (d, J = 13.7 Hz, 1H), 3.32 (td, 
J = 13.3, 2.9 Hz, 1H), 3.19 (dd, J = 13.7, 10.0 Hz, 1H), 2.78 (dd, J = 13.7, 5.5 
Hz, 1H), 1.92 – 1.63 (m, 6H).  
HRMS: Calculated for [C29H27F2N3O2+H]+ = 488.2144, found = 488.2142. 
 
(4-([1,1'-Biphenyl]-4-yl)-1H-1,2,3-triazol-1-yl)(2-benzylpiperidin-1-yl)methanone (KT109) 
Synthesized according to General Procedure 1 from 30 (2.31 g, 10.4 
mmol). The N1-isomer was isolated as first eluting isomer (621 mg, 
1.47 mmol, 14%). 1H NMR (400 MHz, CDCl3) δ 7.87 (s, 2H), 7.75 – 
7.60 (m, 4H), 7.53 – 7.35 (m, 4H), 7.24 (d, J = 15.7 Hz, 6H), 4.86 (s, 
1H), 4.37 (d, J = 13.5 Hz, 1H), 3.31 (d, J = 52.1 Hz, 2H), 2.70 (s, 1H), 
2.11 – 1.62 (m, 6H).  
HRMS: Calculated for [C27H26N4O + H]+ = 423.2179, found = 423.2183. 
  
 




Figure S4.1 | Example DynaFit script. All concentrations are in µM units, rate constants are given in min-1 (koff, kinact 




Figure S4.2 | Absorption of 4-nitrophenol. Linear curve fit of 
absorbance measured for a concentration of 4-nitrophenol in the 
assay buffer. 6 repetitions are given for each condition. Dashed lines 




data = progress | task = fit  
 
[mechanism]  
E + S ---> E + P : kprod  
E + I <==> E.I : kon* koff 
E.I ---> E-I : kinact  
E ---> E* : kdeg  
 
[constants] | kprod = 4.7 ?, kon* = 100000, koff = 400 ?, kinact = 1 ?, kdeg = 0.027 ?  
 
[concentrations] | E = 0.001 ? (0.0005 .. 0.005), S = 600 
 
[responses] | P = 0.001735  
 
[data]  
directory ../Input  
sheet 2018-07-10_filename_001.txt  
column 2 | offset = auto ? (-0.2 .. +0.2) | conc I = 0  
column 7 | offset = auto ? (-0.2 .. +0.2) | conc I = 0.008 
column 8 | offset = auto ? (-0.2 .. +0.2) | conc I = 0.004 
column 9 | offset = auto ? (-0.2 .. +0.2) | conc I = 0.002 
column 10 | offset = auto ? (-0.2 .. +0.2) | conc I = 0.001 
column 11 | offset = auto ? (-0.2 .. +0.2) | conc I = 0.0005 
column 12 | offset = auto ? (-0.2 .. +0.2) | conc I = 0.00025 
column 13 | offset = auto ? (-0.2 .. +0.2) | conc I = 0.000125 
 
[output] 
directory ../Output/2018-07-10_filename_001/2018-07-10_filename_001_compound/  
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5. BIA 10-2474 is a non-selective 












In January 2016, a first-in-human study of the fatty acid amide hydrolase (FAAH) inhibitor 
BIA 10-2474 led to the death of one volunteer and the hospitalization of four others.1–4 All 
patients manifested mild-to-severe neurological symptoms.3 FAAH is a membrane-bound 
serine hydrolase that degrades the endocannabinoid anandamide and related amidated 
lipids.5–8 Three explanations for the clinical neurotoxicity of BIA 10-2474 have been 
proposed: (i) errors may have occurred in the clinical trial itself, either in the manufacturing 
or handling of the compound or in the conduct of the trial; (ii) through its inhibitory effects 
on FAAH, BIA 10-2474 may have produced high levels of long-chain fatty acid amides (e.g., 
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anandamide) and their oxygenated metabolites, which could potentially overstimulate 
cannabinoid CB18, TRPV19, and/or NMDA receptors10; or (iii) BIA 10-2474 and/or its 
metabolites might have off-target activities. The first hypothesis was dismissed by the 
French authorities.4 The second hypothesis is considered unlikely because other FAAH 
inhibitors, such as PF-04457845, have exhibited favourable safety profiles in phase 1 and 
2 clinical trials.11,12 No information has previously been made available regarding the 
protein interaction profile of BIA 10-2474 that could help in defining the cause of its clinical 
toxicity, and in particular to directly evaluate the third hypothesis – the possibility that the 
observed clinical neurotoxicity might have resulted from off-target activity.1 Therefore, 
aided by chemical proteomic methods for mapping the interaction landscapes of 
(ir)reversible serine hydrolase inhibitors13–17, the serine hydrolase target selectivity of BIA 
10-2474 versus other widely used FAAH inhibitors was desired. To this end a comparative 
study was set up to determine and compare the interaction profiles of BIA 10-2474, its 
major metabolite BIA 10-2639, the clinically safe PF-04457845 and URB597. 
 
Results 
BIA 10-2474 (Figure 5.1A) contains an electrophilic imidazole urea that may react with 
the nucleophilic serine of FAAH and other serine hydrolases to form covalent and 
irreversible adducts. On the basis of previously developed chemical proteomic methods to 
map the interaction landscapes of (ir)reversible serine hydrolase inhibitors,13–17 it was 
anticipated that the serine hydrolase targets of BIA 10-2474 could be identified and 
compared to the selectivity profiles of other widely used FAAH inhibitors, such as URB5976 
and the clinical candidate PF-04457845.18 PF-04457845 progressed to phase 2 trials 
without serious adverse events.18 Therefore, BIA 10-2474 along with BIA 10-2639, a 
confirmed metabolite in which the N-oxide is reduced to a pyridine, were synthesized.4 
These compounds were tested for inhibition of FAAH-catalysed conversion of 
[14C]-anandamide to arachidonic acid and [14C]-ethanolamine.19 Surprisingly, BIA 10-2474 
showed very weak inhibitory activity (IC50 > 1 µM) against the FAAH species tested (human, 
mouse) compared to PF-04457845 and URB597, which exhibited IC50 values of ~0.01 and 




Figure 5.1 | Chemical structure and potency of human FAAH inhibitors. A) Structures of BIA 10-2474, 
metabolite BIA 10-2639, PF-04457845 and URB597. B) hFAAH activity relative to control after incubation with 
1, 10 and 50 µM of indicated inhibitors as measured in a radiometric [14C]-anandamide assay on purified 
recombinant hFAAH enzyme. Activity is expressed as mean ± SEM (n=3) with *P<0.05, ** P<0.01, *** 
P<0.001 (two-tailed t-test).  
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Activity-based protein profiling (ABPP) is used for rapid and efficient visualization of 
endogenous serine hydrolase activities in native biological samples.13,15 Comparative and 
competitive gel-based ABPP studies were performed with two different activity-based 
probes: the broad-spectrum serine hydrolase-directed probe fluorophosphonate-
rhodamine (FP-TAMRA)15 and the tailored probe MB064 that preferentially reacts with 
endocannabinoid hydrolases diacylglycerol lipase-α (DAGL-α), α/β-hydrolase domain 
containing protein (ABHD) 6, and ABHD12, along with a handful of other enzymes.14,17 
Together, FP-TAMRA and MB064 provide target engagement assays for FAAH and a broad 
array of other brain serine hydrolases. As a first screen, a gel-based ABPP assay using 
mouse brain proteomes was performed. In total, 50 fluorescent bands were identified 
corresponding to putative serine hydrolases. Representative gel-based ABPP data are 
shown (Figure 5.2). The clinical trial subjects who developed neurological symptoms were 
exposed to a concentration of BIA 10-2474 that was 20 to 50 times higher than required 
for full blockade of FAAH activity.4 Therefore, inhibitor activities against FAAH and other 
serine hydrolases were initially evaluated at two high concentrations (10 and 50 µM) in 
brain soluble and membrane proteomes. All tested compounds inhibited FAAH, with 
BIA 10-2474 showing the weakest activity, while also exhibiting distinctive off-target 
activities. In particular, BIA 10-2474 reduced the intensity of an additional fluorescent band 
in the membrane proteome (red box in panel A), which was identified as ABHD6 based on 
previous research.16 PF-04457845 and URB597 reduced the fluorescent labeling of 2 
other proteins, but ABHD6 was notably not among them. Moreover, BIA 10-2474 did not 
prevent labeling of the endocannabinoid hydrolases monoacylglycerol lipase (MAGL) or 
DAGL-α (Figure 5.2).  
The brain target engagement profiles were confirmed and extended by performing ABPP 
coupled to high-resolution quantitative mass spectrometry (MS). This methodology allows 
for a more accurate quantification by avoiding band overlap (as observed with the gel-based 
assay) and enables screening over a broader range of specified serine hydrolases.13 Mouse 
brain proteomes treated with inhibitor or vehicle were incubated with the serine hydrolase-
directed activity-based probes FP-biotin and MB108, a biotinylated version of MB064. 
Probe-labeled enzymes were enriched by avidin chromatography, digested with trypsin, and 
the resulting tryptic peptides modified by reductive dimethylation (ReDiMe) of the NH2-
groups of N-termini and lysine residues using isotopically heavy and light formaldehyde. In 
these experiments, inhibited serine hydrolases were identified as enzymes exhibiting low 
heavy/light ratios. Quantitative MS confirmed complete inhibition of FAAH and validated 
ABHD6 as a major off-target of BIA 10-2474 and its metabolite, but not PF-04457845 ( 
Figure 5.3). In addition to ABHD6, CES1c and ABHD11 were also identified as partial BIA 
10-2474 off-targets in murine brain. PPME1 was identified as a potential, partial off-target 
for PF-04457845 with a heavy/light ratio < 0.5 ( 
Figure 5.3).  
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Figure 5.2| Identification of serine hydrolase targets of BIA 10-2474, PF-04457845, URB597 and BIA 10-
2639 by competitive ABPP of mouse brain proteome. Mouse brain membrane (A, B) or cytosol (C, D) proteome 
was incubated with inhibitors (10 and 50 µM, 30 min, 37 ˚C) or DMSO as vehicle. Samples were incubated 
with MB064 (A,C) or FP-TAMRA (B,D). Red boxes highlight ABHD6 (A) and FAAH (B). 
 
 
Figure 5.3 | MB108 and FP-biotin based chemoproteomic analysis of serine hydrolase activities in the mouse 
brain proteome treated with inhibitors BIA 10-2474 (A), BIA 10-2639 (B) and PF-04457845 (C) (50 µM, 30 
min, 37 °C). Data is expressed as mean ± SEM (n=3).  
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Using dedicated activity and binding assays it was determined that BIA 10-2474 and 
PF-04457845 did not cross-react with other proteins of the endocannabinoid system, 
including cannabinoid CB1 and CB2 receptors, DAGL-α, DAGL-β, MAGL and N-acyl-
phosphatidylethanolamine phospholipase D (NAPE-PLD), nor with the endocannabinoid-
binding TRP ion channels (TRPV1-4, TRPM8 and TRPA1) (Supplementary Tables 1 and 2). 
Finally, activity-based probes based on the structure of BIA 10-2474 were designed to 
identify potential non-serine hydrolase proteins that are directly modified by the inhibitor. 
To this end, compounds AJ167, AJ179 and AJ198 were synthesized (Figure 5.4), in which 
an alkyne functionality was introduced at different positions in BIA 10-2474. In all three 
probes, the alkyne group serves as a ligation handle to introduce fluorescent reporter 
groups via copper(I)-catalysed azide-alkyne cycloaddition (“click”) chemistry.21 Competitive 
ABPP revealed that compounds AJ179 and AJ198 are effective FAAH inhibitors and that 
ABHD6 can be partially inhibited by compounds AJ167 and AJ198 (Figure 5.5). Reaction of 
mouse brain proteomes treated with compound AJ167, AJ179, or AJ198 to a fluorophore 
using click chemistry revealed labeling of a band at the molecular weight of FAAH for probe 
AJ179 and AJ198. Additionally, compounds AJ179 and AJ198 also labeled a protein at the 
molecular weight of ABHD6. All FAAH and ABHD6 bands could be competed with 
BIA 10-2474. Importantly, these experiments definitively prove covalent binding of AJ179 
and AJ198 to FAAH, which was maintained even under SDS-PAGE denaturing conditions. 
This observation, together with ~3-fold increased potency towards rat brain FAAH following 
a 20 min pre-incubation22, supports an irreversible inhibition mechanism for BIA 10-2474. 
Few additional labeled proteins were detected, indicating that BIA 10-2474 has limited 
























Figure 5.4 | Chemical structures of alkynylated BIA 10-2474-based probes AJ167, 
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Figure 5.5 | Mouse brain membrane (A) or cytosol (B) proteomes were incubated with BIA 10-2474, the alkyne 
probes (50 µM, 30 min, 37 °C) or vehicle (DMSO). Residual activity was labeled with MB064 or FP-TAMRA. 
C-D) Mouse brain membrane (C) or cytosol (D) proteomes were incubated with BIA 10-2474 (50 µM, 30 min, 
37 °C) or vehicle (DMSO). Samples were then incubated with alkyne probes (AJ167, AJ179 or AJ198; 50 µM, 
30 min, 37 °C) or vehicle (DMSO), followed by a copper-catalyzed azide-alkyne cycloaddition to Cy5-azide. 
Competitive ABPP of BIA 10-2474 with MB064 or FP-TAMRA (as described for A, B) is shown as a reference.  
 
As noted above, BIA 10-2474 exhibited weaker in vitro potency for FAAH compared to 
PF-04457845 and other advanced FAAH inhibitors. Remarkably, however, this difference 
was attenuated in situ, as gel-based ABPP experiments revealed that BIA 10-2474 inhibited 
FAAH, as well as other serine hydrolases (e.g., FAAH2, ABHD6) with substantially increased 
potency in human cells (Figure 5.6). The reason for the increased cellular activity of BIA 
10-2474 is at present unclear, but it is not specific to one protein, which may suggest that 
cellular accumulation of the compound provides sufficiently high intracellular 
concentrations to inhibit FAAH and other serine hydrolases (vide infra).  
In light of these data, the structural analogues AJ167, AJ176 and AJ198 were also 
expected to label more efficiently in situ. To test this hypothesis murine neuroblastoma 
(Neuro-2a) cells were treated with medium containing either BIA 10-2474, or either one of 
the three alkynated derivatives (Figure 5.7). From Figure 5.7A, it is clear that the two-step 
probes are much more efficient in situ (IS) than in vitro (IV). Especially AJ198 showed a 
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remarkable increase in labeling. Figure 5.7B shows a competition experiment between BIA 
10-2474 and all three two-step probes. This demonstrated that the two bands shared by 
all probes were in fact FAAH and ABHD6 (red boxes) and these could be outcompeted by 
BIA 10-2474. All other clearly visible bands failed to be outcompeted. Therefore, it was 
decided not to pursue MS-based ABPP with these probes, because it is unlikely that this 
would yield additional off-targets. 
 
 
Figure 5.6 | HEK293T cells transiently overexpressing FAAH (A), endogenously expressing 
ABHD6 (B) and overexpressing FAAH2 (C) were treated with BIA 10-2474 (2 h, 37 °C) or 
DMSO as vehicle (n=3). Membrane fractions of untreated overexpressing cells were 
incubated with BIA 10-2474 (30 min, 37 °C) or DMSO as vehicle (in vitro). All samples 
were labeled with FP-TAMRA. Coomassie staining was used as loading control. 
 
 
Figure 5.7 | In situ and in vitro activity profile of BIA 10-2474, AJ167, AJ179 and AJ198 by two-step competitive 
ABPP. Neuro-2a cells were treated in situ (IS) with BIA 10-2474, AJ167, AJ179 or AJ198 (10 µM, 2 h, 37°C) 
or in vitro (IV) with BIA 10-2474, AJ167, AJ179, AJ198 (10 µM, 30 min, 20/37°C) or vehicle (DMSO). Probe 
labeled targets were ligated to Cy5. Coomassie staining was used as a protein loading control. 
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The adverse effects observed during the clinical trial of BIA 10-2474 were not present 
in the preclinical toxicity profiling.3 It was thus hypothesized that the off-target profile of BIA 
10-2474 might also differ between species. Taking into account the potency difference 
between in situ versus in vitro, BIA 10-2474-treated cultured human neurons were profiled 
in ABPP studies. Several additional off-targets were identified: carboxyl esterase 2 (CES2), 
phospholipase 2 group XV (PLA2G15, also known as lysosomal phospholipase A2 (LPLA2)) 
and patatin-like containing phospholipase domain protein 6 (PNPLA6) (Figure 5.8) by 




Figure 5.8 | In situ treatment of human neuronal cultures reveals additional BIA 10-2474 off-targets. A) Human 
neuronal cultures were treated in situ with BIA 10-2474 (50 µM, 24 h, 37 °C) or DMSO as vehicle (n=3). 
Lysates were incubated with FP-TAMRA or MB064. B) FP-biotin based chemoproteomic analysis of serine 
hydrolase activities in human neuronal cultures treated in situ with BIA 10-2474 or DMSO as vehicle (50 µM, 
24 h, 37 °C). C-E) In situ dose response of BIA 10-2474 (0.1 - 100 µM, 24 h, 37 °C) and DMSO as vehicle on 
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Most of the interaction partners of BIA 10-2474 identified in this study are involved in 
cellular lipid metabolism.23–26 To confirm the interaction of BIA 10-2474 with lipolytic serine 
hydrolase off-targets, these human enzymes were transiently overexpressed in HEK293T 
cells. Concentration-dependent inhibition by BIA 10-2474 was assessed using gel-based 
ABPP (Figure 5.8C-E). BIA 10-2474 was found to inhibit PNPLA6, CES2 and PLA2G15 with 
IC50 values of 11, 16 and 38 µM, respectively. It is also noted that human CES2, as well as 
human ABHD6, were inhibited more potently by BIA 10-2474 and BIA 10-2639 than the 
mouse orthologues of these enzymes (data not shown). The found off-target profile led to 
the hypothesis that prolonged exposure to BIA 10-2474 might result in alterations of lipid 
metabolism in human cells. To test this hypothesis, targeted lipidomics analysis of human 
neuronal cultures treated with vehicle or BIA 10-2474 was performed. In total, 161 lipid 
species were quantified from which significant changes in several lipid classes were 
observed. Levels of N-acylethanolamines, triglycerides, monoacylglycerols and 
(lyso)phosphatidylcholines were increased in BIA 10-2474-treated cells, while those of free 
fatty acids and plasmalogens were reduced (Figure 5.9A). Notably, these alterations in 
cellular lipid metabolism are consistent with the inhibition of FAAH, FAAH2, ABHD6, CES2, 
PLA2G15 and PNPLA6 activities. Neuronal cells treated with PF-04457845 (1 µM) only 
showed significant increase in the N-acylethanolamine levels, consistent with selective 
FAAH inhibition (Figure 5.9B). 
 
 
Figure 5.9 | Volcano plot of lipidomic analysis of human neurons treated in situ with BIA 10-2474 (50 µM, 
48 h, 37 °C) (A) and PF-04457845 (1 µM, 48 h, 37 °C) (B) compared to cells treated with DMSO as vehicle. 
Lipids with a fold change (FC) threshold of ≥1.20 or ≤0.80 and Benjamini–Hochberg false discovery rate (FDR) 
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Discussion 
Severe adverse effects of drug candidates are rarely observed in phase 1 clinical trials, 
due to extensive preclinical toxicological profiling in animals and precautions taken into 
account in the design of first-in-human studies.1 No obvious toxicological results in rodents 
were found that could predict the observed human clinical neurotoxicity. In a study on dogs 
treated for 13 weeks with BIA 10-2474, a dose-dependent pulmonary toxicity was observed 
and two dogs from the subgroup receiving the highest dose were sacrificed. An initial 
toxicology study in primates showed that the highest administered dose led to axonal 
dystrophy in the spinal bulb. A follow-up primate study led to the death of one animal and 
the sacrifice of several others for undisclosed ethical reasons. These findings were not, 
however, considered to be sufficiently concerning to abandon the first-in-human studies 
due to the large therapeutic window in preclinical studies of BIA 10-2474.4 
The main remaining hypothesis to explain the human clinical neurotoxicity of 
BIA 10-2474 as put forward by the French authorities4 (i.e. off-target activity of BIA 10-2474 
and/or its metabolites) was the basis of the here described study. BIA 10-2474 was shown 
to be an irreversible, potent FAAH and FAAH2 inhibitor that increases cellular levels of long-
chain fatty acid ethanolamides. Using ABPP with mouse brain proteomes and human 
cortical neuron proteomes, BIA 10-2474, but not PF-04457845, was found to inhibit 
multiple lipases, including ABHD6, CES2, PLA2G15 and PNPLA6. BIA 10-2474 also 
disrupted neural lipid metabolism as witnessed by increased levels of N-acylethanolamines, 
monoacylglycerols, triglycerides phosphatidylcholine, (lyso)phosphatidylcholine, and 
reductions in free fatty acids and plasmalogens. When considering the basis for 
BIA 10-2474’s broader interaction profile with serine hydrolases compared to 
PF-04457845, it is suspected that the greater intrinsic reactivity of BIA 10-2474 may be a 
contributing factor, though this warrants further investigation. 
 FAAH2 is a human-specific orthologue of FAAH, which also degrades long-chain fatty 
acid amides.27 However, little is known about the neurobiological function of FAAH2. CES2 
is a serine esterase involved in the hydrolysis of ester and amide bonds of xenobiotics and 
prodrugs, but also of endogenous lipids. It is highly expressed in the liver and in endothelial 
cells. Hepatic CES2 is required for triglyceride homeostasis by modulating lipolysis, ER 
stress and lipogenesis.28 PLA2G15 is a lysosomal phospholipase highly expressed in 
alveolar macrophages and microglial cells. Inhibition of PLA2G15 leads to accumulation of 
phosphatidylcholines and phosphatidylethanolamines, and has previously been implicated 
in drug-induced phospholipidosis.25 
PNPLA6 (also known as neuropathy target esterase, NTE) has previously been linked to 
neurodegeneration in humans resulting from exposure to organophosphate-based 
pesticides.24,29 PNPLA6 is a (lyso)phospholipase that uses (lyso)phosphatidylcholine as a 
substrate and is highly expressed in endothelial cells, astrocytes and neurons. Proper 
neuronal phosphatidylcholine homeostasis mediated by PNPLA6 is required for axonal 
maintenance.30 PNPLA6 inhibition leads to neurodegeneration following an age-dependent 
neuropathy of increasing severity in older age. Notably, PNPLA6-mediated neurotoxicity 
following acute organophosphate exposure is species dependent, with less pronounced 
effects in rodents than humans. Mice with a homozygous germline deletion of PNPLA6 have 
embryonic lethality due to placental and vasculature defects, however, brain-specific 
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deletion of PNPLA6 results in prominent neuronal pathology.31 A threshold of >70% PNPLA6 
inhibition has been determined as responsible for developing neurodegeneration upon 
organophosphate exposure in chicken.24,29 In the light of this data, it is remarkable that 
many clinical symptoms arising from PNPLA6-mediated neurological sequelae following 
organophosphate exposure resemble the neuropathology observed in the clinical trial 
participants who received a cumulative dose of 250-300 mg of BIA 10-2474, including 
precedent for human neurotoxicity, brain region sensitivity, age dependency, species 
selectivity, dosing threshold and time course of neuropathology. However, while our data 
provide information about the selectivity of BIA 10-2474, they do not allow us to conclude 
that inhibition of one or more of the identified off-target proteins is responsible for the 
clinical neurotoxicity caused by this drug. Nor can we exclude the possibility that non-
covalent interactions of BIA 10-2474 or its metabolites with other proteins might have 
contributed to the reported clinical effects.32  
Regardless, our study highlights the general utility of ABPP as a versatile chemical 
proteomic method to assess on-target engagement and off-target activity of covalent drugs 
to guide therapeutic development. 
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Methods 
Probes and inhibitors 
Activity based probe TAMRA-fluorophosphonate (FP-TAMRA) was purchased from Thermo Fisher, MB064 was 
synthesized in-house as previously described.14 PF-04457845 was synthesized in house and purchased from 
Sigma Aldrich. URB597 was purchased from Sigma Aldrich. Inhibitor BIA 10-2474, BIA 10-2639 and activity 
based probes AJ167, AJ179 and AJ198 were synthesized as described in the synthetic methods (vide infra). 
All synthesized compounds were at least 95% pure and were analyzed by LC/MS, NMR and HRMS. Other 
chemicals, reagents, and primers were purchased from Sigma Aldrich unless indicated otherwise. 
 
Cloning 
Full-length human cDNA of ABHD6, FAAH, ABHD11, PNPLA6, CES2 (Source Bioscience) and FAAH2 (BioCat) 
was cloned into mammalian expression vector pcDNA3.1, containing genes for ampicillin and neomycin 
resistance. The inserts were cloned in frame with a C-terminal FLAG-tag and site-directed mutagenesis was 
used to remove restriction by silent point mutations. Plasmids were isolated from transformed XL-10 
Z-competent cells (Maxi Prep kit: Qiagen) and sequenced at the Leiden Genome Technology Center. Sequences 




HEK293T (human embryonic kidney) and Neuro-2a (mouse neuroblastoma) cells were cultured at 37 °C under 
7% CO2 in DMEM containing phenol red, stable glutamine, 10% (v/v) New Born Calf Serum (Thermo Fisher), 
and penicillin and streptomycin (200 µg/mL each; Duchefa). Medium was refreshed every 2-3 days and cells 
were passaged twice a week at 80-90% confluence by resuspension in fresh medium.  
Cells lines were purchased from ATCC and were regularly tested for mycoplasma contamination. Cultures were 
discarded after 2-3 months of use. 
 
Human neural cell culture 
Human iPSC-derived neural progenitor cells (NPCs) (Axol Biosciences, line ax0015) were plated on sterile 
coverslips in 12-well plates, coated with poly-L-ornithin/laminin (Sigma-Aldrich), in neural differentiation 
medium (Neurobasal medium, 1% N2 supplement, 2% B27-RA supplement, 1% MEM-NEAA, 20 ng/mL BDNF 
(ProSpec Bio)), 20 ng/mL GDNF (ProSpec Bio), 1 µM db-cAMP (Sigma-Aldrich), 200 µM ascorbic acid (Sigma-
Aldrich), 2 µg/mL laminin, and 1% P/S), resulting in neural networks composed of neurons and glia. Cells were 
refreshed with neural differentiation medium 3 times per week. During weeks 1-4, medium was fully refreshed. 
After 4 weeks of neural differentiation, only half of the volume of medium per well was refreshed.  
 
Transient transfection 
One day prior to transfection HEK293T cells were seeded to 15-cm dishes or 12-well plates (~62.500 
cells/cm2). Prior to transfection, culture medium was aspirated and a minimal amount of medium was added. 
A 3:1 (m/m) mixture of polyethyleneimine (PEI) (60 µg/dish or 1.875 µg/well) and plasmid DNA (20 µg/dish 
or 0.625 µg/well) was prepared in serum-free culture medium and incubated for 15 min at RT. Transfection 
was performed by dropwise addition of the PEI/DNA mixture to the cells. Transfection with the empty pcDNA3.1 
vector was used to generate control samples. After 24 h, medium was refreshed. Medium was aspirated 48 
or 72 h post-transfection and cells were harvested by resuspension in PBS. Cells were pelleted by 
centrifugation (5 min, 1,000 g) and the pellet was washed with PBS. Supernatant was discarded and cell 
pellets were frozen in liquid nitrogen and stored at -80 °C until sample preparation. 
 
In situ treatment of HEK293T or Neuro-2a cells  
In situ treatment was initiated 24 h (for 24 – 48 h treatment) or 48 h (for 2 h treatment) post-transfection in 
12-well plates. Medium was aspirated and medium containing inhibitor or DMSO as vehicle was added 
(0.1-1.0% v/v DMSO, DMSO concentration constant within each experiment). Final concentrations for 
inhibitors are indicated in the main text and figure legends. After 2, 4, 24, or 48 h exposure to treatment 
medium, medium was aspirated and cells were harvested and stored as described above until sample 
preparation (whole cell lysate). 
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In situ treatment of human neural cell culture  
Cells were treated with inhibitor in situ 7-8 weeks after plating of NPCs. Culture slides were then collected from 
6-well culture plates 24 h or 48 h after initiation of in situ treatment with BIA 10-2474 (50 µM, 0.25% DMSO) 
or vehicle (0.25% DMSO). The in situ treated cells were harvested in PBS as described above and stored 
at -80 °C until further use. 
 
Sample preparation 
Whole cell lysate 
Cell pellets were thawed on ice, resuspended in cold lysis buffer (20 mM HEPES, pH 7.2, 2 mM DTT, 250 mM 
sucrose, 1 mM MgCl2, 2.5 U/mL benzonase) and incubated on ice (15-30 min). The cell lysate was used for 
membrane preparation (below) or diluted to appropriate concentration in cold storage buffer (20 mM Hepes, 
pH 7.2, 2 mM DTT) for use as whole lysate (HEK293T: 2.0 mg/mL, human cortical neurons: 0.75 mg/mL, 
human neural cells: 1.5 mg/mL). Protein concentrations were determined by a Quick Start™ Bradford Protein 
Assay and diluted samples were flash frozen in liquid nitrogen and stored at -80 °C until further use. 
 
Tissue lysate 
Mouse brains (C57Bl/6) were isolated according to guidelines approved by the ethical committee of Leiden 
University (DEC#13191), frozen in liquid nitrogen, and stored at -80 °C until use. Tissues were thawed on ice, 
dounce homogenized in cold lysis buffer and incubated on ice (15 min), followed by two low-speed spins (3 min, 
1,400−2,500 g, 4 °C) to remove debris. The supernatant fraction was collected for further use. 
 
Membrane preparation from lysate 
The membrane and cytosolic fractions of cell or tissue lysates were separated by ultracentrifugation (93,000 g, 
45 min, 4°C). The supernatant was collected (cytosolic fraction) and the membrane pellet was resuspended 
in cold storage buffer by thorough pipetting and passage through an insulin needle. Protein concentrations 
were determined by a Quick Start™ Bradford Protein Assay and samples were diluted to 2.0 mg/mL with cold 
storage buffer, flash frozen in liquid nitrogen and stored at -80 °C until further use. FAAH and FAAH2 
overexpression membranes were mixed in an appropriate ratio for ABPP (0.1 mg/mL: 1.0 mg/mL). 
 
Activity based protein profiling 
Gel based: Direct activity based probes 
Gel-based ABPP was performed and analyzed with minor adaptations on previously reported procedures.14 In 
brief, for in vitro inhibition, or mouse brain proteome or cell lysate (15 µL, 0.75, 1.5 or 2.0 mg/mL, lysate, 
cytosol or membrane fraction) was pre-incubated with vehicle or inhibitor (0.375 µL 40* inhibitor stock, 
30 min, 37 °C) followed by an incubation with the activity-based probe (0.375 µL 40* stock, final 
concentrations: 250 nM for MB064 or 500 nM for FP-TAMRA, 20 min, RT). Final concentrations for the 
inhibitors are indicated in the main text and figure legends. For in situ inhibition, the in situ-treated cells (15 µL 
whole lysate) were directly incubated with the activity-based probe (0.375 µL 40* stock, final concentrations: 
250 nM for MB064 or 500 nM for FP-TAMRA, 20 min, RT). Reactions were quenched with 4* Laemmli buffer 
(5 µL, 240 mM Tris (pH 6.8), 8% (w/v) SDS, 40% (v/v) glycerol, 5% (v/v) β-mercaptoethanol, 0.04% (v/v) 
bromophenol blue). 7.5, 15 or 20 µg per reaction was resolved on a 10% acrylamide SDS-PAGE gel (180 V, 75 
min). Gels were scanned using Cy3 and Cy5 multichannel settings (605/50 and 695/55, filters respectively) 
and stained with Coomassie after scanning. Fluorescence was normalized to Coomassie staining and 
quantified with Image Lab (Bio-Rad). IC50 curves were fitted with Graphpad Prism® 7 (Graphpad Software Inc.). 
 
Gel based: Two-step activity based probes  
The two-step labeling protocol was adapted from previously developed methods.33 In brief, human or mouse 
proteome (40 µL, 2 mg/mL, cytosol or membrane fraction) was pre-incubated with vehicle (DMSO) or inhibitor 
(50 µM, 30 min, 37 °C) followed by an incubation with the alkyne probe (50 µM, 30 min, 37 °C). Click reagent 
was freshly prepared by mixing copper sulfate (2 µL/reaction, 100 mM in water), THPTA (0.4 µL/reaction, 
100 mM in water), sodium ascorbate (1.2 µL/reaction, 1 M in water), and Cyanine 5-Azide (Cy5−N3, 
1.60 µL/reaction, 1 mM in DMSO). Click reagent (5.0 µL) was added to each proteome, mixed by brief vortexing 
and incubated (60 min, RT). Proteins were precipitated by adding methanol (50 µL), chloroform (15 µL) and 
water (15 µL), mixed by brief vortexing and pelleted by centrifugation (10 min, 4000 rpm). The supernatant 
was removed and the pellet was washed twice with methanol (50 µL). The pellet was then redissolved in 40 µL 
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of 2* Laemmli buffer (120 mM (pH 6.8), 4% (w/v) SDS, 20% (v/v) glycerol, 2.5% (v/v) β-mercaptoethanol, 
0.02% (v/v) bromophenol blue) by vortexing. Samples were boiled (95 °C, 5 min) and 20 µg proteome per 
reaction was resolved on a 10% acrylamide SDS-PAGE gel (180 V, 75 min). Gels were scanned using Cy3 and 
Cy5 multichannel settings (605/50 and 695/55, filters respectively) and stained with Coomassie after 
scanning. Coomassie staining was performed as a protein loading control. 
 
Activity-based proteomics  
Activity-based proteomics was based on previously described procedures.17 In summary, mouse whole brain 
proteome (250 µL cytosolic or membrane fraction at 1.0 mg/mL) was incubated with vehicle (2% DMSO) or 
inhibitor (BIA 10-2474, BIA 10-2639, or PF-04457845, 50 µM, 30 min, 37 °C). The proteome of in situ treated 
human neural cells (250 µL whole lysate at 0.35 mg/mL, 24 h treatment) was used without additional inhibitor 
incubation. The proteomes were then labeled with MB108 or FP-Biotin (10 µM, 60 min, RT). The labeling 
reaction was quenched and excess probe was removed by chloroform methanol precipitation. Precipitated 
proteome was resuspended in 6 M Urea/25 mM ammonium bicarbonate (250 µL) and incubated (15 min, 
RT). Subsequently DTT (2.5 µL, 1 mM) was added and the mixture was incubated (15 min, 65 °C). The sample 
cooled to RT and iodoacetamide (0.5 M, 20 µL) was added to alkylate the sample (30 min, RT, dark). SDS 
(70 µL, 10% (v/v)) was added and the proteome was heated (5 min, 65 °C). The sample was diluted with PBS 
(3 mL). 50 µL of a 50% slurry of Avidin−Agarose from egg white (Sigma-Aldrich) was washed with PBS and 
added to the proteome sample. The beads were incubated with the proteome (3 h, RT, shaking). The beads 
were isolated by centrifugation (2500 g, 2 min) and washed with SDS in PBS (10 mL, 0.5% (w/v)), followed by 
3 washes with PBS. The beads were transferred to low-binding Eppendorf tubes and proteins were digested 
with sequencing grade trypsin (Promega) (500 ng per sample) in 250 µL buffer (100 mM Tris, 100 mM NaCl, 
1 mM CaCl2, 2 % acetonitrile) (37 °C, O/N, vigorous shaking). The pH was adjusted with formic acid to pH 3 
and the beads were removed by filtration.  
The peptides were isotopically labeled by on stage tip dimethyl labeling according to literature procedures17, 
with the following modification. Dimethyl labeling was performed by the subsequent addition of 20, 20, 30, 30 
and 40 µL of Light (vehicle) or Medium (inhibitor) reagent to the stage tips. The centrifugation speed during 




Lipids were extracted from in situ treated human neural cells (48 h, 50 µM BIA 10-2474 or vehicle (0.25% 
DMSO)). The sample extraction was performed on ice. In brief, cell pellets with 1 million cells were transferred 
to 1.5 mL Eppendorf tubes, spiked with 10 µL each of deuterated labeled internal standard mix for 
endocannabinoids (N-arachidonoyl ethanolamine (AEA)-d8, N-arachidonoyldopamine (NADA)-d8, 
N-docosahexaenoylethanolamide (DHEA)-d4, 2-arachidonoylglycerol (2-AG)-d8, N-stearoylethanolamine 
(SEA)-d3, N-palmitoylethanolamine(PEA)-d4, N-linoleoylethanolamine (LEA)-d3 and N-oleoylethanolamine 
(OEA)-d4), positive apolar lipids (lysophosphatidylcholines (LPC)17:0, phosphatidylethanolamines 
(PE)17:0/17:0, phosphatidylcholines (PC)17:0/17:0, sphingomyelins (SM) d18:1/17:0, triglycerides (TG) 
17:0/17:0/17:0, ceramides (Cer) d18:1/17:0) and negative polar lipids (fatty acid (FA)17:0-d33), followed by 
the addition of ammonium acetate buffer (100 µL, 0.1 M, pH 4). After extraction with methyl tert-butyl ether 
(1 mL), the tubes were thoroughly mixed for 4 min using a bullet blender at medium speed (Next Advance, Inc., 
Averill park, NY, USA), followed by a centrifugation step (5000 g, 12 min, 4 °C). Then 925 µL of the upper layer 
methyl tert-butyl ether was transferred into clean 1.5 mL Eppendorf tubes. Samples were dried in a speed-vac 
followed by reconstitution in acetonitrile:water (50 µL, 90:10, v/v). The reconstituted samples were centrifuged 
(14,000 g, 3 min, 4 °C) before transferring into LC-MS vials. Each sample was injected on three different 
lipidomics platforms: endocannabinoids (5 µL), positive apolar lipids (2 µL) and for negative polar lipids (8 µL).  
 
LC-MS/MS Analysis for endocannabinoids 
A targeted analysis of 21 endocannabinoids and related NAEs (N-acylethanolamines) were measured using an 
Acquity UPLC I class Binary solvent manager pump (Waters, Milford, USA) in conjugation with AB SCIEX 6500 
quadrupole-ion trap (QTRAP) (AB Sciex, Massachusetts, USA). Separation was performed with Acquity HSS T3 
column (1.2 x 100 mm, 1.8 µm) maintained at 45 °C. The aqueous mobile phase A consisted of 2 mM 
ammonium formate and 10 mM formic acid, and the organic mobile phase B was acetonitrile. The flow rate 
was set to 0.4 mL/min; initial gradient conditions were 55% B held for 2 min and linearly ramped to 100% B 
over 6 minutes and held for 2 minutes; after 10 s the system returned to initial conditions and held 2 min 
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before next injection. Electrospray ionization-MS was operated in positive mode for measurement of 21 
endocannabinoids and NAEs, and a selective Multiple Reaction Mode (sMRM) was used for quantification. 
 
LC-MS/MS analysis for positive apolar and negative polar lipids 
Both lipidomics methods are adapted and modified from previously published work.34 Briefly, these methods 
are measured on an Acquity UPLC Binary solvent manager pump (Waters) coupled to an Agilent 6530 
electrospray ionization quadrupole time-of-flight (ESI-Q-TOF, Agilent, Jose, CA, USA) high resolution mass 
spectrometer using reference mass correction. The chromatographic separation was achieved on an Acquity 
HSS T3 column (1.2 x 100 mm, 1.8 µm) maintained at 40 °C for both methods. The positive polar lipids that 
include targets from different lipid classes including (lyso)phosphatidylcholines, triglycerides, ceramides. 
(lyso)phosphatidylethanolamines and sphingomyelins were separated using a flow of 0.4 mL/min over a 
16 min gradient. In positive mode, the aqueous mobile phase A consisted of 60:40 (v/v) acetonitrile:H2O with 
10 mM ammonium formate, and the organic mobile phase B consisted of 10:90 (v/v) acetonitrile:isopropanol 
with 10 mM ammonium formate. The negative apolar lipids that constitute mainly free fatty acids and 
(lyso)phosphatidylcholines were separated with a flow of 0.4 mL/min over 15 min gradient. In negative mode, 
the aqueous mobile phase A consisted of 5:95 (v/v) acetonitrile:H2O with 10 mM ammonium formate, and the 
organic mobile phase B consisted of 99% (v/v) methanol with 10 mM ammonium formate. The targets in both 
lipid methods were detected full scan (100-1000 m/z) in their respective ion charge mode. 
 
Activity assays 
Radiolabeled natural substrate assay hFAAH and mFAAH 
The radiolabeled natural substrate based assay for human and mouse FAAH was performed as reported 
previously.35 In brief, chemicals were of the purest analytical grade. Anandamide (AEA) was purchased from 
Sigma Chemical Co. (St. Louis, MO, USA). URB597 and purified hFAAH were obtained from Cayman Chemical 
(Ann Arbor, MI, USA). [14C-ethanolamine]-anandamide (60 Ci/mmol) was purchased from ARC (St. Louis, MO).  
Mouse brain membranes (50 µg per test), prepared as reported35, or hFAAH (2.5 µg per test) were pre-
incubated for 15 min at room temperature with each compound, then they were incubated with 10 µM 
[14C-ethanolamine]anandamide (15 min, 37 °C, in 500 µL of 50 mM Tris–HCl buffer (pH = 9)). The reaction 
was stopped by the addition of 0.6 mL of ice-cold methanol/chloroform (2:1, v/v). The mixture was centrifuged 
(3000 g, 5 min), the upper aqueous layer was put in a vial containing liquid scintillation cocktail (Ultima Gold 
XR, Perkin Elmer Life Sciences), and radioactivity was quantified in a β-counter. 
 
Natural substrate-based fluorescence assay DAGL-α/β  
The natural DAG substrate assay was performed as reported previously.36 Standard assay conditions: 
0.2 U/mL glycerol kinase (GK), glycerol-3-phosphate oxidase (GPO) and horseradish peroxidase (HRP), 
0.125 mM ATP, 10 µM Amplifu™Red, 5% DMSO in a total volume of 200 µL. The assay additionally contained 
5 µg/mL MAGL-overexpressing membranes, 100 µM SAG and 0.0075% (w/v) Triton X-100, with a final protein 
concentration of 50 µg/mL. The mDAGL-β assay was performed as the hDAGL-α assay, but assay buffer was 
supplemented with 5 mM CaCl2 and the SAG concentration was 75 µM. 
 
Natural substrate-based fluorescence assay MAGL 
The natural substrate MAGL assay was performed as previously published.36 
 
Surrogate substrate assay NAPE-PLD 
The surrogate substrate assay was based on a previously reported method.37 The membrane protein fraction 
HEK293T cells transiently overexpressing NAPE-PLD was diluted to 0.4 mg/mL in assay buffer (50 mM Tris-
HCl (pH 7.5), 0.02% Triton X-100, 150 mM NaCl). The substrate PED6 (Invitrogen) stock (10 mM) was 
consecutively diluted in DMSO (25x) and in assay buffer (10x). Relevant concentrations of compounds were 
prepared in DMSO. The assay was performed in a dark Greiner 96 wells plate, end volume 100 µL. The 
membrane protein lysate (final concentration 0.04 mg/mL) was incubated with inhibitor or vehicle (30 min, 
37 °C). A sample without membrane protein lysate was incorporated for background subtraction. 
Subsequently, substrate was added (PED6, final concentration: 1 µM) and the measurement was started 
immediately on a TECAN infinite M1000 pro (37 °C, scanning at 2 min intervals for 1 h: excitation 485 nm, 
emission 535 nm). 
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Radioligand displacement assays CB1/ CB2-receptor 
[3H]CP55940 displacement assays to determine the affinity for the cannabinoid CB1 and CB2 were performed 
as previously described16,38, with the following changes: ligands of interest were incubated (25 °C, 2 h) with 
membrane aliquots containing 1.5 µg (CHOK1hCB2_bgal) membrane protein in 100 µL assay buffer (50 mM 
Tris–HCl, 5 mM MgCl2, 0.1 % BSA, pH 7.4) with ~1.5 nM [3H]CP55940 per assay point. Non-specific binding 
was determined in the presence of 10 µM AM630. Filtration was performed on 96-well GF/C filters, each well 
presoaked for 30 min with 25 µL 0.25 % PEI, using a 96-wells Filtermate harvester (PerkinElmer). Filter-bound 
radioactivity was determined by scintillation spectrometry using a Microbeta® 2450 microplate counter 
(PerkinElmer). 
 
Fluorescent Ca2+ assays for TRP ion channels 
HEK293 (human embryonic kidney) cells stably over-expressing recombinant human TRPV1 or rat TRPA1, 
TRPV2, TRPV3, TRPV4, or TRPM8 were grown on 100 mm diameter Petri dishes as mono-layers in minimum 
essential medium (MEM) supplemented with non-essential amino acids, 10 % fetal bovine serum, 2 mM 
glutamine, and maintained at 5 % CO2 at 37 °C. Quantitative real time analysis was carried out to measure 
TRP gene over-expression in transfected-cells (data not shown). On the day of the experiment, cells were 
loaded with the methyl ester Fluo-4 AM in MEM (4 µM in DMSO containing 0.02 % Pluronic F-127, Invitrogen), 
kept in the dark at room temperature for 1 h, washed twice with Tyrode’s buffer (145 mM NaCl, 2.5 mM KCl, 
1.5 mM CaCl2, 1.2 mM MgCl2, 10 mM D-glucose, and 10 mM HEPES, pH 7.4), resuspended in the same buffer 
and transferred (about 100,000 cells) to the quartz cuvette of the spectrofluorimeter (PerkinElmer LS50B 
equipped with PTP-1 Fluorescence Peltier System; PerkinElmer Life and Analytical Sciences, Waltham, MA, 
USA) under continuous stirring. The effects on intracellular Ca2+ concentration ([Ca2+]i) before and after the 
addition of various concentrations of test compounds was measured by cell fluorescence (λEX = 488 nm, 
λEM = 516 nm) at 25 °C. The effects of compounds were normalized against the response to ionomycin (4 µM) 
in each experiment. The increases in fluorescence in wild-type HEK293 cells (i.e. not transfected with any 
construct) were used as baseline and subtracted from the values obtained from transfected cells. Efficacy was 
defined as the maximum response elicited by the compounds tested and was determined by comparing their 
effect with the analogous effect observed with 4 µM ionomycin (Cayman), while the potency of the compounds 
(EC50) was determined as the concentration required to produce half-maximal increases in [Ca2+]i. Curve fitting 
(sigmoidal dose–response variable slope) and parameter estimation were performed with GraphPad Prism® 
(GraphPad Software Inc., San Diego, CA). 
Antagonist/desensitizing behavior was evaluated by adding the test compounds in the quartz cuvette 5 min 
before stimulation of cells with agonists. In the case of human TRPV1-expressing HEK293 cells the agonist 
used was capsaicin (0.1 µM, in the case of SR141716A 10 nM was also used), which was able of elevating 
intracellular Ca2+ with a potency of EC50 = 5.3 ± 0.4 nM and efficacy = 78.6 ± 0.6 %.  
For TRPV2, the rat TRPV2-HEK293 cells exhibited a sharp increase in [Ca2+]i upon application of 
lysophosphatidylcholine (LPC) 3 µM. The concentration for half-maximal activation was 3.40 ± 0.02 µM and 
efficacy was 91.7 ± 0.5 %. 
In the case of TRPV3, rat TRPV3-expressing HEK-293 cells were first sensitized with the non-selective agonist 
2-aminoethoxydiphenyl borate (100 µM). Antagonist/desensitizing behavior was evaluated against thymol 
(100 µM), which showed an efficacy of 34.7 ± 0.2 % and a potency of EC50 = 84.1 ± 1.6 µM. In the case of rat 
TRPV4-expressing HEK293 cells the agonist used was GSK1016790A, (10 nM), which was able of elevating 
intracellular Ca2+ with a potency of EC50 = 0.46 ± 0.07 µM, and an efficacy of 51.9 ± 1.7 %. In the case of rat 
TRPM8-expressing HEK293 cells, antagonist/desensitizing behavior was evaluated against icilin at 0.25 µM 
and 0.10 µM. For icilin, efficacy was 75.1 ± 1.1 and potency EC50 = 0.11 ± 0.01 µM. In the case of HEK293 
cells stably over-expressing recombinant rat TRPA1, the effects of TRPA1 agonists are expressed as a 
percentage of the effect obtained with 100 µM allyl isothiocyanate (AITC), which showed a potency of 
EC50 = 1.41 ± 0.04 µM and an efficacy of 65.9 ± 0.5. 
The effect on [Ca2+]i exerted by agonist alone was taken as 100%. Data are expressed as the concentration 
exerting a half-maximal inhibition of agonist-induced [Ca2+]i elevation (IC50), which was calculated again using 
GraphPad. All determinations were performed at least in triplicate. Statistical analysis of the data was 
performed by analysis of variance at each point using ANOVA followed by the Bonferroni’s test. 
 
Statistical methods 
All statistical measures and methods are included in the respective Figure or Table captions. In brief: all data 
are shown as the mean ± SEM where applicable. A Student’s t-test (unpaired, two-tailed) was used to 
determine differences between two groups. Data that included more than two groups or two factors were 
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analyzed by two-way ANOVA, with post-hoc Tukey HSD test. All statistical analyses were conducted using Excel 
or GraphPad Prism version 7, and a p-value less than 0.05 was considered significant throughout unless 
indicated otherwise. For the lipid profiling study (Figure 5.9), a Benjamini Hochberg correction (25 % false 
discovery rate) was applied. 
A sample size of n=3 was sufficient to detect ≥ 50% inhibition of protein labeling with a 20% standard deviation 
and a power of 80% at a p < 0.05. Routinely, a protein is considered to be an off-target, if 50% inhibition of 
activity is reached at 10 µM. Since, BIA 10-2474 was weakly active on FAAH in in vitro assays (IC50 > 1 µM), 




All reactions were performed using oven- or flame-dried glassware and dry solvents. Reagents were purchased 
from Sigma-Aldrich, Acros, and Merck and used without further purification unless noted otherwise. All 
moisture sensitive reactions were performed under an argon atmosphere.  
1H and 13C NMR spectra were recorded on a Bruker AV 400 MHz spectrometer at 400.2 (1H) and 100.6 (13C) 
MHz using CDCl3 as solvent, unless stated otherwise. Chemical shift values are reported in ppm with 
tetramethylsilane or solvent resonance as the internal standard (CDCl3, δ 7.26 for 1H, δ 77.16 for 13C). Data 
are reported as follows: chemical shifts (δ), multiplicity (s = singlet, d = doublet, dd = double doublet, td = triple 
doublet, t = triplet, q = quartet, quintet = quint, br = broad, m = multiplet), coupling constants J (Hz), and 
integration. High-resolution mass spectra were recorded on a Thermo Scientific LTQ Orbitrap XL. Liquid 
chromatography was performed on a Finnigan Surveyor LC/MS system, equipped with a C18 column.  
Flash chromatography was performed using SiliCycle silica gel type SiliaFlash P60 (230−400 mesh). TLC 
analysis was performed on Merck silica gel 60/Kieselguhr F254, 0.25 mm. Compounds were visualized using 
KMnO4 stain (K2CO3 (40 g), KMnO4 (6 g), and water (600 mL)). 
 
Synthesis of BIA 10-2639 (6) and BIA 10-2474 (7) 
 
 
Scheme S5.1 | Reagents and conditions: i) NBS, DMF, RT; ii) 20% Na2SO3 (aq), 100°C, 
20%; iii) TrtCl, DIPEA, DMF, RT, 93%; iv) Cs2CO3, Pd(PPh3)4, pyridin-3-ylboronic acid, 
DMF:H2O (8:1), 95°C, 75%; v) 4N HCl in dioxane, MeOH, RT, 69%; vi) Na2CO3, triphosgene, 
N-methylcyclohexanamine, DCM, 0-20°C; vii) cyclohexyl(methyl)carbamic chloride,  
3-(1H-imidazol-4-yl)pyridine hydrochloride, DMAP, DIPEA, THF, reflux, 74%; viii) peracetic 
acid, DCM, 0-20°C, 97%. 
 
4-Bromo-1H-imidazole (2)  
To a solution of 1H-imidazole 1 (4 g, 58.8 mmol) in DMF (100 mL) a solution of 1-bromopyrrolidine-
2,5-dione (11.50 g, 64.6 mmol) in DMF (100 mL) was added over 1.5 h. Reaction left to stir for 
110 h and concentrated to dryness. The residue obtained was taken up in 20% sodium sulfite 
solution in water and refluxed for 8 h. Upon cooling a precipitate formed which was filtered and dried to yield 
2 (1.735 g, 11.81 mmol, 20%) as an off-white solid. 1H NMR (400 MHz, MeOD) δ 7.61 (s, 1H), 7.11 (s, 1H). 
Spectroscopic data are in accordance with literature values.39 
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4-Bromo-1-trityl-1H-imidazole (3)  
DIPEA (4.06 mL, 23.3 mmol) was added to a solution of trityl chloride (4.87 g, 17.5 mmol) and 
4-bromo-1H-imidazole (1.71 g, 11.6 mmol) in DMF (20 mL). The resulting mixture was left to stir 
for 140 h. The resulting suspension was filtered and the yellowish solid was washed with 
methanol to yield a fine white solid which was purified by column chromatography to yield 3 (4.2 
g, 11 mmol, 93%) as a white solid. 1H NMR (400 MHz, CDCl3) δ 7.43 – 7.30 (m, 10H), 7.19 – 7.04 (m, 6H), 
6.80 (s, 1H). 13C NMR (101 MHz, CDCl3) δ 141.86, 138.71, 129.86, 128.45, 128.33, 120.90. Spectroscopic 
data are in accordance with literature values.40 
 
3-(1-Trityl-1H-imidazol-4-yl)pyridine (4)  
The title compound was synthesised under Suuzuki coupling conditions. Cesium carbonate 
(6.70 g, 20.6 mmol), 3 (2.00 g, 5.14 mmol) and pyridin-3-ylboronic acid (0.631 g, 5.14 
mmol) were suspended in a mixture of DMF (40 mL) and water (5 mL). The resulting 
mixture was degassed by sonication for 30 min under a flow of argon. Tetrakis(triphenyl-
phosphine)palladium(0) (148 mg, 0.128 mmol) was added and the mixture was heated to 90 °C for 16 h. The 
reaction mixture was diluted with EtOAc (100 mL) and washed with water. The organic layer was separated 
and the water layer extracted with EtOAc (2x 100 mL). The combined organic layers were washed with brine, 
dried (MgSO4), filtered and concentrated. The oily residue was purified by column chromatography to yield 4 
(1.50 g, 3.87 mmol, 75%) as a white solid. 1H NMR (400 MHz, CDCl3) δ 8.95 (m, 1H), 8.42 (m, 1H), 8.03 (m, 
1H), 7.99 (s, 1H), 7.68 (m, 1H), 7.56 (d, J = 1.4 Hz, 1H), 7.47 – 7.40 (m, 1H), 7.34 (m, 9H), 7.24 (m, 1H), 7.24 
– 7.16 (m, 7H). 13C NMR (101 MHz, CDCl3) δ 147.70, 146.42, 142.06, 139.66, 137.83, 132.04, 131.90, 
129.97, 129.68, 128.15, 123.40, 117.92, 75.60. 
 
3-(1H-Imidazol-4-yl)pyridine hydrochloride (5)  
To a solution of 4 (1.24 g, 3.20 mmol) in MeOH HCl in dioxane (4 M, 4.0 mL) was added 
and the mixture was stirred for 1 h at RT. A white precipitate formed which was filtered off. 
The filtrate was vigorously stirred and pentane was slowly added to the mixture. More 
precipitate formed which was filtered off. The resulting solids were air dried to yield 5 (401.3 mg, 2.210 mmol, 
69%). 1H NMR (400 MHz, D2O) δ 9.08 (d, J = 2.0 Hz, 1H), 8.84 (d, J = 1.3 Hz, 1H), 8.80 – 8.71 (m, 2H), 8.09 
(dd, J = 8.3, 5.8 Hz, 1H), 8.00 (d, J = 1.3 Hz, 1H). 13C NMR (101 MHz, D2O) δ 143.10, 141.56, 138.96, 136.02, 
127.80, 127.33, 127.14, 118.56. 
 
N-Cyclohexyl-N-methyl-4-(pyridin-3-yl)-1H-imidazole-1-carboxamide (6)  
Triphosgene (0.831 g, 2.80 mmol) was added portionwise to a solution of 
N-methylcyclohexanamine (0.73 mL, 5.6 mmol) in DCM at 0 °C. After addition was 
complete, dried Na2CO3 (1.19 g, 11.2 mmol) was added in one batch and the mixture 
was allowed to warm to RT and stirred for 2 h. Na2CO3 was filtered off and the filtrate 
was concentrated to yield crude cyclohexyl(methyl)carbamic chloride which was used 
without further purification. To a stirred solution of 5 (203 mg, 1.12 mmol), DMAP (68.4 mg, 0.560 mmol) and 
DIPEA (0.587 mL, 3.36 mmol) in dry THF (40 mL) at 0 °C was added a solution of crude cyclo-
hexyl(methyl)carbamic chloride in 5 mL THF. The resulting mixture was refluxed for 6 h under inert atmosphere. 
After the reaction was completed the cooled mixture was poured into saturated aqueous NH4Cl solution and 
extracted three times with EtOAc. The combined organic layers were washed with brine, dried (MgSO4), filtered 
and concentrated in vacuo to yield a white solid. Purification by column chromatography yielded an analytically 
pure sample of 6 (234 mg, 0.823 mmol, 74%). 1H NMR (400 MHz, CDCl3) δ 9.03 (dd, J = 2.3, 0.9 Hz, 1H), 8.54 
(dd, J = 4.9, 1.6 Hz, 1H), 8.20 (dt, J = 8.0, 1.9 Hz, 1H), 7.94 (d, J = 1.3 Hz, 1H), 7.60 (d, J = 1.3 Hz, 1H), 7.41 
(m, 1H), 3.95 (t, J = 12.0 Hz, 1H), 3.01 (s, 3H), 1.97 – 1.77 (m, 5H), 1.71 (d, J = 13.3 Hz, 1H), 1.59 (qd, J = 
12.7, 12.2, 4.0 Hz, 2H), 1.46 – 1.31 (m, 2H), 1.14 (qt, J = 13.1, 3.5 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 
150.98, 147.35, 145.67, 138.79, 137.47, 133.39, 129.63, 123.99, 114.32, 57.72, 31.42, 30.03, 25.44, 
25.24. Spectroscopic data are in accordance with literature values.41 HRMS (ESI+) m/z: calculated for 
C16H21N4O ([M+H]): 285.1710; found: 285.1710. 
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3-(1-(Cyclohexyl(methyl)carbamoyl)-1H-imidazol-4-yl)pyridine 1-oxide (7)  
6 (100 mg, 0.352 mmol) was dissolved in dry DCM (25 mL) and cooled to 0 °C. 
Peracetic acid (0.119 mL, 0.703 mmol) as a 39% solution in acetic acid was added in 
one batch and the resulting mixture was stirred for 16 h. When TLC showed full 
conversion the reaction mixture was concentrated and purified by column 
chromatography to yield 7 (102.6 mg, 0.342 mmol, 97%) as a white solid. 1H NMR 
(400 MHz, CDCl3) δ 8.72 (t, J = 1.6 Hz, 1H), 8.18 (ddd, J = 6.4, 1.8, 1.0 Hz, 1H), 7.93 (d, J = 1.3 Hz, 1H), 7.77 
(dt, J = 8.1, 1.2 Hz, 1H), 7.60 (d, J = 1.3 Hz, 1H), 7.34 (dd, J = 8.0, 6.4 Hz, 1H), 3.99 – 3.84 (m, 1H), 3.00 (s, 
3H), 1.87 (t, J = 13.5 Hz, 4H), 1.71 (d, J = 13.4 Hz, 1H), 1.59 (qd, J = 12.8, 12.2, 3.9 Hz, 2H), 1.45 – 1.29 (m, 
2H), 1.13 (qt, J = 13.1, 3.5 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 150.72, 137.84, 137.66, 136.75, 136.18, 
133.22, 126.25, 124.17, 115.75, 57.95, 31.60, 30.13, 25.56, 25.33. Spectroscopic data are in accordance 
with literature values.42 HRMS (ESI+) m/z: calculated for C16H21N4O2 ([M+H]): 301.1659; found: 301.1659. 
 
Synthesis of three 2-step probes AJ167 (8), AJ179 (9) and AJ198 (10): 
  
 
N-(Prop-2-yn-1-yl)cyclohexanamine (11)  
To a stirred solution of prop-2-yn-1-amine (0.50 mL, 7.8 mmol), cyclohexanone (0.404 mL, 
3.90 mmol) and sodium triacetoxyborohydride (1.655 g, 7.81 mmol) in dry THF (40 mL) was 
slowly added one equivalent of acetic acid (0.223 mL, 3.90 mmol). The resulting mixture was 
stirred for 5 hours at room temperature after which the solvent was evaporated off. The crude 
was purified by column chromatography to yield 11 (0.521 g, 3.80 mmol, 97%) as a colourless oil. 1H NMR 
(400 MHz, CDCl3) δ 3.46 (d, J = 2.5 Hz, 2H), 2.74 – 2.59 (m, 1H), 2.21 (t, J = 2.4 Hz, 1H), 1.92 – 1.80 (m, 2H), 
1.80 – 1.67 (m, 2H), 1.68 – 1.53 (m, 2H), 1.31 – 0.98 (m, 5H). 13C NMR (101 MHz, CDCl3) δ 82.51, 71.04, 
54.95, 35.08, 33.01, 26.11, 24.83. 
 
N-Cyclohexyl-N-(prop-2-yn-1-yl)-4-(pyridin-3-yl)-1H-imidazole-1-carboxamide (12)  
A solution of 11 (227 mg, 1.65 mmol) and triphosgene (163 mg, 0.551 mmol) in 
dry DCM (30 mL) was cooled to 0 °C and sodium carbonate (175 mg, 1.65 mmol) 
was added in one batch. The resulting suspension was stirred for 2 hours at room 
temperature. Na2CO3 was filtered off and the filtrate concentrated in vacuo. To a 
stirred solution of 5 (100 mg, 0.551 mmol), DMAP (67.3 mg, 0.551 mmol) and 
DIPEA (385 µL, 2.20 mmol) in dry THF (30 mL) at 0 °C was added a solution of crude carbamic chloride in 
5 mL THF. The resulting mixture was refluxed for 4 hours under inert atmosphere. After the reaction was 
completed the cooled mixture was poured into saturated aqueous NH4Cl solution and extracted three times 
with EtOAc. The combined organic layers were washed with brine, dried (MgSO4), filtered and concentrated in 
vacuo to yield a white solid. This was purified by column chromatography to yield an analytically pure sample 
of 12 (110 mg, 0.357 mmol, 65%). 1H NMR (500 MHz, CDCl3) δ 9.02 (d, J = 2.2 Hz, 1H), 8.53 (dd, J = 1.6, 4.9 
Hz, 1H), 8.17 (d, J = 1.3 Hz, 1H), 8.13 (dt, J = 1.9, 7.9 Hz, 1H), 7.82 (d, J = 1.3 Hz, 1H), 7.35 (dd, J = 4.8, 7.9 
Hz, 1H), 4.09 (d, J = 2.4 Hz, 2H), 4.00 (tt, J = 3.7, 12.1 Hz, 1H), 2.49 (t, J = 2.4 Hz, 1H), 1.93 (ddt, J = 2.8, 
13.7, 41.4 Hz, 4H), 1.70 (qd, J = 3.5, 12.4 Hz, 2H), 1.47 – 1.09 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 150.70, 
148.50, 146.69, 139.41, 132.62, 129.11, 123.74, 114.03, 79.91, 73.59, 58.82, 35.02, 30.55, 25.70, 
25.26. 
 
3-(1-(Cyclohexyl(prop-2-yn-1-yl)carbamoyl)-1H-imidazol-4-yl)pyridine 1-oxide AJ167 (8)  
12 (20 mg, 0.065 mmol) is dissolved in dry DCM (10 mL) and cooled to 0 °C. 
Peracetic acid (20 µL, 0.118 mmol) as a 39% solution in acetic acid was added in 
one batch and the resulting mixture was stirred for 16 hours, slowly warming up 
to RT. The reaction mixture was concentrated and purified by column 
chromatography to yield 8 (11.5 mg, 0.035 mmol, 55%) as a white solid. 1H NMR 
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(400 MHz, CDCl3) δ 8.68 (s, 1H), 8.16 (d, J = 1.1 Hz, 2H), 7.86 – 7.80 (m, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.34 
(t, J = 7.1 Hz, 1H), 4.07 (d, J = 2.4 Hz, 2H), 3.98 (tt, J = 12.0, 3.6 Hz, 1H), 2.49 (t, J = 2.4 Hz, 1H), 2.01 – 1.85 
(m, 4H), 1.70 (qd, J = 12.2, 3.5 Hz, 2H), 1.46 – 1.10 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 150.24, 137.87, 
137.69, 137.04, 132.80, 126.02, 123.17, 115.26, 79.65, 73.80, 58.89, 35.01, 30.47, 25.64, 25.19. HRMS 
(ESI+) m/z: calculated for C18H20N4O2 ([M+H]): 325.1659; found: 325.1658. 
 
1-(Hex-5-ynoyl)piperidin-4-one (13)  
To a stirred solution of hex-5-ynoic acid (0.396 mL, 3.58 mmol) in a 1:1 mixture (v/v) of 
THF:DCM DIPEA (1.42 mL, 8.14 mmol) and HBTU (2.72 g, 7.16 mmol) were added in one 
batch. After the solution became homogenous piperidin-4-one hydrochloride hydrate 
(0.50 g, 3.3 mmol) was added. The mixture was left to stir for 215 h at room temperature. 
The reaction was quenched with saturated NaHCO3 (aq.) and extracted three times with 
EtOAc. The combined organic layers were washed with brine, dried (MgSO4), filtered and concentrated under 
reduced pressure. The residue was purified by column chromatography to yield 13 (572 mg, 2.96 mmol, 91%) 
as a colourless oil. 1H NMR (400 MHz, CDCl3) δ 3.90 (t, J = 6.4 Hz, 2H), 3.80 (t, J = 6.3 Hz, 2H), 2.58 (t, J = 7.3 
Hz, 2H), 2.53 – 2.46 (m, 4H), 2.33 (td, J = 6.7, 2.7 Hz, 2H), 2.00 (t, J = 2.6 Hz, 1H), 1.91 (p, J = 7.0 Hz, 2H). 
13C NMR (101 MHz, CDCl3) δ 206.91, 171.11, 83.64, 69.32, 44.06, 41.29, 40.90, 38.66, 31.43, 23.68, 
17.92. 
 
1-(4-(Methylamino)piperidin-1-yl)hex-5-yn-1-one (14)  
13 (572 mg, 2.96 mmol) was dissolved in DCM and methanamine hydrochloride (400 mg, 
5.92 mmol), acetic acid (0.373 mL, 6.51 mmol) and DIPEA (1.09 mL, 6.22 mmol) were 
added. When cooled to 0 °C sodium triacetoxyborohydride (1.25 g, 5.92 mmol) was added 
in one portion. The resulting suspension was left to stir for 18 h warming up to RT. The 
reaction was quenched with a saturated aqueous Na2CO3 solution and extracted three times 
with EtOAc. The combined organic layers were washed with brine, dried (MgSO4), filtered and 
concentrated in vacuo. The residue was purified by column chromatography to yield 14 (549 mg, 2.64 mmol, 
89%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 4.44 (m, 1H), 3.86 (m, 1H), 3.09 (m, 1H), 2.75 (m, 1H), 
2.60 (m, 1H), 2.46 (t, J = 7.3 Hz, 2H), 2.44 (s, 3H), 2.27 (td, J = 6.8, 2.7 Hz, 2H), 2.01 (t, J = 2.6 Hz, 1H), 1.98 
– 1.78 (m, 4H), 1.33 – 1.15 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 170.30, 83.68, 69.02, 56.32, 43.98, 40.19, 
33.42, 32.55, 31.72, 31.49, 23.84, 17.88. 
 
N-(1-(Hex-5-ynoyl)piperidin-4-yl)-N-methyl-4-(pyridin-3-yl)-1H-imidazole-1-carboxamide (15)  
14 (274 mg, 1.32 mmol) was dissolved in DCM (25 mL) and cooled to 0 °C. Sodium 
carbonate (209 mg, 1.97 mmol) and triphosgene (390 mg, 1.32 mmol) were added 
and the mixture was stirred for 2 hours at RT. The solids were filtered off and the filtrate 
was concentrated under reduced pressure and redissolved in THF (25 mL). DIPEA 
(0.459 mL, 2.63 mmol), 5 (59.7 mg, 0.329 mmol) and DMAP (161 mg, 1.32 mmol) 
were added and the resulting mixture was refluxed for 4 h. The reaction was quenched 
with saturated aqueous NaHCO3 solution and extracted three times with EtOAc. The 
organic layers were combined, washed with brine, dried (MgSO4) and filtered. The solvent was removed and 
the crude purified by column chromatography to yield 15 (54.0 mg, 0.142 mmol, 43%) as a white solid. 1H 
NMR (400 MHz, CDCl3) δ 9.07 – 8.98 (m, 1H), 8.58 – 8.51 (m, 1H), 8.14 (m, 1H), 7.97 (d, J = 1.3 Hz, 1H), 
7.61 (d, J = 1.3 Hz, 1H), 7.37 (dd, J = 7.9, 4.8 Hz, 1H), 4.85 (m, 1H), 4.29 (tt, J = 12.2, 4.2 Hz, 1H), 4.13 – 
4.00 (m, 1H), 3.22 – 3.09 (m, 1H), 3.02 (s, 3H), 2.63 (m, 1H), 2.51 (t, J = 7.4 Hz, 2H), 2.31 (m, 2H), 1.99 (t, J 
= 2.6 Hz, 1H), 2.01 – 1.83 (m, 4H), 1.76 (qt, J = 12.2, 3.9 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 170.67, 
151.29, 148.44, 146.52, 139.42, 137.50, 132.79, 129.05, 123.80, 114.03, 83.78, 69.20, 55.57, 44.62, 
40.94, 32.15, 31.53, 29.23, 28.53, 23.80, 18.00. 
 
3-(1-((1-(Hex-5-ynoyl)piperidin-4-yl)(methyl)carbamoyl)-1H-imidazol-4-yl)pyridine 1-oxide AJ179 (9)  
A solution of 15 (25 mg, 0.066 mmol) in DCM (25 mL) was cooled to 0 °C and 
peracetic acid (50 µL, 0.30 mmol) was added in one batch. The resulting mixture was 
left to stir for 16 h, after which the solvent was removed in vacuo. The resulting crude 
was purified by column chromatography to yield an analytically pure sample of 9 (4.5 
mg, 0.011 mmol, 17%) as a white solid. 1H NMR (400 MHz, MeOD) δ 8.82 (d, J = 1.7 
Hz, 1H), 8.27 (d, J = 6.0 Hz, 1H), 8.22 (d, J = 1.2 Hz, 1H), 8.17 (d, J = 1.2 Hz, 1H), 
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8.05 (d, J = 8.3 Hz, 1H), 7.61 (dd, J = 8.1, 6.3 Hz, 1H), 4.73 (d, J = 13.3 Hz, 1H), 4.33 – 4.19 (m, 1H), 4.19 – 
4.10 (m, 1H), 3.27 – 3.17 (m, 1H), 3.04 (s, 3H), 2.71 (dd, J = 14.0, 11.2 Hz, 1H), 2.61 – 2.55 (m, 2H), 2.32 – 
2.25 (m, 2H), 2.06 (s, 1H), 2.02 – 1.74 (m, 6H). 13C NMR (101 MHz, MeOD) δ 171.79, 151.05, 138.53, 
137.24, 135.78, 135.46, 133.45, 126.77, 125.67, 116.99, 82.89, 68.90, 55.81, 44.57, 40.74, 31.16, 
29.34, 28.56, 27.88, 24.03, 17.18. 
 
N-Methyl-N-(prop-2-yn-1-yl)-4-(pyridin-3-yl)-1H-imidazole-1-carboxamide (16)  
To a stirred solution of N-methylprop-2-yn-1-amine (0.084 ml, 1.0 mmol) in DCM 
(10 mL) at 0 °C sodium carbonate (106 mg, 1.00 mmol) was added. Triphosgene 
(223 mg, 0.750 mmol) was added and the mixture was stirred at RT for 1 hour. 
The suspension was then filtered and the filtrate was concentrated in vacuo to a 
yellow oil. This was redissolved in dry THF (10 mL, molecular sieves) and 5 (182 mg, 1.00 mmol) and DIPEA 
(0.437 mL, 2.50 mmol) were added. The mixture was heated and refluxed for 16 hours. The reaction was 
quenched by the addition of saturated aqueous NaHCO3 and was extracted three times with EtOAc. The 
combined organic layers were washed with brine, dried (MgSO4), filtered and concentrated. Purification using 
column chromatography yielded 16 (68 mg, 0.28 mmol, 28%). 1H NMR (300 MHz, CDCl3) δ 8.99 (s, 1H), 8.45 
(d, J = 4.9 Hz, 1H), 8.30 – 8.13 (m, 2H), 8.02 (s, 1H), 7.47 (dd, J = 4.9, 8.1 Hz, 1H), 4.29 (d, J = 1.3 Hz, 1H), 
3.22 (s, 4H), 2.93 (q, J = 2.1 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ 148.78, 146.94, 134.57, 125.41, 116.53, 
75.23, 40.81, 36.52, 30.74. 
 
3-(1-(Methyl(prop-2-yn-1-yl)carbamoyl)-1H-imidazol-4-yl)pyridine 1-oxide AJ198 (10)  
16 (20 mg, 0.083 mmol) was dissolved in DCM (10 mL) and cooled to 0 °C. 
Peracetic acid (92 µL, 0.42 mmol) as 30% solution in acetic acid was added in one 
batch. The mixture was stirred for 72 hours, slowly warming up to RT. The crude 
was concentrated under reduced pressure and purified by column 
chromatography to yield 10 (12 mg, 0.047 mmol, 56%) as a white solid. 1H NMR (400 MHz, MeOD) δ 8.80 (t, 
J = 1.7 Hz, 1H), 8.25 (dt, J = 1.3, 6.5 Hz, 1H), 8.22 (d, J = 1.3 Hz, 1H), 8.15 (d, J = 1.3 Hz, 1H), 8.02 (dt, J = 
1.2, 8.1 Hz, 1H), 7.58 (dd, J = 6.4, 8.1 Hz, 1H), 4.29 (d, J = 2.4 Hz, 2H), 3.22 (s, 3H), 2.92 (t, J = 2.5 Hz, 1H). 
HRMS (ESI+) m/z: calculated for C13H12N4O2 ([M+H]): 257.1033; found: 257.1037. 
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Supplementary Tables  
Table S5.1 | Evaluating FAAH inhibitors against other endocannabinoid-related proteins. DAGL-α, DAGL-β, MAGL, 
ABHD6 and NAPE-PLD relative to DMSO as vehicle and [3H]CP55940 displacement at overexpressing hCB1- and 
hCB2-receptor membranes. 
  hDAGL-α mDAGL-β hMAGL hABHD6 hNAPE-PLD 
Compound Remaining activity (%) ± SD 
BIA 10-2474 
10 µM 102.7 ± 9.3 94.1 ± 4.3 117.9 ± 3.0 83.9 ± 8.2 96.9 ± 11.9 
30 µM 113.4 ± 4.0 102.9 ± 1.9 - 31.2 ± 13.2 - 
50 µM - - - - 95.9 ± 10.1 
PF-04457845 
10 µM 99.2 ± 8.7 105.5 ± 0.5 - 108.3 ± 21.6 98.6 ± 6.7 
30 µM 83.0 ± 8.4 106.2 ± 1.5 - 97.5 ± 26.7 - 
50 µM - - - - 70.2 ± 6.8 
BIA 10-2639 
10 µM 107.6 ± 2.6 94.5 ± 1.7 - 111.2 ± 8.3 89.0 ± 7.2 
30 µM 110.2 ± 3.2 102.1 ± 4.2 - 90.3 ± 11.2 - 
50 µM - - - - 89.9 ± 2.6 
 





(%) ± SEM 
BIA 10-2474 
10 µM 29.8 ± 1.5 6.0 ± 5.4 
30 µM - - 
50 µM 38.4 ± 2.3 16.7 ± 8.9 
PF-04457845 
10 µM 59.9 ± 2.5 51.5 ± 4.6 
30 µM - - 
50 µM 103.8 ± 4.6 86.4 ± 1.3 
BIA 10-2639 
10 µM 36.8 ± 4.1 13.4 ± 8.0 
30 µM - - 
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Table S5.2 | Evaluating FAAH inhibitors for efficacy and affinity with TRPV-, TRPA1- and TRPM8-channels. 
Compound 
TRPV1 TRPV2 
Efficacy IC50 Efficacy IC50 
(% ionomycin 4 µM) (capsaicin 0.1 µM) (% ionomycin 4 µM) (LPC 3 µM) 
BIA 10-2474 < 10 > 20 µM < 10 > 20 µM 
PF-04457845 < 10 > 20 µM < 10 > 20 µM 




Efficacy IC50 Efficacy IC50 
(% ionomycin 4 µM) (thymol 100 µM) (% ionomycin 4 µM) (GSK 10 nM) 
BIA 10-2474 < 10 > 20 µM < 10 > 20 µM 
PF-04457845 < 10 > 20 µM < 10 > 20 µM 




Efficacy IC50 IC50 
(%AITC 100 µM) (AITC 100 µM) (icilin 0.25 µM) 
BIA 10-2474 < 10 > 20 µM > 20 µM 
PF-04457845 < 10 > 20 µM > 20 µM 
BIA 10-2639 < 10 > 20 µM > 20 µM 
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6. Development of a multiplexed 
ABPP assay to evaluate activity  












All endocannabinoid hydrolases except N-acetylphosphatidylethanolamine phospho-
lipase D (NAPE-PLD) belong to the family of serine hydrolases. This family consists of over 
200 proteins that use a nucleophilic serine to hydrolyze ester-, amide-, or thioesterbonds 
in small molecules and proteins via a covalent acyl-protein intermediate.1,2 This mode of 
action is exploited in activity-based protein profiling (ABPP).3,4 The archetypical activity-
based probe (ABP) for serine hydrolases is the fluorophosphonate (FP) probe (FP-TAMRA 
(1), Figure 6.1), which was introduced by Liu et al. almost 20 years ago.5 This probe is widely 
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used to study serine hydrolases in complex proteomes.6,7 Although the FP-based probes 
are known for their broad reactivity, they do not react with all serine hydrolases.4 Most 
notably, diacylglycerol lipase α (DAGL-α) is amongst the enzymes which cannot be 
visualized by FP-based ABPs.8 To study DAGL-α, MB064 ((2), Figure 6.1), a tailored chemical 
probe with a BODIPY-TMR as fluorophore, was developed.9 In terms of experimental 
efficiency with respect to time, cost-of-reagents, and use of valuable biological samples, it 
would be optimal to combine the commercially available FP-TAMRA (ActivX™) and MB064 
in the same experiment. However, MB064 cannot be applied in conjunction with FP-TAMRA 
(1), because the excitation/emission spectra of their fluorophores overlap. Therefore, the 
aim of the current study was to synthesize, characterize and apply a new FP-based probe 
(3) with a different reporter tag (BODIPY-FL) that is compatible with MB064. Such a 
multiplexed assay, using different activity-based probes, has been shown to work for other 
enzyme classes in the past.10–12 Here, a multiplexed ABPP assay with ABP (3) and MB064 
was developed and used to study endocannabinoid hydrolase activity and to profile 
inhibitors on activity and selectivity in mouse brain proteomes. 
 
Figure 6.1 | Chemical structures of the four activity-based probes used in this study: FP-TAMRA (1), MB064 
(2), FP-BODIPY (3) and a control probe (4)  
 
Results and discussion  
FP-BODIPY probe (3) was synthesized using a previously described method (Scheme 
S6.1).13 In addition, commercially available FP-TAMRA (probe 1) and control compound 
FP-TAMRA (4), containing the same linker as (3), were synthesized using similar procedures 
(Scheme S6.2 and S6.3, respectively). 
To obtain a broad view of serine hydrolase labeling by the FP-probes in various tissues, 
first FP-TAMRA (1) and FP-BODIPY (3) were incubated with membrane and cytosol fractions 
of a panel of seven mouse tissues (brain, testes, kidney, spleen, heart, liver and pancreas) 
at a concentration of 500 nM (Figure 6.2). The proteins were resolved using SDS-PAGE and 
probe-labeled proteins were visualized by fluorescent scanning of the gel. The overall 
labeling profile in the various proteomes was comparable between probe 1 and 3, but 
several differences were observed, denoted with boxes. In the brain, for example, 
membrane proteome FP-BODIPY (3) labeled additional targets, including in the top left box 
DAGL-α, the identity of which was confirmed by competition with LEI104 (Figure S6.1). 
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Figure 6.2 | Direct comparison of FP-TAMRA (1) and FP-BODIPY (3) labeling patterns 
of seven mouse tissue lysates. Red boxes highlight strong differences between the 
two fluorescent probes.  
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Detailed profiling of the fluorophosphonate probes 1, 3 and 4 
Brain lysates were selected for further profiling of probe 1 and 3, as well as control probe 
4, because the brain is the most studied target organ for ECS modulation. In an initial 
screen, the three ABPs were incubated with both brain membrane and soluble proteomes 
(Figure 6.3A, Figure S6.2). While the labeling profile in the soluble proteome was not 
significantly different between the three probes, FP-BODIPY (3) labeled various proteins at 
lower concentrations in the membrane proteome. To determine the half maximum effect 
(EC50) values of serine hydrolase labeling in the membrane proteome, the probes were 
dosed at a wide range of concentrations (10 pM - 10 µM) and the fluorescent signal of 18 
distinct bands was quantified and corrected for protein loading by coomassie staining 
(Figure S6.2 and S6.3). To study the effect of fluorophore and linker length on serine 
hydrolase labeling by FP-probes in mouse brain membrane proteome, the change in pEC50 
of ABP 3 and 4 relative to ABP 1 was calculated (Figure 6.3B and Table S6.1). The increased 
linker length did not significantly alter the labeling efficiency for FP-TAMRA for most 
proteins, except for fatty acid amide hydrolase (FAAH) (left plot, Figure 6.3C), whereas the 
change in fluorophore led to a 10-fold increased potency in labeling for several proteins (3, 
8 and 18). Of note, FAAH labeling was already visualized at 10 nM FP-BODIPY 3 and DAGL-α 
(band 3) at 500 nM (Figure 6.3C, A, respectively). The third plot in Figure 6.3B, comparing 
probe 3 and 4, which only differ in reporter tag, shows that almost all the difference 
between the commercial FP-TAMRA probe 1 and the newly synthesized FP-BODIPY probe 3 
observed in the central plot is due to the change in fluorophore. The most likely explanation 
for the observed potency increase when changing from TAMRA to BODIPY-FP is the strong 
increase in lipophilicity. The CLogP of BODIPY-FL is 3.7 points higher than that of TAMRA, 
which would make it more favourable to stick to proteins and membranes, possibly causing 
a higher local concentration and thus better labeling. This explanation is in line with the 
observation that the strongest differences are observed in the membrane fractions, and, 
between organs, in the brain. Finally, the impact of the addition of a reporter tag was 
visualized by pre-incubation with ‘dark’ alkyne-FP (5) (Figure 6.4). This competitive labeling 
shows that alkyne-FP only completely prevented labeling by the fluorescent probes at 
5-10 µM, demonstrating the significantly reduced affinity of the fluorophosphonate 
inhibitor when lacking the reporter tag. All together, these data demonstrate that the choice 
of fluorophore influences the labeling efficiency of FP-based probes.  
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Figure 6.3 | Concentration dependent labeling of probes 1, 3, and 4. A) Four doses of the FP probes label 
mouse brain proteome in a distinct pattern with different affinities. B) Quantified affinity-differences among 
the evaluated FP-probes for the 18 bands denoted in A. # indicates a pEC50 ≤ 6 for one of the two probes, 
meaning that the difference is most likely greater than the given value. ~ indicates a pEC50 ≤ 6 for both probes, 
meaning that both probes label these proteins only at high concentrations. All quantifications assumed 100% 
labeling of protein at 10 µM probe. C) Example of the labeling pattern of band 8 (FAAH) and corresponding 
pEC50 curves and values. DAGL-α: diacylglycerol lipase α, ABHD12, ABHD6: α/β hydrolase domain containing 
protein 12, 6, MAGL: monoacylglycerol lipase, FAAH: fatty acid amide hydrolase. 
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Figure 6.4 | Dose response inhibition of probe 1 and 3 by ‘dark’ alkyne-FP (5).  
A) Structure of alkyne-FP (5) B) Mouse brain membrane proteome was 
incubated with 5 in increasing dose to prevent labelling by probe 1 and 3. C) As 
B) but utilizing mouse brain cytosolic proteome. The Figure is a grey scale 
composite of two channels. Fluorescence composite is included, green for 
probe 3 and red for probe 1. Coomassie is shown as protein loading control. 
 Development of a multiplexed ABPP assay to evaluate activity 
of endocannabinoid hydrolase inhibitors  |  115 
 
Next, it was tested whether the activity and selectivity profile of serine hydrolase 
inhibitors would be dependent on the reporter group of the activity-based probe. To this 
end, a covalent irreversible FAAH inhibitor, PF-0445784514, and a reversible inhibitor, 
LEI1049 (Figure 6.5), were tested in a competitive ABPP setting using probe 1 (500 nM) 
and probe 3 (500 and 10 nM) (Figure 6.6A). Importantly, the pIC50 values of both inhibitors 
were not dependent on the fluorescent reporter group of the probe, nor the probe 
concentration. This indicated that FP-BODIPY 3 can be used in a drug discovery setting to 
profile inhibitor activity using ABPP.  
 
Development of a multiplexed assay 
Having developed two complementary probes (FP-BODIPY (3) and MB064) with different 
reporter groups and distinct labeling patterns, it was tested whether they can be used in a 
multiplexed ABPP assay to profile the activity and selectivity of compounds inhibiting 
biosynthetic or catabolic enzymes of the ECS.6,7,15 To this end, a cocktail of FP-BODIPY 3 
(10 nM) and MB064 2 (250 nM) was used to label mouse brain membrane proteomes. 
This enabled the simultaneous visualization and quantification of DAGL-α, DDHD2, α/β 
hydrolase domain containing protein 16a (ABHD16a), FAAH, monoacylglycerol lipase 
(MAGL), ABHD6 and ABHD12 activities in a single experiment (Figure 6.6B). Bands were 
identified based on previous studies.9,16 Phopholipase 2 group IV E (PLA2G4E) and ABHD4 
can be labeled by FP-BODIPY and MB064, respectively, but their endogenous expression in 
brain is too low to be visualized.17 A panel of inhibitors consisting of JZL184 (MAGL)18, 
DH376 (DAGL-α, ABHD6)15, THL (DAGL-α, ABHD6, ABHD12, ABHD16a, DDHD2)19, 
PF-04457845 (FAAH)14, LEI104 (DAGL-α, FAAH)9 and LEI105 (DAGL-α)16 (Figure 6.5) was 
used to confirm the identity of each fluorescent band (Figure 6.6B). As a final validation, 
the inhibitory activities of LEI104 on DAGL-α and FAAH were confirmed in this new 




Figure 6.5 | Structures of endocannabinoid serine hydrolase inhibitors used in Figure 6.6.  
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Figure 6.6 | Illustration of the applicability of the prepared probe cocktail. A) Dose response inhibition of FAAH 
using PF-04457845, covalent irreversible, and LEI104, reversible, to test the dependency of the pIC50 
determination on probe affinity and concentration. No statistical significant differences have been found 
between the probe pairs (p > 0.05, Two-sided Student’s t-test). B) Six inhibitors targeted for different 
endocannabinoid serine hydrolases were shown to inhibit their specific targets using the probe cocktail. C) 
Dose response inhibition with LEI104 shows, in one gel, the inhibition of DAGL-α and FAAH. Quantification 
shows agreement of the pIC50 with literature values.9  
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The validated assay was employed to study the selectivity and activity of two MAGL 
inhibitors. First the recently published β-lactam based MAGL inhibitor NF1819 (6) was 
tested (Figure 6.7A), which was active in several animal models of multiple sclerosis, pain 
and predator stress-induced long-term anxiety.20,21 The target-interaction profile of NF1819 
(6) was compared to the experimental drug ABX-1431 (7), currently in phase 2 clinical trials 
for the treatment of Tourette Syndrome.22–24 To this end, they were incubated at various 
concentrations with mouse brain membrane proteome (Figure 6.7B, 6.7C and Figure S6.4). 
Inhibition of MAGL was confirmed with a pIC50 of 8.1 ± 0.1 for 6 and 6.7 ± 0.1 for 7 (Figure 
6.7D, 6.7F), in accordance with previously published data.20,22 Of note, for 6 various off-
targets were observed, including ABHD6, LYPLA and an unidentified protein (Figure 6.7E). 
ABHD6 was inhibited at equal potency, whereas LYPLA demonstrated a 50-fold lower 
potency. FAAH labeling was only slightly reduced at concentrations > 10 µM. The target-
interaction landscape of 7 is clean, even at 10 µM no clear off-targets were observed. The 
relatively small selectivity window of 6 over ABHD6 should be taken into account during the 
biological evaluations of this inhibitor as it may contribute to the rise of 2-AG levels. 
 
 
Figure 6.7 | Off-target profiling of β-lactam based MAGL inhibitor (6) and clinical candidate ABX-1431 (7) in 
mouse brain membrane proteome. A) Chemical structure of (6) and (7). B) Dose response inhibition with (6) 
shows several off-targets in mouse brain membrane. C) Dose response inhibition with (7) shows selective 
MAGL inhibition in mouse brain membrane. D) pIC50 curves and values of (6) against MAGL. E) pIC50 curves 




118  |  Chapter 6  
 
Conclusion 
In conclusion, FP-BODIPY (3) was synthesized and characterized as a new ABP, 
extending the chemical toolbox to study serine hydrolase activity in native biological 
samples. The choice of fluorophore was found to be of great influence on labeling patterns, 
even for broadly reactive probes such as fluorophosphonates. This finding should be taken 
into account when designing ABPs. FP-BODIPY (3) in conjunction with MB064 (2) was used 
to develop a multiplexed ABPP assay, which was validated by profiling inhibitor activity and 
selectivity on a broad range of endocannabinoid hydrolases in mouse brain tissue in a 
single experiment. This multiplexed ABPP assay was then applied to investigate the 
specificity of a recently published in vivo active MAGL inhibitor and an experimental drug 
currently going through clinical trials.  
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The inhibitors JZL184, PF-04457845 and tetrahydrolipstatin were commercially available (Sigma Aldrich). The 
syntheses of DH376, LEI104, LEI105, NF1819 and ABX-1431 were previously described.9,15,16,20,23 
 
Tissue preparation 
Organs were isolated from mice following standard guidelines as approved by the ethical committee of Leiden 
University (DEC#13191). Isolated organs were frozen in liquid nitrogen and stored at -80 °C. Organs were 
thawed on ice and homogenized by a glass stick douncing homogenizer in cold lysis buffer (20 mM HEPES, pH 
7.2, 2 mM DTT, 1 mM MgCl2, 2.5 U/mL benzonase). The resulting suspension was centrifuged at 1500 rpm 
for 5 minutes at 4 °C to get rid of residual solid tissue. The supernatant was centrifuged 45 minutes at 
93,000 g at 4 °C to separate soluble (cytosol) and insoluble (membrane) fractions. The pellet (membrane) 
was resuspended in storage buffer (20 mM HEPES, pH 7.2, 2 mM DTT) using an insulin syringe. The protein 
concentration was measured using a QubitTM protein assay and was adjusted to 2 mg/mL using storage buffer. 
The resulting lysates were frozen in liquid nitrogen and stored at -80 °C for later use.  
 
Activity-based protein profiling 
Lysate (19 µL, 2 µg/µL) was thawed on ice. For comparative ABPP (one probe and no inhibitor), 1 µL of probe 
(20x stock in DMSO) was added to the sample, vortexed briefly and incubated for 15 minutes at RT. For 
competitive ABPP (one inhibitor and one probe), 0.5 µL of the inhibitor (40x stock in DMSO) or pure DMSO (as 
vehicle) was added to the sample, vortexed briefly and incubated for 20 minutes at RT (37 °C for Figure 6.6A 
and C to compare with literature values). Subsequently, 0.5 µL probe (40x stock in DMSO) was added to the 
proteome sample, vortexed briefly and incubated for 15 minutes at RT. Final volume was 20 µL (5% DMSO). 
The reaction was quenched by the addition of 7.5 µL of 4*Laemmli-buffer (final concentrations: 60 mM Tris 
(pH 6.8), 2% (w/v) SDS, 10% (v/v) glycerol, 1.25% (v/v) β-mercaptoethanol, 0.01% (v/v) bromophenol blue). 9 
µL (12 µg protein) of quenched reaction mixture was resolved on 10% acrylamide SDS-PAGE (180 V, 75 min). 
Fluorescence was measured using a Biorad ChemiDoc MP system (fluorescence channels Cy2, Cy3, Cy5). Gels 
were then stained using coomassie staining and imaged for protein loading control. 
 
Labeling quantification 
Fluorescence quantification was performed using Imagelab 6.0 (Biorad). Intensities were normalized to 10 µM 
(for Figure 6.3) or DMSO control (Figure 6.6 and 6.7) and corrected for protein loading by coomassie staining. 
pEC50 values were calculated using GraphPad Prism 7. For all pEC50 determinations three replicates of each 
condition were used. 
 
Statistical methods 
Two-sided Student’s t-tests were performed using GraphPad Prism 7.0 with the standard Holm-Šídák method 




Reagents were purchased from Sigma Aldrich, Alfa Aesar, AnaSpec or ACROS organics at reagent grade and 
used without further purification. All moisture sensitive reactions were performed under a nitrogen 
atmosphere. All solvents were dried using molecular sieves. Ethyl acetate was distilled before use. Glassware 
was oven dried prior to use. 1H and 13C NMR spectra were recorded on a Bruker DPX-300 (300 MHz), AV-400 
(400 MHz) or Bruker DRX-500 (500 MHz). Used software for interpretation of NMR-data was Bruker TopSpin 
1.3 and MestreNova 11.0. Chemical shift values are reported in ppm with tetramethylsilane or solvent 
resonance as the internal standard (CDCl3: δ 7.26 for 1H, δ 77.16 for 13C). 31P-NMR shifts are given in ppm 
relative to phosphoric acid. 19F-NMR shifts are given in ppm relative to CFCl3. Data are reported as follows: 
chemical shifts (δ), multiplicity (s = singlet, d = doublet, dd = double doublet, td = triple doublet, t = triplet, q = 
quartet, bs = broad singlet, m = multiplet), coupling constants J (Hz), and integration. Liquid chromatography 
analysis was performed on a Finnigan Surveyor LC/MS system, equipped with a C18 column. Flash 
chromatography was performed using SiliCycle silica gel type SiliaFlash P60 (230−400 mesh). TLC analysis 
was performed on Merck silica gel 60/Kieselguhr F254, 0.25 mm. Compounds were visualized using KMnO4 
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stain (K2CO3 (40 g), KMnO4 (6 g), and water (600 mL)) or CAM stain (Ce(NH4)4(SO4)4·2H2O (ceric ammonium 
sulfate: 10.0 g); ammonium molybdate (25 g); conc. H2SO4 (100 mL); H2O (900 mL)). High resolution mass 
spectra (HRMS) were recorded by direct injection on a q-TOF mass spectrometer (Synapt G2-Si) equipped with 
an electrospray ion source in positive mode with Leu-enkephalin (m/z = 556.2771) as an internal lock mass. 
The instrument was calibrated prior to measurement using the MS/MS spectrum of Glu-1-fibrinopeptide B. 
 
 
Scheme S6.1 | Synthesis of probe 3. Reagents and conditions: i) TBDMS-Cl, DMAP, imidazole, DMF, RT, 
42%; ii) I2, triphenylphosphine, THF, RT, 93%; iii) POEt3, reflux, 99%; iv) TBAF, THF, 0 – 20 °C, 86%;  
v) disuccinylcarbonate, triethylamine, DMF, RT, 91%; vi) oxalyl chloride, DCM, RT; vii) DAST, DCM, -78 °C, 
46%; viii) DCM, reflux; ix) triethylamine, BF3·OEt2, DCM, toluene, 50 °C, 46%; x) NaOH, H2O, THF, RT, 82%; 
xi) N-Boc-cadaverine, EDC·HCl, HOBt, triethylamine, DCM, RT, 56%; xii) TFA, DCM, RT, 41%;  
xiii) triethylamine, DCM, DMF, RT, 26%. 
 
10-tert-Butyldimethylsilane-1-decanol (9)  
8 (10.3 g, 57.4 mmol), imidazole (3.91 g, 57.4 mmol) and 4-(dimethylamino)-pyridine 
(80 mg, 0.65 mmol) were dissolved in dry DMF at RT. Subsequently, tert-butyl dimethyl 
silyl chloride (4.45 g, 28.8 mmol) was added and the mixture was stirred at RT for 5 
hours. The mixture was quenched with saturated NaHCO3 (200 mL, aq.) and H2O (200 mL). The mixture was 
extracted with EtOAc (3x 200 mL) and the organic layers were combined and dried (MgSO4), filtered and 
evaporated to afford the crude product as a white solid. Purification was performed using column 
chromatography (5% to 20% EtOAc in pentane). Pure fractions were combined and evaporated to dryness to 
afford the title compound (3.52 g, 12.1 mmol, 42%). 1H NMR (300 MHz, CDCl3) δ 3.69 – 3.49 (m, 4H), 1.64 – 
1.42 (m, 5H), 1.37 – 1.21 (m, 12H), 0.88 (s, 9H), 0.03 (s, 6H). 13C NMR (75 MHz, CDCl3) δ 63.47, 63.14, 
32.99, 32.92, 29.68, 29.55, 26.11, 25.91, 25.87, 18.51, -5.13. 
 
10-Iododecyloxy-1-(tert-butyl)dimethylsilane (10)  
Triphenylphosphine (3.5 g, 13 mmol) and imidazole (1.8 g, 26 mmol) were dissolved in 
THF (62 mL). Subsequently, iodine (3.5 g, 14 mmol) was slowly added to the solution. The 
mixture was stirred for 20 minutes at RT under inert atmosphere. Then, 9 (3.5 g, 12 mmol) 
dissolved in THF (14 mL) was slowly added to the stirred solution. The solution turned brown/red. During the 
reaction, a yellow precipitate formed. The reaction was allowed to stir at RT for 1 hour. The volatiles were 
evaporated and the residue was taken up in an emulsion of Et2O (100 mL) and sodium thiosulfate (100 mL, 
10%, aq.). The yellow colour disappeared after the addition of the thiosulfate. The organic layer was washed 
with water and with brine. The organic layer was dried (MgSO4), filtered, and the solvent evaporated to afford 
white crystals. Purification was done using silica column chromatography (1% Et2O in pentane), affording the 
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title compound as a colourless oil (4.31 g, 11.3 mmol, 93%). 1H NMR (300 MHz, CDCl3) δ 3.60 (t, J = 6.6 Hz, 
2H), 3.19 (t, J = 7.0 Hz, 2H), 1.82 (p, J = 7.0 Hz, 2H), 1.56 – 1.44 (m, 2H), 1.44 – 1.22 (m, 12H), 0.89 (s, 9H), 
0.06 (s, 6H). 13C NMR (75 MHz, CDCl3) δ 63.46, 33.72, 33.02, 30.65, 29.66, 29.51, 28.68, 26.14, 25.93, 
7.49, -5.09. 
 
Diethyl 10-(tert-butyldimethylsiloxy)decylphosphonate (11) 
10 (4.31 g, 11.3 mmol) was dissolved in triethylphosphite (10 mL, 58 mmol). The 
solution was then heated to 155 °C under reflux conditions for 5 hours under inert 
atmosphere. The resulting solution was then concentrated under reduced pressure 
to afford the title compound as a light yellow oil (4.4 g, 11 mmol, 99%). 1H NMR 
(300 MHz, CDCl3) δ 4.21 – 3.98 (m, 4H), 3.59 (t, J = 6.6 Hz, 2H), 1.84 – 1.18 (m, 24H), 0.89 (s, 9H), 0.06 
(s, 6H). 
 
Diethyl 10-hydroxydecylphosphonate (12) 
To a cooled (0 °C) solution of 11 (4.4 g, 11 mmol) in dry THF (40 mL), TBAF (12.3 mL, 
1 M in THF) was slowly added under inert atmosphere. The reaction was allowed to stand 
overnight while warming up to RT. The reaction mixture was concentrated and dissolved 
in 100 mL DCM and washed twice with water (50 mL) and with brine (50 mL). The organic 
layer was dried (MgSO4), filtered, and concentrated. The resulting yellow oil was purified using column 
chromatography (5% MeOH in DCM) to afford the title compound as a light yellow oil (2.84 g, 9.65 mmol, 86%). 
1H NMR (300 MHz, CDCl3) δ 4.23 – 3.95 (m, 4H), 3.64 (t, J = 6.5 Hz, 2H), 1.88 – 1.46 (m, 9H), 1.46 – 1.18 
(m, 16H). 13C NMR (126 MHz, CDCl3) δ 62.98, 61.50 (d, J = 6.6 Hz), 32.87, 30.64 (d, J = 16.8 Hz), 29.56, 
29.45, 29.34, 29.12, 25.82, 25.74 (d, J = 140.4 Hz), 22.44 (d, J = 5.2 Hz), 16.56 (d, J = 6.0 Hz). 31P NMR 
(202 MHz, CDCl3) δ 33.26. 
 
10-(Diethoxyphophoryl) decyl-1-succinimidyl carbonate (13) 
12 (189 mg, 0.64 mmol) was dissolved in 5 mL dry DMF and TEA (0.20 mL, 
1.4 mmol) was added. To the stirred solution N,N’-disuccinimidyl carbonate (328 
mg, 1.28 mmol) was added. The solution was stirred for 40 hours under argon 
atmosphere at RT. The resulting mixture was taken up in an emulsion of water 
(20 mL) and EtOAc (20 mL) and stirred for 10 minutes. Then, H2O (50 mL) was 
added. The layers were separated and the aqueous layer was extracted using EtOAc (3x 20 mL). The combined 
organic layers were washed with brine, dried (MgSO4), filtered and concentrated. Purification was performed 
using silica chromatography (5% MeOH in DCM) to afford 13 as a light yellow oil (254 mg, 0.58 mmol, 91%). 
1H NMR (300 MHz, CDCl3) δ 4.32 (t, J = 6.7 Hz, 2H), 4.18 – 4.01 (m, 4H), 2.84 (s, 4H), 1.81 – 1.65 (m, 4H), 
1.65 – 1.51 (m, 2H), 1.46 – 1.21 (m, 18H). 13C NMR (75 MHz, CDCl3) δ 168.82, 71.74, 61.49 (d, J = 6.5 Hz), 
30.68 (d, J = 17.1 Hz), 29.40, 29.33, 29.13, 28.44, 25.77 (d, J = 140.1 Hz), 25.57, 25.50, 22.50 (d, J = 5.2 
Hz), 16.59 (d, J = 6.0 Hz). 
 
10-(Ethoxyfluorophophoryl) decyl-1-succinimidyl carbonate (14)  
13 (254 mg, 0.58 mmol) was dissolved in 3 mL DCM. Subsequently, oxalyl chloride 
(0.54 mL, 6.2 mmol) was added and the reaction was stirred for 16 hours at room 
temperature under N2-atmosphere. The reaction mixture was diluted with DCM 
(10 mL), then quenched with water (10 mL). The mixture was stirred for 15 minutes. 
The layers were separated and the aqueous layer was extracted using DCM and EtOAc 
(2x). The combined organic layers were dried (MgSO4), filtered and concentrated. The residue was dissolved in 
DCM (3 mL), placed under N2-atmosphere and cooled down to -78 °C. Slowly, diethylaminosulfur trifluoride 
(0.19 mL, 1.4 mmol) was added. The reaction was stirred for 30 minutes at -78 °C. The reaction was quenched 
with water (5 mL) and EtOAc (5 mL) and warmed up to room temperature. The layers were separated and the 
aqueous layer was extracted using EtOAc. The combined organic layers were dried (MgSO4), filtered and 
concentrated in vacuo to afford the crude product. Purification was performed with column chromatography 
(50% EtOAc in pentane) to afford the title compound as a slightly yellow oil (109 mg, 0.27 mmol, 46%). Rf (50% 
EtOAc in pentane) = 0.4. 1H NMR (500 MHz, CDCl3) δ 4.32 (t, J = 6.7 Hz, 2H), 4.29 – 4.18 (m, 2H), 2.84 (s, 
4H), 1.95 – 1.83 (m, 2H), 1.81 – 1.71 (m, 2H), 1.71 – 1.58 (m, 2H), 1.45 – 1.35 (m, 7H), 1.35 – 1.21 (m, 
8H).  13C NMR (126 MHz, CDCl3) δ 168.83, 151.73, 71.75, 63.15 (d, J = 7.3 Hz), 30.37 (d, J = 16.9 Hz), 29.37, 
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= 5.6 Hz). 31P NMR (202 MHz, CDCl3) δ 32.52 (d, J = 1070 Hz). 19F NMR (471 MHz, CDCl3) δ -65.03 (d, J = 
1070 Hz). 
 
4-(4,4-Difluoro-1,3,5,7-tetramethyl-4-bora-3a,4a-diaza-s-indacene-8-yl)-butyric methyl ester (BODIPY-
butyric methyl ester) (16) 
2,4-Dimethylpyrrole (716 mg, 7.3 mmol) was dissolved in DCM (30 mL) and placed under 
argon atmosphere. Then, methyl 5-chloro-5-oxopentanoate 15 (0.68 mL, 4.9 mmol) was 
added to the solution. The mixture was refluxed for 2 hours. TEA (3.5 mL, 25 mmol) was 
dissolved in toluene (20 mL) and was added to the solution. Subsequently, borontrifluoride 
etherate (4.1 mL, 33 mmol) was added and the solution was heated to 50 °C for 1.5 hours. 
The mixture was diluted with DCM. The solution was quenched with HCl (1 M, aq.) and 
water. The layers were separated and the organic layer was washed with HCl (1 M, aq.). The 
combined aqueous layers were extracted three times with DCM. The combined organic layers were dried 
(MgSO4), filtered and concentrated. Purification was performed using silica column chromatography (gradient 
of 10% – 20 % EtOAc in pentane). The product was obtained as a red/brown solid (777 mg). NMR showed 
presence of TEA·HCl, making up for 25%wt, as calculated by NMR-integrals. The resulting crude was used in 
subsequent reactions without further purification (584 mg, 1.68 mmol, 46%). 1H NMR (300 MHz, CDCl3) δ 
6.06 (s, 2H), 3.70 (s, 3H), 3.10 – 2.91 (m, 2H), 2.57 – 2.34 (m, 14H), 2.03 – 1.86 (m, 2H). 
 
4-(4,4-Difluoro-1,3,5,7-tetramethyl-4-bora-3a,4a-diaza-s-indacene-8-yl)-butyric acid (16a) 
16 (285 mg, 0.82 mmol) was dissolved in THF (5 mL). NaOH (4 mL, 2M, aq.) and water 
(3 mL) were added to the solution. The reaction mixture was stirred 16 hours at room 
temperature under inert atmosphere. The mixture was acidified using HCl (6 mL of 2 M aq.) 
and HCl (1 mL 37%wt aq.). The resulting mixture was extracted twice with EtOAc. The 
combined organic layers were dried (MgSO4), filtered and concentrated. Purification was 
performed using column chromatography (5% AcOH and 15% EtOAc in pentane) to afford 
the title compound as a red solid (225 mg, 0.67 mmol, 82%). Rf (15:4:1 
pentane:EtOAc:AcOH) = 0.3. 1H NMR (400 MHz, CDCl3) δ 9.10 (s, 1H), 6.05 (s, 2H), 3.07 – 2.95 (m, 2H), 2.55 
(t, J = 7.2 Hz, 2H), 2.51 (s, 6H), 2.41 (s, 6H), 2.01 – 1.90 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 178.81, 154.36, 
144.85, 140.52, 131.55, 121.96, 34.27, 27.50, 26.63, 16.43, 14.60. 
 
tert-Butyl (5-(4-BODIPY-butanamido)pentyl)carbamate (17) 
16a (225 mg, 0.67 mmol) was dissolved in DCM (30 mL), to which EDC·HCl 
(227 mg, 1.29 mmol), TEA (0.30 mL, 2.1 mmol), N-Boc cadaverine 
(0.25 mL, 1.22 mmol) and HOBt (106 mg, 0.78 mmol) were added. The 
reaction was stirred for 56 hours at room temperature. The reaction was 
quenched with HCl (20 mL, 0.1 M, aq.) and extracted using DCM. The 
combined organic layers were dried (MgSO4), filtered and concentrated. 
Purification using column chromatography (70% EtOAc in pentane) 
afforded the title compound as an orange solid (206 mg, 0.397 mmol, 
56%). 1H NMR (400 MHz, CDCl3) δ 6.05 (s, 2H), 5.77 (s, 1H), 4.60 (s, 1H), 3.27 – 3.19 (m, 2H), 3.11 (q, J = 
6.6 Hz, 2H), 3.04 – 2.96 (m, 2H), 2.51 (s, 6H), 2.42 (s, 6H), 2.33 (t, J = 7.0 Hz, 2H), 2.00 – 1.90 (m, 2H), 1.57 
– 1.46 (m, 4H), 1.44 (s, 9H), 1.39 – 1.30 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 156.30, 154.13, 152.80, 




To a solution of 17 (206 mg, 0.40 mmol) in DCM (15 mL), TFA (1.0 mL, 
13 mmol) was added under inert atmosphere and the reaction mixture was 
stirred for 16 hours at RT. The resulting mixture was concentrated to yield 
the title compound as a dark red solid. LC/MS showed partial removal of 
BF2-group by TFA. The impure product (68 mg) was used without further 
purification for subsequent reactions. 1H NMR (400 MHz, MeOD) δ 6.15 (d, 
J = 8.1 Hz, 2H), 3.19 (t, J = 7.1 Hz, 2H), 3.09 – 2.97 (m, 2H), 2.71 (t, 2H), 
2.45 (d, J = 4.9 Hz, 12H), 2.41 – 2.34 (m, 2H), 2.01 – 1.87 (m, 2H), 1.61 – 1.44 (m, 4H), 1.44 – 1.33 (m, 2H). 
 
 Development of a multiplexed ABPP assay to evaluate activity 
of endocannabinoid hydrolase inhibitors  |  123 
 
10-(Ethoxyfluorophosphoryl)decyl (5-(4-BODIPY-butanamido)pentyl)carbamate (3, BODIPY-FP) 
17a (68 mg) was placed under inert 
atmosphere and dissolved in DCM 
(3 mL). Dry DMF (2 mL) was added 
and 14 (42 mg, 0.10 mmol) was 
added to the solution. The reaction 
mixture was stirred for 4 hours at 
RT. The reaction was quenched with water (5 mL) and EtOAc (5 mL) was added. The aqueous layer was 
extracted with EtOAc (2x) and DCM (2x). The combined organic layers were dried (MgSO4), filtered and 
concentrated. Purification was performed using silica column chromatography (100% EtOAc) to yield 39 mg of 
crude product. Further purification was performed on preparative HPLC (H2O/acetonitrile/TFA). Pure fractions 
were combined and lyophilized to obtain the title compound as a red solid (19 mg, 27 µmol, 26%). 1H NMR 
(500 MHz, CDCl3) δ 6.05 (s, 2H), 5.79 (s, 1H), 4.72 (s, 1H), 4.33 – 4.19 (m, 2H), 4.07 – 3.96 (m, 2H), 3.29 – 
3.20 (m, 2H), 3.20 – 3.11 (m, 2H), 3.05 – 2.95 (m, 2H), 2.51 (s, 6H), 2.43 (s, 6H), 2.39 – 2.29 (m, 2H), 2.01 
– 1.93 (m, 2H), 1.93 – 1.83 (m, 2H), 1.71 – 1.47 (m, 8H), 1.43 – 1.24 (m, 17H). 13C NMR (126 MHz, CDCl3) 
δ 171.77, 157.02, 154.04, 145.32, 140.49, 131.48, 121.74, 64.96, 63.09 (d, J = 7.2 Hz), 40.45, 39.47, 
36.27, 30.23 (d, J = 16.8 Hz), 29.71, 29.37, 29.16, 29.13, 29.01, 28.92 – 28.77 (m), 27.56, 27.49, 25.82, 
24.94 – 23.29 (m), 21.85 (d, J = 5.2 Hz), 16.45, 16.35 (d, J = 5.6 Hz), 14.47. 19F NMR (471 MHz, CDCl3) δ -
64.70 (d, J = 1070 Hz), -144.63 – -150.06 (m). 31P NMR (202 MHz, CDCl3) δ 31.96 (d, J = 1070 Hz). HRMS: 
[M+H]+ calculated for C35H58BF3N4O5P: 713.4184; found: 713.4194 
 
 
Scheme S6.2 | Synthesis of commercially available TAMRA-FP probe 1.  Reagents and conditions: i) MsCl, 
DIPEA, DCM, 0-20 °C; ii) NaN3, DCM, DMF, 50 °C, 45%; iii) oxalyl chloride, DCM, 0-20 °C; iv) DAST, DCM,  
-78 °C, 83%; v) trimethylphospine, THF, 0-20 °C; vi) 5-TAMRA SE (22), NEt3, DCM, RT, 54%. 
 
10-(Diethoxyphosphoryl)decyl methanesulfonate (18)  
Diethyl (10-hydroxydecyl)phosphonate 12 (147 mg, 0.50 mmol) was dissolved in dry 
DCM (10 mL) and cooled to 0 °C. Methanesulfonyl chloride (43 µL, 63 mg, 0.55 mmol) 
and DIPEA (96 µL, 71 mg, 0.55 mmol) were added and the mixture is left to stir for 20 
hours, warming to RT. The reaction was quenched by the addition of aqueous HCl (2 N) 
solution. The aqueous layer was extracted three times with DCM. The combined organic layers were dried 
(MgSO4), filtered and concentrated yielding crude mesylated product which was used directly in the next 
reaction.  
 
Diethyl (10-azidodecyl)phosphonate (19) 
10-(diethoxyphosphoryl)decyl methanesulfonate 18 (186 mg, 0.50 mmol) was dissolved 
in dry DCM (5 mL). Dry DMF (5 mL) and sodium azide (98 mg, 1.50 mmol) were added 
and the mixture was stirred at 50 °C for 72 h. The crude mixture was poured into 
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extracted twice with DCM. The combined organic layers were dried (MgSO4), filtered, and concentrated. 
Purification by column chromatography (50-90% EtOAc in pentane) afforded the product as a colourless oil 
(71 mg, 0.22 mmol, 45% yield over two steps). 1H NMR (400 MHz, CDCl3) δ 4.19 – 4.01 (m, 4H), 3.26 (t, J = 
7.0 Hz, 2H), 1.80 – 1.66 (m, 2H), 1.66 – 1.52 (m, 4H), 1.42 – 1.20 (m, 18H). 13C NMR (101 MHz, CDCl3) δ 
61.43 (d, J = 6.5 Hz), 51.48, 30.69, 30.52, 29.42, 29.27, 29.13, 29.07, 28.85, 26.72, 25.67 (d, J = 140.3 
Hz), 22.41 (d, J = 5.2 Hz), 16.51 (d, J = 6.0 Hz). 
 
Ethyl (10-azidodecyl)phosphonofluoridate (20) 
19 (71 mg, 0.22 mmol) was dissolved in dry DCM (5 mL) and stirred on ice. Oxalyl chloride 
(1.11 mL, 2.22 mmol) was added and stirred overnight, warming up to RT. The reaction 
was quenched by the addition of water (5 mL), diluted with DCM (5 mL) and stirred for 10 
minutes. A cloudy suspension formed. The water layer was separated and extracted twice with DCM (water 
layer still cloudy) and twice with EtOAc (water layer now clear). The organic layers were combined, dried 
(MgSO4), filtered and concentrated. The crude ethyl (10-azidodecyl)phosphonate was brought under nitrogen 
atmosphere, dissolved in dry DCM (3 mL) and cooled to -78 °C. Diethylamino sulfurtrifluoride (88 µL, 
0.67 mmol) was added and the resulting mixture stirred at -78 °C for 30 minutes. The reaction was quenched 
by the addition of a 1:1 mixture (v/v) of water:EtOAc (10 mL). The water layer was separated and extracted 
twice with EtOAc. The organic layers were combined, dried (MgSO4), filtered, and concentrated. Purification by 
column chromatography (50-100 % EtOAc in pentane) yielded the title compound (54 mg, 0.18 mmol, 83%). 
1H NMR (500 MHz, CDCl3) δ 4.32 – 4.21 (m, 2H), 3.26 (t, J = 7.0 Hz, 2H), 1.95 – 1.83 (m, 2H), 1.72 – 1.54 
(m, 4H), 1.46 – 1.15 (m, 15H). 13C NMR (126 MHz, CDCl3) δ 63.11 (d, J = 7.2 Hz), 51.55, 30.40, 30.27, 29.43, 
29.24, 29.16, 29.00, 28.91, 26.76, 24.38 (dd, J = 22.3, 143.1 Hz), 21.97 (d, J = 5.5 Hz), 16.43 (d, J = 5.6 
Hz).31P NMR (202 MHz, CDCl3) δ 32.44 (d, J = 1070 Hz). 19F NMR (471 MHz, CDCl3) δ -64.99 (d, J = 1070 Hz). 
 
Ethyl (10-aminodecyl)phosphonofluoridate (21) 
Ethyl (10-azidodecyl)phosphonofluoridate 20 (18 mg, 0.061 mmol) was coevaporated with 
dry toluene, dissolved in dry THF (5 mL) and cooled on ice. Trimethylphosphine (0.123 mL, 
0.123 mmol) was added as a solution in THF (1 M). The resulting mixture was stirred for 3 h 
at 0°C after which water (0.2 mL) was added. The crude was concentrated in vacuo and 





Crude 21 was dissolved in dry DCM and 5-TAMRA 
succinimidyl ester 22 (5.0 mg, 9.5 µmol) and 
triethylamine (7.9 µL, 0.057 mmol) were added. The 
mixture was stirred at RT overnight. TLC showed 
complete conversion (10% MeOH/EtOAc). The 
reaction mixture was concentrated in vacuo and 
purified by preparative HPLC. After lyophilization a 
purple powder was obtained of sufficient (>90 %) 
purity (3.47 mg, 5.10 µmol, 54% yield over two steps). HRMS: [M+H]+ calculated for C37H48FN3O6P: 680.3259; 
found: 680.3250. 
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Scheme S6.3 | Synthesis of probe 4. Reagents and conditions: i) N-Boc cadaverine, DCM, DMF, RT; ii) TFA, 
DCM, RT; iii) 14, NEt3, DCM, DMF, RT, 70%.   
 
tert-Butyl (5-(5-TAMRA-amino)pentyl)carbamate (23)  
5-TAMRA-succinimidyl ester 22 (5.0 mg, 9.5 µmol) was dissolved in DCM 
(1.5 mL) and DMF (1 mL). To this solution N-Boc cadaverine (2.6 µL, 
12 µmol) and TEA (2.4 µL, 17 µmol) were added. The reaction mixture 
was stirred for 4 hours at room temperature. LC/MS showed full 
conversion of 22. The solvents were removed under low pressure to afford 
the crude product as a pink solid. The resulting crude product was used 
in subsequent reactions without further purification.  
 
 
5-(5-TAMRA-amino)pentan-1-amine (24)  
23 was dissolved in DCM (1.4 mL) and TFA (0.1 mL). The reaction mixture 
was stirred for 3 hours at room temperature, after which LC/MS showed full 
conversion of 23. The solvent was removed under low pressure to afford the 
crude product as a red solid. The resulting crude product was used in 







24 was dissolved in DCM (1.5 mL) 
and DMF (1 mL) and placed under 
inert atmosphere. 14 (19 mg, 
46 µmol) and TEA (7.0 µL, 
50 µmol) were added to the 
solution. The reaction mixture was 
stirred for 4 hours at room 
temperature. The solvent was 
removed under low pressure and 
purification was performed with preparative HPLC (50-55% acetonitrile in water, 0.1% TFA). Pure fractions were 
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5.8 µmol, 61% over three steps). 1H NMR (500 MHz, CDCl3) δ 8.75 (s, 1H), 8.29 (d, J = 7.8 Hz, 1H), 8.17 (s, 
1H), 7.30 (d, J = 7.8 Hz, 1H), 7.19 (d, J = 9.4 Hz, 2H), 6.86 (dd, J = 9.5, 2.4 Hz, 2H), 6.74 (d, J = 2.4 Hz, 2H), 
4.98 (s, 1H), 4.30 – 4.20 (m, 2H), 4.13 – 3.96 (m, 2H), 3.50 (q, J = 6.7 Hz, 2H), 3.28 (s, 12H), 3.16 (d, J = 
16.4 Hz, 2H), 1.96 – 1.80 (m, 2H), 1.78 – 1.51 (m, 8H), 1.50 – 1.22 (m, 17H). 31P NMR (202 MHz, CDCl3) δ 
32.15 (d, J = 1070 Hz). 19F NMR (471 MHz, CDCl3) δ -64.99 (d, J = 1070 Hz). HRMS: [M+H]+ calculated for 
C43H59FN4O8P: 809.4049; found: 809.4059. 
 
  
Scheme S6.4 | Synthesis of ‘dark’ alkyne-FP (5). Reagents and conditions: i) PPh3, imidazole, I2, DCM, 
RT, 20%; ii) P(OEt)3, 160 °C, quantitative; iii) oxalyl chloride, DCM; iv) DAST, DCM, -78 °C, 41%. 
 
11-Iodoundec-1-yne (26) 
Imidazole (102 mg, 1.4 mmol) and triphenylphosphine (355 mg, 1.35 mmol) 
were dissolved in DCM (10 mL) and iodine (330 mg, 1.3 mmol) was added 
gradually. After stirring for 20 min at RT, a solution of 25 (172 mg, 1.0 mmol) in DCM (5 mL) was added 
dropwise to the reaction mixture. After stirring for 16 h a solution of additional imidazole (102 mg, 1.5 mmol), 
PPh3 (393 mg, 1.5 mmol) and I2 (381 mg, 1.5 mmol) in THF (15 mL) was added to the reaction mixture. After 
2 h an aqueous solution of Na2S2O3 (10 mL, 1 M) was added to quench the reaction. The layers were separated 
and the organic layer was dried (MgSO4), filtered and concentrated in vacuo. Purification by column 
chromatography (0-5% EtOAc in pentane) yielded the title compound as a yellow oil (58 mg, 0.20 mmol, 20%). 
1H NMR (400 MHz, CDCl3) δ 3.19 (t, J = 7.0 Hz, 2H), 2.18 (td, J = 2.6, 7.1 Hz, 2H), 1.94 (t, J = 2.6 Hz, 1H), 1.90 
– 1.76 (m, 2H), 1.58 – 1.47 (m, 2H), 1.40 – 1.33 (m, 4H), 1.33 – 1.19 (m, 6H). 13C NMR (101 MHz, CDCl3) δ 
84.73, 68.13, 33.54, 30.49, 30.33, 29.28, 29.01, 28.69, 28.49, 18.41, 7.35. 
 
Diethyl undec-10-yn-1-ylphosphonate (27) 
Compound 28 (58 mg, 0.20 mmol) was dissolved in triethyl phosphite 
(500 µL) and heated to reflux. After stirring for 4 h the reaction mixture 
was cooled to RT and concentrated in vacuo at 75 °C yielding compound 
27 (60 mg, 0.20 mmol, quantitative yield) as a yellow oil that was used 
without further purification. 1H NMR (400 MHz, CDCl3) δ 4.20 – 4.02 (m, 4H), 2.18 (td, J = 7.0, 2.7 Hz, 2H), 
1.95 (t, J = 2.7 Hz, 1H), 1.81 – 1.66 (m, 2H), 1.65 – 1.56 (m, 2H), 1.56 – 1.47 (m, 2H), 1.46 – 1.22 (m, 16H). 
13C NMR (101 MHz, CDCl3) δ 84.77, 68.17, 61.65 – 61.32 (m), 30.72, 30.55, 30.37, 29.77, 29.27, 29.08, 
28.74, 28.50, 25.72 (d, J = 140.4 Hz), 22.44 (d, J = 5.2 Hz), 18.44, 16.55 (d, J = 6.1 Hz). 
 
Ethyl undec-10-yn-1-ylphosphonofluoridate (5) 
A solution of oxalyl chloride in DCM (2.0 M, 1.0 mL, 2.0 mmol) was added 
to 27 (60 mg, 0.20 mmol) and the reaction mixture was stirred overnight 
at RT. DCM and H2O were added and after 10 min of stirring the layers 
were separated and the aqueous layer was extracted two times with DCM. The combined organic layers were 
dried (MgSO4), filtered and concentrated in vacuo. The crude product was coevaporated twice with toluene 
and redissolved in DCM. The reaction mixture was cooled to -78 °C, after which DAST (110 µL, 0.83 mmol) 
was added. After stirring for 30 min the reaction mixture was quenched with H2O and aqueous layer was 
extracted three times with DCM. The combined organic layers were dried (MgSO4), filtered and concentrated 
in vacuo. Purification by column chromatography yielded the title compound (17 mg, 64 µmol, 32%) as a yellow 
oil. 1H NMR (400 MHz, CDCl3) δ 4.32 – 4.20 (m, 2H), 2.18 (td, J = 2.6, 7.1 Hz, 2H), 1.94 (t, J = 2.7 Hz, 1H), 
1.93 – 1.82 (m, 2H), 1.73 – 1.58 (m, 2H), 1.58 – 1.47 (m, 2H), 1.44 – 1.26 (m, 13H). 13C NMR (101 MHz, 
CDCl3) δ 84.85, 68.24, 63.16 (d, J = 7.3 Hz), 30.48, 30.31, 29.26, 29.11, 29.03, 28.79, 28.56, 24.43 (dd, J 
= 22.3, 143.0 Hz), 22.02 (d, J = 5.6 Hz), 18.51, 16.50 (d, J = 5.8 Hz). 31P NMR (162 MHz, CDCl3) δ 32.37 (d, 
J = 1070 Hz). 19F NMR (471 MHz, CDCl3) δ -64.98 (d, J = 1070 Hz). HRMS: [M+Na]+ calculated for 
C13H24FNaO2P: 285.1390; found: 285.1395.  
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Supplementary Tables and Figures 
 
Figure S6.1 | Identification of DAGL-α labeling by probe 3 
(500 nM) in mouse brain membrane proteome. LEI104 shows 
identical inhibition profile of the band at 120 kDa as reported 




Figure S6.2 | Representative gels of the dose response analysis of the three probes of Figure 6.3. Final quantification 
was based on 3 gels.  
 




Figure S6.3 | EC50 curves of the 18 quantified bands of Figure 6.3.  
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Table S6.1 | Overview of pEC50 values of FP probes 1, 3 and 4. Band numbers correspond 
to Figure 6.3. 
 Probe 1 Probe 3 Probe 4 
Band pEC50 ± SEM pEC50 ± SEM pEC50 ± SEM 
1 ≤ 6 - ≤ 6 - ≤ 6 - 
2 8.52 0.07 9.48 0.12 8.71 0.17 
3 ≤ 6 - 7.28 0.09 ≤ 6 - 
4 ≤ 6 0.04 ≤ 6 - ≤ 6 - 
5 ≤ 6 - ≤ 6 - ≤ 6 - 
6 6.94 0.13 7.10 0.15 6.73 0.14 
7 ≤ 6 - ≤ 6 - ≤ 6 - 
8 6.63 0.05 7.87 0.07 7.24 0.08 
9 7.36 0.07 8.35 0.08 7.62 0.11 
10 7.4 0.07 8.45 0.10 7.80 0.07 
11 ≤ 6 - 6.80 0.05 ≤ 6 - 
12 ≤ 6 - 5.87 0.09 ≤ 6 - 
13 7.75 0.07 8.55 0.13 7.98 0.03 
14 7.55 0.07 8.28 0.09 7.74 0.05 
15 ≤ 6 - 6.22 0.09 ≤ 6 - 
16 6.21 0.04 ≤ 6 - 6.09 0.04 
17 7.05 0.04 6.83 0.06 7.29 0.05 
18 ≤ 6 - 6.85 0.05 ≤ 6 - 
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Figure S6.4 | Dose response inhibition of the probe cocktail by NF1819 (6) (A) and ABX-1431 (7) (B) in mouse brain 
membrane proteome, split by fluorescence channel to visualize overlapping bands of MAGL and ABHD6. 
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7. t-Distributed Stochastic 
Neighbour Embeddings 













Chemical space is vast and can only be explored to a small extent by experimental 
methods to find suitable hits for drug discovery programs.1,2 The search for new chemical 
starting points to modulate therapeutic targets is essential for the development of novel 
drugs. Due to the difficulties in finding suitable hits, it has been postulated that the best 
way to find a new drug is to start with an old drug.3 This is in line with the central paradigm 
in medicinal chemistry that similar structures exert similar biological activities.4 This 
paradigm can be mirrored to state that similar biological entities will be subject to 
modulation by similar molecular structures. It is this latter formulation that explains many 
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of the off-target activities observed when studying the inhibitory activity of a hit molecule 
against a subset of enzymes performing a similar function, which are part of the same 
cascade, or belong to a closely related family. An example from the endocannabinoid field 
is LEI104, which was found to be active against fatty acid amide hydrolase (FAAH) and 
diacylglycerol lipase (DAGL) α and DAGL-β. FAAH is responsible for the hydrolysis of 
N-arachidonoylethanolamine (anandamide), whereas the DAGLs produce 2-arachidonoyl-
glycerol (2-AG).5 The high similarity in structure of the substrate and product, respectively, 
of these enzymes implies that the binding pockets of the enzymes are similar, allowing 
LEI104 to bind to both. 
Since most serine hydrolase inhibitors interact with the catalytically active amino acid, 
often in a covalent manner, off-target activity across this family is commonly observed for 
these compounds.6 Such off-target activity is usually unwanted, and may sometimes lead 
to profound toxic effects as discussed in Chapter 5.7 Despite the efficiency of activity-based 
protein profiling and other techniques to determine the selectivity of lead inhibitors, 
extensive screening campaigns are still expensive and time consuming. In the last decade, 
several large datasets with structure-activity relationships (SAR) of serine hydrolase 
inhibitors spanning a number of enzymes have been published.6,8 These empirical datasets 
may serve as guides to explore chemical space around this drug target family and predict 
(off-)target activity using advanced computational chemistry methods, such as quantitative 
SAR models (QSAR), similarity ensemble approach (SEA), support vector machines, 
k-nearest neighbour, random forest, naïve bayes, (deep learning) neural networks (NN) and 
principal component analysis (PCA).9–12 
Advanced machine learning models promise to revolutionize the field of drug discovery. 
Employing large high-dimensional datasets, these models are used to predict a wider range 
of biological activities for a compound, compared to traditional drug design methods (e.g. 
molecular modelling, docking and early QSAR-models, such as Hansch and Free-Wilson 
analysis13). Yet, many machine learning models are hampered in their applicability by lack 
of a clear interpretation and tendency to overfit on the high-dimensional data. Many of the 
best performing machine learning models are a black box in which it is unclear in what way 
the data are used to generate novel hypotheses. They also require in-depth knowledge of 
advanced cheminformatics and highly specialised or purpose-build software. These 
technical requirements slow down the implementation of the tools in the daily practice of 
drug discovery and consequently prevent the research community to take full advantage of 
the wealth of data becoming available. Therefore, there is a clear need for better tools to 
interpret and visualize complex, high-dimensional SAR datasets in an easy and intuitive 
manner and to predict the biological activity profile of novel hits for drug discovery 
programs.  
 
t-Distributed Stochastic Neighbour Embedding 
t-SNE was first published by van Maaten and Hinton in 2008 as the third variant of the 
Stochastic Neighbour Embedding concept.14,15 The aim of the algorithm is to generate 
visualizations of high dimensional data by generating a two or three dimensional 
embedding thereof (see Box 7.1 for more detail). This makes t-SNE foremost a 
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dimensionality reduction algorithm like the more well-known principal component analysis 
(PCA)16 and multidimensional scaling (MDS)17. The main difference, conceptually, between 
t-SNE, PCA and MDS is that the former is non-linear whereas the latter two are linear 
algorithms. This means that in general PCA and MDS predominantly preserve the large 
distances (differences) between points far apart in the high dimensional space, because 
these obtain a larger weight in the optimization algorithm than small differences. The result 
is that global structure is preserved well, but small variations in local structure are poorly 
mapped to the low dimensional embedding. t-SNE, like other algorithms before, aims to 
overcome these shortcomings by utilizing a non-linear cost-function, which weighs both the 
local and global structures. The success and general applicability of the t-SNE algorithm in 
dimensionality reduction is shown by the spur of publications utilizing it to visualize complex 
high-dimensional data sets in diverse experimental settings.18–22  Here, the applicability of 
t-SNE to drug discovery is investigated. The applicability as a similarity metric is studied, 
with the ultimate goal to apply it in a general workflow to predict target-ligand interactions 
naïvely based on the similarity dogma. 
 
Box 7.1 | A brief introduction to the t-SNE algorithm  
t-Distributed Stochastic Neighbour Embedding is a non-linear dimensionality reduction 
algorithm, or ‘manifold learning’ algorithm. This branch of (unsupervised) machine 
learning is based on the premise that many real-world high-dimensional datasets are 
intrinsically low-dimensional. To be interpretable by humans, a low dimensional view of 
data is required. The process of dimensionality reduction is therefore aimed at removing 
redundant dimensions and deflating it to two or three dimensions, primarily to be visually 
interpretable by the analyst.  
 
Mathematical framework 
The original high-dimensional data-space is defined as  and the mapped space , 
where D is the dimensionality. Original data points are denoted as , mapped points . 
The similarity of data point  to datapoint  was defined by Maaten and Hinton as the 
conditional probability, |, that  would be picked as its neighbour by . If neighbours 
are picked in proportion to their probability density under a Gaussian centred at  the 




The perplexity variable, which is set by the user, is directly coupled to the  in (7.1), and 
provides a measure of the smoothness of the embedding.  
In the original SNE, a very similar definition was used for the probability condition for 
the embedding, |, where for convenience the  is set to √ such that:  
 
  (7.2) 
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This definition led to various problems in the optimization procedure and subsequent 
implementations, so in t-SNE a Student t’s distribution is used as the probability condition 
for the low-dimensional map. This leads to a definition of  as follows:  
 
  (7.3) 
 
Where  is the symmetrized version of | according to  
||
 , and likewise for 
. In a perfect embedding,  and  will be equivalent for all possibilities of , so the 
difference between these two quantities needs to be minimized in the embedding 
process. To achieve this, the Kullback-Leibler divergence is employed by t-SNE as a 
measure of the faithfulness of the embedding. The function to minimize, the cost 
function, is then given by:  
 
  (7.4) 
 
in which  and   represent the joint conditional probability distribution summed over all 
points where  ! . The values of  and  are set to zero. The cost function is optimized 
by a gradient descent which is given by: 
 




The optimization generating the low-dimensional embedding can be interpreted as a 
mass-spring system reaching its equilibrium. The magnitude of the Kullback-Leibler 
divergence for a given  will scale linearly with " # $ (7.5), analogous to Hooke’s law, 
which scales linearly with the displacement of points. Intuitively the stiffness of the spring 
connecting  and  is determined by their distance in high-dimensional space, and also 
follows for t-SNE, where  is strongly influenced by " # $. 
 
t-SNE maps molecular similarity of drugs in drug-like chemical space 
Based on the principle that the chemical structure of a compound determines its 
biological and chemical properties, a machine learning algorithm that predicts target-ligand 
interaction landscapes should be able to recognize molecular similarity between different 
molecules. Traditionally, chemical similarity is measured by the Tanimoto coefficient (Tc).23 
To calculate the distance between compounds the Tc uses a molecular fingerprint, which 
is a high-dimensional bit vector that captures the presence or absence of chemical groups 
in a molecule. As a similarity metric the Tc has its limitations, predominantly because it 
averages differences over all bits, thereby losing information.24 Thus, we envisioned that 
the data contained in the molecular fingerprint should be used more efficiently by a 
machine learning algorithm to determine molecular similarity. Moreover, the Tanimoto 
coefficient is principally a distance metric between two fingerprints and does not allow 
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visualization of similarity within a set of molecules, making interpretation of this similarity 
metric nontrivial. t-SNE can be readily applied to bit vectors of any length and as such is 
easily applicable to chemical structures represented by molecular fingerprints. The 
algorithm could thus be used to find and cluster the most similar molecules in a large 
dataset and visualize that similarity clustering in a two- or three-dimensional space. 
The applicability of the t-SNE algorithm to this problem was initially tested by visualizing 
the molecular similarity of molecules from the Drug Repurposing Hub, an online repository 
containing compounds that have been clinically tested or used in humans.25 Only the 
launched drugs (2774) were selected and partially attributed to 27 chemotypes by hand. 
Morgan fingerprints (RD-Kit, 4096-bits, radius = 2, equivalent to ECFP426) were generated 
for each of these 2774 clinical compounds using KNIME, an open source software 
package.27,28 The fingerprints were fed into the Python implementation of the Barnes-Hut 
t-SNE algorithm to generate a map of the drug-like chemical space.29 The resulting map 
(Figure 7.1) shows remarkable co-localization of most of the chemotypes. As an example, 
the family of penicillin-like structures at the far right of the plot (cyan) is completely 
separated from all other chemical matter. Some unannotated molecules (in grey) are visible 
in this cluster, but upon detailed inspection they all constitute β-lactams in which the sulfur 
is either substituted or omitted. In addition, many other highly dense unannotated clusters 
are visible at the boundaries of the map, corresponding to highly defined chemotypes, such 
as the rapamycin, conazole and oxytocin analogues. Of note, even in the apparently less 
defined centre of the map, clear co-localization of similar molecules can be observed, for 
example a cluster of aspirin-like molecules (orange, near origin).  
Quantifying the quality of the generated embedding is not trivial. Despite the broad 
interest in machine learning algorithms and their application in numerous fields, few 
objective quality measures for embeddings are available.30 Often co-ranking histograms 
are constructed, comparing the original high-dimensional space (H-space) to the construc-
ted low-dimensional space (here: t-SNE, PCA or MDS space). Briefly, co-ranking histograms 
are constructed by counting the occurrences of co-ranking for each sample against all other 
samples. As this generates a two dimensional plot, they are often visualized as a heat-map. 
For the current purposes, such co-ranking histograms were constructed for t-SNE, PCA and 
MDS (Euclidian distances calculated in 2D embedding) and that of the Tanimoto distance 
(Figure 7.2A-D). Generally, the co-ranking histogram of t-SNE fanned out somewhat quicker 
than the Tanimoto plots, but for the lower ranked neighbours it corresponded well to the H-
space. Compared to the two linear dimensionality reduction algorithms, t-SNE looks to be 
considerably better based on the heat-maps. There are several ways to summarize the 
information contained in a co-ranking histogram, of which the Q-score is conceptually one 
of the easiest to interpret.30 It assesses the overall quality of the dimensionality reduction 
where 1 is a perfect score, and 0 is the lowest. The Q-score neglects information regarding 
the kind of ranking error (too high or too low) but summarizes the quality up until a certain 
value of the rank, k. The higher rate of co-ranking for low ranks that was visible in the 
histograms is immediately evident from the Q-score graphs (Figure 7.2E and F), which start  
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Figure 7.1 | t-SNE visualization of chemical space. t-SNE embedding of the ‘launched’ drugs 
in the Drug Repurposing Hub.25 Embedding is based on the 4096-bit Morgan fingerprint. 
t-SNE settings: perplexity = 25, learning rate = 50, iterations = 10,000. Markers are coloured 
according to 27 manually attributed chemotypes.  
out high but quickly fall upon increasing k. This behaviour is observed for all three 
dimensionality reductions and the Tanimoto distance. t-SNE however performs much better 
than the two linear algorithms, even for small values of k. When comparing t-SNE for the 
more direct neighbours in the histogram and plot (Figure 7.2A and E) it is clear that t-SNE 
follows the Tanimoto distance quite closely. Of note, this comparison is technically a bit 
skewed, as the Tc is only a different distance measure derived from the same H-space, not 
the result of a dimensionality reduction as is the case for t-SNE. A benefit of the three 
dimensionality reduction algorithms is that the 2D embedding allows for interrogation of 
the directionality of similarity, whereas when using the Tc, it is impossible to assess the 
similarity between two molecules when their Tc distance to a third is known. It can be 
concluded that t-SNE is able to map the local chemical space of approved drugs well, much 
better than linear dimensionality reduction approaches, whilst following a chemist’s 
intuition. It recognizes molecular similarity in a broad set of diverse drug-like molecules and 
is able to present the results in a visually attractive and interpretable manner. 
 
 t-Distributed Stochastic Neighbour Embeddings applied to drug discovery  |  139 
 
 
Figure 7.2 | Assessment of the quality of the dimensionality reduction as performed by t-SNE, PCA and MDS 
on the Drug Repurposing Hub molecules, based on the t-SNE embedding in Figure 7.1, the PCA plot in 
Supplementary Figure 7.1A and the MDS plot in Supplementary Figure 7.1B. Panels A-D show a 
log10-transformed co-ranking histogram for the top 100 ranked molecules for t-SNE (A), the Tanimoto 
coefficient (B), PCA (C) and MDS (D). The bottom panels show Q-score30 graphs corresponding to the 
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t-SNE map of serine hydrolases recapitulates phylogenetic information 
Since closely related proteins typically bind similar endogenous molecules and 
(experimental) drugs, it was investigated whether the t-SNE algorithm is also capable of 
clustering proteins based on the similarity of their amino acids. Conceptually, this approach 
is analogous to proteochemometric modelling.31 To quantify the similarity of serine 
hydrolases, first a manually curated list containing all serine endopeptidases and metabolic 
serine hydrolases (mSHs) was constructed. This was done in a similar manner as reported 
previously.6 The amino acid sequences of the enzymes were then aligned using Clustal 
Omega.32 This alignment was transformed to a fingerprint based on the physicochemical 
properties of the amino acids.33 These fingerprints were used to create a two dimensional 
map of the target space by the t-SNE algorithm. The resulting map (Figure 7.3A) is capable 
of clustering most of the peptidases (triangles) and the mSHs (squares) in separate groups. 
The embedding was compared with a more traditional phylogenetic tree (Figure 7.3B). 
As an illustration, several groups of proteins have been highlighted and annotated in the 
embedding. In purple all phospholipase A2 group IV proteins, except PLA2G4C, are 
clustered together. This separation is also observed in the phylogenetic tree. The small 
group of hepatocyte growth factor proteins (MST1, MST1L and HGF, in red) are related to 
the F2 protein, according to the phylogenetic tree, and contain kringle domains. In the t-SNE 
embedding however, F2 is quite far away, placed directly next to PRSS51 (not annotated), 
to which it is also quite similar. Intriguingly, the HGF related proteins are all expected to be 
catalytically inactive as they lack one or more of the typical catalytic triad residues, whereas 
F2 is confirmed to be a functional peptidase. This could indicate that t-SNE is able to 
separate similar proteins (global properties) on the absence or presence of key amino acids 
(local structure). It might also be one of the reasons why the red group is isolated in the 
plot. Other well defined protein clusters include the carboxylic esterases (CES, blue) and 
the products of genes LIPA, LIPF and LIPM (yellow). The centre of the embedding where 
less clusters are observed, still holds large co-localized families of proteins, e.g. the 
kallikreins (KLK, light green) or the acyl-coenzyme A thioesterases (ACOT, not annotated). 
It appears that t-SNE, when applied to binarized sequence alignments, is able to analyze 
and cluster these entities, maintaining the separation of large groups (peptidases and 
mSHs), whilst also keeping subclasses of proteins closely associated.  
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Figure 7.3 | Comparison of t-SNE embedding (A) and phylogeny tree (B) of the serine hydrolase (SH) 
family. t-SNE settings: perplexity = 30, learning rate = 50, iterations = 10,000. 
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t-SNE analysis of serine hydrolase inhibition 
t-SNE thus presents itself as a similarity visualization technique able to find and quantify 
similarities between molecules and proteins. With this technique a system could be 
envisioned where a newly designed molecule is compared to a large set of available 
molecules of which the bio-activity data is known. If one now finds the most similar known 
compounds utilizing t-SNE, the bio-activity data of those molecules could be used as a 
prediction for the bio-activity of the newly designed inhibitor. The t-SNE embedding of the 
protein space could then be used to append enzymes, for which no bio-activity data is 
available, as potential targets to the prediction based on the fact that they are closely 
related to known targets. Through this intuitive process, targets, or off-targets, of novel 
molecules may be predicted in an efficient way. This approach is comparable to PASS and 
various other techniques, reviewed by Bender et al.34,35 
Currently, the largest dataset reported for serine hydrolases is that of Bachovchin et al.6, 
which screens a library of 140 inhibitors against 72 SHs (10,080 data points). This dataset 
contains bio-activity at one concentration (50 µM) and all inhibitors have a carbamate 
warhead. The predictive utility of this dataset is, therefore, restricted to similar carbamate-
based inhibitors. Another comprehensive serine hydrolase inhibitor dataset was generated 
using the EnPlex assay.8 This dataset has bio-activity data for 55 quite diverse inhibitors 
(Figure 7.4) and 94 serine hydrolases (Figure 7.5). This dataset was processed using t-SNE 
to visualize the inhibition profiles projected on the embedding of molecules and proteins 
and thereby assess the co-localization. 
When the 55 inhibitors were transformed in their respective fingerprints and clustered 
by t-SNE a quite disperse embedding was obtained (Figure 7.4A), in line with the diversity 
in the molecular set. Some more defined groups were observed, which upon inspection 
indeed corresponded to more similar molecules. When the bio-activity data was projected 
on this visualization by colouring the markers according to the pIC50s for specific targets 
(Figure 7.4B-D) very distinct patterns could be observed. All DPP4 inhibitors were positioned 
in the far right of the embedding, with the exception of methoxyarachidonoyl 
fluorophosphonate (MAFP) which is in the centre of the plot and, by its reactive nature, 
inhibits virtually all serine hydrolases tested in this assay. For the endocannabinoid system 
related enzyme FAAH a similar observation can be made, with all inhibitors co-localized to 
the left of the embedding, barring some reactive molecules in the centre. Most of the tested 
FAAH-inhibitors are carbamate based, and this chemotype typically shows off-target activity 
against carboxylic esterases (CES). This is exemplified by Figure 7.4D where the potency 
for CES1 is annotated. Only the more chemically distinct urea based PF-3845 (topmost 
marker) is inactive for CES1.  
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Figure 7.4 | t-SNE embeddings of the serine hydrolase inhibitors screened in the EnPlex assay.8  
A) Unannotated t-SNE clustering. B-D) All reported inhibition interactions of title enzymes are denoted in a 
gradient colouring. Only measured interactions < 10.000 nM are coloured in the embedding. 
 
Next, the protein-target space was analysed. To aid in this analysis, the serine hydrolases 
for which no bio-activity data is available were filtered out (Figure 7.5A), and the markers 
were coloured according to the activity of three dissimilar inhibitors (Figure 7.5B-E). These 
inhibitors vary not only in structure, but also in reactive group (warhead), targeted 
subfamily, and selectivity. The localization of the inhibited SHs in the plots shows clear co-
localization in pairs or groups. For example, JP104 (Figure 7.5B) has six measured IC50s, 
which are arranged in the embedding as three duos. The active metabolite of lactacystin is, 
as might be expected from its small molecular structure containing a reactive β-lactone, 
less selective. Several clear groups of targets can be seen, most notably the seemingly 
unrelated cluster of retinoid inducible serine carboxypeptidase (SCPEP1), probable serine 
carboxypeptidase CPVL (CPVL), lysosomal protective protein (CTSA) and α/β-hydrolase 
domain containing protein 11 (ABHD11). Of note, the only enzyme classified as peptidase 
targeted by lactacystin is located close to several targeted mSHs. Finally, chymostatin is 
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quite selective, with only 2 observed interactions in this enzyme panel. The two peptidases 
targeted, chymase and chymotrypsin-C, are indeed closely related according to the t-SNE 




Figure 7.5 | t-SNE embeddings of the serine hydrolase superfamily. A) Red colouring denotes the inclusion in 
the EnPlex assay. B-D) All reported inhibition interactions of title inhibitor are denoted in blue. Only measured 
serine hydrolases are included in the embedding (those coloured red in A). E) Structures of inhibitors in B-D. 
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Conclusion 
Taken together, it was shown that the dimensionality reduction algorithm t-Distributed 
Stochastic Neighbour Embedding can successfully be applied to molecular fingerprints, and 
that this generates a new, visually interpretable and quantitative similarity metric. 
Annotating a similarity visualization of a small inhibitor set with serine hydrolase inhibition 
data showed very distinct co-localization of activities in the embedding. t-SNE was also able 
to generate similarity maps for the serine hydrolase enzyme family when applied to a 
binarised multiple sequence alignment. This map revealed similarities between proteins 
not necessarily directly related in phylogeny. However, there is significant overlap between 
the traditionally assigned subfamilies and the co-localization in the t-SNE embeddings. By 
superimposing the available bio-activity data as a third dimension in colour on top of the 
t-SNE embeddings, definitive hotspots were shown where co-localized proteins were 
inhibited by the same inhibitor, which not always corresponded to the phylogenetic 
information. Given more (biological) data, it is expected that these mappings combined, in 
principle, could be applied to predict (off-)targets that are in these hotspots, or even predict 
(off-)targets for new molecules based on their molecular similarity to known compounds. It 
is expected that the target space visualization could be enhanced by improving the align-
ment of the enzymes. One option would be to centre the alignment around the catalytic 
serines, to improve the definition of the active site similarities, or truncate the sequences 
such that the alignment is more biased towards the actual binding site of the enzyme. 
The concept presented here can easily be adapted to work with any dataset available. 
Because all data, algorithms, and data processing tools used are in the public domain or 
open source, it is highly adaptable and extensible. Concrete examples include different 
druggable protein classes, such as kinases (Chapter 8), G-protein coupled receptors, ion 
channels or nuclear hormones. It could also be trained on a different molecular set 
altogether, e.g. solubility, membrane permeability, metabolic stability, pharmacokinetics or 








All molecular descriptors, molecular representations (SMILES, InChIKey) and fingerprints were generated using 
the RDKit software, either using the KNIME extensions or as the Python implementation.28 Morgan fingerprints 
(4096-bits, radius 2) were used for all molecular fingerprints. 
 
t-SNE algorithm 
All t-SNE embeddings were generated with the Python Scikit-learn (v. 0.19) implementation of the Barnes-Hut 
t-SNE algorithm, either implemented in a ‘Python for KNIME’ node or as part of a Python script.29  
 
Principal component analysis 
Principal component analysis was performed using the Python Scikit-learn decomposition module (v. 0.19) 
based on the same 4096-bit fingerprints used for the other analyses.  
 
Multidimensional scaling 
The multidimensional scaling was performed using the Python Scikit-learn manifold module (v. 0.19), based 
on the 4096-bit fingerprints used for other analyses. 
 
Co-ranking histogram and Q-scoring 
The co-ranking histograms were constructed in Python, using SciPy’s Rankdata functionality, using ordinal 
ranking.36 Generated histograms were exported to Microsoft Excel 2016 where they were log10 transformed 
and heatmaps were generated.  
The Q-score was calculated as described previously.37 In brief, Q-scores were calculated by summarizing mild 






where N is the total number of identities (2774, the number of molecules) and  
 
  (7.7) 
 
where % denotes the rank in the low-dimensional manifold or the rank according to Tanimoto distance, and 
& the rank in high dimensional space.  
 
Serine hydrolase sequence information and bitstring 
Sequence information of the serine hydrolases was retrieved from Uniprot.38 The proteins were aligned using 
the online Clustal Omega tool provided by the EMBL-EBI using the default settings.32 The standard “Clustal 
w/o numbers” output generated was transformed to a bitstring using the amino acid fingerprints as provided 
in Heil et al.33 with the following additions: alignment dashes (-), stops (*) and blanks (X) were all considered 
empty, and were represented by 23 0’s.  
 
Bioactivity used 








Figure S7.1 | Principal component analysis (A) and multidimensional scaling analysis (B) of the drug 
repurposing hub molecules with the status “Launched”. Embeddings are based on the 4096-bit Morgan 
fingerprint (RD-Kit). Markers are coloured according to 27 manually attributed chemotypes.  
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8. Drug Discovery Maps visualizes 













Protein kinases are an important class of drug targets due to their key role in intracellular 
signal transduction processes involved in cancer, auto-immune diseases, and 
(neuro)inflammation.1,2 The therapeutic value of the protein kinase family is demonstrated 
by the 38 kinase inhibitors currently approved by the FDA and the plethora of molecules 
being tested in clinical trials for this enzyme family.3 It is anticipated that these clinically 
approved kinase inhibitors (KI) can serve as starting points to identify novel drug candidates 
for other kinases.  
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Most KIs interact with the structurally and functionally conserved ATP-binding site, 
present in all >500 human protein kinases. It is well established that KIs bind multiple 
members of the kinase family, and that this may affect their efficacy and toxicity.4 Detailed 
investigation of the target-interaction landscape of KIs is, therefore, important to 
understand their molecular mode of action and offers the opportunity to identify new 
starting points for other therapeutically interesting kinases. Many complex, high-
dimensional datasets with structure-activity relationships (SAR) of KIs over a broad 
selection of kinases have become available (Table 8.1).5–10 The wealth of data present in 
literature has spurred the development of several computational platforms to predict 
kinase activities of inhibitors.11,12 These reported highly specialised computational models 
which were able to predict, to some extent, the inhibition profiles of inhibitors against the 
kinome. 
Given the large amount of data available and the apparent success of previous attempts 
to use these datasets in a predictive manner it was expected that the strategies introduced 
in Chapter 7 could be applied to the field of kinase inhibitors. This approach was dubbed 
Drug Discovery Maps (DDM), a machine learning tool that allows the visualization and 
prediction of target-ligand interaction landscapes. 
 
Table 8.1 | Summary of large experimental (partially) public kinome screens for sets of kinase inhibitors. 
Numbers of inhibitors and kinases are as reported in original publications and include mutants, splicing 
variants and separate kinase domains from the same kinase. Coverage represents the percentage of possible 
kinase-inhibitor pairs for which a data point is reported. 







Karaman et al. 38 317 Dose response** 12046 100% 
Metz et al. 3858 172 Dose response 258094 38.9% 
Anastassiadis et al. 178 300 Single dose 52834 98.9% 
Davis et al. 72 442 Dose response** 31824 100% 
Elkins et al. 367* 224 Two doses 81940 99.9% 
* contains duplicate molecules 
** only if activity is observed at initial 10 µM single dose screen 
 
t-SNE reliably reproduces human chemotype assignments 
In Chapter 7 it was demonstrated that t-SNE is able to visualize molecular similarity in a 
drug-like set of 2774 clinically applied molecules. For the current purposes, it had to be 
verified that t-SNE is still able to recognize molecular similarity within a smaller set of drug-
like molecules that is more homogenous and has higher molecular similarity. To this end, 
a t-SNE-mediated clustering on the molecules from the Published Kinase Inhibitor Set 
(PKIS) was performed.13 The PKIS is a 364-member library of molecules assembled by 
GlaxoSmithKline that are all classified as inhibitors of protein kinases. The PKIS set 
represents 31 manually annotated chemotypes and their activity has been measured and 
published for 200 kinases (Table 8.1, last entry).9 The resulting map of chemical space 
representing the KIs (Figure 8.1A) was coloured according to the manual chemotype 
attribution and showed clear co-localisation of chemotypes. A more in-depth analysis by the 
unsupervised cluster assignment algorithm DBSCAN confirmed the initial visual inspection 
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and shows high statistical correlation between the autonomously derived clustering and 
the human annotation.14 Of the 31 chemotypes annotated, 23 were fully comprised in one 
computationally assigned cluster. For example, the orange and gold clusters on the left of 
the map are completely isolated and comprise all compounds of those chemotypes (Figure 
8.1B). An enlargement of the cluster dominated by 3-amino-pyrazolopyridines (Figure 8.1B) 
showed that in fact three different chemotypes were included. Compounds 1-3 are 
examples of each, and they showed that indeed these compounds are highly similar, and 
perhaps arbitrarily assigned to different chemotypes. The ‘stray’ sky blue compound 4 is 
part of a chemotype that is less well defined in t-SNE space, but the similarities with 
compounds 1-3 are obvious. This analysis showed that t-SNE is capable to recognize and 
cluster molecular entities in a highly specific manner and that it allows the visual inspection 




Figure 8.1 | A) t-SNE embedding of the Published Kinase Inhibitor Set. Embedding is based on the 4096-bit 
Morgan fingerprint. t-SNE settings: perplexity = 50, learning rate = 50, iterations = 10,000. Markers are 
coloured according to 31 manually attributed chemotypes. B) t-SNE embedding as in A) but including a 
background of the DBSCAN generated clustering, coloured by the dominant chemotype in that cluster (grey 
are singletons or duos). Markers are coloured according to the 31 chemotypes defined by Elkins et al. as in A). 
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t-SNE map of the kinase target space  
To generate a visualization of the target space, and to quantify the similarity of kinases, 
first an alignment of the amino acid sequences of the whole kinase domains containing the 
ATP-binding pocket was created. This was translated to a fingerprint based on physico-
chemical properties of the amino acids, analogous to the methods used in Chapter 7.15 
These fingerprints were used to create a two-dimensional map of the target space by the 
t-SNE algorithm. The resulting embedding (Figure 8.2A) is remarkable, as it almost 
seamlessly recreates the phylogenetic tree published by Manning et al. in 2002.16 To assign 
the kinases to clusters, the coordinates of the t-SNE embedding were fed into the DBSCAN 
algorithm. All ten assigned clusters were significantly (P < 0.0001, Hypergeometric test) 
enriched for a specific kinase group as assigned by Manning et al. (Figure 8.2A). Closer 
inspection of some of the kinases unassigned by DBSCAN reveals that they belong to 
distinct branches of the phylogenetic tree, corresponding with their separation from the 
main clusters. As an example, the four tyrosine kinases (TK) in the far right of the 
embedding (burgundy) all belong to the JAK family (JAK1, 2, 3 and Tyk2), but only represent 
their second kinase domain. The first kinase domain is more closely associated with the 
rest of the TK group, and lies just outside the DBSCAN assigned cluster. The close 
association of the second kinase domains with the RGC cluster (coloured brown) is 
especially striking, as these domains, just as the RGC kinases, are considered 
pseudokinases. The same holds true for MLKL, IRAK2 and IRAK3. Intriguingly, the IRAK 
family of TKL kinases has four members, of which IRAK1 and IRAK4 are catalytically active, 
whereas IRAK2 and IRAK3 are not.17 In the t-SNE embedding, the former are located in the 
major TKL cluster (orange) whereas the latter are actually assigned to the RGC-dominated 
cluster. MLKL has also been shown to indeed lack catalytic activity in at least one report.18 
Another interesting feature is the separation of a group (left of plot) of TKL kinases from 
the major cluster. This subset features all but one of the STKR family of cell surface bound 
receptor kinases. Upon closer inspection, even the subfamilies of STRK1 and -2 are 
discernible. Strikingly, the MISR2 (AMHR2) kinase receptor is located with kinases 
categorised as ‘Other’. This receptor kinase has an atypical DFG motif (DLG), and as such 
can indeed be classified as a pseudokinase, although phosphorylating activity has 
experimentally been shown.19 The other members of the STKR family do all share the 
conserved DFG motif. Finally, on the lower side of the t-SNE plot several AGC coloured 
kinases have been clustered with the CAMK kinases. These actually represent the second 
kinase domains of the RSK family, which were also attributed to the CAMK group by 
Manning et al.16  
In summary, this analysis of target space of the binding site of protein kinase domains 
indicated that this embedding is able to recognize overall similarity but also detect subtle 
differences between the different binding domains of most kinase inhibitors.  
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Figure 8.2 | t-SNE visualization of kinase domains reveals phylogenetic information: A) t-SNE embedding of 
physicochemical fingerprint of the kinase domains of 535 human kinase domains. t-SNE settings: perplexity = 50, 
learning rate = 50, iterations = 25,000. Arbitrary t-SNE coordinates are rotated to match dendrogram orientation of 
Manning et al. Markers are coloured according to the 12 groups defined by Manning et al., background is coloured 
based on the DBSCAN generated clustering, coloured by the dominant kinase group in that cluster (blanks are 
unclustered kinases). B) Manning et al. manually curated kinome dendrogram, overlaid with circles coloured 
according to the background colouring from the t-SNE map in A), based on the unsupervised DBSCAN clustering.20 
 
DDM can predict target-ligand interaction landscapes 
Based on the successful analysis of the chemical and target space of kinases and their 
inhibitors, a workflow was set up to predict the activity of novel compounds for the entire 
kinome. The bioactivity data measured by Elkins et al. for the Published Kinase Inhibitor 
Set was used as training set, as it contains the most unique interactions of all open datasets 
(Table 8.1).9 The optimisation of the workflow with all parameters is described in more 
detail in the Methods. The final architecture of the algorithm is depicted in Figure 8.3, 
illustrated for the EGFR inhibitor erlotinib. At first, a t-SNE embedding is generated where 
erlotinib is mapped onto the chemical space of the PKIS (top left). This information is used 
to find the 9 most similar molecules (top right). Of these, the inhibition data measured by 
Elkins et al. is averaged, and all kinases above a threshold value C are considered targets 
(lower right). These kinases are then looked up in the target space map (Figure 8.2A), and 
the most similar kinases are appended (lower left) to yield the final prediction (centre). As 
the molecular t-SNE embedding is slightly stochastic, the described process is repeated 
several times (R) and the number of times a kinase is predicted is tracked.  
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Figure 8.3 | Schematic overview of the DDM workflow. In this example, the targets of erlotinib are predicted. 
Based on a t-SNE embedding (top left) the PKIS inhibitors nearest to erlotinib are found, depicted in the top 
right panel. For these, the inhibition data as measured by Elkins et al. is averaged and used as initial prediction. 
These targeted kinases are then looked up in the t-SNE embedding in the lower left panel, where the most 
similar kinases are added to yield the final prediction (centre).  
 
The DDM model was validated using an independent dataset generated by Karaman et 
al.5 The resulting prediction statistics for each of the 38 compounds in this test set are 
summarised in Table S8.1. The average positive prediction value (PPV) was 40%, with a 
Matthews correlation coefficient (MCC) of 0.21. These statistics were compared with 
previously published methods, and it was found that DDM performed better than QSAR-
models and was equal in performance to random forest based proteochemometric models 
(Figure 8.4). A receiver operating characteristic (ROC) analysis of the performance of DDM 
on this test set shows an area under the curve (AUC) of 0.76 (Figure 8.5). Taken all together, 











Figure 8.4 | Statistical comparison of the new t-SNE based model with four models based on published 
procedures. Bars denote mean ± SD of the 38 inhibitors. Significant improvements over random have been 
highlighted, * p < 0.0332, ** p < 0.0021, *** p < 0.0002, **** p < 0.0001 (Two-way ANOVA, Tukey’s 
multiple comparison test). The relatively low PPV and high NPV for the random predictions are caused by the 




Figure 8.5 | Receiver operating characteristic curve of the test set predictions 
with varying cut-off C values. Marker labels represent C values. The area under 
the curve is 0.76, with the maximum deviation from random at C values between 
25 and 35%. Axes have been normalized to take into account the inability to 
predict all kinases based on the PKIS coverage. 
 
 
Discovery of novel FLT3 inhibitors using DDM 
To investigate the utility of the model in early drug development, it was applied to the 
identification of new inhibitors for FMS-like Tyrosine kinase 3 (FLT3). FLT3 is implicated in 
advanced myeloid leukaemia, where approximately 30% of patients carry an internal 
tandem duplication (ITD) in their FLT3 gene that activates the kinase and acts as a driver 
mutation.21 Recently, midostaurin has been FDA approved for the treatment of AML 
patients and several other inhibitors are currently being tested in clinical trials. However, 
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fast adaptive mutations in the FLT3 gene quickly result in drug-induced resistance of AML, 
warranting the search for novel chemotypes to inhibit this kinase. To this end, the DDM 
model was used to predict the kinome-ligand interaction landscape of a small kinase-
focused library of 1152 molecules. They were analyzed using various values for the activity 
cut-off C, and were ultimately filtered using C = 40%, and a prediction count of at least 9 
out of 10 runs, to have a balanced number of molecules to be tested. These stringent cut-
offs yielded a workable set of 44 compounds predicted to be active against FLT3.  
 To validate our virtual DDM screen, a time-resolved fluorescence-resonance energy 
transfer (FRET)-based biochemical assay was performed with all 1152 compounds against 
FLT3, at an initial concentration of 10 µM. This screen yielded 184 actives, with >50% loss 
of activity (16% of all compounds). Of these compounds, the pIC50 was measured, resulting 
in 135 compounds with a pIC50 > 5, with a mean of 6.7 ± 0.9. 18 of the 184 compounds 
were part of the 44 compounds identified by the DDM screen, which results in a positive 
predicted value (PPV; or hit rate) of 41% (Figure 8.6A, P < 0.0001 (Hypergeometric test)), 
which is almost three-fold higher compared to the hit rate of the biochemical assay. Of note, 
15 of the predicted compounds demonstrated an IC50 of less than 2 µM (34%, P < 0.0001 
(Hypergeometric test)) with an average pIC50 7.3 ± 1.1, and also included the most active 
compound found in the screen (crenolanib, pIC50 of 9.0). The hit rate was nearly identical 
to the validation statistics for the test set (Figure 8.4), where an overall PPV of 40% was 
achieved. The same holds for the negative predictive value (89%) and the sensitivity (11%). 
The successful application of the DDM model for the FLT3 screen may partially be attributed 
to the high coverage for the TK family of kinases. Of note, the relatively low sensitivity (11%) 
is a balanced choice between minimising the number of compounds to screen and finding 
more actual hits. This can easily be tuned by varying the cut-off parameter.  
Two of the predicted compounds, 5 and 6 (Figure 8.6B), were selected based on their 
chemical properties, novelty regarding FLT3 inhibition, and their predicted interaction 
profile (vide infra). These compounds were resynthesized using established methods (see 
Methods). The activity of the compounds was confirmed in a FRET assay using recombinant 
human FLT3 (Figure 8.6C). Compounds 5 and 6 showed a concentration-dependent activity 
with pIC50 values of 7.3 ± 0.1 and 8.8 ± 0.1, respectively. To determine the cellular activity 
of both compounds, a cell proliferation assay using the FLT3-dependent AML cell line 
MV4:11 was performed. Both compound 5 and 6 showed clear cellular activity with pEC50 
values of 6.3 ± 0.1 and 8.5 ± 0.1, respectively. In summary, the experimental validation of 
the hits illustrated the power of the DDM workflow for compound selection in the lab. 
Finally, to explain the potential binding mode of compound 5 and 6 both compounds 
were docked using a DFG-in model (for 5) and the DFG-out structure 4RT7 (for 6) (Figure 
8.6E). Compound 5 binds to the hinge region with the aminopyrimidine moiety in a fashion 
typical for Type 1 kinase inhibitors. Compound 6 binds FLT3 in the DFG-out conformation 
analogous to RIPK2 (5AR7) by forming hydrogen bonds to the DFG-motif using the urea 
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Figure 8.6 | Discovery of novel FLT3 inhibitors using DDM. A) Scatter plot of all compounds and their inhibitory 
effect at 10 µM as measured in the high-througput screen. DDM predicted molecules are marked red. B) 
Structures of the two compounds re-synthesized and tested in situ against MV4:11 cells. C) Dose response 
curves of compounds 5 and 6 against recombinant FLT3 in a FRET-based activity assay. Markers denote 
mean ± SD (N=4). Dotted lines denote 95% confidence interval of EC50 fit. D) Dose response curves of 
compounds 5 and 6 against MV4:11 leukaemia cells. Markers denote mean ± SD (N=3). Dotted lines denote 
95% confidence interval of EC50 fit. E) Docking poses of 5 and 6 in the 3D models of FLT3 and the 
corresponding 2D interaction plots. 
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Kinome activity spectrum prediction using DDM 
To reduce potential toxic side effects, kinase cross reactivity is ideally minimized. DDM 
enables rapid assessment of the predicted cross reactivity, because by default, DDM 
predicts the interactions with the entire kinome. Thus far, however, only the FLT3 prediction 
has been taken into account. As final validation, the activity of the two inhibitors on the 
predicted off-targets was tested in biochemical assays. In addition to FLT3, compounds 5 
and 6 were predicted to be active against 35 and 33 kinases, respectively (C = 40%, 
R > 0.5). The off-targets were validated using KinaseProfiler™ by Eurofins at 10 µM. The 
inhibition data per compound are shown in Table S8.2. For compound 5 the predictions 
were 69% accurate (24 of the 35 off-targets confirmed (<50% remaining activity) with two 
additional off-targets in the low 50% residual activity range). For compound 6 the prediction 
was exceedingly accurate as 26 of the 33 targets (79%) were indeed inhibited >50%. To 
conclude, DDM was able to predict the kinome-inhibitor interaction landscape at a relatively 
high accuracy.  
 
Predicting the activity profile of a large commercially available hinge binder set 
The numerous recent approvals of small molecule kinase inhibitors by the FDA (6 in 
2017, 13 since 2014) conceals the fact that none of the last 13 approvals targeted novel 
kinases or mechanisms. A lot of therapeutic potential may still lie in currently untargeted 
pathways. To aid in the elucidation of signalling pathways and validation thereof, easy 
access to KIs is crucial to allow biochemical evaluation by acute inhibition of regulating 
kinases. To facilitate this, and in the spirit of the Published Kinase Inhibitor Set goals, the 
model was used to predict the interaction landscape of a large commercially available hinge 
binder set. To generate a large dataset like this, the Enamine Kinase Hinge Region Directed 
Library of 18,020 molecules was downloaded and all targets were predicted for these 
molecules (Figure 8.7A).23 After filtering for unpredicted kinases and inert molecules all 
18,020 inhibitors remain, with 290 kinases as targets (confidence ≥ 0.1, C = 20%). The 
distribution of the targets across the kinome tree is quite homogenous, as shown in Figure 
8.7B. The only major group that is underrepresented are the TKL kinases, but this follows 
directly from the t-SNE map depicted in Figure S8.1, as the biochemical data generated for 
the PKIS set did not include many TKL kinases. In total 1,888,418 interactions are 
predicted, with FLT3 as most inhibited kinase. For all compounds a value similar to the 
Selectivity Entropy (Ssel) could also be calculated, when the confidence parameter is 
assumed as the association constant (1/Kd).24 This parameter can be used to judge the 
overall promiscuity of a selected inhibitor, to directly avoid pursuing the least selective 
scaffold.  
As an illustration of the use of this large dataset, two kinase targets were chosen based 
on recent literature, for which few molecular modulators are known and which were not 
included in the PKIS dataset. Homeodomain-interacting protein kinase 3 (HIPK3, also 
known as FIST) is a protein kinase involved in transcription regulation, and is thought to 
negatively regulate apoptosis in certain triple negative breast cancer cell lines. Inhibition of 
this kinase may thus prove useful in treatment of these breast cancers.25 p21-activated  
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Figure 8.7 | A) Heatmap of the enamine inhibitor set. Compounds are hierarchically sorted on the predicted 
activity profile, kinases are sorted by group, then family. Cut-off value of 20% is used to increase sensitivity. B) 
Traditional kinase dendrogram showing the predicted kinases in the Enamine heatmap in red, PAK2 and HIPK3 
are highlighted in blue/green. Picture was generated using KinMap.20  
 
kinase 2 (PAK2) is activated by CDC42 and RAC1. When active it stimulates cell survival 
and growth. Recently it was implicated in oestrogen receptor positive (ER+) breast cancer 
as tamoxifen resistance inducer.26 These two kinases belong to two distinct groups (CMGC 
and STE, respectively), also distinct from FLT3 (TK) treated above. HIPK3 was predicted as 
target quite frequently, leading to a set of 172 potential inhibitors (C = 30%, confi-
dence = 1). PAK2 on the other hand is only rarely predicted, and only 57 molecules were 
found, with poor confidence (C = 20%, confidence = 0.1). The chosen targets are thus also 
at the far ends of the potentially usable spectrum of the dataset. For both targets 10 
molecules were selected based on availability, price, and selectivity entropy. These 20 
compounds were purchased and screened in the KinaseProfiler™ platform against both 
PAK2 and HIPK3. As there was no overlap between the two sets of predicted molecules, 
the molecules chosen for HIPK3 were used as negative controls for PAK2 and vice versa to 
check for specific enrichment by the model. The activity data, together with the molecular 
structures, is summarized in Table S8.3. These data showed no identified actives for HIPK3 
or PAK2. The high positive prediction value reached for FLT3 above is thus shown not to 
hold for all targets.  
 
Discussion 
Drug discovery is still largely an empirical process, which is challenging, time consuming 
and hard.27 The multi-parameter optimization of chemical structures, which is needed to 
balance the activity and selectivity of a drug candidate, requires the understanding of high-
dimensional datasets. Machine learning algorithms have been employed to analyse and 
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predict compound activity using large datasets with varying success.11,12,28 Some of the 
major drawbacks of most computational models are the complexity of the algorithm and 
the ‘black box’ nature of the systems. Implementation and interpretation of such systems 
is not trivial and, consequently, has not been widely adopted by the drug discovery 
community.  
Drug Discovery Maps provides an intuitive, data-driven (bio)molecule similarity clustering 
procedure using state-of-the-art machine learning techniques. The model is based on the 
t-Distributed Stochastic Neighbour Embedding algorithm to generate a visualization of 
molecular similarity in two dimensions.29,30 Colour is used as a third dimension to inter-
actively visualize the biological activity or compound class (chemotype). DDM combines two 
different maps. The first map depicts the chemical space in which compounds are clustered 
based on their molecular similarity, whereas in the second map protein targets are 
clustered based on the chemical similarity of the amino acids making up the kinase domain. 
By combining both maps, DDM was able to predict bio-activities of small molecules across 
a protein family. DDM was applied to visualize the chemical space of the Published Kinase 
Inhibitor Set (PKIS) and the target space of the protein kinase family (kinome). It was able 
to predict the kinome activity profile of another independent set of kinase inhibitors with 
comparable or better scores than the currently available machine learning techniques. 
DDM was then used to identify new hits for the oncogene FMS-like tyrosine kinase 3 (FLT3), 
a validated therapeutic target for the treatment of acute myeloid leukaemia.31 The hits were 
resynthesised and their biological activity was validated in biochemical and cellular assays. 
Finally, the off-target profile of the hits as predicted by DDM was validated in a panel of 
kinase assays. The method was then applied to a large commercially available screening 
collection to predict the interaction landscape of over 18,000 inhibitors. 20 inhibitors, 
predicted to be active for either HIPK3 or PAK2, were purchased and tested in vitro. 
Unfortunately, none proved to be active, which was an illustration of the limits of our 
approach. The average positive predictive value of 40% found in the validation and the FLT3 
screen is apparently not universally achieved. This could be attributed to the sparse data 
density around the two selected targets. Another factor to take into account is plain luck of 
the draw (or lack thereof). If the PPV was 20%, there is an 11% chance of choosing 10 
inactive inhibitors at random from a set of predicted actives.  
Although the model performs equally well or better than the current computational drug 
discovery tools, it is envisioned that it can be further improved when more comprehensive 
datasets become available in the public domain. In the PKIS training set, 364 inhibitors 
were only tested at two concentrations on approximately 200 unique wild-type kinases. A 
more expansive dataset of a broader set of more diverse compounds tested on a larger 
number of kinases in a concentration-response fashion would inherently improve the 
predictions generated over the entire kinome.  
The fact that a complete interaction profile is predicted uniquely enables the ranking of 
predicted hits by selectivity, for example by calculation of the predicted selectivity entropy.24 
This allows medicinal chemists in theory to rank scaffolds based on promiscuity and also 
to select for accepted off-targets, that depend on the biological questions or medical 
indication. This was demonstrated by the KinaseProfiler™ screen of predicted off-targets 
for the two FLT3 inhibitors. 
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To aid in the implementation of the tool as it is presented here, a Python based 
executable including a Graphical User Interface has been made available online32 (Figure 
8.8). The unpackaged Python script with a list of dependencies is also available. Also 
included is a fully annotated KNIME workflow, to allow step by step execution and analysis. 
This set of tools should enable the integration of this data-driven approach into any project 
without any need of investments a priori.  
To conclude, the machine learning algorithm Barnes-Hut t-SNE was successfully 
implemented in a drug discovery setting to predict ligand-protein interaction landscapes. 
The concept of DDM is applicable to a multitude of drug discovery challenges, which, given 
the proper dataset, can be used to design a small molecule with a balanced set of physico-
chemical and biological properties as required for drug candidates. It is envisioned that 
DDM may make the drug discovery process more efficient. 
 
 
Figure 8.8 | Graphical User Interface (left) and generated output (right) of the Python implementation of the 
DDM algorithm presented here. Only a SMILES string is required as input, output is provided as depicted on 
the right. The packaged executable as well as the original Python script have been made available online. 
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Methods 
Training dataset selection 
Several large datasets screening dozens of small molecule inhibitors against hundreds of kinases have 
appeared in literature. Five datasets stand out when judged by size, these are summarized in Table 8.1. The 
first large dataset (>10,000 data points) published was that of Karaman et al. in 2008.5 38 commercially 
available kinase inhibitors were screened in vitro against 287 distinct kinases. In 2011, three large datasets 
were reported. Metz et al.7 published a brief communication describing their analysis of more than 250,000 
data points. However, a large portion of these interactions have not been made public. Later that same year, 
two papers were simultaneously published by Anastassiadis et al. and Davis et al.6,8 Both studies comprise 
known kinase inhibitors and are screened against large portions of the kinome. The latest addition to the field 
is that by Elkins et al., who screened the Published Kinase Inhibitor Set (PKIS) by GlaxoSmithKline in an in vitro 
assay against 224 kinases, including a number of mutants.9,13 This dataset is particularly interesting, as the 
PKIS molecules are available free of charge for academic research, and the set contains the most drug like 
molecules at the largest coverage. For these reasons, the dataset by Elkins et al. was chosen as a starting 
point for our data-driven approach. 
 
t-SNE for the Published Kinase Inhibitor Set 
The curated dataset from ChEMBL 2333 was used, as the original publication contained some duplicate 
molecules, and using the open source software package KNIME, the Morgan fingerprints (RD-Kit, 4096-bits, 
radius = 2) were generated.33–35 These fingerprints were then clustered using the Python implementation of 
Barnes-Hut t-SNE.36 Visual inspection of the embedding shows striking co-localization of the pre-defined 
chemotypes when the chemotype annotation by Elkins et al. is used post-hoc to colour the markers (Figure 
8.1). To quantify the clustering quality, the embedding was analyzed using the DBSCAN algorithm, where the 
eps-parameter was optimized by maximizing the Silhouette Coefficient.14 The best clustering was found for 
eps 0.9, for which the Adjusted Rand Index was 0.774. This unbiased clustering produced 33 clusters (Figure 
8.1), 29 of which were significantly (P < 0.0001, hypergeometric test) enriched for a manually attributed 
chemotype. Of the 31 chemotypes annotated, 23 were fully comprised in one computationally assigned 
cluster. To inspect where it diverges from the human annotation, we inspected the cluster dominated by the 
3-amino-pyrazolopyridines closer (Figure 8.1B). Inspection of the co-clustering of chemotypes shows that this 
cluster also contains all 3-amino-pyrazolopyridazines and the indazole-3-carboxamides, structurally very 
similar classes, as compounds 1, 2 and 3 illustrate.  
 
Nearest neighbour selection of molecules using t-SNE and initial target predictions 
By appending a molecule to the PKIS dataset and regenerating the t-SNE mapping, simple Euclidian distances 
could be used to find its nearest neighbours. Selecting a set of neighbouring molecules should account for 
most chemical variation, leading to an ‘average molecule’ highly similar to our (new) molecule of interest.  
For this set of neighbouring molecules, the interaction landscapes against 200 unique non-mutant kinases 
have been experimentally measured, which can be averaged to yield a predicted inhibition value for the new 
molecule for all these kinases. For the PKIS dataset inhibition was measured at 100 nM and 1 µM. The 
inhibition values measured at 1 µM were used as these have the highest information density and in many 
clinically relevant experiments low micromolar concentrations can (locally) be reached, thus warranting a 
screen for off-targets at this concentration.  
 
Expanding target prediction using t-SNE to find most similar kinases  
To be able to extrapolate from the kinases measured in the PKIS set to incorporate more of the kinome, again 
a t-SNE based approach was used. Of the entire kinome, the amino acid sequences of the kinase domains 
containing the ATP-binding pocket, were aligned and expressed using a fingerprint based on physicochemical 
properties, derived by Heil et al.15 The resulting t-SNE embedding is shown in Figure 8.2 of the main text, and 
reproduced with annotation of the inclusion in the PKIS set (Figure S8.3). With this similarity mapping in hand, 
the prediction based on the training dataset could be expanded to theoretically include the whole human 
kinome, by considering neighbouring kinases as plausible additional targets. The distribution of the measured 
kinases in the PKIS set is visualized in Figure S8.3 and is rather well, but certainly not homogeneous. This 
means that for fair parts of the kinome no truly reliable prediction can be made based only on this set, as there 
are no close neighbouring kinases measured. In the workflow all kinases are however still included, as this will 
allow any dataset to be loaded as training set, without large adaptations.  
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The DDM workflow 
The workflow envisaged was briefly described in Figure 8.3, and is depicted in more detail in Figure S8.1: a 
molecule of interest is converted, via its SMILES representation, into a 4096-bit fingerprint. This fingerprint is 
appended to the PKIS molecules and a 2D t-SNE embedding is generated, as in Figure 8.1A. Based on this 
embedding, the closest molecules are selected and their measured bioactivity is averaged and considered as 
the activity prediction. Then, using the t-SNE embedding of the kinase domains (Figure 8.2), the kinases most 
similar to the predicted kinases are appended to this prediction, which is then the output of the model. Since 
the t-SNE algorithm is inherently stochastic, this whole process is repeated R times, after which the initial 
outputs are weighed and finally returned as overall output. The model thus accepts any molecular string 
representation and returns a list of predicted kinase targets, with a confidence parameter based on the 
number of repetitions in which a specific target has been found. The PKIS molecules the prediction is based 
upon can also be viewed, to assess with a chemical eye whether the prediction is to be trusted. 
Several optimizable parameters naturally arise in this workflow: the number of considered neighbouring 
molecules Nm, the number of considered neighbouring kinases Nk, the number of repetitions of the whole 
process R, and the cut-off value C of the mean inhibition above which an inhibitor is deemed active against 
that kinase.  
 
 
Figure S8.1 | Schematic overview of the DDM workflow. A chemical structure is converted into a Morgan fingerprint 
using the SMILES-string, and appended to the PKIS molecules set. After t-SNE embedding, the closest neighbour 
molecules (Nm) are identified and their biodata is averaged. A minimal average inhibition (C) is used as criterion to 
yield the initial prediction. The Nk kinases with the most similar kinase domain are then found in the kinase t-SNE 
embedding and appended to form the final prediction. This is repeated R times, weighing the final predictions to 
return a weighed final prediction. 
 
Optimization of the model parameters 
To optimize the model parameters and validate our model, the dataset generated by Karaman et al. was used 
as test set as this provided a comprehensive but diverse set of molecules, biochemically tested against a large 
set of kinases. For this test set, all Kd values below 1 µM were considered as actives, to mirror the training set, 
also measured at 1 µM. A multidimensional optimization was performed, initially varying the cut-off C and the 
two neighbouring values, Nm and Nk (Figure S8.2A and S8.2B). The number of repetitions was also optimized, 
as depicted in Figure S8.2C. The best predictions were found for 9 neighbouring molecules, 3 neighbouring 
kinases, and 10 repetitions. The cut-off percentage was found to be a valuable tuning parameter to either have 
a high sensitivity (low C) or rather a high positive predictive value (high C), which can be chosen depending on 
the projects specific demands. This is further illustrated by the ROC-curve in Figure 8.5. The mid-way value of 
C = 30% is recommended. The area under the ROC-curve is 0.76, scoring it as ‘fair’ according to standard 
criteria.  
 
Comparison with state of the art methods 
With this optimization of the model completed, the next step was to compare the new t-SNE based model with 
the state of the art in literature. To this end, three proteochemometric (PCM) models and a QSAR model were 
trained according to published procedures, and the DDM method was compared with those and a random 
model.12,37 The result of this comparison is summarized in Figure 8.4, which shows that the DDM model is 
significantly better than both the random model and the QSAR, and performs similarly when compared to the 
PCM variants. A variant of the DDM model where the standard Tanimoto distances were used to find the 
nearest molecular neighbours in the first step of the workflow was also included in the comparison. t-SNE was 
used in the kinase lookup step. This DDM-Tanimoto variant performed rather well, and not significantly worse 
than our t-SNE based approach, for this test set.  
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Figure S8.2 | Optimization of the model parameters using the Karaman et al. dataset as test set. Optimized 
parameters are the number of neighbouring molecules used (Nm), the number of neighbouring kinases used, Nk, and 
the cut-off inhibition percentage deemed active (C). Markers are sized based on the positive predictive value (PPV) 
and coloured based on the Matthews correlation coefficient (MCC). In A), all possible combinations are shown. In B), 
only the series for Nk = 3 is shown for clarity. 
 
Bioactivity datasets used 
Activity data for Karaman et al. and the Published Kinase Inhibitor Set by Elkins et al. was retrieved from the 
ChEMBL database version 23.33,38 Data was retrieved from a local SQL install, directly from the website or 
through the KNIME extensions provided by the EMBL-EBI.  
 
Kinase sequence information and bitstring 
Sequence information of the kinase domains was retrieved from the KinBase situated on kinase.com, based 
on the paper by Manning et al.16 Missing (pseudo)kinases were appended using data from the ChEMBL 
database version 23 and Uniprot.39 The mapping of ChEMBL, Uniprot and KinBase identifiers was performed 
based on the KinBase website and extensive manual curation. The kinase domains were aligned using the 
online Clustal Omega tool provided by the EMBL-EBI.40 The standard “Clustal w/o numbers” output generated 
was transformed to a bitstring using the amino acid fingerprints as provided in Heil et al.15 with the following 
additions: alignment dashes (-), stops (*) and blanks (X) were all considered empty, represented by 23 0’s.  
 
t-SNE algorithm 
All t-SNE embeddings were generated with the Python Scikit-learn (v. 0.19) implementation of the Barnes-Hut 
t-SNE algorithm, either implemented in a ‘Python for KNIME’ node or as part of a Python script.36  
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DBSCAN algorithm 
The Python implementation of DBSCAN, available through the Scikit-learn module Cluster (v. 0.19) was used.36 
The clustering quality metrics Silhouette Coefficient and Adjusted Rand Index were calculated with the Metrics 
module and the former was optimised by tuning the eps-parameter in steps of 0.05. For the PKIS inhibitors a 
minimal cluster size of 1 was chosen, for the more disperse plotted kinases the minimal cluster size was set 
to 10. Comparisons to manual attributions was done manually. Statistical evaluation was performed using 
Microsoft Excel 2013.  
 
Cheminformatics tools 
All molecular descriptors, molecular representations (SMILES, InChIKey) and fingerprints were generated using 
the RDKit software, either using the KNIME extensions or as the Python implementation.34  
 
QSAR and PCM models 
QSAR and PCM models were trained as has been described before but for PCM using the fully aligned 
sequences rather than the binding site and using classification rather than regression.12,37 PCM models were 
trained at an activity cut-off of 30%, 40%, and 50%. Pipeline Pilot 2016 (version 16.2.0.58 by BioVia) was used 
to process the data and random forests were trained in R (version 3.3, package randomforest) using 500 
trees, equalizing class sizes, and randomly sampling the square root of the total present descriptors at 
individual splits.41 Protein descriptors used were the first three z-scales with a mean value for each sequence 
for each z-scale.42 Chemical descriptors used were circular fingerprints with a diameter of 6 bonds (FCFP_6) 
and physicochemical descriptors as was done previously.37,43 
PCM models were trained on the full set of kinases and PKIs. QSAR models were trained per kinase but only if 
at least 5 active and 10 inactive PKIs per kinase where present (at a cut off of 30%). If no QSAR was trained 
missing predictions were completed to avoid bias and have the ability to compare identical prediction counts. 
This was obtained using a random number generator in the range of 0-1 where > 0.5 was deemed 'active' as 
was done previously.37  
Out of Bag error estimates of PCM models trained on the full set were 8.47% (30% cut off), 8.15 % (40% cut 
off), and 7.83 % (50% cut off). 
 
Docking of 5 and 6 in FLT3 crystal structure 
Docking and structure based modeling was performed in the Schrödinger suite.44 For 5 a DFG-in model was 
constructed on the basis of 4RT7 and 3LCD, in a similar fashion as has been done before,45 using the 
knowledge-based potential in Prime.46,47 Subsequently 5 was docked into this model using induced fit 
docking.48 For the induced fit docking a hydrogen bond constraint on the backbone of Cys96 was used. Since 
6 shares the same substructure as quizartinib, the crystal structure of FLT3 co-crystalized with quizartinib 
(4RT7)49 was used as a starting point. 6 was docked using Glide SP.50 Ligand surfaces, structure renderings 
and 2D interaction plots were generated using Discovery Studio Visualizer v16.1. 
 
Statistical methods 
Clustering enrichment was analysed using a hypergeometric test and was calculated using Microsoft Excel 
2013. Significance was attributed only if P < 0.0001.  
In the comparison of the quality of prediction of the various prediction models a regular 2-way ANOVA with 
Tukey’s multiple comparison test was performed using GraphPad Prism 7. Significance is attributed according 
to the standard GraphPad style: * p < 0.0332, ** p < 0.0021, *** p < 0.0002, **** p < 0.0001.  
 
High Troughput Screening FLT3 
20 nL of 2 mM inhibitor solution in DMSO (row 9-48) or control (DMSO, row 1-8) was dispensed in a 1536-well 
plate. 2 µL assay buffer (50 mM HEPES (pH 7.5), 1 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 2 mM DTT) 
without protein was loaded in row 5-6 as negative controls. Rows 1-4 and 7-48 were charged with 2 µL 0.75 
ng/µL FLT3 in assay buffer. The plates were spun down for 30 seconds at 187.5x g and incubated for 30 
minutes in the dark. Subsequently, 2 µL of substrate solution was added to all wells (50 mM HEPES (pH 7.5), 
1 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 2 mM DTT, 600 µM ATP, 12.5 nM Lance TK-peptide, 4 nM Lance 
anti-phosphotyrosine). The plates were spun down for 30 seconds at 187.5x g and incubated for 90 minutes 
in the dark at RT. Plates were then read on the Envision plate reader (Excitation 337 nm (laser), Emission first 
filter 615 nm, second filter 665 nm). Data was analysed using ActivityBase. Final assay concentrations: 10 µM 
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inhibitor, 300 µM ATP, 0.365 ng/µL FLT3, 6.25 nM (0.5 KM) Lance TK-peptide, 2 nM Lance anti-
phosphotyrosine, 0.5% DMSO.  
 
In vitro FRET based FLT3 assay 
In a 384-wells plate, 5 µL kinase+petide mix (0.06 ng/µL FLT3, 200 nM Lance TK-peptide) in assay buffer 
(50 mM HEPES (pH 7.5), 1 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 2 mM DTT) was dispensed. Seperately 
inhibitor solutions (10 µM – 0.1 pM) were prepared in assay buffer containing 400 µM ATP and 1% DMSO. 
5 µL of these solutions was dispensed and the plate was incubated for 90 minutes in the dark. After 90 
minutes the reaction was quenched by the addition of 10 µL of 20 mM EDTA containing 4 nM Lance anti-
phosphotyrosine. After thorough mixing it was incubated for 60 minutes in the dark. The FRET fluorescence 
was measured on a Tecan Infinite M1000 Pro plate reader (excitation 320 nm, emission first filter 615 nm, 
second filter 665 nm). Data was processed using Microsoft Excel 2013, pIC50 values were fitted using 
GraphPad Prism 7.0. Final assay concentrations during phosphorylation: 200 µM ATP, 0.03 ng/µL FLT3, 
100 nM Lance TK-peptide, 0.5% DMSO) 
 
In situ testing of kinase inhibitors 
MV4:11 cells were grown in IMDM with 10% fetal bovine serum at 37 °C under 5% CO2. For viability assays, 
10,000 cells were seeded per well in a 96-wells plate and inhibitors were added at the indicated concentration. 
Three days later, cell viability was measured using the Cell Titer Blue viability assay (Promega), fluorescence 
was measured using the Clariostar (BMG Labtech). Relative survival was normalized to the untreated control 
and corrected for background signal. 
 
Synthesis of in situ tested kinase inhibitors 
General remarks 
All reactions were performed using oven- or flame-dried glassware and dry solvents. Reagents were purchased 
from Sigma-Aldrich, Acros, and Merck and used without further purification unless noted otherwise. All 
moisture sensitive reactions were performed under a nitrogen atmosphere.  
1H and 13C NMR spectra were recorded on a Bruker AV-400 (400 MHz). Used software for interpretation of 
NMR-data was Bruker TopSpin 1.3 and MestreNova 11.0. Chemical shift values are reported in ppm with 
tetramethylsilane or solvent resonance as the internal standard (CDCl3: δ 7.26 for 1H, δ 77.16 for 13C; DMSO-
d6: δ 2.50 for 1H, δ 39.52 for 13C). Data are reported as follows: chemical shifts (δ), multiplicity (s = singlet, d 
= doublet, dd = double doublet, td = triple doublet, t = triplet, q = quartet, bs = broad singlet, m = multiplet), 
coupling constants J (Hz), and integration. Liquid chromatography was performed on a Finnigan Surveyor 
LC/MS system, equipped with a C18 column. Flash chromatography was performed using SiliCycle silica gel 
type SiliaFlash P60 (230−400 mesh). TLC analysis was performed on Merck silica gel 60/Kieselguhr F254, 
0.25 mm. Compounds were visualized using KMnO4 stain (K2CO3 (40 g), KMnO4 (6 g), and water (600 mL)) or 
CAM stain (Ce(NH4)4(SO4)4·2H2O (ceric ammonium sulfate: 10.0 g); ammonium molybdate (25 g); conc. H2SO4 
(100 mL); H2O (900 mL)). Preparative HPLC (Waters, 515 HPLC pump M; Waters, 515 HPLC pump L; Waters, 
2767 sample manager; Waters SFO System Fluidics Organizer; Waters Acquity Ultra Performance LC, SQ 
Detector; Waters Binary Gradient Module) was performed on a Waters XBridgeTM column (5 µM C18, 150 x 
19 mm). Diode detection was done between 210 and 600 nm. Gradient: ACN in (H2O + 0.2% TFA).  
 
1-(3,4,5-Trimethoxyphenyl)guanidine (7)  
3,4,5-trimethoxyaniline (500 mg, 2.73 mmol) and cyanamide (574 mg, 13.6 mmol) were 
dissolved in ethanol (15 mL) before nitric acid (69%wt, 0.20 mL, 3.0 mmol) was added. 
The mixture was refluxed for 40 h and concentrated in vacuo. The resulting residue was 
suspended in diethylether (10 mL) and kept at 4 °C overnight. It was then filtered and 
air dried. The nitrate salt of the title compound was obtained as a dark purple solid (0.60 
g, 2.1 mmol, 76%). 1H NMR (400 MHz, DMSO) δ 9.51 (bs, 1H), 8.73 – 8.12 (m, 2H), 6.55 (s, 2H), 5.44 (s, 2H), 
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1-(6-Chloropyridin-3-yl)-3-(dimethylamino)prop-2-en-1-one (8) 
1-(6-chloropyridin-3-yl)ethan-1-one (1.00 g, 6.43 mmol) was dissolved in toluene (20 
mL) and dimethylformamide diethylacetal (1.65 mL, 9.64 mmol) was added. The 
mixture was stirred for 16 h at 80 °C. TLC showed near complete conversion. The 
mixture was cooled to 50 °C and slowly concentrated at reduced pressure. The 
resulting crude residue was dissolved in warm toluene and pentane was slowly added. A yellow precipitate 
formed which was filtered off and rinsed with pentane. After drying this yielded the title compound (1.08 g, 
5.12 mmol, 80%) as a yellow solid. 1H NMR (400 MHz, CDCl3) δ 8.85 (dd, J = 0.7, 2.5 Hz, 1H), 8.17 (dd, J = 
2.5, 8.3 Hz, 1H), 7.86 (d, J = 12.2 Hz, 1H), 7.38 (dd, J = 0.8, 8.2 Hz, 1H), 5.63 (d, J = 12.1 Hz, 1H), 3.20 (s, 
3H), 2.97 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 184.90, 155.07, 153.38, 149.08, 138.10, 134.63, 124.10, 
91.54, 45.46, 37.60. 
 
4-(6-Chloropyridin-3-yl)-N-(3,4,5-trimethoxyphenyl)pyrimidin-2-amine (5) 
To a solution of 7 (376 mg, 1.30 mmol) and 8 (250 mg, 1.19 mmol) in ethanol 
(20 mL) K2CO3 (492 mg, 3.56 mmol) was added. The resulting mixture was 
refluxed for 20 h. The reaction was quenched by the addition of saturated 
aqueous Na2CO3 (15 mL) and the water layer was extracted with EtOAc (3x 
25 mL). The combined organic layers were washed with brine, dried (MgSO4), 
filtered and concentrated in vacuo. The resulting crude was purified using 
silica column chromatography (50-70% EtOAc/pentane). The resulting yellow solid was crystallised from warm 
diethylether to yield the title compound (137 mg, 0.37 mmol, 31%) as light yellow crystals. 1H NMR (400 MHz, 
CDCl3) δ 9.07 (dd, J = 0.7, 2.5 Hz, 1H), 8.52 (d, J = 5.2 Hz, 1H), 8.32 (dd, J = 2.5, 8.3 Hz, 1H), 7.46 (dd, J = 
0.7, 8.4 Hz, 1H), 7.38 (s, 1H), 7.14 (d, J = 5.2 Hz, 1H), 6.99 (s, 2H), 3.90 (s, 6H), 3.85 (s, 3H). 13C NMR (101 
MHz, CDCl3) δ 161.53, 160.28, 159.11, 153.74, 153.47, 148.62, 137.11, 135.30, 131.78, 124.52, 108.15, 
97.42, 61.17, 56.26. 
 
4-(Pyridin-4-yloxy)aniline (9) 
4-aminophenol (2.18 g, 20 mmol), 4-chloropyridine (3.15 g, 21 mmol) and NaOH (2.0 g, 
50 mmol) were dissolved in DMSO (50 mL) and heated to 100 °C for 17 h. The mixture 
was cooled to RT and poured into ice water (300 mL). This was extracted with 10% 
MeOH in chloroform (4x 150 mL). The combined organic layers were washed with brine (2x 150 mL), dried 
(Na2SO4), filtered and concentrated in vacuo. The residue was flushed over a silica pad with pure EtOAc and 
concentrated to yield the title compound as a white solid (2.5 g, 13 mmol, 65%). 1H NMR (400 MHz, CDCl3) δ 
8.51 – 8.33 (m, 2H), 6.97 – 6.85 (m, 2H), 6.85 – 6.77 (m, 2H), 6.77 – 6.62 (m, 2H), 3.50 (s, 2H). 13C NMR 
(101 MHz, CDCl3) δ 165.89, 151.25, 145.80, 144.25, 122.12, 116.36, 111.70. 
 
1-(5-(tert-Butyl)isoxazol-3-yl)-3-(4-(pyridin-4-yloxy)phenyl)urea (6) 
3-amino-5-tert-butylisooxazole (0.20 g, 1.4 mmol) was dissolved in DCM (14 
mL) and DIPEA (0.50 mL, 2.9 mmol) was added. The mixture was cooled to 0 
°C and triphosgene (0.42 g, 1.4 mmol) was added. After stirring the mixture 
for 19 h at RT it was refluxed for 1 h before the reaction was quenched by the 
addition of saturated aqueous NaHCO3 (10 mL). The water layer was separated 
and extracted with DCM (3x 10 mL). The combined organic layers were washed 
with brine, dried (Na2SO4) and filtered. The solvent was removed under reduced pressure and the crude 
isocyanate was dissolved in 1,4-dioxane (14 mL). 9 (0.29 g, 1.6 mmol) was added to the solution and the 
mixture was heated to 110 °C for 2.5 h. After cooling to RT the mixture was diluted with DCM (30 mL) and 
saturated aqueous NaHCO3 (30 mL) was added. The water layer was separated and extracted with DCM 
(3x 30 mL). The combined organic layers were washed with brine, dried (Na2SO4), filtered and concentrated in 
vacuo. The resulting yellow oil was purified by preparative HPLC to yield the title compound as a slightly yellow 
oil (0.22 g, 0.62 mmol, 44%). 1H NMR (400 MHz, CDCl3) δ 9.41 (s, 1H), 8.67 (s, 1H), 8.47 (dd, J = 1.5, 5.1 Hz, 
2H), 7.63 – 7.54 (m, 2H), 7.10 – 7.03 (m, 2H), 6.89 – 6.81 (m, 2H), 5.95 (s, 1H), 1.36 (s, 9H). 13C NMR (101 
MHz, CDCl3) δ 181.60, 165.38, 158.45, 152.58, 151.22, 149.95, 135.58, 122.15, 121.60, 112.17, 91.94, 
33.08, 28.75.  
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Supplementary Tables and Figures 
Table S8.1 | Overview of prediction qualities split per compound. Data corresponds to R = 10 and C = 30%.  














PPV NPV MCC 
CHEMBL10 4 8 254 13 0.24 0.97 0.33 0.95 0.24 
CHEMBL101253 7 41 230 1 0.88 0.85 0.15 1.00 0.32 
CHEMBL103667 5 21 228 25 0.17 0.92 0.19 0.90 0.09 
CHEMBL119385 2 11 265 1 0.67 0.96 0.15 1.00 0.31 
CHEMBL124660 9 66 202 2 0.82 0.75 0.12 0.99 0.25 
CHEMBL1336 20 28 217 14 0.59 0.89 0.42 0.94 0.41 
CHEMBL1421 19 5 207 48 0.28 0.98 0.79 0.81 0.40 
CHEMBL14762 0 49 227 3 0.00 0.82 0.00 0.99 -0.05 
CHEMBL1721885 35 29 147 69 0.34 0.84 0.55 0.68 0.20 
CHEMBL191003 20 43 174 42 0.32 0.80 0.32 0.81 0.12 
CHEMBL215152 1 5 258 15 0.06 0.98 0.17 0.95 0.07 
CHEMBL221959 1 46 226 6 0.14 0.83 0.02 0.97 -0.01 
CHEMBL223360 26 62 187 4 0.87 0.75 0.30 0.98 0.41 
CHEMBL24828 20 16 217 26 0.43 0.93 0.56 0.89 0.41 
CHEMBL259084 20 65 191 3 0.87 0.75 0.24 0.98 0.37 
CHEMBL261849 4 74 201 0 1.00 0.73 0.05 1.00 0.19 
CHEMBL278041 2 14 249 14 0.13 0.95 0.13 0.95 0.07 
CHEMBL296468 2 3 250 24 0.08 0.99 0.40 0.91 0.14 
CHEMBL31965 3 3 261 12 0.20 0.99 0.50 0.96 0.29 
CHEMBL388978 57 3 42 179 0.24 0.93 0.95 0.19 0.16 
CHEMBL428690 2 19 228 30 0.06 0.92 0.10 0.88 -0.02 
CHEMBL440084 0 12 263 4 0.00 0.96 0.00 0.99 -0.03 
CHEMBL477772 22 56 185 16 0.58 0.77 0.28 0.92 0.26 
CHEMBL483321 2 4 272 1 0.67 0.99 0.33 1.00 0.46 
CHEMBL522892 24 31 183 41 0.37 0.86 0.44 0.82 0.24 
CHEMBL535 44 30 117 89 0.33 0.80 0.59 0.57 0.14 
CHEMBL553 3 3 253 20 0.13 0.99 0.50 0.93 0.23 
CHEMBL554 2 0 277 0 1.00 1.00 1.00 1.00 1.00 
CHEMBL558752 10 72 185 12 0.45 0.72 0.12 0.94 0.10 
CHEMBL572878 2 11 199 67 0.03 0.95 0.15 0.75 -0.05 
CHEMBL572881 6 16 242 15 0.29 0.94 0.27 0.94 0.22 
CHEMBL573339 0 58 219 2 0.00 0.79 0.00 0.99 -0.04 
CHEMBL574738 48 12 165 54 0.47 0.93 0.80 0.75 0.47 
CHEMBL607707 11 45 203 20 0.35 0.82 0.20 0.91 0.14 
CHEMBL608533 11 10 169 89 0.11 0.94 0.52 0.66 0.10 
CHEMBL91829 1 12 240 26 0.04 0.95 0.08 0.90 -0.01 
CHEMBL939 3 15 254 7 0.30 0.94 0.17 0.97 0.18 
CHEMBL941 10 115 153 1 0.91 0.57 0.08 0.99 0.19 
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Table S8.2 | Summary of the off-target screen performed for the in situ tested compounds 5 and 6. Data are 
















ABL1 P00519 CHEMBL1862 26 ABL1 P00519 CHEMBL1862 23 
ABL2 P42684 CHEMBL4014 12 ABL2 P42684 CHEMBL4014 28 
AurA O14965 CHEMBL4722 2 AurA O14965 CHEMBL4722 60 
AurB Q96GD4 CHEMBL2185 2 AurB Q96GD4 CHEMBL2185 60 
AurC Q9UQB9 CHEMBL3935 8 AurC Q9UQB9 CHEMBL3935 91 
BLK P51451 CHEMBL2250 34 DDR1 Q08345 CHEMBL5319 7 
BRK Q13882 CHEMBL4601 61 DDR2 Q16832 CHEMBL5122 1 
EGFR P00533 CHEMBL203 96 EphA3 P29320 CHEMBL4954 9 
EphA4 P54764 CHEMBL3988 72 EphA4 P54764 CHEMBL3988 28 
EphA5 P54756 CHEMBL3987 52 EphA5 P54756 CHEMBL3987 7 
EphB2 P29323 CHEMBL3290 14 EphA7 Q15375 CHEMBL4602 -2 
EphB3 P54753 CHEMBL4901 100 EphB1 P54762 CHEMBL5072 3 
ErbB2 P04626 CHEMBL1824 94 EphB2 P29323 CHEMBL3290 5 
ErbB4 Q15303 CHEMBL3009 108 EphB3 P54753 CHEMBL4901 55 
FER P16591 CHEMBL3982 52 FER P16591 CHEMBL3982 86 
FES P07332 CHEMBL5455 19 FES P07332 CHEMBL5455 86 
FGFR1 P11362 CHEMBL3650 58 FGFR1 P11362 CHEMBL3650 6 
FGFR3 P22607 CHEMBL2742 48 FGFR3 P22607 CHEMBL2742 29 
FGFR4 P22455 CHEMBL3973 91 FGFR4 P22455 CHEMBL3973 70 
FGR P09769 CHEMBL4454 30 FLT1 P17948 CHEMBL1868 1 
FLT1 P17948 CHEMBL1868 1 FLT3 P36888 CHEMBL1974 1 
FLT3 P36888 CHEMBL1974 3 FLT4 P35916 CHEMBL1955 -1 
FLT4 P35916 CHEMBL1955 1 FMS P07333 CHEMBL1844 -1 
FMS P07333 CHEMBL1844 -1 KDR P35968 CHEMBL279 7 
FYN P06241 CHEMBL1841 9 KIT P10721 CHEMBL1936 7 
HCK P08631 CHEMBL3234 17 MUSK O15146 CHEMBL5684 13 
KDR P35968 CHEMBL279 5 PDGFRa P16234 CHEMBL2007 15 
KIT P10721 CHEMBL1936 2 PDGFRb P09619 CHEMBL1913 9 
LCK P06239 CHEMBL258 15 RET P07949 CHEMBL2041 -2 
LYN P07948 CHEMBL3905 26 TIE2 Q02763 CHEMBL4128 1 
PDGFRa P16234 CHEMBL2007 47 TRKA P04629 CHEMBL2815 5 
PDGFRb P09619 CHEMBL1913 46 TRKB Q16620 CHEMBL4898 0 
RET P07949 CHEMBL2041 53 TRKC Q16288 CHEMBL5608 -2 
SRC P12931 CHEMBL267 4      
TNK1* Q13470 CHEMBL5334 -      
YES P07947 CHEMBL2073 10         
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Table S8.3 | Overview of the molecular structures and biological activity for the 20 purchased Enamine 
small molecules. Biological data are averages of two duplicates, and are percentages activity remaining 
compared to vehicle control. 
Predicted for PAK2 
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Table S8.3 (continued) | Overview of the molecular structures and biological activity for the 20 purchased 
Enamine small molecules. Biological data are averages of two duplicates, and are percentages activity 
remaining compared to vehicle control. 
Predicted for HIPK3 
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Figure S8.3 | t-SNE embedding of physicochemical fingerprint of the kinase domains of 
535 human kinases as in Figure 8.2. Markers are coloured based on the presence (green) 
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I believe that scientific knowledge has fractal properties, that no 
matter how much we learn, whatever is left, however small it may 
































The research presented in this thesis addressed one of the main challenges in modern 
drug development: selectivity. The whole area of target-based drug discovery is built on the 
notion that a certain protein target is a key regulator in a biological process. Although the 
use of this concept as the basis for drug discovery could be debated1, the importance of 
chemical modulators capable of selectively altering the activity of the target protein is 
undisputed. The importance of selective inhibitors is especially great when they are used 
to prove the therapeutic value of a certain target. Generally, a therapeutic window needs to 
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be determined where the target protein is selectively modulated. At higher concentrations 
the effects of binding other targets could lead to side-effects and possible toxicity. 
Because of the importance of selectivity, many techniques have been developed to 
assess the exact binding profiles of inhibitors, such as family-wide activity assays (e.g. for 
kinases and luciferases), and more specific assays like the 44-member CEREP-panel.2 
Other, more untargeted approaches have been developed, e.g. Cellular Thermal Shift Assay 
(CETSA) and a variety of uses of radiolabelled drug analogues. Another technique which has 
proven to be highly flexible and thus has found a large variety of applications in (early) drug 
discovery is activity-based protein profiling (ABPP). The concept of this technique was 
explained in Chapter 1. One field of research where ABPP has shown great use is that 
involving the endocannabinoid system (ECS), which is under active investigation for its role 
in anti-nociceptive and anti-inflammatory effects, amongst others.3–6 This signalling system 
consists of two cannabinoid receptors (CB1 and CB2), and two main endogenous ligands: 
2-arachidonoylglycerol (2-AG) and N-arachidonoylethanolamine (anandamide), and their 
biosynthetic and catabolic enzymes. 2-AG is the most abundant endocannabinoid and is 
mainly produced by diacylglycerol lipase (DAGL) α and β. The different roles of the two 
endocannabinoids and the specific functions of the two isoforms of DAGL are still poorly 
understood. This warrants the search for selective and in vivo active inhibitors to be able to 
study these processes in more detail. 
 
Diacylglycerol lipase inhibitors: activity and specificity 
Chapter 2 introduced the hit-to-lead optimization of a novel DAGL inhibitor scaffold: the 
1,2,4-triazole-sulfonamides. This molecular series was found in a previously reported high-
throughput screen.7 In this Chapter the structure activity relations around the core scaffold 
were explored by screening 65 variants of the HTS-hit molecule. The potency for DAGL-α 
varied 400-fold from an IC50 of approximately 1 µM to 2.5 nM. By screening the library in 
mouse brain proteome using ABPP, the most selective inhibitor was identified and selected 
for further profiling. Compound 1 (Figure 9.1), a 2-benzylpiperidine substituted triazole 
urea, was active in mouse Neuro-2a cells. To test in vivo target engagement, compound 1 
and an alkynylated analogue were administered intraperitoneal to mice. The serine 
hydrolase activities were analysed in the brain and spleen using gel-based ABPP after two 
hours. Both compounds passed the blood-brain barrier and potently engaged DAGL-α in the 
brain.  
A single dose of 50 mg/kg was predominantly chosen to demonstrate target 
engagement in vivo. Due to the high dose, off-target activity was observed. A dose-response 
experiment is advised, which is ideally coupled to pharmacokinetic measurements, to 
determine the optimal dose of target engagement with minimal off-target activity. 
Considering the weak inhibition of DAGL-β in the spleen, it is possible that a dose can be 
selected where DAGL-α is selectively inhibited. This would enable for the first time detailed 
investigations of the separate DAGL isoforms by acute inhibition. In light of the similarities 
in the inhibition profile of 1 and DH3765, pairing the inhibitors might lead to the 
identification of DAGL-β-specific effects in, for example, feeding behaviour.8  
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Figure 9.1 | Chemical structures of inhibitor 1, reference inhibitors DH376 
and DO34 and inhibitor 2.  
 
Chapter 3 was focussed on optimizing the physicochemical properties of compound 1. 
In particular, the topological polar surface area (TPSA) was increased to restrict the 
inhibitors to the periphery to target predominantly DAGL-β. Hit optimization resulted in the 
discovery of highly potent compound 2, in which the piperazine moiety of DO34 (Figure 9.1) 
was incorporated. Next, a small 24-membered library was synthesized in which the 
tert-butyl carbamate was replaced with various amides, ureas, tertiary amines and 
sulfonamides. This led to four highly potent and in vitro selective compounds, which were 
tested in Neuro-2a cells. A more than tenfold drop in IC50 values indicated that cell 
penetration was less efficient, possibly due to a reduced passive diffusion as a result of the 
increased polarity. Remarkably, the in situ the selectivity window was also reduced 
compared to the in vitro values.  
Cellular profiling of the library is advised to assess potency and selectivity of different 
substitution patterns, ideally identifying more promising lead compounds. If more selective 
inhibitors are identified, an in vivo dose-response experiment should be performed to 
identify dosages that show full target engagement in peripheral tissue, but leave the brain 
unaffected. These compounds could then be instrumental in the elucidation of the workings 
and importance of the peripheral endocannabinoid signalling, and the role of DAGL-β in this 
process.  
Chapter 4 showed the in depth investigation of the structure kinetic relationships of a 
small set of DH376 derivatives. A previously reported surrogate substrate assay was 
adapted to determine the affinity (Ki) and reactivity (kinact) of mechanism-based covalent 
inhibitors.3 DynaFit software9 was used to fit a system of differential equations to the 
substrate conversion curves generated by this kinetics assay. Remarkably, the inactivation 
constants (kinact) did not follow the trend in pKa of the heterocycles, which is contradictory 
to standard theories of nucleofugality. In contrast, the change in number and position of 
the nitrogen atoms in the heterocycle strongly influenced the binding constant Ki. The 1,2,3-
triazole based DH376 bound with picomolar affinity.  
The approach to determine the binding affinity and reactivity presented in Chapter 4 is 
based on a traditional biochemical readout. Other novel techniques, such as Surface 
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Plasmon Resonance (SPR) and Isothermal Calorimetry (ITC), have recently been applied for 
in-depth evaluation of the formation of protein-inhibitor complexes.10 The benefit of the 
here presented approach is its low cost and relatively high throughput: the current setup 
uses 96-well plates and allows for 6 compounds to be screened per (duplicate) plate and 
does not require purified enzymes. The original surrogate substrate assay was successfully 
miniaturized to 1536-well format, so there is room to improve the current throughput of the 
kinetics assay.7 The assay could also be easily adopted by other enzymes capable of 
hydrolysing 4-nitrophenyl butyrate or alternative surrogate substrates. This could be 
especially relevant for major off-targets of the current series of inhibitors, like α/β-hydrolase 
domain containing protein 6 (ABHD6). This will guide the discovery of more selective DAGL 
inhibitors, including the inhibitors of Chapter 2 and 3. 
Chapter 4 provided some key insights in the importance of the heterocycle of the DH376 
variants to the binding affinity with DAGL-α. It should be investigated whether this SAR can 
be transferred to the triazole-sulfonamide series developed in Chapters 2 and 3. This can 
be achieved by synthesizing variants of 1 containing a 1,2,3-triazole (3) or pyrazole (4) 
(Scheme 9.1), in an analogous manner as presented in Chapters 2 and 3. Testing these 
compounds alongside 1 in the assay developed in Chapter 4 could provide novel insights 
in the binding-mode of these sulfonamide based inhibitors, and they may have interestingly 
different interaction profiles. 
 
Scheme 9.1 | Synthesis of 1,2,3-triazoles (3a and 3b) and pyrazole (4) derivatives of 1. Reagents and 
conditions: i) benzylbromide, DMF, 18 h, 86%; ii) diphenylcarbamic chloride, DIPEA, DMAP, THF, 65 °C, 18 h, 
71%; iii) HCl, NaOCl, DCM, -10 °C, 20 min, then N-methylaniline, -10 °C → RT, 2h, 65%; iv) KOH, H2O/THF (1:1 
v/v), 18 h, 57%; v) 2-benzylpiperidine, triphosgene, K2CO3, DCM, 0 °C → RT, 1 h, then 9, DIPEA, THF, 6 h, 
65 °C; vi) NaNO2, H2SO4, H2O, then NaOAc, NaOH, 4-fluorobenzylmercaptan, H2O, 1 h, 0 °C, 42%;  
vii) 2-benzylpiperidine, triphosgene, DIPEA, THF, 0 °C, 1 h, then 11, DIPEA, DMAP, THF, 65 °C, 6 h, 48%;  
viii) HCl, NaOCl, DCM, -10 °C, 20 min, then N-methylaniline, -10 °C → RT, 2h.  
 
Summary and Future Prospects  |  181 
 
Activity-based protein profiling to study inhibitor selectivity 
Chapter 5 showcased the utility of activity-based protein profiling in a highly relevant 
study to profile the interactions of the lethal drug-candidate BIA 10-2474, which was 
developed as a fatty acid amide hydrolase (FAAH) inhibitor. During the first-in-human phase 
1 clinical trial held in France in early 2016, 5 members of the highest dosing group were 
hospitalised with severe neurological symptoms.11 One of these volunteers succumbed to 
his symptoms several days after hospitalisation. The main hypothesis to explain the severe 
side effects was the possibility of off-target interactions. To investigate this, BIA 10-2474 
was resynthesised, along with three alkyne-bearing analogues. The inhibitory capacity of 
BIA 10-2474 was assayed in a large panel of endocannabinoid related enzymes and both 
CB-receptors, and was found to only inhibit FAAH weakly in vitro. The interaction profile 
across nearly 50 serine hydrolases was assessed by ABPP using mouse brain proteomes. 
ABHD6 was found as an off-target at similar concentrations required for full FAAH inhibition. 
The covalent mechanism of action of the imidazole urea was shown by the fluorescent 
labeling of both FAAH and ABHD6 using ‘Click’-chemistry on the alkyne analogues under 
denaturing SDS-PAGE conditions. In situ profiling of the inhibitors showed a large increase 
in potency for both FAAH and ABHD6, not observed for the safe FAAH inhibitor 
PF-04457845.12 Using chemical proteomic profiling of in situ treated human neural cell 
cultures with BIA 10-2474 more off-targets were identified, which were subsequently 
verified by overexpression and competitive ABPP. Of note, these off-targets were not shared 
with PF-04457845, a safe FAAH inhibitor tested in phase 2 clinical trials, and were all 
involved in lipid metabolism. Finally, lipid analysis using targeted lipidomics showed a 
strong disruption of lipid networks in cultured neurons. This suggests that promiscuous 
lipase inhibitors have the potential to cause metabolic dysregulation in the nervous system. 
The importance of thorough off-target profiling, possible using ABPP, is emphasized and 
recommended. 
None of the reported animal models used during pre-clinical characterization showed 
toxicity similar to that observed in humans.13 Therefore, the assays performed here on 
mouse brain lysates and (neural) cell cultures should be repeated on actual patient-derived 
brain tissue samples. However, a call for access to the existing patient-material, such as 
blood samples from the trial, including those of unharmed volunteers, has not been 
followed up on by the sponsor of the trial, Bial Pharmaceuticals, thus making any further 
research in this direction infeasible.14  
Another avenue of exploration could be the identification of protein interaction partners 
of BIA 10-2474 that were not targeted by activity-based probes used in the current study. 
To this end, chemical probes were generated based on the structure of BIA 10-2474, 
thereby creating an ABP closely related to the parent molecule. These probes, however, did 
not bind other targets than visualized in the competitive gel-based ABPP experiments with 
FP-TAMRA and MB064. The limitation of this approach is that the targets have to bind 
covalently to the urea electrophile to be visualized. Non-covalent interactions with proteins 
cannot be identified in this manner. Radioactively labelled BIA 10-2474 could aid in finding 
binding partners, but identification of specific proteins would be cumbersome. CETSA could 
be used, but will only reveal targets that are significantly thermally stabilized upon binding 
of BIA 10-2474. Photoaffinity labelling, combined with chemical biology methods, can be 
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used to identify non-covalent interaction partners.15,16 This approach requires a 
photoreactive group to be present in the molecule. Typically, diazirines or benzophenones 
are used, but many other photoreactive groups exist.15 An intriguing possibility arises in the 
case of BIA 10-2474, since the photoreactivity of heterocyclic N-oxides has been studied 
for decades for use in synthetic applications, but, to the best of my knowledge, has never 
been applied in a chemical biology setting.17,18 Irradiation with ultraviolet light triggers a 
sequence of rearrangements, leading, in controlled conditions, to various reaction 
products.17 No information is available regarding the reactivity of these species in close 
proximity to proteins. Experimental validation of this approach could consist of 
photolabelling experiments where the three alkynylated probes are irradiated. Incubation 
with or without BIA 10-2474 or the reduced pyridine metabolite BIA 10-2639, which should 
not be UV-active, can help to identify specific interactions. Conjugation to biotin using 
‘Click’-chemistry and consecutive enrichment for chemical proteomics should show the 
applicability of this photoreactive group in chemical biology. If successful, the abundance 
of pyridines and pyrimidines in drug-like molecules could open up a whole new field of target 
identification using heterocyclic N-oxides as photolabel. Finally, by applying computational 
target prediction algorithms on the BIA 10-2474 structure the amount of targets that need 




Scheme 9.2 | Proposed intermediates in the photoreaction of pyridine N-oxides.17 
The mechanism towards the bracketed transition state is not clear, and is believed 
to occur at a hyperplane.18 
 
 
Chapter 6 described the development and in-depth characterisation of a green-
fluorescent fluorophosphonate-probe, BODIPY-FP, an analogue of the widely used red-
fluorescent TAMRA-fluorophosphonate. This new probe can be used in conjunction with the 
tailored DAG-lipase probe MB064, which carries a red-fluorescent BODIPY-TMR as reporter 
tag. The labeling efficiency of various enzymes with the new BODIPY-FP was found to be 
significantly different from TAMRA-FP. Especially the potency for FAAH and monoacyl-
glycerol lipase (MAGL) was strongly increased. The probe was mixed at low concentration 
(10 nM) with MB064, thereby reliably visualising FAAH and MAGL without interfering with 
the labeling of MB064-targets. This probe cocktail allowed visualisation of most 
endocannabinoid related serine hydrolases in a single sample. This multiplex ABPP method 
was used to profile the selectivity of two MAGL inhibitors, NF1819 and ABX-1431.19,20 The 
former was found to have several off-targets, including ABHD6. ABX-1431 showed no off-
target activity up to 10 µM in mouse brain membrane proteome.  
The combination of multiple probes with different reactive groups, also known as 
warheads, and orthogonal reporter tags, allows profiling of more proteins in a single 
sample. Especially in gel-based techniques broad reactivity of an ABP may lead to 
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overlapping protein bands, which hinders the quantification and identification. Since 
MB064 and BODIPY- or TAMRA-FP combined are not able to provide full coverage of the 
serine hydrolase family, the search for new activity-based probes is warranted. An 
interesting reactive group which has long been used in lipase inhibitors is the bromoenol 
lactone (BEL).21 Previously, the introduction of a ligation handle in the form of an alkyne 
was proposed, but the synthesis proved cumbersome.22 An alternative approach was 
envisioned based on a published synthetic procedure towards guanidine-containing 
protease inhibitors (Scheme 9.3).23 This synthetic route furbished BEL probe 13 and a 
closely related inhibitor 14.  
Initial experiments using probe 13 in situ in a panel of breast cancer cell lines indicated 
that the BEL warhead is indeed able to covalently label several proteins in these cells in a 
dose-dependent manner (Figure 9.2). Most but not all bands could be outcompeted with 
pre-incubation of 14, indicating specific targeting of several proteins. Chemical proteomics 




Scheme 9.3 | Synthesis of bromoenol lactone probe 13 and closely related inhibitor 14. Reagents and 
conditions: i) Boc2O, DCM, 18 h, 77%; ii) BuLi, THF, -30 °C, 30 min, then 4-bromobut-1-yne, -20 °C  0 °C, 
3 h, 40%; iii) K2CO3, DCM, then NBS, H2O, 5 h, 22%; iv) TFA, DCM, 0 °C  RT, 1.5 h, then hex-6-ynoyl chloride, 
TEA, 0 °C 2 h, 53%; v) TFA, DCM, 0 °C  RT, 1.5 h, then butyryl chloride, TEA, 0 °C, 2 h, 63%. 
 
 
184  |  Chapter 9 
 
 
Figure 9.2 | Two-step labelling of breast cancer cell lines with BEL probe 13, competed with a single dose (A) 
or a dose escalation (B) of inhibitor 14. Coomassie staining is shown as protein loading control. 
 
Machine learning as a tool to predict inhibition profiles 
Chapter 7 introduced the application of the machine learning algorithm t-Distributed 
Stochastic Neighbour Embedding (t-SNE) as a similarity metric for (bio)molecules. In 
contrast to the commonly used Tanimoto coefficient (Tc), a bit string compatible distance 
metric, t-SNE generates a two dimensional visualisation of the high-dimensional bit string 
space, to some extent analogous to principal component analysis, which was shown to be 
outperformed by t-SNE in this context. t-SNE allows for a visual inspection of similar 
chemical matter, which is impossible when using the Tc. This similarity visualisation was 
applied to 2774 clinically used molecules as a demonstration of drug-like chemical space. 
This embedding showed strong co-localisation of chemically related compounds. t-SNE was 
further applied to a physicochemical bit string based on the alignment of the proteins of 
the serine hydrolase family. This revealed that t-SNE is capable of recapitulating 
phylogenetic information. The mapping of target-space was annotated with the inhibitory 
potencies of a diverse set of compounds, previously measured in an ABPP-based assay.24 
Despite the small datasets available for serine hydrolases, co-localisation of potently 
inhibited proteins could be observed, suggesting that this approach could be extended to 
predict affinities of inhibitors across an entire protein family.  
Chapter 8 built upon the principles introduced in Chapter 7, but focussed on the large 
protein family of kinases. Very large screening sets are available for kinases, which 
facilitates machine learning approaches such as that described in Chapter 7. The protein 
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kinase space could be reliably mapped using t-SNE. This resulted in a very strong similarity 
between the previously published Kinase Family Tree25 and the t-SNE map. The molecules 
of the Published Kinase Inhibitor Set, combined with the biological data available for ~200 
kinases, provided a large training set to be used in the here developed model, which was 
named Drug Discovery Maps (DDM).26,27 This model was validated using the data from 
Karaman et al. and shown to equal or outperform the state-of-the-art computational 
techniques, such as quantitative structure activity relations (QSAR) and proteochemometric 
modelling.28,29 DDM was applied in a virtual high-throughput assay in search for new 
FMS-like tyrosine kinase 3 (FLT3) inhibitors. A positive predictive value of 41% was 
achieved, identifying 18 actives out of a predicted 44. Two of these hits were resynthesised 
and tested in MV4:11 cells. Both compounds were cellular active and the best compound 
showed single-digit nanomolar potency. The predicted off-targets were validated and 
around 70% of the predicted targets were found to be inhibited. The model was also used 
to predict the interaction profile of a commercially available set of compounds with a hinge-
binding motif. 20 molecules were purchased and tested for their predicted activities against 
HIPK3 and PAK2. Unfortunately, no actives were identified amongst the purchased 
compounds, possibly due to a low coverage of the training data around these targets, or 
poor similarity between the molecules in the training set and the commercial library. 
The workflow presented in Chapter 8 is flexible regarding the training data that is used 
in the t-SNE algorithm. Since the model is in essence retrained for every run, simply loading 
a different list of molecules with associated biological data will provide a new predictive 
model, which can then be optimised by tuning the hyperparameters. Implementing a larger 
training set, such as that described recently by Bembenek et al. could strongly improve the 
predictive capacities of the model, although perhaps hierarchical SNE should be used to 
avoid excessive computational times.30,31 Alternatively, a completely different set of 
molecular data could be used, such as a binding dataset for the GPCRs, or different 
processes altogether, e.g. metabolic data, lipophilicity data or (cyto-)toxicity.   
An interesting but challenging possibility of further exploration is the application of the 
concept of cross-modal, also known as multimodal, clustering.32 This autonomous 
classification technique was designed to use two or more unrelated sensory inputs from 
the same observation, which can be interpreted in the broadest manner, to classify 
unannotated data points into an a priori unknown number of clusters. Cross-modal coupling 
could thus, theoretically, be implemented to use two or more t-SNE embeddings of the 
same set of entities but with different modalities. One set of modalities could be different 
settings in the t-SNE perplexity, which should translate to embeddings using a different 
‘resolution’, shifting the focus of the embedding from more high-level structure (high 
perplexity) to subtler local differences (low perplexity), and combining those views in order 
to gain insight in similarities not immediately evident from either setting separately. Another 
promising direction would be to use the clustering of inhibitors based on (normalized) 
biological data in one embedding, and on a chemical fingerprint in another. Different 
molecular clusters, possibly far separated in chemical space, might show similar trends in 
inhibition profile. These effects could be picked up by cross-modal clustering, and could 
give a whole new aspect to the use of t-SNE embeddings in drug discovery.  
  
 
186  |  Chapter 9 
 
Closing remarks 
Less than 1 in 10 drug candidates that enter phase 1 clinical trials actually gets 
approved for human use. The high failure rate is in part due to unforeseen side effects or 
toxicity. A better understanding of the role of selectivity and a better insight in the off-target 
activities of drug candidates could greatly aid in preventing candidates to fail for these 
reasons. This thesis has tried to address some aspects in this challenging part of drug 
discovery. The use of activity-based protein profiling as presented in Chapters 2 and 3 in 
drug discovery and hit-to-lead optimization, and in Chapter 5 and 6 for the interaction 
profiling of a drug candidate, highlights the versatility and importance of this chemical 
biology technique. Combined with knowledge derived from biochemical assays, such as 
that developed in Chapter 4, ABPP can greatly aid the medicinal chemist. The recent surge 
in popularity of machine learning algorithms, backed by exponential growth of the amount 
of biological data available, holds great promise for drug discovery. Chapters 7 and 8 
showed the applicability of one such algorithm, which was able to quite reliably predict 
interaction profiles. The challenges in finding, determining and predicting selectivity are far 
from solved, but, by incrementally expanding our understanding of the binding of small 
molecules to their (off-)targets, truly selective inhibitors might at some point become a 
reality or their necessity might be mitigated. 
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Methods 
Chemical Biology Methods 
Cell Culture 
BT-20, MDA-MB-468 or SK-BR-3 cells were cultured at 37 °C under 5% CO2 in RPMI medium containing 10% 
(v/v) Fetal Calf Serum (Thermo Fisher), penicillin and streptomycin (200 µg/mL each; Duchefa). Medium was 
refreshed every 2-3 days and cells were passaged twice a week at 80-90% confluence by trypsinisation and 
resuspension in fresh medium.  
Cells lines were purchased from ATCC and were regularly tested for mycoplasma contamination. Cultures were 
discarded after 2-3 months of use. 
 
In situ treatment of breast cancer cell lines  
BT-20, MDA-MB-468 or SK-BR-3 cells were seeded in 6-well plates. In situ treatment was initiated 72 h later. 
Medium was aspirated and medium with serum containing inhibitor or DMSO as vehicle was added (0.1 % 
DMSO). After 1 h exposure to treatment medium at 37 °C, probe or DMSO as vehicle was added and incubated 
for 1 h at 37 °C. The medium was aspirated and cells were harvested, washed with PBS and flash frozen in 
liquid nitrogen and stored at -80 °C until further use. 
 
Cell lysate preparation 
Cell pellets were thawed on ice, resuspended in cold lysis buffer (2.5 U/mL benzonase and 1x protease 
inhibitor (Amresco) in Milli-Q water) and incubated on ice (15-30 min). Protein concentrations were determined 
by a Quick Start™ Bradford Protein Assay. The cell lysate was diluted to 1.0 mg/mL concentration in lysis buffer 
and diluted samples were flash frozen in liquid nitrogen and stored at -80 °C until further use. 
 
Fluorescent ligation and gel-based analysis  
The two-step labeling protocol was adapted from previously developed methods.33 Click reagent was freshly 
prepared by mixing copper sulfate (25 µL, 18 mM in water), THPTA (5 µL, 18 mM in water), sodium ascorbate 
(15 µL, 150 mM in water), and AF-647 (5 µL, 90 µM in DMSO). Click reagent (5.0 µL) was added to each 
proteome (40 µL per condition), mixed by brief vortexing and incubated under continuous shaking (1 h, 37 °C). 
15 µL of 4* Laemmli buffer was added. Samples were boiled (95 °C, 5 min) and 8 µg proteome per reaction 
(12 µL) was resolved on a 10% acrylamide SDS-PAGE gel (180 V, 75 min). Gels were scanned using Cy3 and 
Cy5 multichannel settings (605/50 and 695/55, filters respectively) and stained with Coomassie after 




All reactions were performed using oven- or flame-dried glassware and dry solvents. Reagents were purchased 
from Alfa Aesar, Sigma-Aldrich, Acros, and Merck and used without further purification unless noted otherwise. 
All moisture sensitive reactions were performed under an argon or nitrogen atmosphere. 1H and 13C NMR 
spectra were recorded on a Bruker AV-300 (300 MHz), AV-400 (400 MHz) or DRX-500 (500 MHz). Used 
software for interpretation of NMR-data was Bruker TopSpin 1.3 and MestreNova 11.0. Chemical shift values 
are reported in ppm with tetramethylsilane or solvent resonance as the internal standard (CDCl3: δ 7.26 for 
1H, δ 77.16 for 13C; MeOD: δ 3.31 for 1H, δ 49.00 for 13C).34 Data are reported as follows: chemical shifts (δ), 
multiplicity (s = singlet, d = doublet, dd = double doublet, td = triple doublet, t = triplet, q = quartet, quintet = 
quint, bs = broad singlet, m = multiplet), coupling constants J (Hz), and integration.  
Liquid chromatography analysis was performed on a Finnigan Surveyor LC/MS system, equipped with a C18 
column. Flash chromatography was performed using SiliCycle silica gel type SiliaFlash P60 (230−400 mesh). 
TLC analysis was performed on Merck silica gel 60/Kieselguhr F254, 0.25 mm. Compounds were visualized 
using KMnO4 stain (K2CO3 (40 g), KMnO4 (6 g), and water (600 mL)) or CAM stain (Ce(NH4)4(SO4)4·2H2O (ceric 
ammonium sulfate: 10 g); ammonium molybdate (25 g); conc. H2SO4 (100 mL); H2O (900 mL)). Preparative 
HPLC (Waters, 515 HPLC pump M; Waters, 515 HPLC pump L; Waters, 2767 sample manager; Waters SFO 
System Fluidics Organizer; Waters Acquity Ultra Performance LC, SQ Detector; Waters Binary Gradient Module) 
was performed on a Waters XBridgeTM column (5 µM C18, 150 x 19 mm). Diode detection was done between 
210 and 600 nm. Gradient: ACN in (H2O + 0.2% TFA). High resolution mass spectra (HRMS) were recorded by 
direct injection on a q-TOF mass spectrometer (Synapt G2-Si) equipped with an electrospray ion source in 
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positive mode with Leu-enkephalin (m/z = 556.2771) as an internal lock mass. The instrument was calibrated 
prior to measurement using the MS/MS spectrum of Glu-1-fibrinopeptide B. 
 
4-(Benzylthio)-1H-1,2,3-triazole (6) 
Sodium 1H-1,2,3-triazole-4-thiolate (1.23 g, 10.0 mmol) was dissolved in DMF (25 mL) 
and benzyl bromide (1.31 mL, 11.0 mmol) was added. The mixture was stirred for 18 h. 
The volatiles were removed under reduced pressure. The residue was purified by 
column chromatography to yield the title compound as an off-white solid (1.65 g, 8.64 mmol, 86%). 1H NMR 
(300 MHz, CDCl3) δ 14.54 (s, 1H), 7.48 (s, 1H), 7.21 – 7.05 (m, 5H), 4.04 (s, 2H). 13C NMR (75 MHz, CDCl3) δ 
138.32, 137.00, 131.99, 128.73, 128.38, 127.26, 39.51. 
 
4-(Benzylthio)-N,N-diphenyl-1,2,3-triazole-carboxamide (7) 
6 (1.248 g, 6.53 mmol) was dissolved in dry THF (30 mL) and diphenyl-
carbamic chloride (1.66 g, 7.18 mmol), DIPEA (1.37 mL, 7.83 mmol) and a 
catalytic amount of DMAP were added. The mixture was refluxed for 18 h. The 
reaction was quenched by the addition of sat. aq. Na2CO3 (40 mL). The 
organic layer was separated and the aqueous phase extracted with EtOAc (2x 
40 mL). The combined organic layers were washed with brine (40 mL), dried 
(MgSO4), filtered and concentrated. Column chromatography afforded the title compound as an off-white solid, 
consisting of a mixture of 2 regioisomers (2:1) (1.79 g, 4.62 mmol, 71%). Regioisomer 1: 1H NMR (400 MHz, 
CDCl3) δ 7.47 – 6.60 (m, 16H), 3.84 (s, 2H). Regioisomer 2: 1H NMR (400 MHz, CDCl3) δ 7.47 – 6.59 (m, 16H), 
3.69 (s, 2H) (spectrum shows a mixture of rotamers). 13C NMR (101 MHz, CDCl3) δ 151.18, 141.32, 137.43, 
136.75, 133.21, 130.15, 129.68, 129.55, 129.00, 128.66, 128.57, 128.50, 127.32, 127.24, 127.21, 
127.18, 126.95, 107.18, 106.05, 39.01, 37.26. 
 
4-(N-Methyl-N-phenylsulfamoyl)-N,N-diphenyl-1,2,3-triazole-carboxamide (8) 
4 N HCl in dioxane (5 mL) was added to DCM (20 mL) and cooled to -10 °C. 
15%wt NaOCl (aq., 5 mL) was added slowly, forming a yellow-green Cl2 solution. 
After 30 min 7 (500 mg, 0.259 mmol) was added dropwise as a solution in 
DCM (5 mL). After 20 min N-methylaniline (5.0 mL, 46 mmol) was added. The 
mixture was stirred for 2 h at RT. The reaction was quenched by the addition of 
0.1 M HCl (20 mL). The organic layer was separated and the water layer was 
extracted with EtOAc (2x 20 mL). The combined organic layers were dried (MgSO4), filtered and concentrated. 
The residue was purified by column chromatography to yield the title compound as a brown solid (364 mg, 
0.840 mmol, 65%). 1H NMR (400 MHz, CDCl3) δ 7.58 (s, 1H), 7.45 – 6.79 (m, 15H), 3.01 (s, 3H). 13C NMR 




8 (364 g, 0.84 mmol) was dissolved in 1 N KOH in a 1:1 (v/v) H2O/THF mixture (20 mL). 
The mixture was stirred for 18 h at RT. The mixture was concentrated and the residue was 
purified by column chromatography to yield the title compound (114 mg, 0.48 mmol, 
57%). 1H NMR (400 MHz, MeOD) δ 8.06 (s, 1H), 7.35 – 7.09 (m, 5H), 3.32 (s, 3H). 13C 
NMR (101 MHz, MeOD) δ 145.60, 142.37, 130.68, 130.07, 128.78, 127.98, 39.25. 
 
3-((4-Fluorobenzyl)thio)-1H-pyrazole (11) 
1H-Pyrazol-3-amine 10 (100 mg, 1.20 mmol) was dissolved in 40% aq. H2SO4 
(5 mL). Sodium nitrite (100 mg, 1.44 mmol) in water (5 mL) was added slowly, 
keeping the temperature below 5 °C. After 15 minutes saturated aqueous NaOAc 
was added until the pH was ~5. The mixture was then added slowly to a cooled (0 °C) solution of (4-fluoro-
phenyl)methanethiol (118 µL, 137 mg, 0.963 mmol) in 1 N aqueous NaOH (1 mL). A precipitate formed 
immediately upon addition. After addition was complete, the mixture was stirred for 1 h at 0 °C. The reaction 
mixture was extracted with EtOAc (3x 20 mL). The combined organic layers were washed with brine, dried 
(MgSO4), filtered and concentrated. Column chromatography yielded the title compound (105.7 mg, 0.508 
mmol, 42%) as a white solid. 1H NMR (400 MHz, MeOD) δ 7.54 (d, J = 2.2 Hz, 1H), 7.25 – 7.15 (m, 2H), 6.97 
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– 6.89 (m, 2H), 6.20 (d, J = 2.2 Hz, 1H), 4.02 (s, 2H). 13C NMR (101 MHz, MeOD) δ 163.31 (d, J = 244.1 Hz), 
135.44, 131.65 (d, J = 8.1 Hz), 115.94 (d, J = 21.7 Hz), 109.97, 39.60. 
 
(2-Benzylpiperidin-1-yl)(3-((4-fluorobenzyl)thio)-1H-pyrazol-1-yl)methanone (12) 
2-Benzylpiperidine hydrochloride (50.8 mg, 0.240 mmol) and 
triphosgene (71.2 mg, 0.240 mmol) were dissolved in dry THF (10 mL) 
at 0 °C. DIPEA (194 µL, 1.2 mmol) was added and the resulting mixture 
was stirred for 1 h. The mixture was poured into ice water (10 mL) and 
the organic layer was separated. The aqueous layer was extracted with 
EtOAc (3x 10 mL). The combined organic layers were dried (MgSO4), 
filtered and concentrated under reduced pressure. The residue was taken up in dry THF (10 mL) to which 11 
(50 mg, 0.24 mmol), DMAP (29.3 mg, 0.24 mmol) and DIPEA (194 µL, 1.2 mmol) were added. The mixture 
was heated to reflux for 6 h, after which it was poured into a saturated aqueous NH4Cl solution (10 mL). The 
organic layer was separated and the aqueous layer was extracted with EtOAc (2x 10 mL). The combined organic 
layers were dried (MgSO4), filtered and concentrated. Column chromatography afforded the title compound 
(47.3 mg, 0.116 mmol, 48%) as a white solid. 1H NMR (400 MHz, CDCl3) δ 7.64 (s, 1H), 7.38 – 6.89 (m, 9H), 
6.11 (d, J = 2.8 Hz, 1H), 4.87 (s, 1H), 4.33 – 4.25 (m, 1H), 4.21 (t, J = 12.8 Hz, 2H), 3.28 – 2.97 (m, 2H), 2.84 
(t, J = 10.7 Hz, 1H), 1.88 – 1.53 (m, 6H). 
 
2-(4-((tert-Butoxycarbonyl)amino)phenyl)acetic acid (16) 
2-(4-Aminophenyl)acetic acid 15 (1.0 g, 6.62 mmol) was dissolved in DCM (20 mL). Boc-anhydride 
(1.54 mL, 6.62 mmol) was added and the mixture was stirred for 18 h at RT. The mixture was 
concentrated under reduced pressure. The residue was purified by column chromatography. The 
title compound was obtained as an orange solid (1.28 g, 5.09 mmol, 77%). 1H NMR (400 MHz, 
MeOD) δ 8.75 (s, 1H), 7.34 (d, J = 8.2 Hz, 2H), 7.20 – 7.11 (m, 2H), 3.52 (s, 2H), 1.50 (s, 9H). 13C 
NMR (101 MHz, MeOD) δ 175.67, 155.16, 139.14, 129.89, 119.81, 80.70, 41.18, 28.69. 
 
2-(4-((tert-Butoxycarbonyl)amino)phenyl)hex-5-ynoic acid (17) 
16 (620 mg, 2.47 mmol) was dissolved in THF (25 mL) and cooled to -30 °C, butyllithium 
(1.6 M in pentane, 5.09 mL, 8.14 mmol) was added dropwise. The mixture was stirred for 
30 min. 4-Bromobut-1-yne (0.764 mL, 8.14 mmol) was slowly added and the mixture stirred 
for 2 h at -20 °C. The mixture was left to warm up to 0 °C over the course of 1 h. The 
reaction was quenched by the addition of ice. The organic layer was separated. The 
waterlayer was acidified to pH ~ 2 with 2 N HCl (aq.) and extracted with EtOAc (3x 50 mL). 
The combined organic layers were dried (MgSO4), filtered and concentrated. The residue 
was purified using flash column chromatography. The desired product was obtained as a white powder 
(302 mg, 0.996 mmol, 40%). 1H NMR (400 MHz, CDCl3) δ 9.71 (bs, 1H), 7.41 – 7.06 (m, 4H), 6.74 (bs, 1H), 
3.82 – 3.64 (m, 1H), 2.36 – 2.14 (m, 2H), 2.14 – 1.86 (m, 3H), 1.51 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 
179.44, 137.86, 132.24, 128.75, 119.26, 83.05, 69.62, 49.29, 31.36, 28.38, 16.28. 
 
tert-Butyl (4-(6-(bromomethylene)-2-oxotetrahydro-2H-pyran-3-yl)phenyl)carbamate (18) 
17 (150 mg, 0.494 mmol) was dissolved in dry DCM (7 mL). K2CO3 (41 mg, 0.30 mmol) was added 
to the solution. The resulting suspension was degassed for 15 min in a sonicator under continuous 
N2-flow. N-Bromosuccinimide (97 mg, 0.54 mmol) and water (36 µL, 2 mmol) were added and the 
mixture was stirred for 5 h. The reaction mixture was quenched by the addition of Na2S2O3 (5% aq., 
10 mL). The organic layer was separated and diluted with DCM (10 mL), washed with H2O (10 mL) 
and brine (5 mL). The combined organic layers were dried (MgSO4), filtered and concentrated. The 
residue (yellow oil) was purified by column chromatography to yield the title compound as a white 
solid (42 mg, 0.11 mmol, 22%). 1H NMR (400 MHz, CDCl3) δ 7.44 – 7.30 (m, 2H), 7.18 – 7.07 (m, 
2H), 6.60 (s, 1H), 6.12 – 6.03 (m, 1H), 3.74 (dd, J = 10.4, 5.4 Hz, 1H), 2.89 – 2.58 (m, 2H), 2.29 
– 2.06 (m, 2H), 1.51 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 168.76, 152.81, 151.62, 138.08, 131.42, 128.65, 
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Hex-5-ynoyl chloride (19) 
Hex-5-ynoic acid (0.197 mL, 1.78 mmol) was dissolved in DCM (10 mL) and oxalyl chloride 
(1.56 mL, 17.8 mmol) was slowly added. The mixture was refluxed for 2 h. The solvent and 
excess oxalyl chloride were removed in vacuo and the resulting oil was coevaporated twice 
with toluene. The crude hex-5-ynoyl chloride was used without further purification. 
 
 N-(4-(6-(bromomethylene)-2-oxotetrahydro-2H-pyran-3-yl)phenyl)hex-5-ynamide (13) 
To a stirred solution of 18 (30 mg, 0.078 mmol) in DCM (3 mL) at 0 °C trifluoroacetic 
acid (0.302 mL, 3.92 mmol) was added. The mixture was stirred for 1.5 h at RT. 19 
(102 mg, 0.785 mmol) was added and the mixture was cooled to 0 °C. TEA (0.60 mL, 
4.3 mmol) was added and the mixture was stirred for 2 h at RT. The volatiles were 
evaporated under reduced pressure. Flash column chromatography yielded the title 
compound (15.6 mg, 0.041 mmol, 53%) as a white solid. 1H NMR (400 MHz, CDCl3) 
δ 7.58 – 7.45 (m, 2H), 7.40 (s, 1H), 7.21 – 7.11 (m, 2H), 6.11 (t, J = 1.8 Hz, 1H), 3.75 
(dd, J = 10.6, 5.4 Hz, 1H), 2.96 – 2.81 (m, 1H), 2.76 – 2.64 (m, 1H), 2.51 (t, J = 7.3 
Hz, 2H), 2.35 – 2.29 (m, 2H), 2.29 – 2.08 (m, 2H), 2.02 (t, J = 2.6 Hz, 1H), 1.94 (q, J 
= 7.3 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 170.74, 168.78, 151.55, 137.53, 132.76, 
128.71, 120.31, 91.71, 83.55, 69.60, 46.88, 36.04, 25.89, 24.00, 23.94, 17.90. HRMS: Calculated for 
[C18H18BrNO3 + H]+ = 376.0542, found = 376.0548. 
 
N-(4-(6-(Bromomethylene)-2-oxotetrahydro-2H-pyran-3-yl)phenyl)butyramide (14) 
18 (10 mg, 0.026 mmol) was dissolved in DCM (1 mL) and trifluoroacetic acid (101 µL, 
1.31 mmol) was added. The mixture was stirred for 1.5 h at RT, after which TLC showed full 
conversion of starting material. Butyryl chloride (27.1 µL, 0.262 mmol) was added and the 
mixture was cooled to 0 °C. Triethylamine (201 µL, 1.44 mmol) was added and the mixture 
stirred for 2 h at RT. The reaction mixture was concentrated and purified by column 
chromatography to yield the title compound (5.81 mg, 0.016 mmol, 63%) as a white solid. 
1H NMR (400 MHz, CDCl3) δ 7.52 (d, J = 8.4 Hz, 2H), 7.21 – 7.11 (m, 3H), 6.11 (t, J = 1.8 
Hz, 1H), 3.76 (dd, J = 10.5, 5.4 Hz, 1H), 2.93 – 2.81 (m, 1H), 2.77 – 2.63 (m, 1H), 2.34 (t, 
J = 7.4 Hz, 2H), 2.29 – 2.06 (m, 2H), 1.76 (h, J = 7.4 Hz, 2H), 1.01 (t, J = 7.4 Hz, 3H). 13C 
NMR (101 MHz, CDCl3) δ 168.69, 151.57, 137.63, 132.69, 128.74, 120.26, 91.69, 46.87, 
39.81, 25.91, 23.92, 19.18, 13.88.  
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Ik geloof dat wetenschappelijke kennis fractale eigenschappen 
heeft, dat het niet uitmaakt hoeveel we leren, hetgeen overblijft,  
hoe klein het ook mag lijken, is nog steeds zo oneindig complex 
als het geheel was aan het begin. 































Het gepresenteerde onderzoek in dit proefschrift betreft één van de grootste uitdagingen 
in de moderne medicijnontwikkeling: selectiviteit. Het medicijnonderzoek dat gericht is op 
een moleculair doel, is gebaseerd op de notie dat een specifiek eiwit een sleutelrol speelt 
in een bepaald biologisch proces. Hoewel deze aanpak van medicijnontwikkeling kan 
worden bekritiseerd1, staat het belang van selectieve aanpassing van doel-eiwitten met 
behulp van chemische modulatoren buiten kijf. Het belang van selectiviteit wordt nog 
versterkt wanneer de modulatoren worden gebruikt om het therapeutische potentieel van 
het doel-eiwit te bewijzen. In de regel dient in de praktijk een therapeutische marge te 
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worden bepaald, waarbinnen het doeleiwit selectief gemoduleerd wordt. Bij hogere 
concentraties kunnen de effecten van het binden van andere eiwitten tot bijwerkingen en 
zelfs tot toxiciteit leiden. 
Vanwege het belang van selectiviteit zijn er veel technieken ontwikkeld om de 
selectiviteit van remmers te bepalen, zoals familie-brede activiteitstesten (bijvoorbeeld 
voor kinases en luciferases) en specifiekere tests zoals het 44 eiwitten tellende CEREP-
panel.2 Een andere veelgebruikte techniek is activiteit-gebaseerde eiwit profilering (in het 
Engels: activity-based protein profiling of ABPP). Deze techniek heeft haar flexibiliteit 
bewezen en heeft daardoor tot een grote variëteit aan toepassingen geleid binnen de 
medicijnontwikkeling. Het principe achter ABPP is geïntroduceerd in Hoofdstuk 1. Een 
specifiek veld waarbinnen ABPP haar waarde heeft bewezen is het onderzoek naar het 
endocannabinoïde systeem (ECS).3–6 Het ECS staat in de belangstelling vanwege zijn rol in 
pijnperceptie en inflammatie. Het signaleringssysteem bestaat in hoofdzaak uit de twee 
cannabinoïde receptoren (CB1 en CB2) en de belangrijkste endogene liganden, 
2-arachidonoylglycerol (2-AG) en N-arachidonoyl ethanolamine (anandamide). Daarnaast 
spelen de synthetische en katabolische enzymen een belangrijke rol. 2-AG is de meest 
voorkomende endocannabinoïde en wordt voornamelijk geproduceerd door diacylglycerol 
lipase (DAGL) α en β. De verschillende rollen van de twee ECS signaallipides en de precieze 
functies van de twee isovormen van DAG-lipase zijn nog verre van duidelijk. Om onderzoek 
naar de functies van DAG-lipase mogelijk te maken is het nodig om in vivo actieve remmers 
te vinden, en om die specifiek en in meer detail te kunnen bestuderen. 
 
Diacylglycerol lipase remmers: activiteit en specificiteit 
Hoofdstuk 2 introduceerde de hit-to-lead optimalisatie van een nieuw chemotype als 
DAGL-remmer, de 1,2,4-triazool-sulfonamides. Dit type moleculen werd gevonden in een 
eerder beschreven screening van ruim 300.000 stoffen.7 In dit hoofdstuk zijn de structuur-
activiteitsrelaties bestudeerd door het testen van 65 varianten. Tijdens deze optimalisatie 
werd de inhibitie van DAGL-α met een factor 500 verbeterd, van een half-maximale inhibitie 
concentratie (IC50) van ongeveer 1 µM tot slechts 2.5 nM. Door met ABPP de hele set ook 
in eiwitpreparaten van muizenhersenen te testen, kon de meest selectieve remmer worden 
geïdentificeerd om deze vervolgens te profileren. Stof 1 (Figuur 1), een 2-gesubstitueerde 
benzylpiperidine triazool ureum, bleek actief te zijn in culturen van Neuro-2a cellen. Om ook 
de in vivo werking van deze stof te bepalen, werd zij, samen met een gealkynyleerd 
analogon, intra peritoneaal geïnjecteerd in muizen. Na een incubatie van twee uur werden 
de hersenen en de milt geprepareerd en geanalyseerd met gel-gebaseerde ABPP. Hierdoor 
kon de resterende activiteit van de serine hydrolases worden gevisualiseerd. Beide stoffen 
bleken de bloed-brein barrière te kunnen passeren en remden DAGL-α sterk in het 
hersenweefsel. 
Hoofdstuk 3 draaide om de optimalisatie van de fysicochemische eigenschappen van 
stof 1. De focus lag op het verhogen van het topologische polaire oppervlak om hierdoor de 
verspreiding van de remmers tot de perifere organen te beperken, om hierdoor 
voornamelijk de perifeer gelokaliseerde DAGL-β te remmen. De optimalisatie werd 
begonnen door de piperazine uit de eerder gepubliceerde stof DO34 op te nemen in de 
structuur, wat leidde tot de zeer potente remmer 2 (Figuur 1). Vervolgens werd een 
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coherente set van 24 varianten gesynthetiseerd waarin de tert-butyl carbamaat substitutie 
vervangen werd door een selectie van amides, ureum-verbindingen, tertiaire amines en 
sulfonamides. Dit leidde tot vier zeer potente en in vitro selectieve remmers welke in 
Neuro-2a culturen werden getest. Een ruime tienvoud afname in de inhibitieconstante 
toonde aan dat de cellulaire opname minder efficiënt verliep. Dit kan mogelijk worden 
verklaard door een verminderde passieve diffusie over het celmembraan als gevolg van de 
sterk verhoogde polariteit van de verbindingen. Opvallend genoeg bleek de selectiviteit die 




Figuur 1 | Chemische structuren van remmer 1, referentiestof DH376 en 
DO34 en remmer 2. 
 
 
Hoofdstuk 4 beschreef de nauwgezette bestudering van de structuur-kinetiek relaties 
van een kleine set DH376 derivaten. Een eerder gepubliceerde biochemische surrogaat 
substraat analyse werd aangepast om de affiniteit (Ki) en reactiviteit (kinact) van deze 
mechanisme-gebaseerde covalente remmers afzonderlijk te kunnen bepalen.3 DynaFit 
programmatuur8 werd gebruikt om een systeem van differentiaal vergelijkingen numeriek 
op te lossen, op basis van de door de kinetische analyse gegenereerde substraat 
omzettingscurves. Onverwachts volgden de inactivatie constantes (kinact) totaal niet de 
trend in zuurtegraad (pKa) van de heterocyclische verbindingen, wat op basis van de 
standaardtheorieën aangaande nucleofugiciteit werd voorspeld. Het bleek juist dat de 
positie en het aantal stikstofatomen in de heterocycle sterk de bindingsconstante Ki 
beïnvloedden. De 1,2,3-triazool van DH376 bleek te binden met een picomolaire affiniteit. 
 
Activiteit-gebaseerde eiwit profilering om de selectiviteit van remmers te bestuderen 
Hoofdstuk 5 demonstreerde de kracht van activiteit-gebaseerde eiwit profilering in een 
zeer relevante studie naar de interactieprofielen van het dodelijke kandidaat medicijn 
BIA 10-2474. Deze stof was ontworpen als fatty acid amide hydrolase (FAAH) remmer. 
Tijdens een fase 1 klinische studie in Frankrijk, begin 2016, moesten 5 deelnemers aan de 
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hoogste doseringsgroep worden opgenomen in het ziekenhuis met ernstige neurologische 
klachten. Een van de vrijwilligers overleed enkele dagen later. De belangrijkste hypothese 
om deze ernstige bijwerkingen te verklaren richtte zich op de mogelijkheid van zogenaamde 
bijvangsten, onbedoeld gebonden eiwitten. Om deze hypothese te kunnen testen werd 
BIA 10-2474 gesynthetiseerd, samen met drie alkyn-gesubstitueerde analoga. De inhibitie 
van BIA 10-2474 werd getest in een breed palet van ECS gerelateerde enzymen, alsmede 
beide CB-receptoren, en bleek in vitro enkel FAAH-activiteit (zwak) te remmen. Het inter-
actieprofiel van BIA 10-2474 tegen 50 serine hydrolases werd getest met ABPP in lysaat 
van muizenhersenen. ABHD6 werd gevonden als bijvangst met een inhibitieconstante in 
dezelfde ordegrootte als nodig voor de volledige inhibitie van FAAH. Het covalente karakter 
van de inhibitie door de imidazool-ureum werd gedemonstreerd door de alkyn-analoga te 
ligeren aan fluoroforen met behulp van zogenaamde ‘click’-chemie. Onder denaturerende 
SDS-PAGE-condities bleken FAAH en ABHD6 nog steeds meetbaar fluorescent gelabeld te 
worden. In situ profilering van de remmers toonde een dramatische toename in 
inhibitiecapaciteit voor zowel FAAH als ABHD6. Deze toename werd niet gevonden voor een 
veilige FAAH-remmer, PF-04457845.9 Door in situ behandelde neurale celculturen te 
analyseren met hoge resolutie massaspectrometrische analyse technieken, werden 
additionele beiwitten geïdentificeerd. Deze werden gevalideerd door ze tot overexpressie 
te brengen en de in situ inhibitie vervolgens met ABPP te visualiseren. Een belangrijk punt 
is dat deze eiwitten niet werden geremd door PF-04457845, een FAAH-remmer die zich 
veilig heeft bewezen in fase 1 en 2 klinische studies. Alle eiwitten hadden met het 
lipidemetabolisme te maken, daarom werden de lipideniveaus geanalyseerd met gerichte 
lipodomics. Dit legde een ingrijpende verstoring van de lipidenetwerken in deze gecultuurde 
neuronen bloot. Dit suggereert dat niet-selectieve lipaseremmers metabolische deregulatie 
in het zenuwstelsel kunnen veroorzaken. Het belang van grondige interactieprofilering, 
mogelijk gemaakt door ABPP, werd nogmaals benadrukt en het gebruik ervan 
aangemoedigd. 
Hoofdstuk 6 beschreef de ontwikkeling en diepgaande karakterisering van een groen-
fluorescente fluorofosfonaat sensor, BODIPY-FP, een analogon van de veelgebruikte rood-
fluorescente TAMRA-fluorofosfonaat. Deze nieuwe moleculaire sensor kan onafhankelijk 
van de DAG-lipase gerichtte, eveneens rood-fluorescente, sensor MB064 worden 
uitgelezen. De labelingsefficiëntie van verscheidene eiwitten door de nieuwe BODIPY-FP 
bleek significant af te wijken van TAMRA-FP. Met name de affiniteit voor FAAH en monoacyl-
glycerol lipase (MAGL) bleek sterk verhoogd. Hierdoor kon BODIPY-FP op zeer lage 
concentratie (10 nM) gemengd worden met MB064 en detecteerbaar FAAH en MAGL 
labelen, zonder te interfereren met het labelingspatroon van MB064. Deze cocktail maakte 
het mogelijk om bijna alle endocannabinoïde gerelateerde serine hydrolases in een enkel 
monster te profileren. Deze multiplex ABPP-methode werd gebruikt om de selectiviteit van 
twee MAGL-remmers te testen, NF1819 en ABX-1431.10,11 NF1819 bleek nog enkele 
andere eiwitten te remmen, waaronder ABHD6. ABX-1431 liet geen andere inhibitie 
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Automatisch leren om inhibitieprofielen te voorspellen 
Hoofdstuk 7 introduceerde de toepassing van het automatisch lerende algoritme 
t-Distributed Stochastic Neighbour Embedding (t-SNE) als maat voor de vergelijkbaarheid 
van (bio)moleculen. In tegenstelling tot de veelgebruikte Tanimoto coëfficiënt (Tc), een 
afstandsmaat die met (moleculaire) bitstrings overweg kan, genereert t-SNE een 
tweedimensionale visualisatie van de hoogdimensionale bitstring ruimte. Dit maakt het 
mogelijk om de omringende chemische materie visueel te inspecteren, iets wat niet kan 
wanneer men de Tc gebruikt. De t-SNE vergelijkbaarheidsvisualisatie werd toegepast op 
2774 klinisch toegepaste moleculen als demonstratie van de medicijnachtige chemische 
ruimte. Deze visualisatie toonde sterke colokalisering van chemisch gerelateerde stoffen. 
t-SNE werd ook toegepast op een fysicochemische bitstring gebaseerd op de uitgelijnde 
aminozuurvolgordes van eiwitten uit de serine hydrolase familie. Hiermee werd aangetoond 
dat t-SNE in staat is om hieruit fylogenetische informatie te herleiden. De in kaart gebrachte 
eiwitruimte werd geannoteerd met de inhibitiewaardes van een diverse set stoffen, eerder 
gemeten in een ABPP-gebaseerde analyse.12 Ondanks het beperkte formaat van de 
beschikbare dataset kon enige groepering in de sterk geremde eiwitten worden opgemerkt. 
Dit duidt erop dat deze aanpak in theorie uitgebreid zou kunnen worden om de affiniteiten 
van remmers over de hele eiwitfamilie te voorspellen. 
Hoofdstuk 8 bouwt voort op de principes die in Hoofdstuk 7 werden geïntroduceerd, 
maar concentreert zich op de grote familie van de kinases. Van deze eiwitfamilie zijn grote 
datasets beschikbaar in de wetenschappelijke literatuur die het mogelijk maken om 
automatisch lerende algoritmes zoals beschreven in het vorige hoofdstuk toe te passen. 
Ook de kinasefamilie liet zich uitstekend in kaart brengen met behulp van t-SNE, en toonde 
hierin sterke overeenkomsten met een eerder gepubliceerde kinasestamboom.13 De 
stoffen die opgenomen zijn in de Published Kinase Inhibitor Set gecombineerd met de 
biologische data die beschikbaar is voor ± 200 kinases, vormden de basis voor de 
oefendata die gebruikt werd om het hier ontwikkelde Drug Discovery Maps model te 
onderwijzen.14,15 Dit model werd gevalideerd aan de hand van de data van Karaman et al. 
en toonde zich evenwaardig of superieur aan geavanceerde computertechnieken als 
kwantitatieve structuur-activiteitsrelaties en proteochemometrische modellen.16 Het 
ontwikkelde model werd toegepast in een virtuele zoektocht naar nieuwe FLT3-remmers. 
Een correct voorspelde ratio van 41% werd behaald, met 18 van de 44 voorspelde remmers 
inderdaad actief. Twee van deze stoffen werden gesynthetiseerd en getest in MV4:11 
celculturen en beide bleken cellulair (zeer) actief. De andere kinases die voorspeld waren 
als doeleiwit van deze moleculen werden ook getest. Hieruit bleek dat ongeveer 70% van 
deze eiwitten inderdaad geremd werden. Tot slot werd het model gebruikt om de interactie-
profielen te voorspellen van een commercieel verkrijgbare set stoffen die een motief 
bevatten, die de zogenaamde scharnierregio van kinases zou kunnen binden. Twintig 
stoffen hiervan werden gekocht en getest op hun activiteit tegen de kinases HIPK3 en 
PAK2. Helaas bleek geen van deze stoffen daadwerkelijk te werken, wat mogelijk te wijten 
is aan de lage dekkingsgraad van de oefendata rond deze doeleiwitten, of de matige 
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Tot slot 
Minder dan 1 op 10 kandidaat medicijnen die beginnen aan fase 1 klinische studies 
worden uiteindelijk goedgekeurd voor menselijk gebruik. Onverwachte bijwerkingen en 
toxiciteit zijn hier mede debet aan. Een beter begrip van de rol van selectiviteit en een beter 
inzicht in welke eiwitten daadwerkelijk door kandidaat medicijnen worden gebonden, 
kunnen bijdragen aan het voorkomen dat kandidaat medicijnen om deze redenen niet 
verder ontwikkeld worden. Dit proefschrift heeft enkele van deze uitdagende aspecten van 
de medicijnontwikkeling bestudeerd. Het gebruik van activiteit-gebaseerde eiwit profilering 
zoals in Hoofdstukken 2 en 3 tijdens medicijnontwikkeling en –optimalisatie, en in 
Hoofdstukken 5 en 6 om de interacties van een kandidaat medicijn in kaart te brengen, 
illustreert de veelzijdigheid en het belang van deze techniek uit de chemische biologie. 
Gecombineerd met de kennis verkregen uit biochemische analyses, zoals die ontwikkeld in 
Hoofdstuk 4, kan de medicinaal chemicus veel aan ABPP hebben. De recente enorme 
toename in de populariteit van zelflerende algoritmes, ondersteund door de exponentiële 
groei van beschikbare biologische data, biedt grote kansen voor de medicijnontwikkeling. 
Hoofdstukken 7 en 8 toonden de toepasbaarheid van één van die algoritmes aan, welke in 
staat bleek redelijk betrouwbare voorspellingen te doen over interactieprofielen van kinase-
remmers. De moeilijkheden in het vinden, bepalen en voorspellen van selectiviteit zijn verre 
van opgelost, maar door ons begrip van de binding van remmers aan eiwitten, bedoeld of 
onbedoeld, te blijven uitbreiden, kunnen werkelijk selectieve remmers wellicht ooit 
werkelijkheid worden.  
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